<SEC-DOCUMENT>0001213900-22-025709.txt : 20220512
<SEC-HEADER>0001213900-22-025709.hdr.sgml : 20220512
<ACCEPTANCE-DATETIME>20220512074229
ACCESSION NUMBER:		0001213900-22-025709
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		54
CONFORMED PERIOD OF REPORT:	20220331
FILED AS OF DATE:		20220512
DATE AS OF CHANGE:		20220512

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Gamida Cell Ltd.
		CENTRAL INDEX KEY:			0001600847
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			L3
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38716
		FILM NUMBER:		22915749

	BUSINESS ADDRESS:	
		STREET 1:		5 NAHUM HAFZADI STREET
		CITY:			JERUSALEM
		STATE:			L3
		ZIP:			95484
		BUSINESS PHONE:		97226595666

	MAIL ADDRESS:	
		STREET 1:		5 NAHUM HAFZADI STREET
		CITY:			JERUSALEM
		STATE:			L3
		ZIP:			95484
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>f10q0322_gamidacell.htm
<DESCRIPTION>QUARTERLY REPORT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Wed May 11 15:03:38 UTC 2022 -->
<html xmlns:compsci="http://compsciresources.com" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:dtr="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:gmda="http://www.gamidacell.com/20220331" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:pf0="http://fasb.org/srt/2022" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:us-types="http://fasb.org/us-types/2022" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://www.w3.org/1999/xhtml" xmlns:xml="http://www.w3.org/XML/1998/namespace"><head>
     <title> </title>

<meta content="text/html" http-equiv="Content-Type" />
</head>
<body><div style="font: 10pt Times New Roman, Times, Serif"><div>

</div><p style="margin: 0"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="text-align: center; margin-top: 0; margin-bottom: 0">&#160;</p><div>

</div><p style="font: 18pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>UNITED STATES</b></p><div>

</div><p style="font: 18pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>SECURITIES AND EXCHANGE
COMMISSION</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>WASHINGTON, DC 20549</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p><div>

</div><!-- Field: Rule-Page --><div style="margin: 0pt auto; width: 25%"><div style="font-size: 1pt; border-top: Black 1.5pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 18pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>FORM <ix:nonNumeric contextRef="c0" name="dei:DocumentType">10-Q</ix:nonNumeric></b></p><div>

</div><p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7.2pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><!-- Field: Rule-Page --><div style="margin: 0pt auto; width: 25%"><div style="font-size: 1pt; border-top: Black 1.5pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7.2pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-style: normal; font-weight: normal">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>(Mark One)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><ix:nonNumeric contextRef="c0" format="ixt:fixed-true" name="dei:DocumentQuarterlyReport">&#9746;</ix:nonNumeric>&#160;</span><b>QUARTERLY
REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></p><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>For the quarterly period
ended <ix:nonNumeric contextRef="c0" format="ixt:date-monthname-day-year-en" name="dei:DocumentPeriodEndDate">March 31, <ix:nonNumeric contextRef="c0" name="dei:DocumentFiscalYearFocus">2022</ix:nonNumeric></ix:nonNumeric></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>OR</b></p><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="dei:DocumentTransitionReport">&#9744;</ix:nonNumeric>&#160;</span><b>TRANSITION
REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></p><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>For the transition period
from to</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>Commission file number:
<ix:nonNumeric contextRef="c0" name="dei:EntityFileNumber">001-38716</ix:nonNumeric></b></p><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><!-- Field: Rule-Page --><div style="margin: 0pt auto; width: 25%"><div style="font-size: 1pt; border-top: Black 1.5pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 24pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><ix:nonNumeric contextRef="c0" name="dei:EntityRegistrantName"><b>GAMIDA CELL LTD.</b></ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7.2pt; text-align: center"><b>(Exact Name of Registrant as Specified
in its Charter)</b></p><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></p><div>

</div><!-- Field: Rule-Page --><div style="margin: 0pt auto; width: 25%"><div style="font-size: 1pt; border-top: Black 1.5pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7.2pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr> <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; width: 49%; font-size: 10pt; text-align: center"><ix:nonNumeric contextRef="c0" format="ixt-sec:edgarprovcountryen" name="dei:EntityIncorporationStateCountryCode"><b>Israel</b></ix:nonNumeric></td> <td style="padding-bottom: 1.5pt; vertical-align: top; width: 2%; font-size: 10pt; text-align: center">&#160;</td> <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; width: 49%; font-size: 10pt; text-align: center"><b><span style="-sec-ix-hidden: hidden-fact-0">Not Applicable</span></b></td></tr> <tr> <td style="vertical-align: bottom; font-size: 10pt; text-align: center"><span style="font-size: 10pt"><b>(State or other jurisdiction of<br/> incorporation or organization)</b></span></td> <td style="vertical-align: top; font-size: 10pt; text-align: center">&#160;</td> <td style="vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(I.R.S. Employer</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Identification No.)</b></p></td></tr> </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="text-align: center; width: 49%"><ix:nonNumeric contextRef="c0" name="dei:EntityAddressAddressLine1"><b>116 Huntington Avenue</b></ix:nonNumeric></td> <td style="text-align: center; width: 2%">&#160;</td> <td style="text-align: center; width: 49%">&#160;</td></tr> <tr style="vertical-align: top"> <td style="border-bottom: Black 1.5pt solid; text-align: center"><b><ix:nonNumeric contextRef="c0" name="dei:EntityAddressCityOrTown">Boston</ix:nonNumeric>, <ix:nonNumeric contextRef="c0" name="dei:EntityAddressStateOrProvince">MA</ix:nonNumeric></b></td> <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td> <td style="border-bottom: Black 1.5pt solid; text-align: center"><ix:nonNumeric contextRef="c0" name="dei:EntityAddressPostalZipCode"><b>02116</b></ix:nonNumeric></td></tr> <tr style="vertical-align: top"> <td style="text-align: center"><span style="font-size: 10pt"><b>(Address of principal executive offices)</b></span></td> <td style="text-align: center">&#160;</td> <td style="text-align: center"><span style="font-size: 10pt"><b>(Zip Code)</b></span></td></tr> </table><div>
</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-size: 6pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7.2pt; text-align: center"><b><ix:nonNumeric contextRef="c0" name="dei:CityAreaCode">(617)</ix:nonNumeric> <ix:nonNumeric contextRef="c0" name="dei:LocalPhoneNumber">892-9080</ix:nonNumeric></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7.2pt; text-align: center"><b>(Registrant</b>&#8217;<b>s telephone
number, including area code)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7.2pt"><span style="font-size: 6pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7.2pt; text-align: center"><b>N/A</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7.2pt; text-align: center"><b>(Former name, former address and
former fiscal year, if changed since last report)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7.2pt; text-indent: 28pt"><span style="font-size: 6pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7.2pt; text-indent: 28pt">Securities registered pursuant to Section
12(b) of the Act:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7.2pt"><span style="font-size: 6pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="border-bottom: Black 1.5pt solid; text-align: center; width: 32%"><span style="font-size: 10pt"><b>Title of each class</b></span></td> <td style="padding-bottom: 1.5pt; text-align: center; width: 2%"><b>&#160;</b></td> <td style="border-bottom: Black 1.5pt solid; text-align: center; width: 32%"><span style="font-size: 10pt"><b>Trading Symbol</b></span></td> <td style="padding-bottom: 1.5pt; text-align: center; width: 2%"><b>&#160;</b></td> <td style="border-bottom: Black 1.5pt solid; text-align: center; width: 32%"><span style="font-size: 10pt"><b>Name of exchange on which registered</b></span></td></tr> <tr style="vertical-align: top; background-color: rgb(204,238,255)"> <td style="text-align: center"><ix:nonNumeric contextRef="c0" name="dei:Security12bTitle"><span style="font-size: 10pt">Ordinary Shares, par value NIS 0.01 per share</span></ix:nonNumeric></td> <td style="text-align: center">&#160;</td> <td style="text-align: center"><ix:nonNumeric contextRef="c0" name="dei:TradingSymbol"><span style="font-size: 10pt">GMDA</span></ix:nonNumeric></td> <td style="text-align: center">&#160;</td> <td style="text-align: center"><ix:nonNumeric contextRef="c0" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName"><span style="font-size: 10pt">The Nasdaq Stock Market LLC</span></ix:nonNumeric></td></tr> </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7.2pt"><span style="font-size: 6pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-indent: 28pt">Indicate by check mark whether the registrant
(1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12
months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements
for the past 90 days. <ix:nonNumeric contextRef="c0" name="dei:EntityCurrentReportingStatus">Yes</ix:nonNumeric> <span style="font-family: Times New Roman, Times, Serif">&#9746;</span> No <span style="font-family: Times New Roman, Times, Serif">&#9744;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7.2pt; text-indent: 28pt"><span style="font-size: 6pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-indent: 28pt">Indicate by check mark whether the registrant
has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405
of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). <ix:nonNumeric contextRef="c0" name="dei:EntityInteractiveDataCurrent">Yes</ix:nonNumeric>
<span style="font-family: Times New Roman, Times, Serif">&#9746;</span> No <span style="font-family: Times New Roman, Times, Serif">&#9744;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7.2pt; text-indent: 28pt"><span style="font-size: 6pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-indent: 28pt">Indicate by check mark whether the registrant
is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company.
See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221;
and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7.2pt"><span style="font-size: 6pt">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 25%"><span style="font-size: 10pt">Large accelerated filer </span></td> <td style="width: 48%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></td> <td style="width: 25%"><span style="font-size: 10pt">Accelerated filer </span></td> <td style="width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></td></tr> <tr style="vertical-align: top"> <td><span style="font-size: 10pt"><ix:nonNumeric contextRef="c0" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory">Non-accelerated filer</ix:nonNumeric> </span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;</span></td> <td><span style="font-size: 10pt">Smaller reporting company </span></td> <td><ix:nonNumeric contextRef="c0" format="ixt:fixed-true" name="dei:EntitySmallBusiness"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;</span></ix:nonNumeric></td></tr> <tr style="vertical-align: top"> <td><span style="font-size: 10pt">Emerging growth company </span></td> <td><ix:nonNumeric contextRef="c0" format="ixt:fixed-true" name="dei:EntityEmergingGrowthCompany"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;</span></ix:nonNumeric></td> <td><span style="font-size: 10pt">&#160;</span></td> <td><span style="font-size: 10pt">&#160;</span></td></tr> </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7.2pt"><span style="font-size: 6pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-indent: 28pt">If an emerging growth company, indicate
by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act. <ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="dei:EntityExTransitionPeriod"><span style="font-family: Times New Roman, Times, Serif">&#9744;</span></ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7.2pt; text-indent: 28pt"><span style="font-size: 6pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-indent: 28pt">Indicate by check mark whether the registrant
is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes <span style="font-family: Times New Roman, Times, Serif">&#9744;
</span>No <ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="dei:EntityShellCompany"><span style="font-family: Times New Roman, Times, Serif">&#9746;</span></ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7.2pt; text-indent: 28pt"><span style="font-size: 6pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-indent: 28pt"><span style="font-size: 10pt">The registrant
had <ix:nonFraction contextRef="c1" decimals="INF" format="ixt:num-dot-decimal" name="dei:EntityCommonStockSharesOutstanding" scale="0" unitRef="shares">59,946,298</ix:nonFraction> ordinary shares outstanding as of May </span>9<span style="font-size: 10pt">, 2022.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-indent: 28pt"><span style="font-size: 6pt">&#160;</span></p><div>

</div><!-- Field: Rule-Page --><div style="width: 100%"><div style="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-indent: 28pt"><span style="font-size: 6pt">&#160;</span></p><div>

</div><!-- Field: Page; Sequence: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="margin: 0pt">&#160;</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7.2pt; text-align: center"><b>Gamida Cell Ltd.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7.2pt; text-align: center"><b>Index</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="width: 90%"><a href="#a_001">Part I&#8212;Financial Information</a></td>
    <td style="text-align: center; width: 10%">1</td></tr>
  <tr style="vertical-align: top; ">
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><a href="#a_002">Item 1. Financial Statements.</a></td>
    <td style="text-align: center">1</td></tr>
  <tr style="vertical-align: top; ">
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><a href="#a_003">Condensed Consolidated Balance Sheets</a></td>
    <td style="text-align: center">1</td></tr>
  <tr style="vertical-align: top; ">
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><a href="#a_004">Condensed Consolidated Statements of Operations</a></td>
    <td style="text-align: center">3</td></tr>
  <tr style="vertical-align: top; ">
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><a href="#a_005">Condensed Consolidated Statements of Changes in Shareholders&#8217; Equity</a></td>
    <td style="text-align: center">4</td></tr>
  <tr style="vertical-align: top; ">
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><a href="#a_006">Condensed Consolidated Statements of Cash Flows</a></td>
    <td style="text-align: center">5</td></tr>
  <tr style="vertical-align: top; ">
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><a href="#a_007">Notes to the Unaudited Condensed Consolidated Financial Statements</a></td>
    <td style="text-align: center">6</td></tr>
  <tr style="vertical-align: top; ">
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><a href="#a_008">Item 2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.</a></td>
    <td style="text-align: center">15</td></tr>
  <tr style="vertical-align: top; ">
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><a href="#a_009">Item 3. Quantitative and Qualitative Disclosures About Market Risk.</a></td>
    <td style="text-align: center">24</td></tr>
  <tr style="vertical-align: top; ">
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><a href="#a_010">Item 4. Controls and Procedures.</a></td>
    <td style="text-align: center">24</td></tr>
  <tr style="vertical-align: top; ">
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><a href="#a_011">Part II&#8212;Other Information</a></td>
    <td style="text-align: center">26</td></tr>
  <tr style="vertical-align: top; ">
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><a href="#a_012">Item 1. Legal Proceedings.</a></td>
    <td style="text-align: center">26</td></tr>
  <tr style="vertical-align: top; ">
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><a href="#a_013">Item 1A. Risk Factors.</a></td>
    <td style="text-align: center">26</td></tr>
  <tr style="vertical-align: top; ">
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><a href="#a_014">Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.</a></td>
    <td style="text-align: center">80</td></tr>
  <tr style="vertical-align: top; ">
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><a href="#a_015">Item 3. Defaults Upon Senior Securities.</a></td>
    <td style="text-align: center">80</td></tr>
  <tr style="vertical-align: top; ">
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><a href="#a_016">Item 4. Mine Safety Disclosures.</a></td>
    <td style="text-align: center">80</td></tr>
  <tr style="vertical-align: top; ">
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><a href="#a_017">Item 5. Other Information.</a></td>
    <td style="text-align: center">80</td></tr>
  <tr style="vertical-align: top; ">
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><a href="#a_018">Item 6. Exhibits.</a></td>
    <td style="text-align: center">81</td></tr>
  <tr style="vertical-align: top; ">
    <td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><a href="#a_019">Signatures</a></td>
    <td style="text-align: center">82</td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9pt">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Trademarks and Trade Names</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">Unless the context requires
otherwise, &#8220;Gamida,&#8221; &#8220;Gamida Cell,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our&#8221; or the &#8220;Company&#8221;
mean Gamida Cell Ltd. and its wholly-owned subsidiary, Gamida Cell Inc.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">Gamida Cell is a trademark
of ours that we use in this quarterly report on Form 10-Q, or Quarterly Report. This Quarterly Report also includes trademarks, tradenames,
and service marks that are the property of other organizations. Solely for convenience, our trademarks and tradenames referred to in
this Quarterly Report appear without the &#174; or &#8482; symbols, but those references are not intended to indicate, in any way, that
we will not assert, to the fullest extent under applicable law, our rights, or the right of the applicable licensor to our trademark
and tradenames. We do not intend our use or display of other companies&#8217; trade names or trademarks to imply a relationship with,
or endorsement or sponsorship of us by, any other companies.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>


</div><!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_001"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7.2pt; text-align: center">Part I&#8212;Financial Information</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7.2pt; text-align: center">&#160;</p><div>

</div><div><a id="a_002"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Item 1. Financial Statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7.2pt; text-align: center"><b>&#160;</b></p><div>

</div><div><a id="a_003"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7.2pt; text-align: center"><b>Gamida Cell Ltd.</b></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7.2pt; text-align: center">Condensed Consolidated Balance
Sheets</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7.2pt; text-align: center"><b>(unaudited; in thousands, except
share amounts and par value)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7.2pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; white-space: nowrap">&#160;</td><td style="padding-bottom: 1.5pt; white-space: nowrap; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center">March 31,<br/>
    2022</td><td style="padding-bottom: 1.5pt; white-space: nowrap; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; white-space: nowrap; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center">December 31,<br/>
    2021</td><td style="padding-bottom: 1.5pt; white-space: nowrap; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: left">Assets</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Current assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-left: 0.125in">Cash and cash equivalents</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" unitRef="usd">42,057</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" unitRef="usd">55,892</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.125in">Marketable securities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:MarketableSecuritiesCurrent" scale="3" unitRef="usd">27,661</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:MarketableSecuritiesCurrent" scale="3" unitRef="usd">40,034</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left; padding-left: 0.125in">Prepaid expenses and other current assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" unitRef="usd">2,994</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" unitRef="usd">2,688</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Total current assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="3" unitRef="usd">72,712</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="3" unitRef="usd">98,614</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Non-current assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.125in">Restricted deposits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RestrictedInvestmentsNoncurrent" scale="3" unitRef="usd">3,893</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RestrictedInvestmentsNoncurrent" scale="3" unitRef="usd">3,961</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.125in">Property, plant and equipment, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" unitRef="usd">37,533</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" unitRef="usd">35,180</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.125in">Operating lease right-of-use assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" unitRef="usd">6,722</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" unitRef="usd">7,236</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in">Severance pay fund</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherLongTermInvestments" scale="3" unitRef="usd">2,046</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherLongTermInvestments" scale="3" unitRef="usd">2,148</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; text-align: left; padding-left: 0.125in">Other long-term assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" unitRef="usd">1,632</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" unitRef="usd">1,647</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; text-align: left; padding-left: 0.125in">Total non-current assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsNoncurrent" scale="3" unitRef="usd">51,826</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsNoncurrent" scale="3" unitRef="usd">50,172</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt; text-align: left">Total assets</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="3" unitRef="usd">124,538</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="3" unitRef="usd">148,786</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
</table><div>

</div><p style="margin: 0">&#160;</p><div>

</div><p style="margin: 0"></p><div>

</div><!-- Field: Page; Sequence: 3; Options: NewSection; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="margin: 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; white-space: nowrap">&#160;</td><td style="padding-bottom: 1.5pt; white-space: nowrap; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center">March 31,<br/>
    2022</td><td style="padding-bottom: 1.5pt; white-space: nowrap; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; white-space: nowrap; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold; text-align: center">December 31,<br/>
    2021</td><td style="padding-bottom: 1.5pt; white-space: nowrap; font-weight: bold">&#160;</td></tr>

<tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: center; width: 76%">Liabilities and Shareholders&#8217; Equity</td><td style="width: 1%">&#160;</td>
    <td style="text-align: left; width: 1%">&#160;</td><td style="text-align: right; width: 9%">&#160;</td><td style="text-align: left; width: 1%">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="text-align: left; width: 1%">&#160;</td><td style="text-align: right; width: 9%">&#160;</td><td style="text-align: left; width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">Current liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.125in">Trade payables</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableCurrent" scale="3" unitRef="usd">4,346</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableCurrent" scale="3" unitRef="usd">8,272</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.125in">Employees and payroll accruals</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" unitRef="usd">4,119</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" unitRef="usd">4,957</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.125in">Operating lease liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" unitRef="usd">2,596</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" unitRef="usd">2,699</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.125in">Accrued interest of convertible senior notes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NotesPayableCurrent" scale="3" unitRef="usd">551</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NotesPayableCurrent" scale="3" unitRef="usd">1,640</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left; padding-left: 0.125in">Accrued expenses and other current liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" unitRef="usd">8,866</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" unitRef="usd">7,865</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="3" unitRef="usd">20,478</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="3" unitRef="usd">25,433</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Non-current liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.125in">Convertible senior notes, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ConvertibleLongTermNotesPayable" scale="3" unitRef="usd">71,607</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ConvertibleLongTermNotesPayable" scale="3" unitRef="usd">71,417</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.125in">Accrued severance pay</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAccruedLiabilitiesNoncurrent" scale="3" unitRef="usd">2,327</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAccruedLiabilitiesNoncurrent" scale="3" unitRef="usd">2,396</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left; padding-left: 0.125in">Long-term operating lease liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" unitRef="usd">5,142</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" unitRef="usd">5,603</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left">Total non-current liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesNoncurrent" scale="3" unitRef="usd">79,076</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesNoncurrent" scale="3" unitRef="usd">79,416</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Contingent liabilities and commitments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-1">&#160;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-2">&#160;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Shareholders&#8217; equity:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -9pt; padding-left: 0.25in">Ordinary shares NIS <ix:nonFraction contextRef="c2" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="ilsPershares"><ix:nonFraction contextRef="c3" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="ilsPershares">0.01</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction contextRef="c2" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" unitRef="shares"><ix:nonFraction contextRef="c3" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" unitRef="shares">150,000,000</ix:nonFraction></ix:nonFraction> shares authorized at
March 31, 2022 (unaudited) and December 31, 2021; <ix:nonFraction contextRef="c2" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares">60,021,415</ix:nonFraction> and <ix:nonFraction contextRef="c3" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares">59,970,389</ix:nonFraction> shares issued at March 31, 2022 (unaudited) and December 31,
2021, respectively; <ix:nonFraction contextRef="c2" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares">59,946,298</ix:nonFraction> and <ix:nonFraction contextRef="c3" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares">59,970,389</ix:nonFraction> shares outstanding as of March 31, 2022 (unaudited) and December 31, 2021, respectively</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockValue" scale="3" unitRef="usd">169</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockValue" scale="3" unitRef="usd">169</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.125in; padding-left: 0.25in">Treasury ordinary shares of NIS <ix:nonFraction contextRef="c2" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquitySharesAuthorized" scale="0" unitRef="shares"><ix:nonFraction contextRef="c3" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquitySharesAuthorized" scale="0" unitRef="shares">0.01</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction contextRef="c2" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:TreasuryStockShares" scale="0" unitRef="shares">75,117</ix:nonFraction> and <ix:nonFraction contextRef="c3" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:TreasuryStockShares" scale="0" unitRef="shares">0</ix:nonFraction> shares at March 31, 2022 (unaudited) and December 31, 2021 respectively.</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-3">*</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-4">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 0.25in">Additional paid-in capital</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="3" unitRef="usd">382,495</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="3" unitRef="usd">381,225</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left; text-indent: -9pt; padding-left: 0.25in">Accumulated deficit</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" sign="-" unitRef="usd">357,680</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" sign="-" unitRef="usd">337,457</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; text-align: left">Total Shareholders&#8217; Equity</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd">24,984</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd">43,937</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt; text-align: left">Total Liabilities and Shareholders&#8217; Equity</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" unitRef="usd">124,538</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" unitRef="usd">148,786</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7.2pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left">*</td><td style="text-align: justify"><ix:footnote id="ix_0_footnote" xml:lang="en-US">represents an amount lower than $1.</ix:footnote></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7.2pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">The accompanying notes are
an integral part of these condensed consolidated financial statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7.2pt; text-align: center">&#160;</p><div>


</div><!-- Field: Page; Sequence: 4; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7.2pt; text-align: center">&#160;</p><div>

</div><div><a id="a_004"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>Gamida Cell Ltd.</b></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Condensed Consolidated
Statements of Operations</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>(unaudited; in thousands,
except share and per share amounts)</b></p><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the Three Months Ended<br/> March
    31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-left: 0.125in">Research and development expenses, net</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="gmda:ResearchAndDevelopmentExpensesNet" scale="3" unitRef="usd">11,305</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="gmda:ResearchAndDevelopmentExpensesNet" scale="3" unitRef="usd">11,360</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.125in">Commercial expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="gmda:CommercialExpenses" scale="3" unitRef="usd">3,879</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="gmda:CommercialExpenses" scale="3" unitRef="usd">4,231</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.125in">General and administrative expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="gmda:GeneralAndAdministrativeExpenses" scale="3" unitRef="usd">4,139</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="gmda:GeneralAndAdministrativeExpenses" scale="3" unitRef="usd">3,513</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Total operating loss</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="3" sign="-" unitRef="usd">19,323</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="3" sign="-" unitRef="usd">19,104</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Financial expenses, net</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NonoperatingIncomeExpense" scale="3" sign="-" unitRef="usd">900</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NonoperatingIncomeExpense" scale="3" sign="-" unitRef="usd">82</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Loss</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="3" sign="-" unitRef="usd">20,223</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProfitLoss" scale="3" sign="-" unitRef="usd">19,186</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Net loss per share attributable to ordinary shareholders, basic and diluted</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" unitRef="usdPershares">0.34</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasic" scale="0" unitRef="usdPershares">0.32</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Weighted average number of shares used in computing net
    loss per share attributable to ordinary shareholders, basic and diluted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" unitRef="shares">59,474,366</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" unitRef="shares">59,122,973</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">The accompanying notes are
an integral part of these condensed consolidated financial statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7.2pt">&#160;</p><div>


</div><!-- Field: Page; Sequence: 5; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_005"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>Gamida Cell Ltd.</b></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Condensed Consolidated
Statements of Changes in Shareholders&#8217; Equity</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>(unaudited; in thousands,
except share amounts)</b></p><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0pt; text-align: right; text-indent: 0pt">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Ordinary shares</td><td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Additional<br/>
    paid-in</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Accumulated</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Total shareholders&#8217;</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0pt; text-align: right; text-indent: 0pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">capital</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">deficit</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">equity</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0pt; text-indent: 0pt">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 40%; text-indent: 0pt; padding-left: 0pt">Balance as of December 31, 2020</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c5" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares">59,000,153</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd">166</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd">376,369</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" sign="-" unitRef="usd">247,664</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c8" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd">128,871</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: 0pt; padding-left: 0pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: 0pt; padding-left: 0pt">Grant of restricted shares</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c9" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" scale="0" unitRef="shares">159,134</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-5">*</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-6">*</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: 0pt; padding-left: 0pt">Exercise of options</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c9" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" unitRef="shares">247,685</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c9" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" unitRef="usd">1</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c10" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" unitRef="usd">501</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" unitRef="usd">502</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: 0pt; padding-left: 0pt">Share-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c10" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EmployeeBenefitsAndShareBasedCompensation" scale="3" unitRef="usd">913</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EmployeeBenefitsAndShareBasedCompensation" scale="3" unitRef="usd">913</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; text-indent: 0pt; padding-left: 0pt">Loss</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c11" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd">19,186</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd">19,186</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: 0pt; padding-left: 0pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt; text-indent: 0pt; padding-left: 0pt">Balance as of March 31, 2021</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c12" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares">59,406,972</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c12" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd">167</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c13" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd">377,783</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c14" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" sign="-" unitRef="usd">266,850</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c15" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd">111,100</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: right">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Ordinary shares</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">Treasury</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">Additional <br/> paid-in</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">Accumulated</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">Total shareholders&#8217;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: right">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">capital</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">deficit</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">equity</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 28%; text-indent: -11.35pt; padding-left: 14.2pt">Balance as of December 31, 2021</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c16" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares">59,970,389</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c16" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd">169</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">-</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c17" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd">381,225</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c18" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" sign="-" unitRef="usd">337,457</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd">43,937</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -11.35pt; padding-left: 14.2pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -11.35pt; padding-left: 14.2pt">Grant of restricted shares</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c19" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" scale="0" unitRef="shares">3,600</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-7">*</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-8">*</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-9">*</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -11.35pt; padding-left: 14.2pt">Treasury shares</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c19" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:TreasuryStockSharesRetired" scale="0" sign="-" unitRef="shares">75,117</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-10">*</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-11">*</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-12">*</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -11.35pt; padding-left: 14.2pt">Exercise of options</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c19" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" unitRef="shares">47,426</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-13">*</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c20" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" unitRef="usd">76</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" unitRef="usd">76</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -11.35pt; padding-left: 14.2pt">Share-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c20" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EmployeeBenefitsAndShareBasedCompensation" scale="3" unitRef="usd">1,194</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EmployeeBenefitsAndShareBasedCompensation" scale="3" unitRef="usd">1,194</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-indent: -11.35pt; padding-left: 14.2pt">Loss</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c22" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd">20,223</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd">20,223</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -11.35pt; padding-left: 14.2pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt; text-indent: -11.35pt; padding-left: 14.2pt">Balance as of March 31, 2022</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c23" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares">59,946,298</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c23" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd">169</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-14">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;*</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c25" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd">382,495</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c26" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" sign="-" unitRef="usd">357,680</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd">24,984</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left">*</td><td style="text-align: justify"><ix:footnote id="ix_1_footnote" xml:lang="en-US">Represents an amount lower than $1.</ix:footnote></td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">The accompanying notes are
an integral part of these condensed consolidated financial statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7.2pt; text-align: center">&#160;</p><div>


</div><!-- Field: Page; Sequence: 6; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_006"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>Gamida Cell Ltd.</b></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Condensed Consolidated
Statements of Cash Flows</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>(unaudited; in thousands)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Three Months Ended<br/> March 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: left">Cash Flows From Operating Activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; padding-left: 0.125in">Loss</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd">20,223</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd">19,186</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 12.75pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.125in">Adjustment to reconcile loss to net cash used in operating activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 12.75pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.125in">Depreciation of property, plant and equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="3" unitRef="usd">112</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Depreciation" scale="3" unitRef="usd">98</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.125in">Financing expense (income), net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CostsAndExpenses" scale="3" sign="-" unitRef="usd">1,172</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CostsAndExpenses" scale="3" unitRef="usd">220</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.125in">Share-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="3" unitRef="usd">1,194</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="3" unitRef="usd">913</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.125in">Amortization of issuance costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="3" unitRef="usd">191</ix:nonFraction></td><td style="text-align: left"></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="3" unitRef="usd">323</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.125in">Operating lease right-of-use assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" unitRef="usd">562</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" unitRef="usd">516</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.125in">Operating lease liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" scale="3" sign="-" unitRef="usd">613</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" scale="3" sign="-" unitRef="usd">929</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.125in">Accrued severance pay, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInPostemploymentObligations" scale="3" unitRef="usd">33</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.125in">Increase in prepaid expenses and other assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" unitRef="usd">889</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" unitRef="usd">515</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.125in">Increase (decrease) in trade payables</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsPayableTrade" scale="3" sign="-" unitRef="usd">3,927</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsPayableTrade" scale="3" unitRef="usd">907</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.125in">Decrease in accrued expenses and current liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="3" sign="-" unitRef="usd">996</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="3" sign="-" unitRef="usd">3,192</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 12.75pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.125in">Net cash used in operating activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" sign="-" unitRef="usd">25,728</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" sign="-" unitRef="usd">20,845</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left">Cash Flows From Investing Activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.125in">Purchase of property, plant and equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" unitRef="usd">723</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" unitRef="usd">2,806</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.125in">Purchase of marketable securities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquireMarketableSecurities" scale="3" unitRef="usd">2,086</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.125in">Proceeds from maturity of marketable securities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" scale="3" unitRef="usd">14,126</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.125in">Proceeds from restricted deposits</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" scale="3" sign="-" unitRef="usd">500</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 12.75pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.125in">Net cash provided by (used in) investing activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" unitRef="usd">11,817</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" sign="-" unitRef="usd">2,806</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Cash Flows From Financing Activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in">Proceeds from exercise of options</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" unitRef="usd">76</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" unitRef="usd">502</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.125in">Proceeds from issuance of convertible senior notes, net</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" unitRef="usd">70,777</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 12.75pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.125in">Net cash provided by financing activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" unitRef="usd">76</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" unitRef="usd">71,279</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Increase (decrease) in cash and cash equivalents</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" scale="3" sign="-" unitRef="usd">13,835</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" scale="3" unitRef="usd">47,628</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Cash and cash equivalents at beginning of period</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="3" unitRef="usd">55,892</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c8" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="3" unitRef="usd">127,170</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Cash and cash equivalents at end of period</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="3" unitRef="usd">42,057</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c15" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="3" unitRef="usd">174,798</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Significant non-cash transactions:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Issuance expenses on credit</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">-</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="gmda:IssuanceExpensesOnCredit" scale="3" unitRef="usd">235</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Purchase of property, plant and equipment on credit</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" scale="3" unitRef="usd">1,160</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" scale="3" unitRef="usd">216</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left">Supplemental disclosures of cash flow information:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Cash paid for interest</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestPaidNet" scale="3" unitRef="usd">2,203</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">-</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">The accompanying notes are
an integral part of these condensed consolidated financial statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7.2pt; text-align: center">&#160;</p><div>


</div><!-- Field: Page; Sequence: 7; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_007"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>Gamida Cell Ltd.</b></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Notes to the Unaudited
Condensed Consolidated Financial Statements</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2cm; text-align: justify; text-indent: -2cm">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2cm; text-align: justify; text-indent: -2cm">NOTE 1:- GENERAL</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2cm; text-align: justify; text-indent: 0cm">&#160;</p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_2" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.75in"></td><td style="width: 0.5in; text-align: left"><span style="font-size: 10pt">a.</span></td><td style="text-align: justify">Gamida
                                            Cell Ltd. (the &#8220;Company&#8221;), founded in 1998, is an advanced cell therapy company
                                            committed to cures for blood cancers and serious hematologic diseases. The Company harnesses
                                            its cell expansion platform to create therapies with the potential to redefine standards
                                            of care in areas of serious medical need</td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3cm; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_3" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_2"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top">
<td style="width: 0.75in"></td><td style="width: 0.5in">b.</td><td style="text-align: justify">The Company has leveraged its NAM platform,
                                            or nicotinamide cell expansion technology platform, to develop a pipeline of product candidates
                                            designed to address the limitations of other cell therapies. The Company&#8217;s proprietary
                                            technology allows for the proliferation and enhancement of donor cells, which allows for
                                            maintenance of the cells&#8217; functional therapeutic characteristics, providing a potential
                                            treatment alternative for patients.</td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3cm; text-align: justify; text-indent: -1cm">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_4" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The lead product candidate, omidubicel,
is an advanced cell therapy in development as a potential life-saving treatment option for patients in need of a bone marrow transplant
(BMT). In May 2020, the Company reported that omidubicel met its primary endpoint in an international, randomized, multi-center Phase
3 clinical study in 125 patients with high-risk hematologic malignancies undergoing bone marrow transplant and who had no available matched
donor. The study evaluated the safety and efficacy of omidubicel compared to standard umbilical cord blood. BMT with a graft derived
from bone marrow or peripheral blood cells of a matched donor is currently the standard of care treatment for many of these patients,
but there is a significant unmet need for patients who cannot find a fully matched donor.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3cm; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_5" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">In October 2021, the complete results
from the Company&#8217;s pivotal Phase 3 clinical study of omidubicel in 125 patients with various hematologic malignancies were published
in the peer-reviewed medical journal Blood. The trial achieved its primary endpoint of time to neutrophil engraftment as well as all
three of the prespecified secondary endpoints. These secondary endpoints were the proportion of patients who achieved platelet engraftment
by day 42, the proportion of patients with grade 2 or grade 3 bacterial or invasive fungal infections in the first 100 days following
transplant, and the number of days alive and out of the hospital in the first 100 days following transplant. All three secondary endpoints
demonstrated statistical significance in an intent-to-treat analysis.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3cm; text-align: justify; text-indent: 0cm">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_6" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Omidubicel is the first bone marrow
transplant product to receive Breakthrough Therapy Designation from the U.S. Food and Drug Administration and has received orphan drug
designation in the U.S. and in Europe.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3cm; text-align: justify; text-indent: 0cm">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_7" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">In addition to omidubicel, the Company
is developing GDA-201, an investigational natural killer (&#8220;NK&#8221;) cell-based cancer immunotherapy that is intended to be used
in combination with standard-of-care therapeutic antibodies, as well as other product candidates in the Company&#8217;s NK cell pipeline.
NK cells have potent anti-tumor properties and have the advantage over other oncology cell therapies of not requiring genetic matching,
potentially enabling NK cells to serve as a universal donor-based therapy when combined with certain antibodies. GDA-201 is currently
in an investigator-sponsored Phase 1/2 study for the treatment of relapsed or refractory non-Hodgkin lymphoma (NHL). Data from the 35
patients in the Phase 1/2 study demonstrated that GDA-201 was clinically active and generally well tolerated. <ix:nonNumeric contextRef="c0" name="gmda:ResponseRatePercentage">Among the 19 patients with
NHL, 13 complete responses and one partial response were observed, with an overall response rate of 74% and a complete response rate
of 68%.</ix:nonNumeric></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3cm; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3cm; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 8; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3cm; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0in; text-align: left"><b>NOTE 1:-&#160;GENERAL (Cont.)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3cm; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_8" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_7"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">At the December 2021 Annual Meeting
of America Society of Hematology, the Company reported two-year follow-up data from this clinical trial on outcomes and cytokine biomarkers
associated with survival. <ix:nonNumeric contextRef="c27" name="gmda:ClinicalTrialOnOutcomes">The data demonstrated a median duration of response of 16 months (range 5-36 months), an overall survival at
two years of 78% (95% CI, 51%&#8211;91%) and a safety profile similar to that reported previously.</ix:nonNumeric></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3cm; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_9" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_8"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top">
<td style="width: 0.75in"></td><td style="width: 0.5in">c.</td><td style="text-align: justify">Basis of presentation of the financial
                                            statements:</td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3cm; text-align: justify; text-indent: 0cm">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_10" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_9"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The accompanying unaudited condensed
consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States
of America (&#8220;U.S. GAAP&#8221;) for interim financial information and in accordance with the instructions to Form 10-Q and Article
10 of Regulation S-X promulgated by the U.S Securities and Exchange Commission (the &#8220;SEC&#8221;). Certain information or footnote
disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted, pursuant
to the rules and regulations of the SEC for interim financial reporting. Accordingly, they do not include all the information and footnotes
necessary for a complete presentation of financial position, results of operations, or cash flows. In the opinion of management, the
accompanying unaudited condensed consolidated financial statements include all adjustments, consisting of a normal recurring nature,
which are necessary for a fair presentation of the financial position, operating results and cash flows for the periods presented.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3cm; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_11" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_10"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The accompanying unaudited condensed
consolidated financial statements should be read in conjunction with the Company&#8217;s Annual Report on Form 10-K as of December 31,
2021 filed with the SEC on March 24, 2022. The interim period results do not necessarily indicate the results that may be expected for
any other interim period or for the full fiscal year.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3cm; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_12" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_11"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Prior to 2021, the Company prepared
its financial statements in accordance with International Financial Reporting Standards (IFRS), as issued by the International Accounting
Standards Board (IASB), as permitted in the United States based on the Company&#8217;s qualification as a &#8220;foreign private issuer&#8221;
under the rules and regulations of the SEC. In connection with the loss of the Company&#8217;s status as a foreign private issuer effective
on January 1, 2022, the Company, as a domestic filer, prepared its consolidated financial statements in accordance with U.S. GAAP.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3cm; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_13" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_12"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.75in"></td><td style="width: 0.5in; text-align: left">d.</td><td style="text-align: justify">The Company continues to devote substantially all of its efforts toward
research and development activities. In the course of such activities, the Company has sustained operating losses and expects such losses
to continue in the foreseeable future. The Company's accumulated deficit as of March&#160;31, 2022 was $<ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="gmda:AccumulatedDeficit" scale="3" unitRef="usd">357,680</ix:nonFraction> and negative cash flows
from operating activities during the three-month period ended March 31, 2022 was $<ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InvestmentsAndCash" scale="3" unitRef="usd">25,728</ix:nonFraction>. The Company is planning to finance its operations
from its existing and future working capital resources and to continue to evaluate additional sources of capital and financing. However,
there is no assurance that additional capital and/or financing will be available to the Company, and even if available, whether it will
be on terms acceptable to the Company or in amounts required. The Company believes that its existing capital resources will be adequate
to satisfy its expected liquidity requirements for at least twelve months from the issuance of the condensed consolidated financial statements.</td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3cm; text-align: justify; text-indent: -1cm"><b>&#160;</b></p></ix:continuation><div>

</div><div>

</div><ix:continuation id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_13"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top">
<td style="width: 0.75in"></td><td style="width: 0.5in">e.</td><td style="text-align: justify">The Company has a wholly owned U.S. subsidiary, Gamida Cell Inc. (the &#8220;Subsidiary&#8221;), which was incorporated in 2000, under the laws of the State of Delaware. The Company has <ix:nonFraction contextRef="c0" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:NumberOfOperatingSegments" scale="0" unitRef="pure">one</ix:nonFraction> operating segment and reporting unit.</td></tr></table></ix:continuation><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0cm">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0cm"></p><div>

</div><!-- Field: Page; Sequence: 9; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0cm">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_1" escape="true" name="us-gaap:SignificantAccountingPoliciesTextBlock"><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0cm">NOTE 2:- SIGNIFICANT ACCOUNTING
POLICIES</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_2" id="_SignificantAccountingPoliciesTextBlock-c0_cont_1"><ix:nonNumeric contextRef="c0" continuedAt="_UseOfEstimates-c0_cont_1" escape="true" name="us-gaap:UseOfEstimates"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top">
<td style="width: 0.75in"></td><td style="width: 0.5in">a.</td><td>Use of estimates:</td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3cm; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_3" id="_SignificantAccountingPoliciesTextBlock-c0_cont_2"><ix:continuation id="_UseOfEstimates-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The preparation of condensed financial
statements in conformity with U.S. GAAP requires management to make estimates, judgments and assumptions that affect the amounts reported
in the consolidated financial statements and accompanying notes. The Company&#8217;s management believes that the estimates, judgment
and assumptions used are reasonable based upon information available at the time they are made. These estimates, judgments and assumptions
can affect the reported amounts of assets and liabilities at the dates of the consolidated financial statements, and the reported amount
of expenses during the reporting periods. Actual results could differ from those estimates.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_4" id="_SignificantAccountingPoliciesTextBlock-c0_cont_3"><ix:nonNumeric contextRef="c0" continuedAt="_ConvertibleSeniorNotesPolicyTextBlock-c0_cont_1" escape="true" name="gmda:ConvertibleSeniorNotesPolicyTextBlock"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top">
<td style="width: 0.75in"></td><td style="width: 0.5in">b.</td><td>Convertible senior notes:</td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.85pt; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_5" id="_SignificantAccountingPoliciesTextBlock-c0_cont_4"><ix:continuation id="_ConvertibleSeniorNotesPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The Company accounts for its convertible
senior notes in accordance with ASC 470-20 &#8220;Debt with Conversion and Other Options&#8221;. The Company early adopted ASU 2020-06
using the modified retrospective approach. The convertible senior notes are accounted for as a single liability measured at its amortized
cost, as no other embedded features require bifurcation and recognition as derivatives according to ASC 815-40.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_6" id="_SignificantAccountingPoliciesTextBlock-c0_cont_5"><ix:nonNumeric contextRef="c0" continuedAt="_EarningsPerSharePolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:EarningsPerSharePolicyTextBlock"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top">
<td style="width: 0.75in"></td><td style="width: 0.5in">c.</td><td>Basic and diluted net loss per share:</td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 88.85pt; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_7" id="_SignificantAccountingPoliciesTextBlock-c0_cont_6"><ix:continuation continuedAt="_EarningsPerSharePolicyTextBlock-c0_cont_2" id="_EarningsPerSharePolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The Company computes net loss per
share using the&#160;two-class&#160;method required for participating securities. The&#160;two-class&#160;method requires income available
to ordinary shareholders for the period to be allocated between ordinary shares and participating securities based upon their respective
rights to receive dividends as if all income for the period had been distributed. The Company considers its restricted shares to be participating
securities as the holders of the restricted shares would be entitled to dividends that would be distributed to the holders of ordinary
shares, on a&#160;pro-rata&#160;basis. These participating securities do not contractually require the holders of such shares to participate
in the Company&#8217;s losses. As such, net loss for the periods presented was not allocated to the Company&#8217;s participating securities.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 84.45pt; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation id="_SignificantAccountingPoliciesTextBlock-c0_cont_7"><ix:continuation id="_EarningsPerSharePolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The Company&#8217;s basic net loss
per share is calculated by dividing net loss attributable to ordinary shareholders by the weighted-average number of shares of ordinary
shares outstanding for the period, without consideration of potentially dilutive securities. The diluted net loss per share is calculated
by giving effect to all potentially dilutive securities outstanding for the period using the treasury share method or the&#160;if-converted&#160;method
based on the nature of such securities. Diluted net loss per share is the same as basic net loss per share in periods when the effects
of potentially dilutive ordinary shares are anti-dilutive.</p></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 84.45pt; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_LesseeOperatingLeasesTextBlock-c0_cont_1" escape="true" name="us-gaap:LesseeOperatingLeasesTextBlock"><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0cm">NOTE 3:-	LEASES</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 74.7pt; text-align: justify; text-indent: 0cm"><b>&#160;</b></p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_LesseeOperatingLeasesTextBlock-c0_cont_2" id="_LesseeOperatingLeasesTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The Company entered into operating
leases primarily for its production plant, and its laboratories and offices. The leases have remaining lease terms of up&#160;to&#160;<ix:nonNumeric contextRef="c2" format="ixt-sec:durwordsen" name="us-gaap:LesseeOperatingLeaseRemainingLeaseTerm">six
years</ix:nonNumeric>, and the Company does not assume renewals in its determination of the lease term unless the renewals are considered as reasonably
certain at lease commencement.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2cm; text-align: justify; text-indent: 0cm">&#160;</p></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2cm; text-align: justify; text-indent: 0cm"></p><div>

</div><!-- Field: Page; Sequence: 10; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2cm; text-align: justify; text-indent: 0cm">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><b>NOTE 3:-	LEASES (Cont.)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2cm; text-align: justify; text-indent: 0cm">&#160;</p><div>

</div><ix:continuation continuedAt="_LesseeOperatingLeasesTextBlock-c0_cont_3" id="_LesseeOperatingLeasesTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The components of operating lease
costs were as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3cm 0pt 0; text-align: justify; text-indent: 0cm">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_LesseeOperatingLeasesTextBlock-c0_cont_4" id="_LesseeOperatingLeasesTextBlock-c0_cont_3"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:LeaseCostTableTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; padding-left: 0pt; text-indent: 0pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Three months ended<br/>
    March 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; padding-left: 0pt; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2022</b></span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2021</b></span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0pt; text-indent: 0pt">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: 0pt; padding-left: 0pt">Operating lease costs</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseCost" scale="3" unitRef="usd">636</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseCost" scale="3" unitRef="usd">585</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: 0pt; padding-left: 0pt">Short-term lease costs</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShortTermLeaseCost" scale="3" unitRef="usd">24</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShortTermLeaseCost" scale="3" unitRef="usd">60</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: 0pt; padding-left: 0pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: 0pt; padding-left: 0pt">Total lease costs</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LeaseCost" scale="3" unitRef="usd">660</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LeaseCost" scale="3" unitRef="usd">645</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3cm"><b>&#160;</b></p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_LesseeOperatingLeasesTextBlock-c0_cont_5" id="_LesseeOperatingLeasesTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Supplemental balance sheet information
related to operating leases is as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3cm 0pt 0; text-align: justify; text-indent: 0cm">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_LesseeOperatingLeasesTextBlock-c0_cont_6" id="_LesseeOperatingLeasesTextBlock-c0_cont_5"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:OperatingLeasesOfLesseeDisclosureTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Three months<br/>

    ended<br/>
    March 31,<br/>
 2022</td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="width: 88%; text-indent: -8.5pt; padding-left: 11.35pt">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Weighted average remaining lease term (in years)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonNumeric contextRef="c2" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1">4.12</ix:nonNumeric></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Weighted average discount rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" unitRef="pure">2.56</ix:nonFraction></td><td style="text-align: left">%</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3cm 0pt 0; text-align: justify; text-indent: 0cm">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_LesseeOperatingLeasesTextBlock-c0_cont_7" id="_LesseeOperatingLeasesTextBlock-c0_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Maturities of lease liabilities were
as follows<span style="font-family: Times New Roman, Times, Serif">:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3cm 0pt 0; text-align: center; text-indent: 0cm">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation id="_LesseeOperatingLeasesTextBlock-c0_cont_7"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0pt; white-space: nowrap; text-align: left; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Three months<br/>

    ended <br/> March 31,<br/>
 2022</td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0pt; text-align: left">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left; padding-left: 0pt">2022</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="3" unitRef="usd">2,042</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0pt">2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="3" unitRef="usd">1,742</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0pt">2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears" scale="3" unitRef="usd">1,748</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0pt">2025</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFiveYears" scale="3" unitRef="usd">1,316</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0pt">2026</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="gmda:LesseeOperatingLeaseLiabilityPaymentsDueYearSix" scale="3" unitRef="usd">790</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt">Thereafter</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" scale="3" unitRef="usd">613</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0pt; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0pt">Total undiscounted lease payments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="3" unitRef="usd">8,251</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt">Less: Imputed interest</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="3" unitRef="usd">513</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; padding-left: 0pt">Present value of lease liabilities</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PresentValueOfFutureMinimumLeasePaymentsSaleLeasebackTransactions" scale="3" unitRef="usd">7,738</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 74.7pt; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_DisclosureOfNotesAndOtherExplanatoryInformationsExplanatoryTextBlock-c0_cont_1" escape="true" name="gmda:DisclosureOfNotesAndOtherExplanatoryInformationsExplanatoryTextBlock"><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2cm; text-align: justify; text-indent: -2cm">NOTE 4: CONVERTIBLE
SENIOR NOTES, NET</p><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2cm; text-align: justify; text-indent: -2cm">&#160;</p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfNotesAndOtherExplanatoryInformationsExplanatoryTextBlock-c0_cont_2" id="_DisclosureOfNotesAndOtherExplanatoryInformationsExplanatoryTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">On February 16,
2021, the Subsidiary issued convertible senior notes (the &#8220;Convertible Notes&#8221;) due in 2026, in the aggregate principal amount
of $<ix:nonFraction contextRef="c28" decimals="-6" format="ixt:num-dot-decimal" name="gmda:PrincipalAmount" scale="6" unitRef="usd">75</ix:nonFraction> million, pursuant to an Indenture between the Company, the Subsidiary, and Wilmington Savings Fund Society, FSB, dated February
16, 2021 (the &#8220;Indenture&#8221;). The Convertible Notes bear interest payable semiannually in arrears, at a rate of <ix:nonFraction contextRef="c29" decimals="5" format="ixt:num-dot-decimal" name="gmda:AnnualInterestPercentage" scale="-2" unitRef="pure">5.875</ix:nonFraction>% per
year. The Convertible Notes will mature on <ix:nonNumeric contextRef="c2" format="ixt:date-monthname-day-year-en" name="us-gaap:DebtInstrumentConvertibleConversionDate">February 15, 2026</ix:nonNumeric>, unless earlier converted, redeemed or repurchased in accordance with their
terms.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2cm 0pt 1.25in; text-align: justify; text-indent: 0.25in">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfNotesAndOtherExplanatoryInformationsExplanatoryTextBlock-c0_cont_3" id="_DisclosureOfNotesAndOtherExplanatoryInformationsExplanatoryTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">Subject to the provisions
of the Indenture, the holders of the Convertible Notes have the right, prior to the close of business on the second scheduled trading
day immediately preceding February 15, 2026, to convert any Convertible Notes or portion thereof that is $<ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ConvertibleNotesPayable" scale="3" unitRef="usd">1,000</ix:nonFraction> or an integral multiple
thereof, into the Company&#8217;s ordinary shares at an initial conversion rate of <ix:nonFraction contextRef="c2" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquitySharesIssued" scale="0" unitRef="shares">56.3063</ix:nonFraction> shares per $<ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ConvertibleNotesPayableCurrent" scale="3" unitRef="usd">1,000</ix:nonFraction> principal amount of Convertible
Notes (equivalent to an exchange price of $<ix:nonFraction contextRef="c2" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharePrice" scale="0" unitRef="usdPershares">17.76</ix:nonFraction> per share). The conversion rate is subject to adjustment in specified events.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 4cm 0pt 1.25in; text-align: justify; text-indent: 0.25in">&#160;</p></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 4cm 0pt 1.25in; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 11; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 4cm; margin-bottom: 0pt; text-align: left">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 4cm; margin-bottom: 0pt; text-align: left"><b>NOTE
4: CONVERTIBLE SENIOR NOTES, NET  (Cont.)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 4cm; margin-bottom: 0pt; text-align: left">&#160;</p><div>

</div><ix:continuation continuedAt="_DisclosureOfNotesAndOtherExplanatoryInformationsExplanatoryTextBlock-c0_cont_4" id="_DisclosureOfNotesAndOtherExplanatoryInformationsExplanatoryTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">Upon the occurrence
of a fundamental change (as defined in the Indenture), holders of the Convertible Notes may require the Company to repurchase for cash
all or a portion of their Convertible Notes, in multiples of $<ix:nonFraction contextRef="c30" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ConvertibleNotesPayableCurrent" scale="3" unitRef="usd">1,000</ix:nonFraction> principal amount, at a repurchase price equal to <ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentRedemptionPricePercentage" scale="-2" unitRef="pure">100</ix:nonFraction>% of the principal
amount of the Convertible Notes, plus any accrued and unpaid interest, if any, to, but excluding, interest accrued after the date of
such repurchase notice. If certain fundamental changes referred to as make-whole fundamental changes occur, the conversion rate for the
Convertible Notes may be increased.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 4cm 0pt 1.25in; text-align: justify; text-indent: 0.25in">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfNotesAndOtherExplanatoryInformationsExplanatoryTextBlock-c0_cont_5" id="_DisclosureOfNotesAndOtherExplanatoryInformationsExplanatoryTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">Subject to the provisions
of the Indenture, the Subsidiary may redeem for cash all or a portion of the Convertible Notes for cash, at its option, at a redemption
price equal to <ix:nonFraction contextRef="c31" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentRedemptionPricePercentage" scale="-2" unitRef="pure">100</ix:nonFraction>% of the principal amount of the Convertible Notes to be redeemed, plus accrued and unpaid interest on the notes to
be redeemed, if the last reported closing price of the Company&#8217;s ordinary shares has been at least <ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="gmda:ExchangePricePercentage" scale="-2" unitRef="pure">130</ix:nonFraction>% of the exchange price then
in effect for at least 20 trading days during any 30 consecutive trading day period, and in the event of certain tax law changes.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0cm">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfNotesAndOtherExplanatoryInformationsExplanatoryTextBlock-c0_cont_6" id="_DisclosureOfNotesAndOtherExplanatoryInformationsExplanatoryTextBlock-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">The Convertible
Notes are accounted for as a single liability measured at its amortized cost, as no other embedded features require bifurcation and recognition
as derivatives according to ASC 815-40.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2cm; text-align: justify; text-indent: 0cm">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfNotesAndOtherExplanatoryInformationsExplanatoryTextBlock-c0_cont_7" id="_DisclosureOfNotesAndOtherExplanatoryInformationsExplanatoryTextBlock-c0_cont_6"><ix:nonNumeric contextRef="c0" escape="true" name="gmda:ScheduleOfLiabilityAndEquityComponentConvertibleNotesTableTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Three months<br/>
 ended<br/>
    March 31,<br/>
 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: right">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Liability component:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">Principal amount</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="gmda:AmountOfPrincipal" scale="3" unitRef="usd">75,000</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; text-align: left">Issuance costs</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="gmda:UnamortizedIssuanceCosts" scale="3" sign="-" unitRef="usd">4,223</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="gmda:NetIssuanceCosts" scale="3" unitRef="usd">70,777</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Amortized issuance costs</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AmortizationOfFinancingCosts" scale="3" unitRef="usd">830</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Net carrying amount</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="gmda:NetCarryingAmountincludingAccruedInterest" scale="3" unitRef="usd">71,607</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2cm; text-align: justify; text-indent: -2cm">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation id="_DisclosureOfNotesAndOtherExplanatoryInformationsExplanatoryTextBlock-c0_cont_7"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The total issuance costs of the Convertible
Notes amounted to $<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" scale="3" unitRef="usd">4,223</ix:nonFraction> and are amortized to interest expense at an annual effective interest rate of <ix:nonNumeric contextRef="c0" name="us-gaap:DebtInstrumentInterestRateBasisForEffectiveRate">7.37%</ix:nonNumeric>, over the term of the Convertible
Notes.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2cm; text-align: justify; text-indent: 0cm">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_FairValueDisclosuresTextBlock-c0_cont_1" escape="true" name="us-gaap:FairValueDisclosuresTextBlock"><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2cm; text-align: justify; text-indent: -2cm">NOTE 5:	FAIR
VALUE MEASUREMENTS</p><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2cm; text-align: justify; text-indent: -2cm">&#160;</p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_FairValueDisclosuresTextBlock-c0_cont_2" id="_FairValueDisclosuresTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The following tables present the fair
value of money market funds and marketable securities as of March 31, 2022 and December 31, 2021:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation id="_FairValueDisclosuresTextBlock-c0_cont_2"><ix:nonNumeric contextRef="c0" escape="true" name="gmda:ScheduleOfFairValueOfMoneyMarketFundsAndMarketableSecuritiesTableTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0pt; text-indent: 0pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">March 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0pt; text-indent: 0pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Level 1</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Level 2</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Level 1</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Level 2</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; text-indent: 0pt; padding-left: 0pt">Cash equivalents:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 28%; text-align: left; text-indent: 0pt; padding-left: 0pt">Money market funds</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c32" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:MoneyMarketFundsAtCarryingValue" scale="3" unitRef="usd">36,581</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-15">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:MoneyMarketFundsAtCarryingValue" scale="3" unitRef="usd">36,581</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c34" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:MoneyMarketFundsAtCarryingValue" scale="3" unitRef="usd">51,021</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-16">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:MoneyMarketFundsAtCarryingValue" scale="3" unitRef="usd">51,021</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: 0pt; padding-left: 0pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; text-indent: 0pt; padding-left: 0pt">Marketable securities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: 0pt; padding-left: 0pt">Corporate debentures</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-17">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c33" decimals="-3" format="ixt:num-dot-decimal" name="gmda:CorporateDebentures" scale="3" unitRef="usd">13,389</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="gmda:CorporateDebentures" scale="3" unitRef="usd">13,389</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-18">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c35" decimals="-3" format="ixt:num-dot-decimal" name="gmda:CorporateDebentures" scale="3" unitRef="usd">19,605</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="gmda:CorporateDebentures" scale="3" unitRef="usd">19,605</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: 0pt; padding-left: 0pt">Government debentures</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-19">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c33" decimals="-3" format="ixt:num-dot-decimal" name="gmda:GovernmentDebentures" scale="3" unitRef="usd">14,272</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="gmda:GovernmentDebentures" scale="3" unitRef="usd">14,272</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-20">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c35" decimals="-3" format="ixt:num-dot-decimal" name="gmda:GovernmentDebentures" scale="3" unitRef="usd">20,429</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="gmda:GovernmentDebentures" scale="3" unitRef="usd">20,429</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: 0pt; padding-left: 0pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: 0pt; padding-left: 0pt">Total assets measured at fair value</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c32" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FairValueNetAssetLiability" scale="3" unitRef="usd">36,581</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c33" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FairValueNetAssetLiability" scale="3" unitRef="usd">27,661</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FairValueNetAssetLiability" scale="3" unitRef="usd">64,242</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c34" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FairValueNetAssetLiability" scale="3" unitRef="usd">51,021</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c35" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FairValueNetAssetLiability" scale="3" unitRef="usd">40,034</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FairValueNetAssetLiability" scale="3" unitRef="usd">91,055</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 12; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock"><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2cm; text-align: justify; text-indent: -2cm">NOTE 6:	CONTINGENT
LIABILITIES AND COMMITMENTS</p><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2cm; text-align: justify; text-indent: -2cm">&#160;</p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_2" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top">
<td style="width: 0.75in"></td><td style="width: 0.5in">a.</td><td style="text-align: justify">Legal proceedings:</td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2cm; text-align: justify; text-indent: 0cm">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_3" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0cm">From time to time
the Company or its subsidiaries may be involved in legal proceedings and/or litigation arising in the ordinary course of business. While
the outcome of these matters cannot be predicted with certainty, the Company does not believe it will have a material effect on its consolidated
financial position, results of operations, or cash flows.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2cm; text-align: justify; text-indent: 0cm">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_4" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_3"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top">
<td style="width: 0.75in"></td><td style="width: 0.5in">b.</td><td style="text-align: justify">Bank guarantees:</td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2cm; text-align: justify; text-indent: 0cm">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_5" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0cm">As of March 31,
2022, the Company obtained bank guarantees in the amount of $<ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RoyaltyGuaranteesCommitmentsAmount" scale="3" unitRef="usd">3,266</ix:nonFraction>, primarily in connection with an Investment Center grant of up to
$<ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:BorrowingsUnderGuaranteedInvestmentAgreements" scale="3" unitRef="usd">3,106</ix:nonFraction> expected to be received in 2022 which requires a bank guarantee in order to ensure the fulfillment of the grant terms.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 74.7pt; text-align: justify"><b>&#160;</b></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_6" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_5"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top">
<td style="width: 0.75in"></td><td style="width: 0.5in">c.</td><td>Government grants:</td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2cm; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0cm">The Company has received grants from the IIA to finance its research
and development programs in Israel, through which the Company received IIA participation payments in the aggregate amount of $<ix:nonFraction contextRef="c2" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:GrantsReceivableCurrent" scale="6" unitRef="usd">37.3</ix:nonFraction> million
through March 31, 2022, of which $<ix:nonFraction contextRef="c0" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:RoyaltyExpense" scale="6" unitRef="usd">34.7</ix:nonFraction> million is royalty-bearing grants and $<ix:nonFraction contextRef="c0" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:AmortizationOfAdvanceRoyalty" scale="6" unitRef="usd">2.6</ix:nonFraction> million is non-royalty-bearing grants. In return, the
Company is committed to pay IIA royalties at a rate of&#160;<ix:nonFraction contextRef="c36" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:DerivativeForwardInterestRate" scale="-2" unitRef="pure">3</ix:nonFraction>-3<ix:nonFraction contextRef="c37" decimals="3" name="us-gaap:DerivativeForwardInterestRate" scale="-2" unitRef="pure">.5</ix:nonFraction>%&#160;of future sales of the developed products, up to <ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockPercentageOfOwnershipAfterTransaction" scale="-2" unitRef="pure">100</ix:nonFraction>%of the amount
of grants received plus interest at LIBOR rate. Through March&#160;31, 2022, no royalties have been paid or accrued. The Company&#8217;s
contingent royalty liability to the IIA at March&#160;31, 2022, including grants received by the Company and the associated LIBOR interest
on all such grants totaled to $<ix:nonFraction contextRef="c2" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:GrantsReceivable" scale="6" unitRef="usd">44.9</ix:nonFraction> million.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 74.7pt; text-align: justify"><b>&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock"><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2cm; text-align: justify; text-indent: -2cm">NOTE 7:	SHAREHOLDERS'
EQUITY</p><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2cm; text-align: justify; text-indent: -2cm">&#160;</p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_2" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top">
<td style="width: 0.75in"></td><td style="width: 0.5in"><span style="font-weight: normal">a.</span></td><td style="text-align: justify"><span style="font-weight: normal">Ordinary
                                            shares:</span></td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2cm; text-align: justify; text-indent: -2cm"><span style="font-weight: normal">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:nonNumeric contextRef="c0" name="gmda:UnderwritersDescription"><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_3" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0cm">Subject to the Company&#8217;s
amended and restated Articles of Association, the holders of the Company&#8217;s ordinary shares have the right to receive notices to
attend and vote in general meetings of the Company&#8217;s shareholders, and the right to share in dividends and other distributions
upon liquidation<span style="font-family: Times New Roman, Times, Serif">.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2cm; text-align: justify; text-indent: 0cm">&#160;</p></ix:continuation></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_4" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_3"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top">
<td style="width: 0.75in"></td><td style="width: 0.5in">b.</td><td style="text-align: justify">Warrants to investors:</td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2cm; text-align: justify; text-indent: 0cm">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0cm"><ix:nonNumeric contextRef="c0" name="gmda:ExpiryDate">As part of its 2017
investment round, the Company granted certain investors <ix:nonFraction contextRef="c38" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" scale="0" unitRef="shares">4,323,978</ix:nonFraction> warrants that will expire in July 2022.</ix:nonNumeric> As of March 31, 2022, <ix:nonFraction contextRef="c39" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" scale="0" unitRef="shares">1,010,466</ix:nonFraction>
of such warrants have been exercised into the Company&#8217;s ordinary shares.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2cm; text-align: justify; text-indent: 0cm">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_1" escape="true" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 8:	SHARE-BASED COMPENSATION</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3cm; text-align: justify; text-indent: -1cm">&#160;</p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_2" id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top">
<td style="width: 0.75in"></td><td style="width: 0.5in">a.</td><td style="text-align: justify">Option plans:</td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 74.7pt; text-align: justify; text-indent: 0cm">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_3" id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0cm">On November 23,
2014, the Company&#8217;s Board of Directors approved, subject to the approval of the shareholders, creation of the Company&#8217;s ordinary
C share class, with nominal value NIS 0<ix:nonFraction contextRef="c40" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" unitRef="ilsPershares">.01</ix:nonFraction> per share and classification of <ix:nonFraction contextRef="c40" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:EmployeeStockOwnershipPlanESOPNumberOfAllocatedShares" scale="0" unitRef="shares">1,500,000</ix:nonFraction> ordinary shares for such class of shares, whereby
<ix:nonFraction contextRef="c41" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:EmployeeStockOwnershipPlanESOPNumberOfSuspenseShares" scale="0" unitRef="shares">1,152,044</ix:nonFraction> of such shares were allocated to the Company&#8217;s employees under the amended 2014 Israel Share Option Plan (the &#8220;2014
Plan&#8221;). The exercise price of the options granted under the 2014 Plan may not be less than the nominal value of the shares into
which the options are exercised. The options vest primarily over <ix:nonNumeric contextRef="c42" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">three years</ix:nonNumeric>. There are no cash settlement alternatives. On December
29, 2014, the Company&#8217;s shareholders ratified and approved the aforesaid actions.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3cm; text-align: justify; text-indent: 0cm">&#160;</p></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3cm; text-align: justify; text-indent: 0cm"></p><div>

</div><!-- Field: Page; Sequence: 13; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3cm; text-align: justify; text-indent: 0cm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
8:	SHARE-BASED COMPENSATION (Cont.)</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3cm; text-align: justify; text-indent: 0cm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><ix:continuation continuedAt="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_4" id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0cm">On January 23, 2017,
the Company&#8217;s Board of Directors approved the Company&#8217;s 2017 Share Incentive Plan (the &#8220;2017 Plan&#8221; and together
with the 2014 Plan, the &#8220;Option Plans&#8221;), and the subsequent grant of options to the Company&#8217;s employees, officers and
directors. Pursuant to the 2017 Plan, the Company initially reserved for issuance <ix:nonFraction contextRef="c43" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" unitRef="shares">312,867</ix:nonFraction> ordinary shares, nominal value NIS 0<ix:nonFraction contextRef="c43" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" unitRef="ilsPershares">.01</ix:nonFraction> each.
On February 28, 2017, the Company&#8217;s shareholders approved the 2017 Plan.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0cm">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_5" id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0cm">The 2017 Plan provides
for the grant of awards, including options, restricted shares and restricted share units to the Company&#8217;s directors, employees,
officers, consultants and advisors.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0cm">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_6" id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0cm">On June 26, 2017
and on December 28, 2017, the Company&#8217;s Board of Directors approved the reservation of <ix:nonFraction contextRef="c44" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" unitRef="shares">463,384</ix:nonFraction> and <ix:nonFraction contextRef="c45" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" unitRef="shares">559,764</ix:nonFraction> additional ordinary
shares, respectively, for issuance under the 2017 Plan (totaling, including previous plans, an aggregate of <ix:nonFraction contextRef="c46" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" unitRef="shares">1,338,015</ix:nonFraction> ordinary Shares).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0cm">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_7" id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">On February 25, 2021 and November
17, 2021, the board of directors and shareholders, respectively, approved an amendment and restatement of the 2017 Plan. The 2017 Plan,
as amended, also contains an &#8220;evergreen&#8221; provision, which provides for an automatic allotment of ordinary shares to be added
every year to the pool of ordinary shares available for grant under the 2017 Plan. Under the evergreen provision, on January 1 of each
year (beginning January 1, 2022), the number of ordinary shares available under the 2017 Plan automatically increases by the lesser of
the following: (i) <ix:nonFraction contextRef="c2" decimals="2" format="ixt:num-dot-decimal" name="gmda:OrdinarySharesOutstandingPercentage" scale="-2" unitRef="pure">4</ix:nonFraction>% of our outstanding ordinary shares on the last day of the immediately preceding year; and (ii) an amount determined
in advance of January 1 by the board of directors.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3cm; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_8" id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_7"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0cm">The Company estimates
the fair value of stock options granted using the binominal option-pricing model. The option-pricing model requires a number of assumptions,
of which the most significant are the expected stock price volatility and the expected option term.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0cm">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_9" id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_8"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0cm">Expected volatility
was calculated based upon the Company&#8217;s historical share price and historical volatilities of similar entities in the related sector
index. The expected term of the options granted is derived from output of the option valuation model and represents the period of time
that options granted are expected to be outstanding. The risk-free interest rate is based on the yield from U.S. treasury bonds with
an equivalent term. The Company has historically not paid dividends and has no foreseeable plans to pay dividends.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_10" id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_9"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0cm">The following table
lists the inputs to the binomial option-pricing model used for the fair value measurement of equity-settled share options for the above
Options Plans as of March 31, 2022:&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4cm; text-align: justify; text-indent: -1cm">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_11" id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_10"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Three months<br/>

    ended <br/>
    March 31,<br/>
 2022</td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left; text-indent: -11.35pt; padding-left: 14.15pt">Dividend yield</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" unitRef="pure">0</ix:nonFraction></td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -11.35pt; padding-left: 14.15pt">Expected volatility of the share prices</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" unitRef="pure">66</ix:nonFraction></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -11.35pt; padding-left: 14.15pt">Risk-free interest rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" unitRef="pure">1.8</ix:nonFraction></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -11.35pt; padding-left: 14.15pt">Expected term (in years)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonNumeric contextRef="c0" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">8</ix:nonNumeric></td><td style="text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3cm">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_12" id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_11"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0cm">Based on the above
inputs, the fair value of the options was determined to be $<ix:nonFraction contextRef="c47" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" scale="0" unitRef="usdPershares">1.71</ix:nonFraction> - $<ix:nonFraction contextRef="c48" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" scale="0" unitRef="usdPershares">1.85</ix:nonFraction> per option at the grant date.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 74.7pt; text-align: justify; text-indent: 0cm">&#160;</p></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 74.7pt; text-align: justify; text-indent: 0cm"></p><div>

</div><!-- Field: Page; Sequence: 14; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 74.7pt; text-align: justify; text-indent: 0cm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
8:	SHARE-BASED COMPENSATION (Cont.)</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 74.7pt; text-align: justify; text-indent: 0cm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><div>

</div><ix:continuation continuedAt="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_13" id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_12"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top">
<td style="width: 0.75in"></td><td style="width: 0.5in">b.</td><td style="text-align: justify">The following table summarizes the number
                                            of options granted to employees under the Option Plans as of March 31, 2022 and related information:</td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3cm; text-align: justify; text-indent: -1cm">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_14" id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_13"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0pt; text-indent: 0pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Amount</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>of</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>options</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Weighted</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>average</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>exercise</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>price</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0pt; text-indent: 0pt">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-indent: 0pt; padding-left: 0pt">Balance as of December 31, 2021</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" unitRef="shares">4,411,424</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" unitRef="usdPershares">6.01</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: 0pt; padding-left: 0pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: 0pt; padding-left: 0pt">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="gmda:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrosses" scale="0" unitRef="shares">1,181,100</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" unitRef="usdPershares">2.93</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: 0pt; padding-left: 0pt">Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="gmda:StockIssuedDuringPeriodSharesStockOptionesExercised" scale="0" unitRef="shares">47,426</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" unitRef="usdPershares">1.60</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: 0pt; padding-left: 0pt">Forfeited</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="gmda:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriods" scale="0" unitRef="shares">301,215</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" unitRef="usdPershares">6.74</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; text-indent: 0pt; padding-left: 0pt">Expired</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" scale="0" unitRef="shares">18,349</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right"><ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" scale="0" unitRef="usdPershares">6.70</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: 0pt; padding-left: 0pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt; text-indent: 0pt; padding-left: 0pt">Balance as of March 31, 2022</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" unitRef="shares">5,225,534</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right"><ix:nonFraction contextRef="c2" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" unitRef="usdPershares">5.31</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: 0pt; padding-left: 0pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt; text-indent: 0pt; padding-left: 0pt">Exercisable as of March 31, 2022</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="gmda:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableInPeriod" scale="0" unitRef="shares">2,417,453</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right"><ix:nonFraction contextRef="c2" decimals="2" format="ixt:num-dot-decimal" name="gmda:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisableInPeriodWeightedAverageExercisePrice" scale="0" unitRef="usdPershares">5.90</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3cm">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_15" id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_14"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0cm">As of March 31,
2022, there are $<ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" scale="3" unitRef="usd">11,848</ix:nonFraction> of total unrecognized costs related to share-based compensation that are expected to be recognized over a period
of up to <ix:nonNumeric contextRef="c0" format="ixt-sec:durwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">four years</ix:nonNumeric>.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3cm; text-align: justify; text-indent: 0cm">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_16" id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_15"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top">
<td style="width: 0.75in"></td><td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">c.</span></td><td style="text-align: justify">A summary of restricted shares and restricted share units activity
as of March&#160;31, 2022 is as follows:</td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 74.7pt 0pt 0; text-align: justify; text-indent: 0cm">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_17" id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_16"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0pt; text-indent: 0pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Amount of</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>restricted
                                            shares and restricted shares units</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Weighted</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>average</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>grant
                                            date<br/>
 fair value</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0pt; text-indent: 0pt">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-indent: 0pt; padding-left: 0pt">Unvested as of December 31, 2021</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" unitRef="shares">531,477</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue" scale="0" unitRef="usdPershares">5.48</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: 0pt; padding-left: 0pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: 0pt; padding-left: 0pt">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" unitRef="shares">937,300</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue" scale="0" unitRef="usdPershares">2.93</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: 0pt; padding-left: 0pt">Vested</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="0" unitRef="shares">42,911</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodIntrinsicValue" scale="0" unitRef="usdPershares">9.46</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-indent: 0pt; padding-left: 0pt">Forfeited</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="0" unitRef="shares">75,117</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right"><ix:nonFraction contextRef="c0" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue" scale="0" unitRef="usdPershares">6.26</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: 0pt; padding-left: 0pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt; text-indent: 0pt; padding-left: 0pt">Unvested as of March 31, 2022</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" unitRef="shares">1,350,749</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right"><ix:nonFraction contextRef="c2" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue" scale="0" unitRef="usdPershares">3.54</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 15; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE
8:	SHARE-BASED COMPENSATION (Cont.)</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p><div>

</div><ix:continuation continuedAt="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_18" id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_17"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top">
<td style="width: 0.75in"></td><td style="width: 0.5in"><span style="font-size: 10pt">d.</span></td><td style="text-align: justify">The
                                            total share-based compensation expense related to all of the Company's equity-based awards,
                                            recognized for the three months ended March 31, 2022 and 2021 is comprised as follows:</td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_18"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0pt; text-indent: 0pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Three months ended<br/>
    March 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0pt; text-indent: 0pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0pt; text-indent: 0pt">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: 0pt; padding-left: 0pt">Research and development expenses, net</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" unitRef="usd">465</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" unitRef="usd">311</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: 0pt; padding-left: 0pt">Commercial expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CostsAndExpensesRelatedParty" scale="3" unitRef="usd">290</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CostsAndExpensesRelatedParty" scale="3" unitRef="usd">171</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: 0pt; padding-left: 0pt">General and administrative expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" unitRef="usd">439</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" unitRef="usd">431</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: 0pt; padding-left: 0pt">Total share-based compensation</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" unitRef="usd">1,194</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" unitRef="usd">913</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_EarningsPerShareTextBlock-c0_cont_1" escape="true" name="us-gaap:EarningsPerShareTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 9:	BASIC AND DILUTED NET LOSS PER SHARE</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3cm; text-align: justify; text-indent: -1cm">&#160;</p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_EarningsPerShareTextBlock-c0_cont_2" id="_EarningsPerShareTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0cm"><span style="font-weight: normal">Basic
net loss per ordinary share is computed by dividing net loss for each reporting period by the weighted-average number of ordinary shares
outstanding during each year. Diluted net loss per ordinary share is computed by dividing net loss for each reporting period by the weighted
average number of ordinary shares outstanding during the period, plus dilutive potential ordinary shares considered outstanding during
the period, in accordance with ASC No. 260-10 &#8220;Earnings Per Share&#8221;. The Company experienced a loss as of March 31, 2022;
hence all potentially dilutive ordinary shares were excluded due to their anti-dilutive effect.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3cm; text-align: justify; text-indent: -1cm">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_EarningsPerShareTextBlock-c0_cont_3" id="_EarningsPerShareTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">Details of the number
of shares and loss used in the computation of loss per share:</p><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3cm; text-align: justify; text-indent: -2cm">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation id="_EarningsPerShareTextBlock-c0_cont_3"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Three months ended March 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="text-align: center; font-weight: bold; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted number of shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Net loss attributable to equity holders of
                                                                                 the Company</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted number of shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Net loss attributable to equity holders of
                                                                                 the Company</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="width: 52%; text-indent: -8.5pt; padding-left: 11.35pt">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -8.5pt; padding-left: 11.35pt">For the computation of basic and diluted
    loss</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c49" decimals="INF" format="ixt:num-dot-decimal" name="gmda:WeightedAverageNumberOfSharesOutstandingBasicAndDiluted" scale="0" unitRef="shares">59,474,366</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c49" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" scale="3" unitRef="usd">20,223</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c50" decimals="INF" format="ixt:num-dot-decimal" name="gmda:WeightedAverageNumberOfSharesOutstandingBasicAndDiluted" scale="0" unitRef="shares">59,122,973</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c50" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" scale="3" unitRef="usd">19,186</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3cm; text-align: justify; text-indent: -1cm">&#160;</p><div>


</div><!-- Field: Page; Sequence: 16; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="a_008"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Item 2. Management&#8217;s Discussion and
Analysis of Financial Condition and Results of Operations.</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>The following discussion and analysis of our
financial condition and results of operations should be read in conjunction with our unaudited condensed consolidated financial statements
and related notes included in this Quarterly Report and the audited financial statements and notes thereto as of and for the year ended
December 31, 2021 and the related Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations, both of
which are contained in our Annual Report on Form 10-K for the year ended December 31, 2021, or Annual Report, which was filed with the
Securities and Exchange Commission, or the SEC, on March 24, 2022. The information in this discussion contains forward-looking statements
and information within the meaning of Section 27A of the Securities Act of 1933, as amended, or the Securities Act, and Section 21E of
the Securities Exchange Act of 1934, as amended, or the Exchange Act, which are subject to the &#8220;safe harbor&#8221; created by those
sections. These forward-looking statements include, but are not limited to, statements concerning our strategy, future operations, future
financial position, future revenues, projected costs, prospects and plans and objectives of management. The words &#8220;anticipates,&#8221;
&#8220;believes,&#8221; &#8220;estimates,&#8221; &#8220;expects,&#8221; &#8220;intends,&#8221; &#8220;may,&#8221; &#8220;plans,&#8221;
&#8220;projects,&#8221; &#8220;will,&#8221; &#8220;would&#8221; and similar expressions are intended to identify forward-looking statements,
although not all forward-looking statements contain these identifying words. We may not actually achieve the plans, intentions or expectations
disclosed in our forward-looking statements and you should not place undue reliance on our forward-looking statements. These statements
speak only as of their date. Actual results or events could differ materially from the plans, intentions and expectations disclosed in
the forward-looking statements that we make. These forward-looking statements involve risks and uncertainties that could cause our actual
results to differ materially from those in the forward-looking statements, including, without limitation, the risks set forth in Part
II, Item 1A, &#8220;Risk Factors&#8221; in this Quarterly Report. The forward-looking statements are applicable only as of the date on
which they are made, and we do not assume any obligation to update any forward-looking statements.</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>&#160;</i></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Company Overview</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">We are an advanced cell therapy
company committed to cures for blood cancers and serious hematologic diseases. We harness our cell expansion platform to create therapies
with the potential to redefine standards of care in areas of serious medical need. While cell therapies have the potential to address
a variety of diseases, they are limited by availability of donor cells, matching a donor to the patient, and the decline in donor cell
functionality when expanding the cells to achieve a therapeutic dose. We have leveraged our NAM platform, or nicotinamide cell expansion
technology platform to develop a pipeline of product candidates designed to address the limitations of other cell therapies. Our proprietary
technology allows for the proliferation and enhancement of donor cells, which allows for maintaining the cells&#8217; functional therapeutic
characteristics, providing a treatment alternative for patients.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">HSCT is subject to a number
of significant limitations, including: (i) delays in finding a suitable match, during which disease progression may make patients ineligible
for transplant&#894; (ii) an insufficient number or delayed engraftment of donor cells, leaving patients without a functioning immune
system and leading to potentially life-threatening immune deficiency following transplant&#894; (iii) a lack of long-term compatibility
between the donor cells and the patient&#8217;s own cells, resulting in potentially fatal graft versus host disease, or GvHD; and (iv)
older donor age may correspond to a negative impact on the patient&#8217;s outcome. In addition, there is ethnic and racial disparity
in access to HSCT: data from 2018 indicate that white patients of European descent are approximately four times more likely to receive
a transplant than Black patients.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">Umbilical cord blood is a
readily available source of stem cells for patients who need HSCT and do not have a matched related donor. It is easier to find a match
when using stem cells derived from cord blood, since a full match is not required for a successful transplant using cord blood. However,
on average, a typical cord blood graft contains approximately one-tenth the number of stem and progenitor cells compared to stem cell
grafts from adult bone marrow or peripheral blood donors. This lower number of cells may delay engraftment of the donor cells and reconstitution
of the immune system. This, in turn, increases both time in the hospital and the likelihood that a patient might contract a life-threatening
infection.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">Omidubicel, our lead product
candidate, is designed to address the limitations of hematopoietic stem cell transplantation. Omidubicel consists of NAM-expanded and
enhanced hematopoietic stem cells and differentiated immune cells, including T cells. The final cell therapy product is cryopreserved
until the patient is ready to begin the transplant, when it is thawed and infused. Omidubicel has the potential to be a stem cell graft
in two broad patient groups: (i) patients with high-risk leukemias and lymphomas who require HSCT but who lack access to an appropriate
matched related donor&#894; and (ii) patients with severe hematologic disorders such as severe aplastic anemia.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt"></p><div>

</div><!-- Field: Page; Sequence: 17; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">In October 2021, the complete
results from our pivotal Phase 3 clinical study of omidubicel in 125 patients with various hematologic malignancies were published in
the peer-reviewed medical journal <i>Blood</i>. The trial achieved its primary endpoint of time to neutrophil engraftment as well as
all three of the prespecified secondary endpoints. These secondary endpoints were the proportion of patients who achieved platelet engraftment
by day 42, the proportion of patients with grade 2 or grade 3 bacterial or invasive fungal infections in the first 100 days following
transplant, and the number of days alive and out of the hospital in the first 100 days following transplant. All three secondary endpoints
demonstrated statistical significance in an intent-to-treat analysis.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">In December 2021, we also
reported data from an analysis of a subset of 37 patients from the Phase 3 randomized trial of omidubicel at Annual Meeting of the American
Society of Hematology, or ASH. The analysis was aimed at investigating the reduced infection rates observed in the study and showed that
the omidubicel-treated patients had more rapid recovery of a wide variety of immune cells including CD4+ T cells, B cells, NK cells and
dendritic cell subtypes. The robust recovery of the immune system provides rationale for fewer severe bacterial, fungal and viral infections
in patients treated with omidubicel. Additional analyses are ongoing to further characterize the immune recovery following omidubicel
transplantation. In early 2022, the FDA agreed that the initiation of our rolling BLA submission for omidubicel was appropriate and we
initiated the rolling submission process. We plan to submit the full BLA for omidubicel to the FDA by the end of the second quarter of
2022.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">In addition, we have applied
our NAM cell expansion technology to natural killer, or NK, cells, to develop our initial NK product candidate, GDA-201, an investigational,
NK cell-based immunotherapy for the treatment of hematologic and solid tumors in combination with standard of care antibody therapies.
GDA-201 is currently being evaluated in a Phase 1/2 investigator-sponsored trial for the treatment of relapsed or refractory non-Hodgkin
lymphoma, or NHL, and multiple myeloma, or MM. Data from the trial demonstrate that GDA-201 was well-tolerated and no dose-limiting toxicities
were observed in 19 patients with NHL and 16 patients with MM. The data show that therapy using GDA-201 with monoclonal antibodies demonstrated
significant clinical activity in heavily pretreated patients with advanced NHL. Of the 19 patients with NHL, 13 complete responses and
one partial response were observed, with an overall response rate of 74% and a complete response rate of 68%. At the December 2021 Annual
Meeting of ASH, we reported two-year follow-up data from this clinical trial and reported on two-year outcomes and cytokine biomarkers
associated with survival. The data demonstrated a median duration of response of 16 months (range 5-36 months), an overall survival at
two years of 78% (95% CI, 51%&#8211;91%) and a safety profile similar to that reported previously.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">In September 2021, we submitted
an investigational new drug application, or IND, for a Phase 1/2 clinical trial of GDA-201 in patients with follicular and diffuse large
B-cell lymphomas. The FDA placed this IND on clinical hold prior to the initiation of patient dosing. The FDA has requested modifications
in donor eligibility procedures and sterility assay qualification. On April 21, 2022, we received correspondence from the FDA indicating
that we satisfactorily addressed all clinical hold issues identified by the FDA and that the FDA has removed the clinical hold and cleared
our IND for GDA-201. We expect to open sites for enrollment in our Phase 1/2 study of GDA-201 in patients with follicular and diffuse
large B-cell lymphomas in the second quarter of 2022.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt"></p><div>

</div><!-- Field: Page; Sequence: 18; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">We have incurred significant
net losses since our formation in 1998. Our net losses were $20.2 million and $19.2 million for the three months ended March 31, 2022
and 2021, respectively. As of March 31, 2022, our accumulated deficit was $357.7 million. We expect to continue to incur losses for the
foreseeable future, and our losses may fluctuate significantly from year to year. We expect that our expenses will increase substantially
in connection with our ongoing activities as we:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18pt"></td><td style="width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">submit
                                            our BLA on a rolling basis to seek regulatory approval for omidubicel&#894;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -18pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18pt"></td><td style="width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify">establish
                                            a sales, marketing and distribution infrastructure, if we do not pursue a strategic partnership
                                            for commercialization, and scale up manufacturing capabilities to commercialize omidubicel
                                            upon obtaining regulatory approval&#894;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -18pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18pt"></td><td style="width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify">initiate
                                            our planned Phase 1/2 clinical trial of GDA-201 in patients with NHL&#894;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -18pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18pt"></td><td style="width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify">continue
                                            the preclinical development of our other product candidates&#894;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -18pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18pt"></td><td style="width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify">maintain,
                                            expand and protect our intellectual property portfolio&#894;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -18pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18pt"></td><td style="width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify">add
                                            equipment and physical infrastructure to support our research and development and commercialization
                                            efforts&#894;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -18pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18pt"></td><td style="width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify">hire
                                            additional clinical development, regulatory, commercial, quality control and manufacturing
                                            personnel&#894; and</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -18pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18pt"></td><td style="width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify">add
                                            operational, financial and management information systems and personnel, including personnel
                                            to support our product development and planned future commercialization.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -18pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">Although we completed two
equity financing transactions in 2020 and a convertible debt financing in 2021, we will need substantial additional funding to support
our operating activities as we advance our product candidates through clinical development, seek regulatory approval and prepare for
and, if any of our product candidates are approved, proceed to commercialization. Adequate funding may not be available to us on acceptable
terms, or at all.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">To continue to fund our operations,
we expect to continue to raise capital. We may obtain additional financing in the future through the issuance of our ordinary shares,
through other equity or debt financings or through collaborations or partnerships with other companies. We may not be able to raise additional
capital on terms acceptable to us, or at all, and any failure to raise capital as and when needed could compromise our ability to execute
on our business plan. Although it is difficult to predict future liquidity requirements, we believe that our current total existing funds
will be sufficient to fund our operations into mid-2023. However, our ability to successfully transition to profitability or cash flow
positivity will be dependent upon achieving a level of revenue adequate to support our cost structure. We cannot assure you that we will
ever be profitable or generate positive cash flow from operating activities.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Components of Results of Operations</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Revenue</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">We do not currently have any
products approved for sale and, to date, we have not recognized any revenue. In the future, we may generate revenue from a combination
of product sales, reimbursements, up-front payments and future collaborations. If we fail to achieve clinical success or obtain regulatory
approval of any of our product candidates in a timely manner, our ability to generate future revenue will be impaired.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Research and development expenses,
net</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">The largest component of our
total operating expenses has historically been, and we expect will continue to be, research and development. Our research and development
expenses, net of IIA grants, consist primarily of:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18pt"></td><td style="width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify">salaries
                                            and related costs, including share-based compensation expense, for our personnel in research
                                            and development functions;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -18pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18pt"></td><td style="width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify">expenses
                                            incurred under agreements with third parties, including CROs, subcontractors, suppliers and
                                            consultants, for the conduct of our preclinical studies and clinical trials;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -18pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18pt"></td><td style="width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify">expenses
                                            incurred to acquire, develop and manufacture preclinical study and clinical trial materials;
                                            and</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -18pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18pt"></td><td style="width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify">facility
                                            and equipment costs, including depreciation expense, maintenance and allocated direct and
                                            indirect overhead costs.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -18pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -18pt"></p><div>

</div><!-- Field: Page; Sequence: 19; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -18pt">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Research and development expenses
(net of grants) are recognized in the consolidated statements of comprehensive loss when incurred.</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">Through March 31, 2022, we
have received an aggregate of approximately $37.3 million in grants from the Israeli Innovation Authority, or the IIA, including from
the Bereshit Consortium sponsored by the IIA, of which $34.7 million is royalty-bearing grants, and $2.6 million is non-royalty-bearing
grants, and all of which was awarded for research and development funding. Pursuant to the terms of the royalty-bearing grants, we are
obligated to pay the IIA royalties at the rate of between 3% to 3.5% on all our revenue, up to a limit of 100% of the amounts of the
U.S. dollar-linked grants received, plus annual interest calculated at a rate based on the 12-month LIBOR. We have not paid any royalties
to the IIA to date. The Bereshit Consortium program does not require payments of royalties to the IIA, but all other restrictions under
the Innovation Law, such as local manufacturing obligations and know-how transfer limitations, as further detailed hereunder, are applicable
to the know how developed by us with the funding received in such consortium program.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">On July 27, 2017, the United
Kingdom&#8217;s Financial Conduct Authority (&#8220;FCA&#8221;), which regulates LIBOR, announced that it intends to phase out LIBOR
by the end of 2021. Following consultations in December 2020 and January 2021, the ICE Benchmark Administration Limited (the &#8220;IBA&#8221;)
announced that (i) it intended to cease publication of 1-week and 2-month U.S. dollar LIBOR at the end of 2021 and (ii) subject to compliance
with applicable regulations, it intends to continue publication of the remaining U.S. dollar LIBOR tenors until June 30, 2023, effectively
extending the LIBOR transition period to June 30, 2023. However, the FCA has indicated it will not compel panel banks to continue to
contribute to LIBOR after the end of 2021 and the Federal Reserve Board, the Office of the Comptroller of the Currency, and the Federal
Deposit Insurance Corporation have encouraged banks to cease entering into new contracts that use U.S. dollar LIBOR as a reference rate
no later than December 31, 2021. There is currently no definitive information regarding the future utilization of LIBOR or of any particular
replacement rate.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">A committee established by
the Federal Reserve, the Alternative Reference Rates Committee, announced the replacement of LIBOR with a new index, based on overnight
repurchase agreements collateralized by U.S. Treasury securities, called the Secured Overnight Financing Rate (&#8220;SOFR&#8221;). The
Federal Reserve Bank of New York began publishing SOFR in April 2018. Other jurisdictions have also proposed their own alternative to
LIBOR, including the Sterling Overnight Index Average for Sterling markets, the Euro Short Term Rate for Euros and Tokyo Overnight Average
Rate for Japanese Yen. Although SOFR appears to be the preferred replacement rate for U.S. dollar LIBOR, at this time, it is not possible
to predict whether SOFR will attain market traction as a LIBOR replacement tool, and the future of LIBOR is still uncertain. The effect
of any such changes, any establishment of alternative reference rates or any other reforms to LIBOR or other reference rates that may
be enacted in the United Kingdom or elsewhere cannot be predicted at this time, and it is not possible to predict whether LIBOR will
continue to be viewed as an acceptable market benchmark, what rate or rates may become accepted alternatives to LIBOR, or what the effect
of any such changes in views or alternatives may have on the financial markets for financial instruments based on LIBOR.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">In addition to paying any
royalties due, we must abide by other restrictions associated with receiving such grants under the Encouragement of Research, Development
and Technological Innovation in the Industry Law 5744-1984, which will also continue to apply to us following the repayment in full of
the amounts due to the IIA. The Innovation Law restricts our ability to manufacture products and transfer technologies outside of Israel,
and may impair our ability to enter into agreements that involve IIA-funded products or know-how without the approval of the IIA. Any
approval, if given, will generally be subject to additional financial obligations by us. Failure to comply with the requirements under
the Innovation Law may subject us to mandatory repayment of grants received by us, together with interest and penalties, as well as expose
us to criminal proceedings.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">Pursuant to the IIA&#8217;s
licensing rules, or the Licensing Rules, a grant recipient may enter into licensing arrangements or grant other rights in know-how developed
under IIA programs outside of Israel, subject to the prior consent of the IIA and payment of license fees, calculated in accordance with
the Licensing Rules. The amount of the license fees is based on various factors, including the consideration received by the licensor
in connection with the license, and shall not exceed six times the amount of the grants received by the grant recipient (plus accrued
interest) for the applicable know-how being licensed. In certain cases, such as when the license consideration includes nonmonetary compensation
or when a &#8220;special relationship&#8221; exists between the licensor and licensee (<i>e.g.</i> when a party controls the other party
or is the other party&#8217;s exclusive distributor), or when the agreed upon consideration does not reflect, in the IIA&#8217;s opinion,
the market value of the license, the IIA may base the value of the transaction on an economic assessment that it obtains for such purpose.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt"></p><div>

</div><!-- Field: Page; Sequence: 20; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">We are currently focused on
advancing our product candidates, and our future research and development expenses will depend on their clinical success. Research and
development expenses will continue to be significant and will increase over at least the next several years as we continue to develop
our product candidates and conduct preclinical studies and clinical trials of our product candidates. Government grants received from
the IIA are recognized as a reduction of the related research and development expenses.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">We do not believe that it
is possible at this time to accurately project total expenses required for us to reach commercialization of omidubicel or any of our
other product candidates. However, with the objective of extending our cash runway into mid-2023, consistent with the anticipated timeline
for potential U.S. approval of omidubicel, we are reducing operating expenses primarily by implementing a workforce reduction of approximately
10% and delaying other hiring and planned spending in 2022. A majority of the anticipated savings is in research and development expenses.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Commercial expenses</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">Commercial expenses consist
primarily of personnel costs, including share-based compensation, related to executive and commercial functions, and external consulting
service fees.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">General and administrative expenses</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">General and administrative
expenses consist primarily of personnel costs, including share-based compensation, related to directors, executive, finance, and administrative
functions, facility costs and external professional service costs, including legal, accounting and audit services and other consulting
fees.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">We anticipate that we will
incur increased expenses related to audit, legal, regulatory and tax-related services associated with additional reporting requirements
as a result of losing our status as a foreign private issuer at the end of the 2021 fiscal year, and maintaining compliance with the
Nasdaq and SEC requirements, director and officer insurance premiums, executive compensation, and other customary costs associated with
being a public company subject to US domestic issuer listing requirements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Financial expenses, net</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">Financial expenses, net, is
our financing expenses from convertible senior notes after deducting financing income from deposits and marketable securities.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Income taxes</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">We have yet to generate taxable
income in Israel, as we have historically incurred operating losses resulting in carry forward tax losses totaling approximately $237.4
million (including capital losses of $0.5 million) as of December 31, 2021. In addition, the US subsidiary has net operating losses carryforward
of $33.1 million for federal tax purposes as of December 31, 2021. We anticipate that we will continue to generate tax losses for the
foreseeable future and that we will be able to carry forward these tax losses indefinitely to future taxable years. Accordingly, we do
not expect to pay taxes in Israel until we have taxable income after the full utilization of our carry forward tax losses. We provided
a full valuation allowance, to reduce deferred tax assets to their estimated realizable value, since it is more likely than not that
all of the deferred tax assets will not be realized.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Analysis of Results of Operations</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Comparison of the three months ended
March 31, 2022 and 2021</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">The following table summarizes
our results of operations for the three months ended March 31, 2022 and 2021:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Three months ended <br/> March 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">(in thousands)</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Operating Expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Research and development expenses, net<span style="font-size: 10pt"><sup>(1)</sup></span></td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">11,305</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">11,360</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>Commercial expenses<span style="font-size: 10pt"><sup>(1)</sup></span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,879</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,231</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">General and administrative expenses<span style="font-size: 10pt"><sup>(1)</sup></span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,139</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,513</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Operating loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">19,323</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">19,104</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Financial expenses, net</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">900</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">82</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt">Loss</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">20,223</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">19,186</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 1pt; margin-bottom: 1pt; width: 25%"><div style="font-size: 1pt; border-top: black 1.5pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0"></td><td style="width: 18pt">(1)</td><td>Includes share-based compensation expense as follows:</td></tr></table><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 21; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Three months ended <br/> March 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">(in thousands)</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Research and development expenses, net</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">465</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">311</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Commercial expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">290</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">171</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">General and administrative expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">439</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">431</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Total share-based compensation</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,194</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">913</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><div>


</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Research and development expenses, net</p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">Research and development expenses,
net, decreased by approximately $0.1 million to $11.3 million in the three months ended March 31, 2022 from $11.4 million in the three
months ended March 31, 2021. The decrease was attributable mainly to a $1.1 million decrease in clinical activities relating to the conclusion
of our Phase 3 clinical trial and decrease in GDA 201 clinical program offset by an increase of $1.0 million in salaries and benefits,
consisting primarily of additional headcount focused on operational activities towards BLA submission.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">&#160;</p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Commercial expenses</p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">Our commercial expenses decreased
by approximately $0.3 million to $3.9 million in the three months ended March 31, 2022 from $4.2 million in the three months ended March
31, 2021. The decrease was attributable mainly to an approximate $1.7 million decrease in launch readiness activities, offset by an increase
of $1.4 million in headcount related expenses, including restructuring.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">&#160;</p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">General and administrative expenses</p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">General and administrative
expenses increased by approximately $0.6 million to $4.1 million in the three months ended March 31, 2022, up from $3.5 million in the
three months ended March 31, 2021. The increase was attributable to a $0.2 million increase in professional services expenses and a new
U.S. office lease agreement and of $0.4 million increase in headcount related expenses, including restructuring.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">&#160;</p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Financial expenses, net</p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">Financial expenses, net, increased
by approximately $0.8 million to $0.9 million in the three months ended March 31, 2022, compared to $0.1 million in the three months
ended March 31, 2021. The increase was primarily due to $0.6 million in financing interest expenses from our convertible senior notes
and $0.3 million decrease in the fair value of bonds, offset by an increase of $0.1 million in interest income from cash management.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Critical Accounting Policies and Estimates</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">This discussion and analysis
of our consolidated financial statements has been prepared in accordance with generally accepted accounting principles in the United
States, or U.S. GAAP, as set forth in the Financial Accounting Standards Board, or FASB, Accounting Standards Codification, or ASC.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">Prior to 2021, we prepared
our financial statements in accordance with International Financial Reporting Standards, or IFRS, as issued by the International Accounting
Standards Board, or IASB, as permitted in the United States, based on our status as a foreign private issuer. At the end of the 2021
fiscal year, we lost our status as a foreign private issuer, and became subject to the U.S. domestic filer requirements, one of which
requires us to prepare our consolidated financial statements in accordance with U.S. generally accepted accounting principles, or U.S.
GAAP.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt"></p><div>

</div><!-- Field: Page; Sequence: 22; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">We are devoting substantially
all of our efforts toward research and development activities. In the course of such activities, we have sustained operating losses and
we expect such losses to continue in the foreseeable future. Our accumulated deficit as of March 31, 2022 was $357.7 million and negative
cash flows from operating activities during the three months ended March 31, 2022 was $25.7 million. We are planning to finance our operations
from our existing and potential future working capital resources and we continue to evaluate additional sources of capital and financing.
However, there is no assurance that additional capital and/or financing will be available to us, and even if available, whether it will
be on acceptable terms or in the amounts required. Based on our assessment of our financial position at the date of issuance of our consolidated
financial statements for the three months ended March 31, 2022, we believe that our existing capital resources will be adequate to satisfy
our expected liquidity requirements for at least twelve months from the issuance of the consolidated financial statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">While our significant accounting
policies are more fully described in the notes to our consolidated financial statements appearing elsewhere in this Quarterly Report
on Form 10-Q, as well as in our consolidated financial statements appearing in our Annual Report on form 10-K for the year ended December
31, 2021, we believe that the accounting policies discussed below are critical to our financial results and to the understanding of our
past and future performance, as these policies relate to the more significant areas involving management&#8217;s estimates and assumptions.
We consider an accounting estimate to be critical if: (i) it requires us to make assumptions because information was not available at
the time or it included matters that were highly uncertain at the time we were making our estimate; and (ii) changes in the estimate
could have a material impact on our financial condition or results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Convertible senior notes</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">On February 16, 2021 Gamida
Cell Ltd.&#8217;s wholly owned U.S. subsidiary, Gamida Cell Inc., issued convertible senior notes, or the Notes, with an aggregate original
principal amount of $75.0 million in a private placement. The Notes were issued on a senior unsecured basis, have a maturity date of
February 15, 2026, bear 5.875% interest, and may be exchanged, at the election of the holder, for ordinary shares of Gamida Cell Ltd.
at an initial per share price of $17.76, subject to adjustments. We account for the Notes in accordance with ASC 470-20 &#8220;Debt with
Conversion and Other Options.&#8221; We early adopted ASU 2020-06 using the modified retrospective approach. The convertible senior notes
are accounted for as a single liability measured at its amortized cost, as no other embedded features require bifurcation and recognition
as derivatives according to ASC 815-40.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">The Notes are included in
the calculation of diluted earnings per share, or EPS, if the assumed conversion into ordinary shares is dilutive, using the &#8220;if-converted&#8221;
method. This involves adding back the periodic interest expense net of taxes associated with the Notes to the numerator and by adding
the shares that would be issued in an assumed conversion (regardless of whether the conversion option is in or out of the money) to the
denominator for the purposes of calculating diluted EPS. Since the effect of the Notes on the diluted EPS was antidilutive, we did not
include them in our calculation of the diluted EPS.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Share-based compensation</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">We account for share-based
compensation in accordance with ASC No. 718 &#8220;Compensation - Stock Compensation,&#8221; or ASC No. 718, which requires companies
to estimate the fair value of equity-based payment awards on the date of grant using an option-pricing model. The value of the award
is recognized as an expense over the requisite service periods, which is the vesting period of the respective award, on a straight-line
basis when the only condition to vesting is continued service. We selected the binominal option-pricing model as the most appropriate
fair value method for our option awards. The fair value of restricted shares, is based on the closing market value of the underlying
shares at the date of grant. Since our initial public offering, the fair value of our ordinary shares has been determined based on the
closing price of our ordinary shares on the Nasdaq Global Market. We recognize forfeitures of equity-based awards as they occur.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt"></p><div>

</div><!-- Field: Page; Sequence: 23; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Significant Accounting Policies</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">See note 2 of the accompanying
unaudited consolidated financial statements for the three months ended March 31, 2022 for a discussion of significant accounting policies.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Internal Control over Financial Reporting</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0cm"><i>Disclosure Controls and
Procedures</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0cm"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">Our management, under the
supervision and with the participation of our principal executive officer and principal financial officer, completed the process of determining
whether our existing internal controls over financial reporting systems are compliant with Section 404 and whether there are any material
weaknesses or significant deficiencies in our existing internal controls. Based on this process, our principal executive officer and
principal financial officer concluded that our disclosure controls and procedures were effective as of the end of the period covered
by this report.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0cm"><i>Changes in Internal Control
over Financial Reporting</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0cm"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">There have been no changes
in our internal control over financial reporting (as defined in Rule 13a-15(f) of the Exchange Act) that occurred during our most recent
fiscal quarter that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 22.5pt">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Liquidity and Capital Resources.</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Sources of Liquidity</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">Since our inception, we have
incurred losses and negative cash flows from our operations. For the three months ended March 31, 2022 and March 31, 2021, we incurred
a net loss of $20.2 million and $19.2 million, respectively, and net cash of $25.7 million and $20.8 million, respectively, was used
in our operating activities. As of March 31, 2022 and December 31, 2021 we had working capital of $52.2 million and $73.2 million, respectively,
and an accumulated deficit of $357.7 million and $337.5 million, respectively. Our principal sources of liquidity as of March 31, 2022
and December 31, 2021 consisted of cash and cash equivalents and trading financial assets of $69.7 million and $95.9 million, respectively.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Capital Resources</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Overview</p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">Through March 31, 2022, we
have financed our operations primarily through private placements and public offerings of equity securities and through the grants received
from the IIA.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">&#160;</p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Cash flows</p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">The following table summarizes
our statement of cash flows for the three months ended March 31, 2022 and 2021:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Three months ended <br/> March 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center">(in thousands)</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Net cash provided by (used in)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Operating activities</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(25.7</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">(20.8</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Investing activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">11.8</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2.8</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Financing activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.1</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">71.3</td><td style="text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Net cash used in operating activities</p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">The cash used in operating
activities during the aforementioned periods resulted primarily from our net losses incurred during such periods, as adjusted for non-cash
charges and measurements and changes in components of working capital. Adjustments to net losses for non-cash items mainly share based
compensation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">Net cash used in operating
activities was $25.7 million during the three months ended March 31, 2022, compared to $20.8 million used in operating activities during
the three months ended March 31, 2021. The $4.9 million increase in cash used was attributable primarily due to cash payment relating
to delays in launch readiness.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt"></p><div>

</div><!-- Field: Page; Sequence: 24; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">&#160;</p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Net cash provided by (used in) investing
activities</p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">Net cash provided by investing
activities was $11.8 million during the three months ended March 31, 2022, compared to $2.8 million used in investing activities during
the three months ended March 31, 2021. The $14.6 million increase is primarily related to increase of $12.5 million of proceeds from
maturity and purchase of marketable securities and changes in bank deposits, and, by an increase of $2.1 million from the Kiryat Gat
equipment purchase.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">&#160;</p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Net cash provided by financing activities</p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">Net cash provided by financing
activities was $0.1 million during the three months ended March 31, 2022, compared to $71.3 million during the three months ended March
31, 2021. The $71.2 million decrease is primarily related to net proceeds of $70.8 million received from the 2021 issuance of our convertible
senior notes.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">&#160;</p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Funding Requirements</p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">We believe that our existing
funds will enable us to fund our operating expenses and capital expenditure requirements through mid-2023. We have based this estimate
on assumptions that may prove to be wrong, and we could use our capital resources sooner than we currently expect.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">Our present and future funding
requirements will depend on many factors, including, among other things:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18pt"></td><td style="width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify">the
                                            progress of the rolling submission of our BLA for omidubicel;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -18pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18pt"></td><td style="width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify">the
                                            progress, timing and completion of preclinical studies and clinical trials for GDA-201 or
                                            any of our other product candidates;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -18pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18pt"></td><td style="width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify">the
                                            costs related to obtaining regulatory approval for omidubicel and any of our other product
                                            candidates, and any delays we may encounter as a result of regulatory requirements or adverse
                                            clinical trial results with respect to any of these product candidates;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -18pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18pt"></td><td style="width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify">selling,
                                            marketing and patent-related activities undertaken in connection with the commercialization
                                            of omidubicel, if we determine to internally commercialize the product, if approved;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -18pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18pt"></td><td style="width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify">the
                                            costs involved in filing and prosecuting patent applications and obtaining, maintaining and
                                            enforcing patents or defending against claims or infringements raised by third parties, and
                                            license royalties or other amounts we may be required to pay to obtain rights to third-party
                                            intellectual property rights; and</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -18pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18pt"></td><td style="width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify">establishing
                                            a sales, marketing and distribution infrastructure and scaling up manufacturing capabilities
                                            to commercialize any products for which we obtain regulatory approval and determine to commercialize
                                            internally.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -18pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">We have annual operating lease
obligations related to our Haddasah production facility of approximately $1.0 million, which is included in research and development
expense. We additionally have annual operating lease obligations related to our Boston and Kiryat Gat facilities in aggregate of $1.1
million, which is included in general and administrative expense.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">Furthermore, we expect to
continue to incur additional costs associated with operating as a public company subject to US domestic filer regulations. Accordingly,
we will need to obtain substantial additional funding in connection with our continuing operations. If we are unable to raise capital
when needed or on attractive terms, we would be forced to delay, reduce or eliminate our research and development programs or future
commercialization efforts.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt"></p><div>

</div><!-- Field: Page; Sequence: 25; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">Until such time, if ever,
as we can generate substantial product revenue, we may finance our cash needs through a combination of equity offerings, debt financings,
collaborations, strategic alliances and licensing arrangements. To the extent that we raise additional capital through the sale of equity
or convertible debt securities, your ownership interest will be diluted, and the terms of any additional securities may include liquidation
or other preferences that adversely affect your rights as a shareholder. Debt financing, if available, may involve agreements that include
covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures
or declaring dividends. If we raise funds through additional collaborations, strategic alliances or licensing arrangements with third
parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates
or to grant licenses on terms that may not be favorable to us.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">Additional financing may not
be available when we need it or may not be available on terms that are favorable to us. If we are unable to raise additional funds through
equity or debt financings when needed, we may be required to delay, limit, reduce or terminate our product development or future commercialization
efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves. For
more information as to the risks associated with our future funding needs, see &#8220;Item 1A. Risk Factors&#8212;Principal Risk Factors.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">&#160;</p><div>

</div><div><a id="a_009"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Item 3. Quantitative and Qualitative Disclosures
About Market Risk.</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">&#160;</p><div>

</div><div><a id="a_010"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Item 4. Controls and Procedures.</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Evaluation of Disclosure Controls and Procedures</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">We have established disclosure
controls and procedures, as such term is defined in Rule 13a-15(e) under the Securities Exchange Act of 1934. Under the supervision and
with the participation of our management, we conducted an evaluation of the effectiveness of our disclosure controls and procedures as
of March 31, 2022 to ensure that the information required to be disclosed by us in the reports that we file or submit under the Securities
Exchange Act of 1934 is recorded, processed, summarized, and reported within the time periods specified in the SEC&#8217;s rules and
forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required
to be disclosed by us in the reports that we file or submit under the Securities Exchange Act of 1934 is accumulated and communicated
to our management, including our principal executive officer and principal financial officer as appropriate, to allow timely decisions
regarding required disclosure. Our management, with participation of our principal executive officer and principal financial officer,
has evaluated the effectiveness of our disclosure controls and procedures as of March 31, 2022. Based on that evaluation, our principal
executive officer and principal financial officer concluded that our disclosure controls and procedures were effective as of March 31,
2022 to provide reasonable assurance that the information required to be disclosed by us in this Quarterly Report was (a) reported within
the time periods specified by SEC rules and regulations and (b) communicated to our management, including our Chief Executive Officer
and Chief Financial Officer, to allow timely decisions regarding any required disclosure.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Management&#8217;s Report on Internal Control
Over Financial Reporting</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">Our management is responsible
for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Exchange Act Rules 13a-15(f)
and 15d-15(f). Under the supervision and with the participation of our management, including our principal executive, financial and accounting
officer, we conducted an evaluation of the effectiveness of our internal control over financial reporting as of March 31, 2022 based
on the framework in Internal Control&#8212;Integrated Framework 2013 issued by the Committee of Sponsoring Organizations of the Treadway
Commission (COSO). Based on that evaluation, our management concluded that our internal control over financial reporting was effective
as of March 31, 2022.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt"></p><div>

</div><!-- Field: Page; Sequence: 26; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Attestation Report of the Registered Public
Accounting Firm</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">This Quarterly Report does
not include an attestation report of our registered public accounting firm due to the Company&#8217;s emerging growth company status
which provides an exemption.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Cybersecurity</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">We utilize information technology
for internal and external communications with vendors, clinical sites, banks, investors and shareholders. Loss, disruption or compromise
of these systems could significantly impact operations and results.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">We are not aware of any material
cybersecurity violation or occurrence. We believe our efforts toward prevention of such violation or occurrence, including system design
and controls, processes and procedures, training and monitoring of system access, limit, but may not prevent unauthorized access to our
systems.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">Other than temporary disruption
to operations that may be caused by a cybersecurity breach, we consider cash transactions to be the primary risk for potential loss.
We and our financial institution take steps to minimize the risk by requiring multiple levels of authorization and other controls.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Changes in Internal Control Over Financial
Reporting</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">There were no changes in our
internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) during the fiscal quarter ended
March 31, 2022 that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Inherent Limitations on Effectiveness of
Internal Controls</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">In designing and evaluating
the disclosure controls and procedures, management does not expect that our internal control over financial reporting will prevent or
detect all errors and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute,
assurance that the objectives of the control systems are met. Further, the design of a control system must reflect the fact that there
are resource constraints, and the benefits of controls must be considered relative to their costs. The design of any disclosure controls
and procedures also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that
any design will succeed in achieving its stated goals under all potential future conditions. Our management, including our Chief Executive
Officer and Chief Financial Officer, believes that our disclosure controls and procedures and internal control over financial reporting
are designed to provide reasonable assurance of achieving their objectives and are effective at the reasonable assurance level. However,
our management does not expect that our disclosure controls and procedures or our internal control over financial reporting will prevent
all errors and all fraud.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>


</div><!-- Field: Page; Sequence: 27; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><div><a id="a_011"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7.2pt; text-align: center">Part II&#8212;Other Information</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 7.2pt; text-align: center">&#160;</p><div>

</div><div><a id="a_012"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Item 1. Legal Proceedings.</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">From time to time, we may
become party to litigation or other legal proceedings that we consider to be part of the ordinary course of business. We are not currently
party to any material legal proceedings.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">&#160;</p><div>

</div><div><a id="a_013"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Item 1A. Risk Factors.</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt"><i>Investing in our ordinary
shares involves a high degree of risk. You should carefully consider the risks and uncertainties described below, in addition to the
other information set forth in this Quarterly Report, including the consolidated financial statements and the related notes included
elsewhere in this Quarterly Report, before purchasing our ordinary shares. If any of the following risks actually occurs, our business,
financial condition, cash flows and results of operations could be negatively impacted. In that case, the trading price of our ordinary
shares would likely decline and you might lose all or part of your investment. Additional risks and uncertainties not presently known
to us or that we currently deem immaterial also may impair our business operations.</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Principal Risk Factors</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">Our business is subject to
numerous risks that you should be aware of before making an investment decision. These risks are described more fully in this &#8220;Risk
Factors&#8221; section and include, among others:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18pt"></td><td style="width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify">We
                                            have incurred significant losses since our inception. We anticipate that we will continue
                                            to incur significant losses for the foreseeable future, and we may never achieve or maintain
                                            profitability.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -18pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18pt"></td><td style="width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify">We
                                            will need to raise substantial additional funding, which may not be available on acceptable
                                            terms, or at all. Failure to obtain funding on acceptable terms and on a timely basis may
                                            require us to curtail, delay or discontinue our product development efforts or other operations.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -18pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18pt"></td><td style="width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify">We
                                            may not have the ability to raise the funds necessary to repurchase our 5.875% convertible
                                            senior notes due 2026, or the Notes, for cash upon a fundamental change.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -18pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18pt"></td><td style="width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify">The
                                            Indenture governing the Notes contains restrictions and other provisions regarding events
                                            of default that may make it more difficult to execute our strategy or to effectively compete
                                            or that could adversely affect our liquidity.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -18pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18pt"></td><td style="width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify">Raising
                                            additional capital may cause dilution to our shareholders and our share price to fall, restrict
                                            our operations or require us to relinquish rights to our technologies or product candidates.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -18pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18pt"></td><td style="width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify">We
                                            have never generated any revenue from product sales and may never be profitable.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -18pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18pt"></td><td style="width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify">Our
                                            business has been and could continue to be adversely affected by the evolving and ongoing
                                            COVID-19 global pandemic in regions where we or third parties on which we rely have significant
                                            manufacturing facilities, concentrations of clinical trial sites or other business operations.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -18pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18pt"></td><td style="width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify">We
                                            are heavily dependent on the success of our product candidates, including obtaining regulatory
                                            approval to market our product candidates in the United States, the European Union and other
                                            geographies.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -18pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18pt"></td><td style="width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify">We
                                            have experienced delays in regulatory approvals for omidubicel and GDA-201, and we may be
                                            unable to obtain further regulatory approvals for omidubicel, GDA-201, and our other potential
                                            product candidates.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -18pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18pt"></td><td style="width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify">The
                                            results of earlier studies and trials may not be predictive of future trial results, and
                                            our clinical trials may fail to adequately demonstrate the safety and efficacy of our product
                                            candidates.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -18pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18pt"></td><td style="width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify">Interim,
                                            &#8220;topline&#8221; and preliminary data from our clinical trials that we announce or publish
                                            from time to time may change as more patient data become available and are subject to audit
                                            and verification procedures that could result in material changes in the final data.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -18pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -18pt"></p><div>

</div><!-- Field: Page; Sequence: 28; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -18pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18pt"></td><td style="width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify">The
                                            success of our NAM technology platform and our product candidates is substantially dependent
                                            on developments within the emerging field of cellular therapies, some of which are beyond
                                            our control.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -18pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18pt"></td><td style="width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify">Because
                                            our product candidates are based on novel technologies, it is difficult to predict the time
                                            and cost of development and our ability to successfully complete clinical development of
                                            these product candidates and obtain the necessary regulatory approvals for commercialization.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -18pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18pt"></td><td style="width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify">We
                                            may find it difficult to enroll patients in our clinical studies, which could delay or prevent
                                            us from proceeding with clinical trials.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -18pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18pt"></td><td style="width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify">Our
                                            product candidates and the administration process may cause undesirable side effects or have
                                            other properties that could delay or prevent their regulatory approval, limit the commercial
                                            profile of an approved label or result in significant negative consequences following marketing
                                            approval, if any, and result in costly and damaging product liability claims against us.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -18pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18pt"></td><td style="width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify">Even
                                            if we complete the necessary clinical trials, we cannot predict when, or if, we will obtain
                                            regulatory approval to commercialize any of our product candidates, and the approval may
                                            be for a narrower indication than we seek or be subject to other limitations or restrictions
                                            that limit its commercial profile.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -18pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18pt"></td><td style="width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify">Even
                                            if we obtain regulatory approval for a product candidate, our products will remain subject
                                            to regulatory scrutiny.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -18pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18pt"></td><td style="width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify">A
                                            Breakthrough Therapy Designation by the FDA may not lead to a faster development or regulatory
                                            review or approval process and it does not increase the likelihood that our product candidates
                                            will receive marketing approval.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -18pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18pt"></td><td style="width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify">We
                                            may be unable to maintain the benefits associated with orphan drug designations that we have
                                            obtained, including market exclusivity, which may cause our revenue, if any, to be reduced.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -18pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18pt"></td><td style="width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify">Enacted
                                            and future healthcare legislation may increase the difficulty and cost for us to obtain marketing
                                            approval of and commercialize our product candidates and may affect the prices we may set.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -18pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18pt"></td><td style="width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify">Our
                                            business operations and current and future relationships with investigators, healthcare professionals,
                                            consultants, third-party payers, patient organizations and customers will be subject to applicable
                                            healthcare regulatory laws, which could expose us to penalties.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -18pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18pt"></td><td style="width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify">Legislative
                                            or regulatory healthcare reforms in the United States may make it more difficult and costly
                                            for us to obtain regulatory clearance or approval of our product candidates and to produce,
                                            market and distribute our products after clearance or approval is obtained.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -18pt">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have incurred significant losses
since our inception. We anticipate that we will continue to incur significant losses for the foreseeable future, and we may never achieve
or maintain profitability.</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">We are a clinical-stage biopharmaceutical
company. We have incurred net losses each year since our inception in 1998, including net losses of $89.8 million and $61.6 million for
the years ended December 31, 2021 and 2020, respectively. As of March 31, 2022, we had an accumulated deficit of $357.7 million.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">We have devoted substantially
all our financial resources to designing and developing our product candidates, including conducting preclinical studies and clinical
trials, building a manufacturing facility at Kiryat Gat, Israel and providing general and administrative support for these operations.
We expect to continue to incur significant expenses and increasing operating losses for the foreseeable future. Our ability to ultimately
achieve recurring revenue and profitability, which we do not expect to occur for at least several years, is dependent upon our ability
to successfully complete the development of our product candidates, and to obtain necessary regulatory approvals for and successfully
manufacture, market and commercialize our products.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt"></p><div>

</div><!-- Field: Page; Sequence: 29; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">We anticipate that our expenses
will increase substantially based on a number of factors, including to the extent that we:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18pt"></td><td style="width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify">prepare
                                            for potential commercialization and/or strategic partnerships for omidubicel, if and when
                                            approved for marketing&#894;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -18pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18pt"></td><td style="width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify">continue
                                            our clinical development of omidubicel, GDA-201 and other potential product candidates&#894;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -18pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18pt"></td><td style="width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify">seek
                                            regulatory and marketing approvals for our product candidates that successfully complete
                                            clinical studies&#894;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -18pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18pt"></td><td style="width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify">identify,
                                            assess, acquire, license and/or develop other product candidates&#894;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -18pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18pt"></td><td style="width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify">establish
                                            and validate our commercial-scale manufacturing facilities in accordance with current good
                                            manufacturing practices, or cGMP&#894;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -18pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18pt"></td><td style="width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify">establish
                                            a sales, marketing and distribution infrastructure to commercialize any products for which
                                            we may obtain marketing approval&#894;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -18pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18pt"></td><td style="width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify">hire
                                            personnel and invest in additional infrastructure to support our operations as a public company
                                            and expand our product development&#894;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -18pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18pt"></td><td style="width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify">enter
                                            into agreements to license intellectual property from, or to, third parties&#894;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -18pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18pt"></td><td style="width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify">develop,
                                            maintain, protect and expand our intellectual property portfolio&#894; and</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -18pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18pt"></td><td style="width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify">experience
                                            any delays or encounter issues with respect to any of the above, including but not limited
                                            to, failed studies, complex results, manufacturing issues or other regulatory challenges
                                            that require longer follow-up of existing studies, additional major studies or additional
                                            supportive studies in order to pursue marketing approval.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -18pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">To date, we have financed
our operations primarily through our public offerings of equity securities, private placements of debt and equity securities and royalty-bearing
grants that we received from the Israeli Innovation Authority, or the IIA, formerly known as the Office of the Chief Scientist of the
Ministry of Economy and Industry, including from Bereshit Consortium, sponsored by the IIA. The amount of our future net losses will
depend, in part, on the rate of our future expenditures and our ability to obtain funding through equity or debt financings, strategic
collaborations, or grants. Even if we obtain regulatory approval to market omidubicel or any other product candidates, our future revenue
will depend upon the size of any markets in which such product candidates receive approval, and our ability to achieve sufficient market
acceptance, pricing and reimbursement from third-party payers for such product candidates. Further, the net losses that we incur may
fluctuate significantly from quarter to quarter and year to year, such that a period-to-period comparison of our results of operations
may not be a good indication of our future performance. We may also incur other unanticipated costs from our operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Operating our business and servicing
our debt requires a significant amount of cash, and we will need to obtain additional funding in the future to continue to sufficiently
fund our operations and pay our substantial debt, including our convertible senior notes that mature in February 2026.</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">Our financial statements have been prepared on a going concern basis under which an entity is able to realize its assets and satisfy its
liabilities in the ordinary course of business. Our future operations are dependent upon the identification and successful completion
of equity or debt financing and the achievement of profitable operations at an indeterminate time in the future. There can be no assurances
that we will be successful in completing equity or debt financing or in achieving profitability. The financial statements do not give
effect to any adjustments relating to the carrying values and classification of assets and liabilities that would be necessary should
the Company be unable to continue as a going Additional financing may not be available when we need it or may not be available on terms
that are favorable to us. If we are unable to raise the requisite funds, we will need to curtail or cease operations concern. Developing
our product candidates is expensive, and we expect our research and development expenses to increase substantially in connection with
our ongoing activities, particularly as we advance our product candidates through preclinical studies and clinical development in an effort
to obtain regulatory approval. We recently initiated submission of a Biologics License Application, or BLA, for omidubicel on a rolling
basis, and we plan to submit the full BLA to the FDA in the second quarter of 2022. We also plan to continue our Phase 1/2 investigator-sponsored
clinical trial of omidubicel for the treatment of severe aplastic anemia, and we expect to initiate a Phase 1/2 clinical trial of GDA-201
in patients with follicular and diffuse large B-cell lymphomas in 2022.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt"></p><div>

</div><!-- Field: Page; Sequence: 30; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">In addition, our ability to
make scheduled payments of the principal of, to pay interest on, or to refinance our indebtedness, including the Notes, depends on our
future performance, which is subject to economic, financial, competitive and other factors beyond our control. Our business may never
generate cash flow from operations sufficient to support our operations, service our debt and make necessary capital expenditures. As
a result, we may be required to adopt one or more alternatives, subject to the restrictions contained in the Indenture between Gamida
Cell Ltd., Gamida Cell Inc., and Wilmington Savings Fund Society, FSB, entered into on February 16, 2021, or the Indenture, governing
the Notes, such as selling assets, restructuring debt or obtaining additional equity capital on terms that may be onerous and which are
likely to be highly dilutive. As of March 31, 2022, we had cash and cash equivalents and trading financial assets of $69.7 million. We
currently believe that our existing capital resources will be sufficient to meet our projected operating requirements into mid-2023.
We will require significant additional financing in the future to fund our operations. Our future funding requirements will depend on
many factors, including, but not limited to:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18pt"></td><td style="width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify">the
                                            cost, timing and outcomes of regulatory reviews of omidubicel, GDA-201 and our other potential
                                            product candidates&#894;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -18pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18pt"></td><td style="width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify">the
                                            progress, results and costs of our current and planned clinical trials of GDA-201 and our
                                            other product candidates&#894;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -18pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18pt"></td><td style="width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify">the
                                            costs of qualifying our planned commercial-scale cGMP manufacturing facility at Kiryat Gat,
                                            Israel, and/or engaging third-party manufacturers&#894;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -18pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18pt"></td><td style="width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify">the
                                            scope, progress, results and costs of product development, laboratory testing, manufacturing,
                                            preclinical development and clinical trials for any other product candidates that we may
                                            develop or otherwise obtain in the future&#894;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -18pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18pt"></td><td style="width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify">the
                                            cost of our future activities, including establishing sales, marketing and distribution capabilities
                                            for any product candidates in any particular geography where we receive marketing approval
                                            for such product candidates&#894;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -18pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18pt"></td><td style="width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify">the
                                            terms and timing of any collaborative, licensing and other arrangements that we may establish&#894;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -18pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18pt"></td><td style="width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify">the
                                            costs of preparing, filing and prosecuting patent applications, maintaining and enforcing
                                            our intellectual property rights and defending intellectual property-related claims&#894;
                                            and</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -18pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18pt"></td><td style="width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify">the
                                            level of revenue, if any, received from commercial sales of any product candidates for which
                                            we receive marketing approval.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -18pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">Identifying potential product
candidates and conducting preclinical testing and clinical trials is a time-consuming, expensive and uncertain process that takes years
to complete, and we may never generate the necessary data or results required to obtain marketing approval and achieve product sales.
In addition, our product candidates, if approved, may not achieve commercial success. Our product revenue, if any, will be derived from
or based on sales of product candidates that may not be commercially available for many years, if at all. Accordingly, we will need to
continue to rely on additional financing to achieve our business objectives. Any additional fundraising efforts may divert our management
from their day-to-day activities, which may adversely affect our ability to develop and commercialize our product candidates. We cannot
guarantee that future financing will be available in sufficient amounts or on terms acceptable to us, if at all, and the terms of any
financing may adversely affect the interests or rights of our shareholders.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We may not have the ability to raise
the funds necessary to repurchase the Notes for cash upon a fundamental change.</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">Holders of the Notes have
the right to require us to repurchase their Notes for cash upon the occurrence of a fundamental change at a repurchase price equal to
100% of the principal amount of the Notes to be repurchased, plus accrued and unpaid interest, if any. This use of cash may have a material
adverse effect on our liquidity. Furthermore, we may not have enough available cash or be able to obtain financing at the time we are
required to repurchase the Notes. In addition, our ability to repurchase the Notes for cash may be limited by law, regulatory authority
or agreements governing our future indebtedness. Our failure to repurchase Notes for cash at a time when the repurchase is required by
the Indenture pursuant to which the Notes were issued would constitute a default under the Indenture.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt"></p><div>

</div><!-- Field: Page; Sequence: 31; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Indenture governing the Notes
contains restrictions and other provisions regarding events of default that may make it more difficult to execute our strategy or to
effectively compete or that could adversely affect our liquidity.</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">Subject to certain exceptions
and qualifications, the Indenture governing the Notes restricts our ability to, among other things, (i) pay dividends or make other payments
or distributions on capital stock, or purchase, redeem, defease or otherwise acquire or retire for value any capital stock, (ii) incur
indebtedness or issue preferred stock, other than certain forms of permitted debt, (iii) sell assets or dispose of certain material assets,
(iv) enter into certain transactions with affiliates or (v) merge, consolidate or sell all or substantially all assets. The Indenture
also requires us to make an offer to repurchase the Notes upon the occurrence of certain asset sales or disposition of certain material
assets. These restrictions may make it difficult to successfully execute our business strategy or effectively compete with companies
that are not similarly restricted. The Indenture governing the Notes also provides that a number of events will constitute an event of
default, including, among other things, (i) a failure to pay interest or additional amounts for 30 days, (ii) failure to pay the principal
of the notes when due at maturity, upon redemption, upon any required repurchase, upon declaration of acceleration or otherwise, (iii)
failure to comply with our obligation to exchange the Notes in accordance with the Indenture upon a holder&#8217;s exercise of its exchange
right, (iv) not issuing certain notices required by the Indenture within a timely manner, (v) failure to comply with the other covenants
or agreements in the Notes or the Indenture, (vi) a default or other failure by us to make required payments under our other indebtedness
having an outstanding principal amount of $10.0 million or more, (vii) failure by us to pay final judgments aggregating in excess of
$20.0 million, and (viii) certain events of bankruptcy or insolvency. In the case of an event of default arising from certain events
of bankruptcy or insolvency with respect to us, all outstanding Notes will become due and payable immediately without further action
or notice. If any other event of default occurs and is continuing, the trustee or the holders of at least 25% in aggregate principal
amount of the then outstanding Notes may declare all the Notes to be due and payable immediately. Such acceleration of our debt could
have a material adverse effect on our liquidity if we are unable to negotiate mutually acceptable terms with the holders of the Notes
or if alternate funding is not available to us. Furthermore, if we are unable to repay the Notes upon an acceleration or otherwise, we
would be forced into bankruptcy or liquidation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Raising additional capital may cause
dilution to our shareholders and our share price to fall, restrict our operations or require us to relinquish rights to our technologies
or product candidates.</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">Until such time, if ever,
as we can generate substantial product revenue, we expect to obtain additional capital through a combination of equity offerings, debt
financings, collaborations and strategic and licensing arrangements. To the extent that we raise additional capital through the sale
of equity or convertible debt securities, your ownership interest will be diluted, and the terms of such securities may include liquidation
or other preferences that adversely affect your rights as a shareholder. Debt financing, if available, may involve covenants restricting
our operations or our ability to incur additional debt. If we raise additional funds through collaboration and licensing arrangements
with third parties, it may be necessary to relinquish certain rights to our technologies or our product candidates, or to grant licenses
on terms that are not favorable to us.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">Even if we believe that we
have sufficient funds for our current or future operating plans, we may seek additional capital if market conditions are favorable or
if we have specific strategic considerations. The issuance of additional securities, whether equity or debt, by us, or the possibility
of such issuance, may cause the market price of our shares to decline.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">We have also entered into
an Open Market Sale Agreement, or the Sales Agreement under which we may offer and sell our ordinary shares having an aggregate gross
sales price of up to $50 million from time to time through Jefferies LLC. Pursuant to the Sales Agreement and upon delivery of notice
by the Company, Jefferies may sell our ordinary shares under an &#8220;at the market offering&#8221;. The sale of a substantial amount
of our ordinary shares in this manner may depress the market price for our ordinary shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">If we are unable to obtain
funding on acceptable terms and on a timely basis, we may be required to significantly curtail, delay or discontinue one or more of our
research, development or manufacturing programs or the commercialization of any approved product, or be unable to expand our operations
or otherwise capitalize on our business opportunities, as desired, which could materially affect our business, financial condition and
results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt"></p><div>

</div><!-- Field: Page; Sequence: 32; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have never generated any revenue
from product sales and may never be profitable.</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">We have no products approved
for marketing in any jurisdiction, and we have never generated any revenue from product sales. Our ability to generate revenue and achieve
profitability depends on our ability, alone or with strategic collaboration partners, to successfully complete the development of, and
obtain the regulatory and marketing approvals necessary to commercialize one or more of our product candidates. Our ability to generate
future revenue from the commercialization of omidubicel is uncertain. If we decide to commercialize omidubicel on our own, we will have
to undertake sufficient costs to build out a sales and distribution team. If we enter into one or more partnerships for the commercialization
of omidubicel, we will surrender a portion of our revenue to our partner or partners, and if we securitize royalty streams related to
omidubicel, future revenues would be held in trust for beneficiaries of the financing in exchange for which we would receive certain
payments based on an assessment of future sales. Furthermore, revenue from product sales will depend heavily on our ability to:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18pt"></td><td style="width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify">obtain
                                            regulatory approvals and marketing authorizations for omidubicel and those of our other product
                                            candidates for which we complete clinical studies&#894;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -18pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18pt"></td><td style="width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify">develop
                                            and obtain regulatory approval for a sustainable and scalable in-house and/or third-party
                                            manufacturing process for omidubicel that meets all applicable regulatory standards&#894;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -18pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18pt"></td><td style="width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify">establish
                                            and maintain supply and, if applicable, manufacturing relationships with third parties that
                                            can provide adequate, in both amount and quality, products to support clinical development
                                            and the market demand for our product candidates, if and when approved&#894;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -18pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18pt"></td><td style="width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify">complete
                                            research and preclinical and clinical development of our product candidates in a timely and
                                            successful manner&#894;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -18pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18pt"></td><td style="width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify">launch
                                            and commercialize our product candidates for which we obtain regulatory and marketing approval,
                                            either directly by establishing a sales force, marketing and distribution infrastructure,
                                            and/or with collaborators or distributors&#894;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -18pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18pt"></td><td style="width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify">expose,
                                            educate and train physicians and other medical professionals to use our products&#894;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -18pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18pt"></td><td style="width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify">price
                                            omidubicel and our other product candidates, if and when approved, in a manner designed to
                                            encourage market acceptance from the medical community and third-party payers&#894;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -18pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18pt"></td><td style="width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify">ensure
                                            procedures utilizing our product candidates are approved for coverage and adequate reimbursement
                                            from governmental agencies, private insurance plans, managed care organizations, and other
                                            third-party payers in jurisdictions where they have been approved for marketing&#894;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -18pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18pt"></td><td style="width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify">address
                                            any competing technological and market developments that impact our product candidates or
                                            their prospective usage by medical professionals&#894;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -18pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18pt"></td><td style="width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify">identify,
                                            assess, acquire and/or develop new product candidates&#894;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -18pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18pt"></td><td style="width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify">negotiate
                                            favorable terms in any collaboration, licensing or other arrangements into which we may enter
                                            and perform our obligations under such collaborations&#894;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -18pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18pt"></td><td style="width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify">maintain,
                                            protect and expand our portfolio of intellectual property rights, including patents, patent
                                            applications, trade secrets and knowhow&#894;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -18pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18pt"></td><td style="width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify">avoid
                                            and defend against third-party interference, infringement or other intellectual property
                                            related claims&#894; attract, hire and retain qualified personnel&#894; and</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -18pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18pt"></td><td style="width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify">locate
                                            and lease or acquire suitable facilities to support our clinical development, manufacturing
                                            facilities and commercial expansion.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -18pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -18pt"></p><div>

</div><!-- Field: Page; Sequence: 33; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -18pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">Even if one or more of our
product candidates is approved for marketing and sale, we anticipate incurring significant incremental costs associated with commercializing
such product candidates. Our expenses could increase beyond expectations if we are required by the U.S. Food and Drug Administration,
or the FDA, the European Medicines Agency, or the EMA, or other regulatory agencies or ethical committees in medical centers, to change
our manufacturing processes or assays or to perform clinical, nonclinical, or other types of studies in addition to those that we currently
anticipate. Even if we are successful in obtaining regulatory approvals to market one or more of our product candidates, our revenue
earned from such product candidates will be dependent in part upon the size of the markets in the territories for which we gain regulatory
approval for such products, the accepted price for such products, our ability to obtain reimbursement for such products at any price,
whether we own the commercial rights for that territory in which such products have been approved and the expenses associated with manufacturing
and marketing such products for such markets. Therefore, we may not generate significant revenue from the sale of such products, even
if approved. Further, if we are not able to generate significant revenue from the sale of our approved products, we may be forced to
curtail or cease our operations. Due to the numerous risks and uncertainties involved in product development, it is difficult to predict
the timing or amount of increased expenses, or when, or if, we will be able to achieve or maintain profitability.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our business could be adversely affected
by the evolving and ongoing COVID-19 global pandemic in regions where we or third parties on which we rely have significant manufacturing
facilities, concentrations of clinical trial sites or other business operations. The COVID-19 pandemic could adversely affect our operations,
as well as the business or operations of our manufacturers, CROs or other third parties with whom we conduct business.</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">Our business could be adversely
affected by the effects of the recent and evolving COVID-19 pandemic, which was declared by the World Health Organization as a global
pandemic. The COVID-19 pandemic has resulted in travel and other restrictions in order to reduce the spread of the disease including
in the Commonwealth of Massachusetts, where our U.S. operations are focused.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">Some of our third-party manufacturers
which we use for the supply of materials for product candidates or other materials necessary to manufacture product to conduct preclinical
tests and clinical trials are located in countries affected by COVID-19. Quarantines, shelter-in-place and similar government orders,
or the perception that such orders, shutdowns or other restrictions on the conduct of business operations could occur, whether related
to COVID-19 or other infectious diseases could impact personnel at third-party manufacturing facilities, or the availability or cost
of materials, which would disrupt our supply chain, and should they experience additional disruptions, such as temporary closures or
suspension of services, we would likely experience delays in advancing these tests and trials. Currently, we expect no material impact
on the clinical supply of omidubicel or GDA-201.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">Our clinical trials may also
be affected by the COVID-19 pandemic. Clinical site initiation and patient enrollment may be delayed due to prioritization of hospital
resources toward the COVID-19 pandemic. Some patients may not be able to comply with clinical trial protocols if quarantines impede patient
movement or interrupt healthcare services. Similarly, our ability to recruit and retain patients and principal investigators and site
staff who, as healthcare providers, may have heightened exposure to COVID-19 and adversely impact our clinical trial operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">The spread of COVID-19, which
has caused a broad impact globally, may materially affect us economically. While the potential economic impact brought by, and the duration
of, COVID-19 may be difficult to assess or predict, a widespread pandemic could result in significant disruption of global financial
markets, reducing our ability to access capital, which could in the future negatively affect our liquidity. In addition, a recession
or other market corrections resulting from the spread of COVID-19 could materially affect our business and the value of our ordinary
shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">The global pandemic of COVID-19
continues to rapidly evolve. The extent to which the COVID-19 pandemic impacts our business, our clinical development and regulatory
efforts will depend on future developments that are highly uncertain and cannot be predicted with confidence, such as the ultimate geographic
spread of the disease, the duration of the outbreak, efficacy of vaccines, travel restrictions, quarantines, social distancing requirements
and business closures in the United States and other countries, business disruptions and the effectiveness of actions taken in the United
States and other countries to contain and treat the disease. Accordingly, we do not yet know the full extent of potential delays or impacts
on our business, our clinical and regulatory activities, healthcare systems or the global economy as a whole. However, these impacts
could adversely affect our business, financial condition, results of operations and growth prospects.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">In addition, to the extent
the ongoing COVID-19 pandemic adversely affects our business and results of operations, it may also have the effect of heightening many
of the other risks and uncertainties described in this &#8220;Risk Factors&#8221; section and in the &#8220;Risk Factors&#8221; incorporated
by reference herein.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt"></p><div>

</div><!-- Field: Page; Sequence: 34; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Risks Related to the Discovery, Development
and Clinical Testing of Our Product Candidates</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are heavily dependent on the success
of our product candidates, including obtaining regulatory approval to market our product candidates in the United States, the European
Union and other geographies.</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">To date, we have deployed
all our efforts and financial resources to: (i) research and develop our NAM, or nicotinamide, cell expansion platform, our lead product
candidate, omidubicel, for the treatment of hematologic malignancies, and our second product candidate, GDA-201, for the treatment of
NHL, and our other potential product candidates, including conducting preclinical and clinical studies and providing general and administrative
support for these operations&#894; and (ii) develop and secure our intellectual property portfolio for our product candidates. Our future
success is dependent on our ability to successfully develop, obtain regulatory approval for and commercialize one or more of our current
and future product candidates. Our product candidates&#8217; marketability is subject to significant risks associated with successfully
completing current and future clinical trials and commercializing our product candidates that receive regulatory approval, including:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18pt"></td><td style="width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify">our
                                            ability to develop, qualify and maintain a commercially viable manufacturing process that
                                            is compliant with cGMP and produces omidubicel that has the same treatment profile as the
                                            products used in our clinical trials, whether at our facility at Kiryat Gat or through third
                                            party manufacturers&#894;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -18pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18pt"></td><td style="width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify">completion
                                            of the Phase 1/2 clinical trial of GDA-201 and the acceptance by the FDA of the sufficiency
                                            of early development data to support approval of the IND application that we submitted&#894;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -18pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18pt"></td><td style="width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify">acceptance
                                            by the FDA, EMA or other regulatory agencies of our parameters for regulatory approval relating
                                            to omidubicel and our other product candidates, including our proposed indications, primary
                                            and secondary endpoint assessments and measurements, safety evaluations and regulatory pathways&#894;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -18pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18pt"></td><td style="width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify">the
                                            acceptance by the FDA, EMA or other regulatory agencies of the number, design, size, conduct
                                            and implementation of our clinical trials, our trial protocols and the interpretation of
                                            data from preclinical studies or clinical trials&#894;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -18pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18pt"></td><td style="width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify">our
                                            ability to successfully complete the clinical trials of our product candidates, including
                                            timely patient enrollment and acceptable safety and efficacy data and our ability to demonstrate
                                            the safety and efficacy of the product candidates undergoing such clinical trials&#894;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -18pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18pt"></td><td style="width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify">the
                                            acceptance by the FDA of the sufficiency of the data we collect from our preclinical studies
                                            and our investigator-sponsored Phase 1/2 clinical trial of omidubicel for the treatment of
                                            severe aplastic anemia&#894;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -18pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18pt"></td><td style="width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify">the
                                            willingness of the FDA, EMA or other regulatory agencies to schedule an advisory committee
                                            meeting in a timely manner to evaluate and decide on the approval of our regulatory filings,
                                            if such advisory committee meetings are required&#894;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -18pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18pt"></td><td style="width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify">the
                                            recommendation of the FDA&#8217;s advisory committee to approve our applications to market
                                            omidubicel and our other product candidates in the United States, and the EMA in the European
                                            Union, if such advisory committee reviews are scheduled, without limiting the approved labeling,
                                            specifications, distribution or use of the products, or imposing other restrictions&#894;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -18pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18pt"></td><td style="width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify">the
                                            satisfaction of the FDA, EMA or other regulatory agencies with the safety and efficacy of
                                            our product candidates&#894;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -18pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18pt"></td><td style="width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify">the
                                            prevalence and severity of adverse events associated with our product candidates&#894;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -18pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18pt"></td><td style="width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify">the
                                            timely and satisfactory performance by third-party contractors, trial sites and principal
                                            investigators of their obligations in relation to our clinical trials&#894;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -18pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18pt"></td><td style="width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify">our
                                            success in educating medical professionals and patients about the benefits, administration
                                            and use of our product candidates, if approved&#894;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -18pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -18pt"></p><div>

</div><!-- Field: Page; Sequence: 35; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -18pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18pt"></td><td style="width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify">the
                                            availability, perceived advantages, relative cost, safety and efficacy of alternative and
                                            competing treatments for the indications addressed by our product candidates&#894;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -18pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18pt"></td><td style="width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify">the
                                            effectiveness of our marketing, sales and distribution strategy, and operations, as well
                                            as that of any current and future licensees&#894;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -18pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18pt"></td><td style="width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify">the
                                            extent to which third-party payers provide coverage and adequate reimbursement for procedures
                                            utilizing our products&#894; and/or</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -18pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18pt"></td><td style="width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify">our
                                            ability to obtain, maintain, protect and enforce our intellectual property rights with respect
                                            to our product candidates and to regulatory guidelines.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -18pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">Many of these clinical, regulatory
and commercial risks are beyond our control. Accordingly, we cannot assure you that we will be able to advance any of our product candidates
through clinical development, or to obtain regulatory approval of or commercialize any of our product candidates. If we fail to achieve
these objectives or overcome the challenges presented above, we could experience significant delays or an inability to successfully commercialize
our product candidates. Accordingly, we may not be able to generate sufficient revenue through the sale of our product candidates to
enable us to continue our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We may be unable to obtain regulatory
approval for our product candidates.</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">The research, development,
testing, manufacturing, labeling, packaging, approval, promotion, advertising, storage, recordkeeping, marketing, distribution, post-approval
monitoring and reporting and export and import of drug products are subject to extensive regulation by the FDA, the EMA and by regulatory
authorities in other countries. These regulations differ from country to country. To gain approval to market our product candidates,
we must provide data from well-controlled clinical trials that adequately demonstrate the safety and efficacy of the product for the
intended indication to the satisfaction of the FDA, EMA or other regulatory authority. We have not yet obtained regulatory approval to
market any of our product candidates in the United States or any other country. The FDA, EMA or other regulatory agencies can delay,
limit or deny approval of our product candidates for many reasons, including:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18pt"></td><td style="width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify">regulatory
                                            requests for additional analyses, reports, data, non-clinical and preclinical studies and
                                            clinical trials, including with respect to our and our third-party manufacturer&#8217;s production
                                            of omidubicel in commercial processes that has the same treatment profile as the product
                                            used in our successful Phase 3 clinical trial&#894;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -18pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18pt"></td><td style="width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify">our
                                            inability to demonstrate that the product candidates are safe and effective for the target
                                            indication to the satisfaction of the FDA, EMA or other regulatory agencies&#894;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -18pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18pt"></td><td style="width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify">regulatory
                                            requests to provide additional data regarding analytical and clinical comparability from
                                            our planned commercial manufacturing sites, or the failure of a regulatory agency to accept
                                            the manufacturing processes or facilities at our manufacturing site or those of third-party
                                            manufacturers with which we contract&#894;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -18pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18pt"></td><td style="width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify">the
                                            FDA&#8217;s, EMA&#8217;s, or other regulatory agencies&#8217; disagreement with our clinical
                                            trial protocol, the interpretation of data from preclinical studies or clinical trials, or
                                            adequacy of the conduct and control of clinical trials;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -18pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18pt"></td><td style="width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify">clinical
                                            holds, other regulatory objections to commencing or continuing a clinical trial or the inability
                                            to obtain regulatory approval to commence a clinical trial in countries that require such
                                            approvals, including the clinical hold the FDA placed on our GDA-201 IND prior to the initiation
                                            of patient dosing for our planned Phase 1/2 study in NHL, which was removed by the FDA on
                                            April 21, 2022&#894;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -18pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -18pt"></p><div>

</div><!-- Field: Page; Sequence: 36; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -18pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18pt"></td><td style="width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify">the
                                            population studied in the clinical trial may not be sufficiently broad or representative
                                            to assess safety in the patient population for which we seek approval&#894;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -18pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18pt"></td><td style="width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify">unfavorable
                                            or inconclusive results of clinical trials and supportive non-clinical studies, including
                                            unfavorable results regarding safety or efficacy of our product candidates observed in clinical
                                            trials&#894;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -18pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18pt"></td><td style="width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify">our
                                            inability to demonstrate that clinical or other benefits of our product candidates outweigh
                                            any safety or other perceived risks&#894;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -18pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18pt"></td><td style="width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify">any
                                            determination that a clinical trial presents unacceptable health risks to subjects&#894;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -18pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18pt"></td><td style="width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify">our
                                            inability to obtain approval from institutional review boards, or IRBs, to conduct clinical
                                            trials at their respective sites&#894;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -18pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18pt"></td><td style="width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify">the
                                            non-approval of the formulation, labeling or the specifications of our product candidates&#894;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -18pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18pt"></td><td style="width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify">the
                                            potential for approval policies or regulations of the FDA, EMA or other regulatory agencies
                                            to significantly change in a manner rendering our clinical data insufficient for approval&#894;
                                            or</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -18pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18pt"></td><td style="width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify">resistance
                                            to approval from the advisory committees of the FDA, EMA or other regulatory agencies for
                                            any reason including safety or efficacy concerns.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -18pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">In the United States, we are
required to submit a BLA to obtain FDA approval before marketing omidubicel or any of our product candidates. A BLA must include extensive
preclinical and clinical data and supporting information to establish the product candidate&#8217;s safety, purity and potency, or efficacy,
for each desired indication. The BLA must also include significant information regarding the chemistry, manufacturing and controls for
the product. In November 2021, we completed a Type B Pre-Biologics License Application, or pre-BLA meeting with the FDA for omidubicel
during which the FDA requested that we provide revised analysis of the manufacturing data generated at our wholly-owned commercial manufacturing
facility in Kiryat Gat, Israel to demonstrate the comparability to the omidubicel that was produced at the clinical manufacturing sites
for the Phase 3 study. Although the FDA has agreed that we established analytical comparability between the omidubicel product that is
manufactured at our commercial manufacturing facility and the omidubicel product that was manufactured for the Phase 3 trial, there is
no guarantee that we will continue to meet the FDA&#8217;s manufacturing requirements in the future.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">In connection with our BLA
submission, the FDA may conduct an inspection of our Kiryat Gat, Israel manufacturing facility to ensure that it can manufacture omidubicel
and our other product candidates, if and when approved, in compliance with the applicable regulatory requirements. The FDA may also inspect
our clinical trial sites to ensure that our studies are properly conducted. Obtaining approval of a BLA is a lengthy, expensive and uncertain
process, and approval may not be obtained. Upon submission of a BLA, the FDA must make an initial determination that the application
is sufficiently complete to accept the submission for filing. We cannot be certain that our rolling BLA submission for omidubicel, or
any future submissions, will be accepted for filing and review by the FDA, or ultimately be approved. If our planned application for
omidubicel is not accepted for review or approval, the FDA may require that we conduct additional clinical or preclinical trials, or
take other actions before it will reconsider our application. If the FDA requires additional studies or data, we would incur increased
costs and delays in the marketing approval process, which may require us to expend more resources than we have available. In addition,
the FDA may not consider any additional information to be complete or sufficient to support approval.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">Regulatory authorities outside
of the United States, such as in the European Union, also have requirements for approval of biologics for commercial sale with which
we must comply prior to marketing in those areas. Regulatory requirements can vary widely from country to country and could delay or
prevent the introduction of our product candidates. Clinical trials conducted in one country may not be accepted by regulatory authorities
in other countries, and obtaining regulatory approval in one country does not mean that regulatory approval will be obtained in any other
country.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt"></p><div>

</div><!-- Field: Page; Sequence: 37; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">However, the failure to obtain
regulatory approval in one jurisdiction could have a negative impact on our ability to obtain approval in a different jurisdiction. Approval
processes vary among countries and can involve additional product candidate testing and validation and additional administrative review
periods. Seeking additional regulatory approvals outside the United States and European Union could require additional nonclinical studies
or clinical trials, which could be costly and time consuming. These regulatory approvals may include all of the risks associated with
obtaining FDA or EMA approval. For all of these reasons, if we seek such regulatory approvals for any of our other product candidates,
we may not obtain such approvals on a timely basis, if at all.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">Even if we receive approval
of any regulatory filing for omidubicel, the FDA may grant any such approval contingent on the performance of costly and potentially
time-consuming additional post-approval clinical trials or subject to contraindications, black box warnings, restrictive surveillance
or a Risk Evaluation and Mitigation Strategy, or REMS. Further, the FDA, EMA or other regulatory authorities may also approve our product
candidates for a more limited indication or a narrower patient population than we originally requested, and these regulatory authorities
may not approve the labeling that we believe is necessary or desirable for the successful commercialization of our product candidates.
Following any approval for commercial sale of omidubicel or our product candidates, certain changes to the product, such as changes in
manufacturing processes and additional labeling claims, as well as new safety information, will be subject to additional FDA notification,
or review and approval. Also, regulatory approval for any of our product candidates may be withdrawn. To the extent we seek regulatory
approval in jurisdictions outside of the United States and European Union, we may face challenges similar to those described above with
regulatory authorities in applicable jurisdictions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">Any delay in obtaining, or
inability to obtain, applicable regulatory approval for any of our product candidates would delay or prevent commercialization of our
product candidates and would thus negatively impact our business, results of operations and prospects.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Clinical development is difficult
to design and implement and involves a lengthy and expensive process with uncertain outcomes.</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">Clinical testing is expensive
and can take many years to complete, and its outcome is inherently uncertain. Bone marrow transplant and cell-based therapies that appear
promising in the early phases of development may fail to reach the market. Further, a failure of one or more of our clinical trials can
occur at any time during the clinical trial process. We do not know whether future clinical trials, if any, will begin on time, need
to be redesigned, enroll an adequate number of patients on time or be completed on schedule, if at all. Clinical trials can be delayed,
suspended or terminated for a variety of reasons, including failure to:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18pt"></td><td style="width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify">generate
                                            sufficient preclinical, toxicology, or other in vivo or in vitro data to support the initiation
                                            or continuation of clinical trials&#894;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -18pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18pt"></td><td style="width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify">obtain
                                            regulatory approval, or feedback on trial design, in order to commence a trial&#894;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -18pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18pt"></td><td style="width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify">identify,
                                            recruit and train suitable clinical investigators&#894;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -18pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18pt"></td><td style="width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify">reach
                                            agreement on acceptable terms with prospective contract research organizations, or CROs,
                                            and clinical trial sites, the terms of which can be subject to extensive negotiation and
                                            may vary significantly among CROs and clinical trial sites, and have such CROs and sites
                                            effect the proper and timely conduct of our clinical trials&#894;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -18pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18pt"></td><td style="width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify">obtain
                                            and maintain IRB approval at each clinical trial site&#894;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -18pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18pt"></td><td style="width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify">identify,
                                            recruit and enroll suitable patients to participate in a trial&#894;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -18pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18pt"></td><td style="width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify">have
                                            a sufficient number of patients complete a trial or return for post-treatment follow-up&#894;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -18pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18pt"></td><td style="width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify">ensure
                                            clinical investigators and clinical trial sites observe trial protocol or continue to participate
                                            in a trial&#894;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -18pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18pt"></td><td style="width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify">address
                                            any patient safety concerns that arise during the course of a trial&#894;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -18pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18pt"></td><td style="width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify">address
                                            any conflicts with new or existing laws or regulations&#894;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -18pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18pt"></td><td style="width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify">add
                                            a sufficient number of clinical trial sites&#894;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -18pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18pt"></td><td style="width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify">manufacture
                                            sufficient quantities at the required quality of product candidate for use in clinical trials&#894;
                                            or</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -18pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18pt"></td><td style="width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify">raise
                                            sufficient capital to fund a trial.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -18pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -18pt"></p><div>

</div><!-- Field: Page; Sequence: 38; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -18pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">We may also experience numerous
unforeseen events during, or as a result of, clinical trials that could delay or prevent our ability to receive marketing approval or
commercialize our product candidates, including:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18pt"></td><td style="width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify">we
                                            may receive feedback from regulatory authorities that requires us to modify the design of
                                            our clinical trials&#894;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -18pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18pt"></td><td style="width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify">clinical
                                            trials of our product candidates may produce negative or inconclusive results, and we may
                                            decide, or regulators may require us, to conduct additional clinical trials or abandon development
                                            programs&#894;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -18pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18pt"></td><td style="width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify">the
                                            number of patients required for clinical trials of our product candidates may be larger than
                                            we anticipate, enrollment in these clinical trials may be slower than we anticipate or participants
                                            may drop out of these clinical trials at a higher rate than we anticipate&#894;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -18pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18pt"></td><td style="width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify">our
                                            third-party contractors may fail to comply with regulatory requirements or meet their contractual
                                            obligations to us in a timely manner, or at all&#894;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -18pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18pt"></td><td style="width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify">regulators
                                            or IRBs may not authorize us or our investigators to commence a clinical trial or conduct
                                            a clinical trial at a prospective trial site or amend a trial protocol&#894;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -18pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18pt"></td><td style="width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify">we
                                            may have delays in reaching or fail to reach agreement on acceptable clinical trial contracts
                                            or clinical trial protocols with prospective trial sites and CROs&#894;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -18pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18pt"></td><td style="width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify">we
                                            or our investigators might have to suspend or terminate clinical trials of our product candidates
                                            for various reasons, including noncompliance with regulatory requirements, a finding that
                                            our product candidates have undesirable side effects or other unexpected characteristics,
                                            or a finding that the participants are being exposed to unacceptable health risks&#894;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -18pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18pt"></td><td style="width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify">the
                                            cost of clinical trials of our product candidates may be greater than we anticipate&#894;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -18pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18pt"></td><td style="width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify">the
                                            supply or quality of our product candidates or other materials necessary to conduct clinical
                                            trials of our product candidates may be insufficient or inadequate&#894;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -18pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18pt"></td><td style="width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify">there
                                            may be changes in government regulations or administrative actions&#894;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -18pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18pt"></td><td style="width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify">our
                                            product candidates may have undesirable adverse effects or other unexpected characteristics&#894;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -18pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18pt"></td><td style="width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify">we
                                            may not be able to demonstrate that a product candidate&#8217;s clinical and other benefits
                                            outweigh its safety risks&#894;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -18pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18pt"></td><td style="width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify">we
                                            may not be able to demonstrate that a product candidate provides an advantage over current
                                            standards of care of future competitive therapies in development&#894;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -18pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18pt"></td><td style="width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify">regulators
                                            may revise the requirements for approving our product candidates, or such requirements may
                                            not be as we anticipate&#894; and</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -18pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18pt"></td><td style="width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify">any
                                            future collaborators that conduct clinical trials may face any of the above issues, and may
                                            conduct clinical trials in ways they view as advantageous to them but that are suboptimal
                                            for us.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -18pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">We may also encounter delays
if a clinical trial is suspended or terminated by us, by the IRBs of the institutions in which such trials are being conducted, by the
trial&#8217;s data safety monitoring board, by the FDA, EMA or other regulatory agencies. Such authorities may suspend or terminate one
or more of our clinical trials due to a number of factors, including our failure to conduct the clinical trial in accordance with relevant
regulatory requirements or clinical protocols, inspection of the clinical trial operations or trial site by the FDA, EMA or other regulatory
agencies resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit
from using a drug, changes in governmental regulations or administrative actions or lack of adequate funding to continue the clinical
trial.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt"></p><div>

</div><!-- Field: Page; Sequence: 39; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">Further, conducting clinical
trials in countries outside of the United States and European Union, as we plan to do for our product candidates, presents additional
risks that may delay completion of our clinical trials. These risks include the failure of enrolled patients in foreign countries to
adhere to clinical protocol as a result of differences in healthcare services or cultural customs, managing additional administrative
burdens associated with jurisdiction-specific regulatory schemes, as well as political and economic risks relevant to such jurisdictions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">In addition, disruptions caused
by the COVID-19 pandemic may increase the likelihood that we encounter difficulties or delays in initiating, screening, enrolling, conducting,
or completing our ongoing and planned preclinical studies and clinical trials. Clinical site initiation and patient screening and enrollment
may be delayed due to prioritization of hospital resources toward the COVID-19 pandemic. Investigators and patients may not be able to
comply with clinical trial protocols if quarantines impede patient movement or interrupt healthcare services. Similarly, our ability
to recruit and retain patients and principal investigators and site staff who, as healthcare providers, may have heightened exposure
to COVID-19, could be limited, which in turn could adversely impact our clinical trial operations. Additionally, we may experience interruption
of key clinical trial activities, such as clinical trial site monitoring, due to limitations on travel, quarantines or social distancing
protocols imposed or recommended by federal or state governments, employers and others in connection with the ongoing COVID-19 pandemic.
As a result of the COVID-19 pandemic, we have faced and may continue to face delays in meeting our anticipated timelines for our ongoing
and planned clinical trials. Specifically, the initial timeline for submission of our BLA for omidubicel was delayed, in part, as a result
of the impact of the COVID-19 pandemic on our operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">If we experience delays in
carrying out or completing any clinical trial of our product candidates, the commercial prospects of our product candidates may be harmed,
and our ability to generate product revenue from any of these product candidates will be delayed. In addition, any delays in completing
our clinical trials will increase our costs, slow down our product candidate development and approval process and jeopardize our ability
to commence product sales and generate revenue. Any of these occurrences may significantly harm our business and financial condition.
In addition, many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately
lead to the denial of regulatory approval of our product candidates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The results of earlier studies and
trials may not be predictive of future trial results, and our clinical trials may fail to adequately demonstrate the safety and efficacy
of our product candidates.</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">Results from preclinical studies
or early-stage clinical trials are not necessarily predictive of future clinical trial results, and interim results of a clinical trial
are not necessarily indicative of final results. For example, our Phase 1/2 clinical trial of GDA-201 demonstrated significant clinical
activity in patients with non-Hodgkin lymphoma, with 13 complete responses and one partial response observed in 19 patients, for a response
rate of 74%. However, further clinical trials may show that the response rate in a larger sample size is lower than 74%. A decrease in
the response rate could cause us to abandon further development of GDA-201 in this indication.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">There is a high failure rate
for product candidates proceeding through clinical trials. Many companies in the pharmaceutical industry have suffered significant setbacks
in late-stage clinical trials even after achieving promising results in preclinical testing and earlier-stage clinical trials. Data obtained
from preclinical and clinical activities are subject to varying interpretations, including conclusions about relapse rates that are based
on small sample sizes of data, which may delay, limit or prevent regulatory approval. In addition, we may experience regulatory delays
or rejections as a result of many factors, including due to changes in regulatory policy during the period of our product candidate development.
Success in preclinical testing and early clinical trials does not ensure that later clinical trials will generate the same results or
otherwise provide adequate data to demonstrate the efficacy and safety of a product candidate.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt"></p><div>

</div><!-- Field: Page; Sequence: 40; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Interim, &#8220;topline&#8221; and
preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available
and are subject to audit and verification procedures that could result in material changes in the final data.</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">From time to time, we may
publish interim, &#8220;top-line&#8221; or preliminary data from our clinical studies. Interim data from clinical trials that we may
complete are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and
more patient data become available. Preliminary or &#8220;top-line&#8221; data also remain subject to audit and verification procedures
that may result in the final data being materially different from the preliminary data previously published. In addition, successful
results in one or a few patients may not be indicative of the final results after completion of treatment of all patients in a clinical
trial. As a result, interim and preliminary data should be viewed with caution until the final data are available. Adverse changes between
preliminary or interim data and final data could significantly harm our business prospects.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The success of our NAM technology
platform and our product candidates is substantially dependent on developments within the emerging field of cellular therapies, some
of which are beyond our control.</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">Our NAM expansion technology
platform and our product candidates are designed to increase the therapeutic functionality of cell therapy products, which represents
a novel development within the field of cellular therapeutics. Stem cell therapies in turn represent a relatively new therapeutic area
that presents a number of scientific, clinical, regulatory and ethical challenges. Any adverse developments in the field of stem cell
therapies generally, and in the practice of hematopoietic stem cell transplant in particular, will negatively impact our ability to develop
and commercialize our product candidates. In particular, we currently anticipate that omidubicel and any additional product candidates
that we develop from our NAM technology platform would be adopted into the current standard of care for hematopoietic stem cell transplant,
or HSCT, procedures. If the market for HSCT procedures declines or fails to grow at anticipated levels for any reason, or if the development
and commercialization of therapies targeted at the underlying cause of diseases addressed by omidubicel obviate the need for patients
to undergo HSCT procedures, our business prospects will be significantly harmed.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Because our product candidates are
based on novel technologies, it is difficult to predict the time and cost of development and our ability to successfully complete clinical
development of these product candidates and obtain the necessary regulatory approvals for commercialization.</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">Our product candidates are
based on our novel NAM technology platform, and unexpected problems related to this new technology may arise that could cause us to delay,
suspend or terminate our development efforts. Regulatory approval of novel product candidates such as ours can be more expensive and
take longer, than for other more well-known or extensively studied pharmaceutical or biopharmaceutical product candidates due to our
and regulatory agencies&#8217; lack of experience with them. Stem cell therapies represent a relatively new therapeutic area, and the
FDA has cautioned consumers about potential safety risks associated with these therapies. To date, there are relatively few approved
stem cell products.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">Regulatory requirements governing
cell therapy products have changed frequently and may continue to change in the future. For example, the FDA established the Office of
Cellular, Tissue and Gene Therapies within its Center for Biologics Evaluation and Research, or CBER, to consolidate the review of gene
therapy and related products, and the Cellular, Tissue and Gene Therapies Advisory Committee to advise CBER on its review. In addition,
adverse developments in clinical trials of potential stem cell therapies conducted by others may cause the FDA or other regulatory bodies
to change the requirements for approval of any of our product candidates. These regulatory authorities and advisory groups and the new
requirements or guidelines they promulgate may lengthen the regulatory review process, require us to perform additional studies, increase
our development costs, lead to changes in regulatory positions and interpretations, delay or prevent approval and commercialization of
our product candidates or lead to significant post-approval limitations or restrictions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt"></p><div>

</div><!-- Field: Page; Sequence: 41; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We may find it difficult to enroll
patients in our clinical studies, which could delay or prevent us from proceeding with clinical trials.</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">Identifying and qualifying
patients to participate in clinical studies of our product candidates is critical to our success. The timing of our clinical trials depends
in part on the speed at which we can recruit patients to participate in testing our product candidates, and we may experience delays
in our clinical trials if we encounter difficulties in enrollment. Patient enrollment and retention in clinical trials depends on many
factors, including the size of the patient population, the nature of the trial protocol, our ability to recruit clinical trial investigators
with the appropriate competencies and experience, the existing body of safety and efficacy data with respect to the study drug, the number
and nature of competing treatments and ongoing clinical trials of competing drugs for the same indication, the proximity of patients
to clinical sites, clinicians&#8217; and patients&#8217; perceptions as to the potential advantages of the product candidate being studied
in relation to other available therapies, including any drugs that may be approved for the indications we are investigating, the eligibility
criteria for the study, our ability to obtain and maintain patient consents and the risk that patients enrolled in clinical trials will
drop out of the trials before completion. For example, patients may prefer to undergo treatment with stem cell transplantation with cells
sourced from matched related donors, matched unrelated donors or haploidentical donors, as opposed to being treated with omidubicel,
which would adversely affect the enrollment of our clinical trials.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">We may not be able to identify,
recruit and enroll a sufficient number of patients to complete our clinical studies because of the perceived risks and benefits of the
product candidate under study, the availability and efficacy of competing therapies and clinical studies, the proximity and availability
of clinical study sites for prospective patients and the patient referral practices of physicians. If patients are unwilling to participate
in our studies for any reason, the timeline for recruiting patients, conducting studies, and obtaining regulatory approval of potential
products will be delayed.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">In addition, any negative
results we may report in clinical trials of our product candidate may make it difficult or impossible to recruit and retain patients
in other clinical trials of that same product candidate. Delays or failures in planned patient enrollment or retention may result in
increased costs, program delays or both, which could have a harmful effect on our ability to develop our product candidates, or could
render further development impossible. For example, the impact of public health epidemics, such as the ongoing COVID-19 pandemic, may
delay or prevent patients from enrolling or from receiving treatment in accordance with the protocol and the required timelines, which
could delay our clinical trials, or prevent us from completing our clinical trials at all, and harm our ability to obtain approval for
such product candidate. Further, if patients drop out of our clinical trials, miss follow-up visits, or otherwise fail to follow clinical
trial protocols, whether as a result of the COVID-19 pandemic or actions taken to slow the spread of COVID-19 or otherwise, the integrity
of data from our clinical trials may be compromised or not accepted by the FDA or other regulatory authorities, which would represent
a significant setback for the applicable program. In addition, we may rely on CROs and clinical trial sites to ensure proper and timely
conduct of our future clinical trials and, while we intend to enter into agreements governing their services, we will be limited in our
ability to compel their actual performance.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our product candidates and the administration
process may cause undesirable side effects or have other properties that could delay or prevent their regulatory approval, limit the
commercial profile of an approved label or result in significant negative consequences following marketing approval, if any, and result
in costly and damaging product liability claims against us.</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">Undesirable side effects,
including toxicology, caused by our product candidates, or the drugs encapsulated by our product candidates, could cause us or regulatory
authorities to interrupt, delay or halt clinical studies and could result in a more restrictive label or the delay or denial of regulatory
approval by the FDA, EMA or other regulatory agencies. Results of our studies could reveal a high and unacceptable severity and prevalence
of these or other side effects. In such an event, our clinical studies could be suspended or terminated, and the FDA, EMA or other regulatory
agencies could order us to cease further development of or deny or withdraw approval of our product candidates for any or all targeted
indications. Moreover, during the conduct of clinical trials, patients report changes in their health, including illnesses, injuries
and discomforts, to their study doctor. Often, it is not possible to determine whether or not the product candidate being studied caused
these conditions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">Drug-related, drug-product
related, formulation-related and administration-related side effects could affect patient recruitment, the ability of enrolled patients
to complete the clinical study or result in potential product liability claims, which could exceed our clinical trial insurance coverage.
We obtain clinical trial insurance policies with respect to all our clinical studies. The insurance policies are in accordance with the
local regulations applicable in the jurisdictions where the studies are performed outside of clinical trials.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt"></p><div>

</div><!-- Field: Page; Sequence: 42; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">Further, patients with the
diseases targeted by our product candidates are often already in severe and advanced stages of disease and have both known and unknown
significant pre-existing and potentially life-threatening health risks. Severe (grade 4) infusion reactions have also been reported in
approximately 4% of patients treated with omidubicel. The most common adverse events related to omidubicel were graft versus host disease,
or GvHD, (10%), pain (8%), transplant failure (4%), hypertension (4%), and dyspnea (2%). During the course of treatment, patients may
suffer adverse events, including death, for reasons that may be related to our product candidates. In our Phase 1/2 clinical trial of
omidubicel for the treatment of sickle cell disease, or SCD, which is a chronic illness, two of the patients died: one due to chronic
GvHD and the other due to secondary graft failure. In our Phase 1/2 trial of omidubicel for the treatment of hematologic malignancies,
approximately 10% of patients who received omidubicel experienced serious GvHD. In our Phase 1/2 clinical trial of GDA-201, adverse events
included one patient who died of E. coli sepsis. There was also a low level of sporadic engraftment failures. Such events could subject
us to costly litigation, require us to pay substantial amounts of money to injured patients, delay, negatively impact or end our opportunity
to receive or maintain regulatory approval to market our products, or require us to suspend or abandon our commercialization efforts.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">Even in a circumstance in
which we do not believe that an adverse event is related to our products, the investigation into the circumstance may be time-consuming
or inconclusive. For instance, allogeneic bone marrow transplant, the area in which omidubicel is being used, is associated with serious
complications, including death. In addition, there are expected toxicities for patients who receive an allogeneic bone marrow transplant,
such as infertility. Thus, while not directly associated with omidubicel, there are attendant risks with the space in which our product
candidates operate, and any related investigations may interrupt our development and commercialization efforts, delay our regulatory
approval process, or impact and limit the type of regulatory approvals our product candidates receive or maintain. As a result of these
factors, a product liability claim, even if successfully defended, could have a material adverse effect on our business, financial condition
or results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">Additionally, if one or more
of our product candidates receives marketing approval, and we or others later identify undesirable side effects caused by such products,
a number of potentially significant negative consequences could result, including, but not limited to:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18pt"></td><td style="width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify">regulatory
                                            authorities may suspend or withdraw approvals of such product&#894;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -18pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18pt"></td><td style="width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify">regulatory
                                            authorities may require additional warnings on the label, such as a &#8220;black box&#8221;
                                            warning or contraindication&#894;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -18pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18pt"></td><td style="width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify">additional
                                            restrictions may be imposed on the marketing of the particular product or the manufacturing
                                            processes for the product or any component thereof&#894;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -18pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18pt"></td><td style="width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify">we
                                            may be required to create a REMS, which could include a medication guide outlining the risks
                                            of such side effects for distribution to patients, a communication plan for healthcare providers
                                            and/or other elements to assure safe use&#894;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -18pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18pt"></td><td style="width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify">we
                                            may be required to recall a product, change the way a product candidate is administered or
                                            conduct additional clinical trials&#894;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -18pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18pt"></td><td style="width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify">we
                                            could be sued and held liable for harm caused to patients&#894;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -18pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18pt"></td><td style="width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify">the
                                            product may become less competitive&#894; and</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -18pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 18pt"></td><td style="width: 18pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td><td style="text-align: justify">our
                                            reputation may suffer.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -18pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">Any of these events could
prevent us from achieving or maintaining market acceptance of the particular product candidate, if approved, and could significantly
harm our business, results of operations and prospects.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt"></p><div>

</div><!-- Field: Page; Sequence: 43; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Risks
Related to Government Regulation</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>Even
if we complete the necessary clinical trials, we cannot predict when, or if, we will obtain regulatory approval to commercialize any
of our product candidates, and the approval may be for a narrower indication than we seek or be subject to other limitations or restrictions
that limit its commercial profile</i></b>.</span></p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">We
cannot commercialize a product candidate until the appropriate regulatory authorities have reviewed and approved the product candidate.
Even if our current or future product candidates meet safety and efficacy endpoints in clinical trials, the regulatory authorities may
not complete their review processes in a timely manner, or we may not be able to obtain regulatory approval. Additional delays may result
if an FDA Advisory Committee or other regulatory authority recommends non-approval or restrictions on approval. In addition, we may experience
delays or rejections based upon additional government regulation from future legislation or administrative action, or changes in regulatory
authority policy during the period of product development, clinical trials and the review process.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Regulatory
authorities also may approve a product candidate for more limited indications than requested or they may impose significant limitations
in the form of warnings or a REMS. These regulatory authorities may require precautions or contra-indications with respect to conditions
of use or they may grant approval subject to the performance of costly post-marketing clinical trials. In addition, regulatory authorities
may not approve the labeling claims that are necessary or desirable for the successful commercialization of any of our product candidates.
Any of the foregoing scenarios could materially harm the commercial prospects for our product candidates and materially and adversely
affect our business, financial condition, results of operations and prospects.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Even
if we obtain regulatory approval for a product candidate, our products will remain subject to regulatory scrutiny.</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">If
one of our product candidates is approved, it will be subject to ongoing regulatory requirements for manufacturing, labeling, packaging,
storage, advertising, promotion, sampling, record-keeping, conduct of post-marketing studies, and submission of safety, efficacy, and
other post- market information, including both federal and state requirements in the United States and European Union and requirements
of comparable regulatory authorities.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Manufacturers
and manufacturers&#8217; facilities are required to comply with extensive FDA, EMA and the requirements of additional regulatory authorities,
including ensuring that quality control and manufacturing procedures conform to cGMP regulations. As such, we and our contract manufacturers
will be subject to continual review and inspections to assess compliance with cGMP and adherence to commitments made in any approved
marketing application. Accordingly, we and others with whom we work must continue to expend time, money, and effort in all areas of regulatory
compliance, including manufacturing, production, and quality control.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">We
will have to comply with requirements concerning advertising and promotion for our products. Promotional communications with respect
to prescription drugs and biologics are subject to a variety of legal and regulatory restrictions and must be consistent with the information
in the product&#8217;s approved label. As such, we may not promote our products &#8220;off-label&#8221; for indications or uses for which
they do not have approval. The holder of an approved application must submit new or supplemental applications and obtain approval for
certain changes to the approved product, product labeling, or manufacturing process. We could also be asked to conduct post-marketing
clinical studies to verify the safety and efficacy of our products in general or in specific patient subsets. An unsuccessful post- marketing
study or failure to complete such a study could result in the withdrawal of marketing approval.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">If
a regulatory agency discovers previously unknown problems with a product, such as adverse events of unanticipated severity or frequency,
or problems with the facility where the product is manufactured, or disagrees with the promotion, marketing or labeling of a product,
such regulatory agency may impose restrictions on that product or us, including requiring withdrawal of the product from the market.
If we fail to comply with applicable regulatory requirements, a regulatory agency or enforcement authority may, among other things:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">issue
                                            warning letters&#894;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">impose
                                            civil or criminal penalties&#894;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">suspend
                                            or withdraw regulatory approval&#894;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">suspend
                                            any of our clinical studies&#894;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"></p><div>

</div><!-- Field: Page; Sequence: 44; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">refuse
                                            to approve pending applications or supplements to approved applications submitted by us&#894;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">impose
                                            restrictions on our operations, including closing our contract manufacturers&#8217; facilities&#894;
                                            or</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">seize
                                            or detain products, or require a product recall.</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Any
government investigation of alleged violations of law could require us to expend significant time and resources in response and could
generate negative publicity. Any failure to comply with ongoing regulatory requirements may significantly and adversely affect our ability
to commercialize and generate revenue from our products. If regulatory sanctions are applied or if regulatory approval is withdrawn,
the value of our company and our operating results will be adversely affected.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Moreover,
the policies of the FDA and of other regulatory authorities may change and additional government regulations may be enacted that could
prevent, limit or delay regulatory approval of our product candidates. We cannot predict the likelihood, nature or extent of government
regulation that may arise from future legislation or administrative or executive action, either in the United States or abroad. If we
are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able
to maintain regulatory compliance, we may lose any marketing approval that we may have obtained and we may not achieve or sustain profitability.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">A
Breakthrough Therapy Designation by the FDA may not lead to a faster development or regulatory review or approval process and it does
not increase the likelihood that our product candidates will receive marketing approval.</span></p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">We
have obtained Breakthrough Therapy Designation for omidubicel for the treatment of hematologic malignancies and may receive it in the
future if the clinical data support such a designation for one or more of our other product candidates. A breakthrough therapy is defined
as a drug or biologic that is intended, alone or in combination with one or more other drugs or biologics, to treat a serious or life-threatening
disease or condition and preliminary clinical evidence indicates that the drug, or biologic, may demonstrate substantial improvement
over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical
development. For product candidates that have been designated as breakthrough therapies, interaction and communication between the FDA
and the sponsor of the trial can help to identify the most efficient path for clinical development while minimizing the number of patients
placed in ineffective control regimens. Biologics designated as breakthrough therapies by the FDA may also be eligible for accelerated
approval.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Designation
as a breakthrough therapy is within the discretion of the FDA. Accordingly, even if we believe one of our current or future product candidates
meets the criteria for designation as a breakthrough therapy, the FDA may disagree and instead determine not to make such designation.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">In
any event, the receipt of a Breakthrough Therapy Designation for omidubicel for the treatment of hematologic malignancies may not result
in a faster development process, review or approval compared to drugs considered for approval under non-expedited FDA review procedures
and does not assure ultimate approval by the FDA. In addition, the FDA may later decide that the product no longer meets the conditions
to qualify for Breakthrough Therapy Designation.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">We
may be unable to maintain the benefits associated with orphan drug designations that we have obtained, including market exclusivity,
which may cause our revenue, if any, to be reduced.</span></p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">We
have obtained orphan drug designation for omidubicel from the FDA and the EMA for the treatment of hematologic malignancies, and we may
pursue orphan drug designation for certain of our future product candidates. Under the Orphan Drug Act, the FDA may designate a drug
or biologic product as an orphan drug if it is intended to treat a rare disease or condition, defined as a patient population of fewer
than 200,000 in the United States, or a patient population greater than 200,000 in the United States where there is no reasonable expectation
that the cost of developing the drug will be recovered from sales in the United States. In the European Union, the EMA&#8217;s Committee
for Orphan Medicinal Products, or COMP, grants orphan drug designation to promote the development of products that are intended for the
diagnosis, prevention, or treatment of a life-threatening or chronically debilitating condition affecting not more than five in 10,000
persons in the European Union. Additionally, designation is granted for products intended for the diagnosis, prevention, or treatment
of a life-threatening, seriously debilitating or serious and chronic condition when, without incentives, it is unlikely that sales of
the drug in the European Union would be sufficient to justify the necessary investment in developing the drug or biological product or
where there is no satisfactory method of diagnosis, prevention, or treatment, or, if such a method exists, the medicine must be of significant
benefit to those affected by the condition.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 45; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">In
the United States, orphan drug designation entitles a party to financial incentives such as opportunities for grant funding towards clinical
trial costs, tax advantages, and application fee waivers. In addition, if a product receives the first FDA approval for the indication
for which it has orphan designation, the product is entitled to orphan drug exclusivity, which means the FDA may not approve any other
application to market the same drug for the same indication for a period of seven years, except in limited circumstances, such as a showing
of clinical superiority over the product with orphan exclusivity or where the manufacturer is unable to assure sufficient product quantity
the orphan patient population. In the European Union, orphan drug designation entitles a party to financial incentives such as reduction
of fees or fee waivers and ten years of market exclusivity following drug or biological product approval. This period may be reduced
to six years if the orphan drug designation criteria are no longer met, including where it is shown that the product is sufficiently
profitable not to justify maintenance of market exclusivity.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Even
though we have obtained orphan drug designation for omidubicel from the FDA and the EMA for the treatment of hematologic malignancies,
we may not be the first to obtain marketing approval for such indication due to the uncertainties associated with developing pharmaceutical
products. Further, orphan drug exclusivity may not effectively protect the product candidate from competition because different drugs
with different active moieties can be approved for the same condition. Even after an orphan drug is approved, the FDA or EMA can subsequently
approve the same drug with the same active moiety for the same condition if the FDA or EMA concludes that the later drug is clinically
superior in that it is safer, more effective, or makes a major contribution to patient care. Orphan drug designation neither shortens
the development time or regulatory review time of a drug or biologic nor gives the drug or biologic any advantage in the regulatory review
or approval process.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Enacted
and future healthcare legislation may increase the difficulty and cost for us to obtain marketing approval of and commercialize our product
candidates and may affect the prices we may set.</span></p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">In
the United States, the European Union and other jurisdictions, there have been, and we expect there will continue to be, a number of
legislative and regulatory changes and proposed changes to the healthcare system that could affect our future results of operations.
In particular, there have been and continue to be a number of initiatives at the U.S. federal and state levels that seek to reduce healthcare
costs and improve the quality of healthcare. For example, in March 2010, the Patient Protection and Affordable Care Act, as amended by
the Health Care and Education Reconciliation Act, or collectively the PPACA, was enacted, which substantially changed the way healthcare
is financed by both governmental and private payers. Among the provisions of the PPACA, those of greatest importance to the pharmaceutical
and biotechnology industries include the following: an annual, non-deductible fee payable by any entity that manufactures or imports
certain branded prescription drugs and biologic agents (other than those designated as orphan drugs), which is apportioned among these
entities according to their market share in certain government healthcare programs&#894;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">new
                                            requirements to report certain financial arrangements with physicians and teaching hospital
                                            personnel including transplant teams, including reporting &#8220;transfers of value&#8221;
                                            made or distributed to physicians, as defined by such law, and reporting investment interests
                                            held by physicians and their immediate family members&#894;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">a
                                            new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program
                                            are calculated for drugs that are inhaled, infused, instilled, implanted or injected&#894;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">expansion
                                            of eligibility criteria for Medicaid programs by, among other things, allowing states to
                                            offer Medicaid coverage to certain individuals with income at or below 133% of the federal
                                            poverty level, thereby potentially increasing a manufacturer&#8217;s Medicaid rebate liability&#894;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">a
                                            licensure framework for follow-on biologic products&#894;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">a
                                            new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and
                                            conduct comparative clinical effectiveness research, along with funding for such research&#894;
                                            and</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">establishment
                                            of a Center for Medicare Innovation at the Centers for Medicare &amp; Medicaid Services,
                                            or CMS, to test innovative payment and service delivery models to lower Medicare and Medicaid
                                            spending, potentially including prescription drug spending.</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"></p><div>

</div><!-- Field: Page; Sequence: 46; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">There
have been judicial and Congressional challenges to certain aspects of the PPACA. For example, tax legislation enacted on December 22,
2017, titled &#8220;an Act to provide for reconciliation pursuant to titles II and V of the concurrent resolution on the budget for fiscal
year 2018,&#8221; or the Tax Act, included a provision repealing, effective January 1, 2019, the tax-based shared responsibility payment
imposed by the PPACA on certain individuals who fail to maintain qualifying health coverage for all or part of a year that is commonly
referred to as the &#8220;individual mandate&#8221;. On June 17, 2021, the U.S. Supreme Court dismissed a challenge on procedural grounds
that argued the PPACA is unconstitutional in its entirety because the &#8220;individual mandate&#8221; was repealed by Congress. Thus,
the PPACA will remain in effect in its current form. Further, prior to the U.S. Supreme Court ruling, on January 28, 2021, President
Biden issued an executive order to initiate a special enrollment period from February 26, 2021 through August 15, 2021 for purposes of
obtaining health insurance coverage through the PPACA marketplace. The executive order also instructed certain governmental agencies
to review and reconsider their existing policies and rules that limit access to healthcare, including among others, reexamining Medicaid
demonstration projects and waiver programs that include work requirements, and policies that create unnecessary barriers to obtaining
access to health insurance coverage through Medicaid or the PPACA. It is possible that the PPACA will be subject to judicial or Congressional
challenges in the future. It is unclear how such challenges and the healthcare reform measures of the Biden administration.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">In
addition, other legislative changes have been proposed and adopted in the United States since the PPACA was enacted. In August 2011,
the Budget Control Act of 2011, among other things, led to aggregate reductions of Medicare payments to providers of 2% per fiscal year.
These reductions went into effect in April 2013 and, due to subsequent legislative amendments to the statute, will remain in effect through
2031 with the exception of a temporary suspension from May 1, 2020 through March 31, 2022 unless additional action is taken by Congress.
Under current legislation, the actual reduction in Medicare payments will vary from 1% in 2022 to up to 3% in the final fiscal year of
this sequester. In January 2013, the American Taxpayer Relief Act of 2012 was signed into law, which, among other things, further reduced
Medicare payments to several types of providers, including hospitals, imaging centers and cancer treatment centers, and increased the
statute of limitations period for the government to recover overpayments to providers from three to five years. Additionally, Congress
is considering additional health reform measures. These new laws or any other similar laws introduced in the future may result in additional
reductions in Medicare and other health care funding, which could negatively affect our customers and accordingly, our financial operations.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Moreover,
payment methodologies are subject to changes in healthcare legislation and regulatory initiatives. For example, CMS has developed value-based
payment models for a variety of care settings, including the inpatient prospective payment system used for reimbursing inpatient hospital
services. In addition, recently there has been heightened governmental scrutiny over the manner in which manufacturers set prices for
their marketed products, which has resulted in several U.S. Presidential executive orders, Congressional inquiries and proposed and enacted
federal and state legislation designed to, among other things, bring more transparency to drug pricing, reduce the cost of prescription
drugs under government payer programs, and review the relationship between pricing and manufacturer patient programs. At the federal
level, the Trump administration used several means to propose or implement drug pricing reform, including through federal budget proposals,
executive orders and policy initiatives. For example, on July 24, 2020 and September 13, 2020, the Trump administration announced several
executive orders related to prescription drug pricing that seek to implement several of the administration&#8217;s proposals. As a result,
the FDA concurrently released a final rule and guidance in September2020, providing pathways for states to build and submit importation
plans for drugs from Canada. Further, on November 20, 2020, HHS finalized a regulation removing safe harbor protection for price reductions
from pharmaceutical manufacturers to plan sponsors under Part D, either directly or through pharmacy benefit managers, unless the price
reduction is required by law. The implementation of the rule has been delayed by the Biden administration from January 1, 2022 to January
1, 2023 in response to ongoing litigation. The rule also creates a new safe harbor for price reductions reflected at the point-of-sale,
as well as a new safe harbor for certain fixed fee arrangements between pharmacy benefit managers and manufacturers, the implementation
of which have also been delayed by the Biden administration until January 1, 2023. On November 20, 2020, CMS issued an interim final
rule implementing the Trump administration&#8217;s Most Favored Nation executive order, which would tie Medicare Part B payments for
certain physician-administered drugs to the lowest price paid in other economically advanced countries, effective January 1, 2021. As
a result of litigation challenging the Most Favored Nation model, on December 27, 2021, CMS published a final rule that rescinds the
Most Favored Nation model interim final rule. Additionally, in July 2021, the Biden administration released an executive order, &#8220;Promoting
Competition in the American Economy,&#8221; with multiple provisions aimed at prescription drugs. In response to Biden&#8217;s executive
order, on September 9, 2021, HHS released a Comprehensive Plan for Addressing High Drug Prices that outlines principles for drug pricing
reform and sets out a variety of potential legislative policies that Congress could pursue as well as potential administrative actions
HHS can take to advance these principles. No legislation or administrative actions have been finalized to implement these principles.
It is unclear whether these or similar policy initiatives will be implemented in the future.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 47; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">We
expect that additional U.S. federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that
the U.S. federal government will pay for healthcare products and services, which could result in reduced demand for our product candidates
or additional pricing pressures.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Individual
states in the United States have also increasingly passed legislation and implemented regulations designed to control pharmaceutical
and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access
and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and
bulk purchasing. Legally mandated price controls on payment amounts by third- party payers or other restrictions could harm our business,
results of operations, financial condition and prospects. In addition, regional healthcare authorities and individual hospitals are increasingly
using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription drug and
other healthcare programs. This could reduce the ultimate demand for our product candidates or put pressure on our product pricing.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">In
the European Union, similar political, economic and regulatory developments may affect our ability to profitably commercialize our product
candidates, if approved. In addition to continuing pressure on prices and cost containment measures, legislative developments at the
European Union or member state level may result in significant additional requirements or obstacles that may increase our operating costs.
The delivery of healthcare in the European Union, including the establishment and operation of health services and the pricing and reimbursement
of medicines, is almost exclusively a matter for national, rather than European Union, law and policy. National governments and health
service providers have different priorities and approaches to the delivery of health care and the pricing and reimbursement of products
in that context. In general, however, the healthcare budgetary constraints in most European Union member states have resulted in restrictions
on the pricing and reimbursement of medicines by relevant health service providers. Any increase in European Union and national regulatory
burdens on those wishing to develop and market products could prevent or delay marketing approval of our product candidates, restrict
or regulate post- approval activities and affect our ability to commercialize our product candidates, if approved. In markets outside
of the United States and European Union, reimbursement and healthcare payment systems vary significantly by country, and many countries
have instituted price ceilings on specific products and therapies.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">We
cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action
in the United States, the European Union or any other jurisdiction. It is also possible that additional government action is taken in
response to the COVID-19 pandemic. If we or any third parties we may engage are slow or unable to adapt to changes in existing requirements
or the adoption of new requirements or policies, or if we or such third parties are not able to maintain regulatory compliance, our product
candidates may lose any regulatory approval that may have been obtained and we may not achieve or sustain profitability.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Our
business operations and current and future relationships with investigators, healthcare professionals, consultants, third-party payers,
patient organizations and customers will be subject to applicable healthcare regulatory laws, which could expose us to penalties.</span></p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Our
business operations and current and future arrangements with investigators, healthcare professionals, consultants, third-party payers,
patient organizations and customers, may expose us to broadly applicable fraud and abuse, privacy and security and other healthcare laws
and regulations. These laws may constrain the business or financial arrangements and relationships through which we conduct our operations,
including how we research, market, sell and distribute our product candidates, if approved. Such laws include:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">the
                                            U.S. federal Anti-Kickback Statute, which prohibits, among other things, persons or entities
                                            from knowingly and willfully soliciting, offering, receiving or providing any remuneration
                                            (including any kickback, bribe, or certain rebate), directly or indirectly, overtly or covertly,
                                            in cash or in kind, to induce or reward, or in return for, either the referral of an individual
                                            for, or the purchase, lease, order or recommendation of, any good, facility, item or service,
                                            for which payment may be made, in whole or in part, under any U.S. federal healthcare program,
                                            such as Medicare and Medicaid. A person or entity does not need to have actual knowledge
                                            of the statute or specific intent to violate it in order to have committed a violation&#894;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"></p><div>

</div><!-- Field: Page; Sequence: 48; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">the
                                            U.S. federal civil and criminal false claims, including the civil False Claims Act, which
                                            prohibit, among other things, including through civil whistleblower or qui tam actions, and
                                            civil monetary penalties laws which prohibit individuals or entities from knowingly presenting,
                                            or causing to be presented, to the U.S. federal government, claims for payment or approval
                                            that are false or fraudulent, knowingly making, using or causing to be made or used, a false
                                            record or statement material to a false or fraudulent claim, or from knowingly making a false
                                            statement to avoid, decrease or conceal an obligation to pay money to the U.S. federal government.
                                            Pharmaceutical manufacturers can cause false claims to be presented to the U.S. federal government
                                            by engaging in impermissible marketing practices, such as the off-label promotion of a product
                                            for an indication for which it has not received FDA approval. In addition, the government
                                            may assert that a claim including items and services resulting from a violation of the U.S.
                                            federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the
                                            civil False Claims Act&#894;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">the
                                            Health Insurance Portability and Accountability Act, or HIPAA, which imposes criminal and
                                            civil liability for, among other things, knowingly and willfully executing, or attempting
                                            to execute, a scheme to defraud any healthcare benefit program, or knowingly and willfully
                                            falsifying, concealing or covering up a material fact or making any materially false statement,
                                            in connection with the delivery of, or payment for, healthcare benefits, items or services.
                                            Similar to the U.S. federal Anti-Kickback Statute, a person or entity does not need to have
                                            actual knowledge of the healthcare fraud statute implemented under HIPAA or specific intent
                                            to violate it in order to have committed a violation&#894;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">HIPAA,
                                            as amended by the Health Information Technology for Economic and Clinical Health Act, or
                                            HITECH, and its implementing regulations, which also imposes certain obligations, including
                                            mandatory contractual terms, with respect to safeguarding the privacy and security of individually
                                            identifiable health information of covered entities subject to the rule, such as health plans,
                                            healthcare clearinghouses and certain healthcare providers, as well as their business associates,
                                            independent contractors of a covered entity that perform certain services involving the use
                                            or disclosure of individually identifiable health information on their behalf and their subcontractors
                                            that use, disclose, access, or otherwise process individually identifiable health information&#894;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">the
                                            Food Drug and Cosmetic Act, or the FDCA, which prohibits, among other things, the adulteration
                                            or misbranding of drugs, biologics and medical devices&#894;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">the
                                            U.S. Public Health Service Act, which prohibits, among other things, the introduction into
                                            interstate commerce of a biological product unless a biologics license is in effect for that
                                            product&#894;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">the
                                            U.S. Physician Payments Sunshine Act and its implementing regulations, which requires certain
                                            manufacturers of drugs, devices, biologics and medical supplies that are reimbursable under
                                            Medicare, Medicaid, or the Children&#8217;s Health Insurance Program, with specific exceptions,
                                            to report annually to the government information related to certain payments and other transfers
                                            of value to physicians (defined to include doctors, dentists, optometrists, podiatrists,
                                            and chiropractors), certain other healthcare professionals (such as physician assistants
                                            and nurse practitioners), and teaching hospitals, as well as ownership and investment interests
                                            held by physicians and their immediate family members&#894;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"></p><div>

</div><!-- Field: Page; Sequence: 49; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">analogous
                                            U.S. state laws and regulations, including: state anti-kickback and false claims laws, which
                                            may apply to our business practices, including but not limited to, research, distribution,
                                            sales and marketing arrangements and claims involving healthcare items or services reimbursed
                                            by any third-party payer, including private insurers&#894; state laws that require pharmaceutical
                                            companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines
                                            and the relevant compliance guidance promulgated by the U.S. federal government, or otherwise
                                            restrict payments that may be made to healthcare providers and other potential referral sources&#894;
                                            state laws and regulations that require drug manufacturers to file reports relating to pricing
                                            and marketing information, which requires tracking gifts and other remuneration and items
                                            of value provided to healthcare professionals and entities&#894; state and local laws requiring
                                            the registration of pharmaceutical sales representatives&#894; and state laws governing the
                                            privacy and security of health information in certain circumstances, many of which differ
                                            from each other in significant ways and often are not preempted by HIPAA, thus complicating
                                            compliance efforts&#894; the U.S. Foreign Corrupt Practices Act of 1977, as amended, which
                                            prohibits, among other things, U.S. companies and their employees and agents from authorizing,
                                            promising, offering, or providing, directly or indirectly, corrupt or improper payments or
                                            anything else of value to non-U.S. government officials, employees of public international
                                            organizations and non-U.S. government owned or affiliated entities, candidates for non-U.S.
                                            political office, and non-U.S. political parties or officials thereof&#894; and</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">similar
                                            healthcare laws and regulations in the European Union and other jurisdictions, including
                                            reporting requirements detailing interactions with and payments to healthcare providers.</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Ensuring
that our internal operations and future business arrangements with third parties comply with applicable healthcare laws and regulations
will involve substantial costs. It is possible that governmental authorities will conclude that our business practices do not comply
with current or future statutes, regulations, agency guidance or case law involving applicable fraud and abuse or other healthcare laws
and regulations. If our operations are found to be in violation of any of the laws described above or any other governmental laws and
regulations that may apply to us, we may be subject to significant penalties, including civil, criminal and administrative penalties,
damages, fines, exclusion from government-funded healthcare programs, such as Medicare and Medicaid or similar programs in other countries
or jurisdictions, integrity oversight and reporting obligations to resolve allegations of non-compliance, disgorgement, individual imprisonment,
contractual damages, reputational harm, diminished profits and the curtailment or restructuring of our operations. If any of the physicians
or other providers or entities with whom we expect to do business are found to not be in compliance with applicable laws, they may be
subject to criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs and imprisonment,
which could affect our ability to operate our business. Further, defending against any such actions can be costly, time-consuming and
may require significant personnel resources. Therefore, even if we are successful in defending against any such actions that may be brought
against us, our business may be impaired.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Legislative
or regulatory healthcare reforms in the United States may make it more difficult and costly for us to obtain regulatory clearance or
approval of our product candidates and to produce, market and distribute our products after clearance or approval is obtained.</span></p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">From
time to time, legislation is drafted and introduced in Congress that could significantly change the statutory provisions governing the
regulatory clearance or approval, manufacture and marketing of regulated products or the reimbursement thereof. In addition, FDA regulations
and guidance are often revised or reinterpreted by the FDA in ways that may significantly affect our business and our products. Any new
regulations or revisions or reinterpretations of existing regulations may impose additional costs or lengthen review times of our product
candidates. We cannot determine what effect changes in regulations, statutes, legal interpretation or policies, when and if promulgated,
enacted or adopted may have on our business in the future. Such changes could, among other things, require:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">changes
                                            to manufacturing methods&#894;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">change
                                            in protocol design&#894;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">additional
                                            treatment arm (control)&#894;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">recall,
                                            replacement, or discontinuance of one or more of our products&#894; and</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">additional
                                            recordkeeping.</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"></p><div>

</div><!-- Field: Page; Sequence: 50; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">We
face competition from other biotechnology and pharmaceutical companies, and our operating results will suffer if we fail to compete effectively.</span></p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">The
biotechnology and pharmaceutical industries are intensely competitive and subject to rapid and significant technological change. We face
competition from major multinational pharmaceutical companies, established and early-stage biotechnology companies, and universities
and other research institutions. Many of our competitors have greater financial and other resources, such as larger research and development
staff and more experienced marketing and manufacturing organizations. Large pharmaceutical companies, in particular, have extensive experience
in clinical testing, obtaining regulatory approvals, recruiting patients and manufacturing pharmaceutical products. These companies also
have significantly greater research, sales and marketing capabilities and collaborative arrangements in our target markets with leading
companies and research institutions.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Established
pharmaceutical companies may also invest heavily to accelerate discovery and development of novel therapeutics or to in-license novel
therapeutics that could make the product candidates that we develop obsolete. As a result of all of these factors, our competitors may
succeed in obtaining patent protection or FDA approval or discovering, developing and commercializing treatments in the rare disease
indications that we are targeting before we do. Smaller or early-stage companies may also prove to be significant competitors, particularly
through collaborative arrangements with large, established companies.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Doctors
may recommend that patients undergo stem cell transplantation using cells from matched related donors, matched or mismatched unrelated
donors, haploidentical donors or unmodified umbilical cord blood instead of using omidubicel or may choose other therapy options instead
of our other NAM-derived product candidates. In addition, there are several clinical-stage development programs that seek to improve
umbilical cord blood transplantation through the use of ex vivo expansion technologies to increase the quantity of hematopoietic stem
cells for use in HSCT or the use of ex vivo differentiation technologies to increase the quantity of hematopoietic progenitor cells for
use in HSCT. We are aware of several other companies with product candidates in various stages of development for allogeneic HSCT grafts,
including Magenta Therapeutics, ExCellThera, Garuda Therapeutics and Bellicum Pharmaceuticals, and for NK cells, including, Takeda Pharmaceutical
Company Limited, Fate Therapeutics, Artiva, Sanofi, MiNK Therapeutics, ONK Therapeutics, Shoreline, Cellularity, NKarta, Wugen, Century
Therapeutics, Appia Bio and FujiFilm Cellular Dynamics. In addition, many universities and private and public research institutes may
develop technologies of interest to us but license them to our competitors. Our competitors may succeed in developing, acquiring or licensing
on an exclusive basis, technologies and drug products that are more effective or less costly than omidubicel or any other product candidates
that we are currently developing or that we may develop, which could render our products obsolete and noncompetitive.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">We
believe that our ability to successfully compete will depend on, among other things:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">the
                                            results of our preclinical studies and clinical trials&#894;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">our
                                            ability to recruit and enroll patients for our clinical trials&#894;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">the
                                            efficacy, safety and reliability of our product candidates&#894;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">the
                                            speed at which we develop our product candidates&#894;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">our
                                            ability to design and successfully execute appropriate clinical trials&#894;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">our
                                            ability to protect, develop and maintain intellectual property rights related to our products&#894;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">our
                                            ability to maintain a good relationship with regulatory authorities&#894;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">the
                                            timing and scope of regulatory approvals, if any&#894;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">our
                                            ability to commercialize and market any of our product candidates that receive regulatory
                                            approval&#894;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">market
                                            perception and acceptance of stem cell therapeutics&#894;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"></p><div>

</div><!-- Field: Page; Sequence: 51; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">acceptance
                                            of our product candidates by physicians and institutions that perform HSCT procedures&#894;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">the
                                            price of our products&#894;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">coverage
                                            and adequate levels of reimbursement under private and governmental health insurance plans,
                                            including Medicare&#894; and</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">our
                                            ability to manufacture and sell commercial quantities of any approved products to the market.</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">If
our competitors market products that are more effective, safer or less expensive than our future products, if any, or that reach the
market sooner than our future products, if any, we may not achieve commercial success. Any inability to successfully compete effectively
will adversely impact our business and financial prospects.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Even
if we obtain and maintain approval for omidubicel or our other product candidates from the FDA, we may never obtain approval outside
of the United States, which would limit our market opportunities and adversely affect our business.</span></p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Approval
of a product candidate in the United States by the FDA does not ensure approval of such product candidate by regulatory authorities in
other countries or jurisdictions, and approval by non-U.S. regulatory authority does not ensure approval by regulatory authorities in
other countries or by the FDA. However, the failure to obtain approval from the FDA or other regulatory authorities may negatively impact
our ability to obtain approval in non-U.S. countries. Sales of omidubicel or our other product candidates outside of the United States
will be subject to the regulatory requirements of other jurisdictions governing clinical trials and marketing approval. Even if the FDA
grants marketing approval for a product candidate, comparable regulatory authorities in other countries also must approve the manufacturing
and marketing of the product candidate in those countries. Approval procedures vary among jurisdictions and can involve requirements
and administrative review periods different from, and more onerous than, those in the United States, including additional preclinical
studies or clinical trials. In many countries outside the United States, a product candidate must be approved for reimbursement before
it can be approved for sale in that country. In some cases, the price that we intend to charge for our product candidates, if approved,
is also subject to approval.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">We
intend to submit a marketing authorization application to the EMA for approval of omidubicel in the European Union, but obtaining such
approval from the European Commission following the opinion of the EMA is a lengthy and expensive process. Even if a product candidate
is approved, the applicable regulatory agency may limit the indications for which the product may be marketed, require extensive warnings
on the product labeling or require expensive and time-consuming additional clinical trials or reporting as conditions of approval. Regulatory
authorities in countries outside of the United States and the European Union also have requirements for approval of product candidates
with which we must comply prior to marketing in those countries. Obtaining non-U.S. regulatory approvals and compliance with non-U.S.
regulatory requirements could result in significant delays, difficulties and costs for us and could delay or prevent the introduction
of our product candidates in certain countries.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Further,
clinical trials conducted in one country may not be accepted by regulatory authorities in other countries. Also, regulatory approval
for a product candidate may be withdrawn. If we fail to comply with the regulatory requirements, our target market will be reduced and
our ability to realize the full market potential of omidubicel or our other product candidates will be harmed and our business, financial
condition, results of operations and prospects will be adversely affected.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
misuse or off-label use of our products may harm our reputation in the marketplace, result in injuries that lead to product liability
suits or result in costly investigations, fines or sanctions by regulatory bodies if we are deemed to have engaged in the promotion of
these uses, any of which could be costly to our business.</span></p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">We
initially intend to seek marketing approval for omidubicel for the treatment of hematologic malignancies. We will train our marketing
and sales personnel or the marketing and sales personnel of any strategic partner to not promote our products, if approved, for any other
uses outside of any FDA-cleared indications for use, known as &#8220;off-label use.&#8221;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 52; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">We
cannot, however, prevent a physician from using our products off-label, when in the physician&#8217;s independent professional medical
judgment, he or she deems it appropriate. As a result, there may be increased risk of injury to patients if physicians attempt to use
our products for these uses for which they are not approved. Furthermore, the use of our products for indications other than those approved
by the FDA or any non-U.S. regulatory body may not effectively treat such conditions, which could harm our reputation in the marketplace
among physicians and patients.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">If
the FDA, EMA or any other regulatory body in a jurisdiction in which we operate determines that our promotional materials or training
constitute promotion of an off-label use, it could request that we modify our training or promotional materials or subject us to regulatory
or enforcement actions, including the issuance or imposition of an untitled letter, which is used for violators that do not necessitate
a warning letter, injunction, seizure, civil fine or criminal penalties. It is also possible that other federal, state or non-U.S. enforcement
authorities might take action under other regulatory authority, such as false claims laws, if they consider our business activities to
constitute promotion of an off-label use, which could result in significant penalties, including, but not limited to, criminal, civil
and administrative penalties, damages, fines, disgorgement, exclusion from participation in government healthcare programs and the curtailment
of our operations.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Collection
and use of data, including personal information, is governed by restrictive regulations that could lead to government enforcement actions,
private litigation, adverse publicity, or other adverse actions that could negatively affect our operating results of business</span></p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">The
collection and use of personal health data in the European Union are governed by the provisions of the General Data Protection Regulation
((EU) 2016/679), or GDPR. This legislation imposes requirements relating to (a) having legal bases for processing personal information
relating to identifiable individuals and transferring such information outside the European Economic Area including to the United States,
(b) providing details to those individuals regarding the processing of their personal information, (c) keeping personal information secure
and confidential, (d) having data processing agreements with third parties who process personal information, (e) responding to individuals&#8217;
requests to exercise their rights in respect of their personal information, (f) reporting security breaches involving personal data to
the competent national data protection authority and, possibly, affected individuals, (g) appointing data protection officers, (h) conducting
data protection impact assessments and (i) recordkeeping. The GDPR imposes additional responsibilities and liabilities in relation to
personal data that we process and we may be required to put in place additional mechanisms ensuring compliance with the new data protection
rules. Further, the GDPR prohibits the transfer of personal data to countries outside the European Economic Area, such as the United
States, which are not considered by the European Commission to provide an adequate level of data protection. Switzerland has adopted
similar restrictions. Although there are legal mechanisms to allow for the transfer of personal data from the EEA and Switzerland to
the United States, they are subject to legal challenges and uncertainty regarding compliance with the European Union data protections
laws. Failure to comply with the requirements of the GDPR and related national data protection laws of the member states of the European
Union may result in substantial fines (up to or the great of &#8364;20 million or 4% of annual global revenue), other administrative penalties
and civil claims being brought against us, which could have a material adverse effect on our business, results of operations and financial
condition. Such civil claims, based on a private right of actions in the GDPR, allow data subjects and consumer associations to lodge
complaints with supervisory authorities, seek judicial remedies, and obtain compensation for damages resulting from violations of the
GDPR.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Risks
Related to our Reliance on Third Parties</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">We
rely on third parties to conduct certain elements of our preclinical studies and clinical trials and perform other tasks for us. If these
third parties do not successfully carry out their contractual duties, meet expected deadlines or comply with regulatory requirements,
we may not be able to obtain regulatory approval for or commercialize our product candidates.</span></p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">We
have relied upon, and plan to continue to rely upon, third-party vendors, including CROs, to monitor and manage data for our ongoing
preclinical studies and clinical trials. We rely on these parties for execution of our preclinical studies and clinical trials, and we
control only certain aspects of their activities. Nevertheless, we are responsible for ensuring that each of our studies is conducted
in accordance with the applicable protocol, legal, regulatory and scientific standards, and our reliance on the vendors and CROs does
not relieve us of our regulatory responsibilities.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 53; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">We
and our CROs and other vendors are required to comply with good clinical practice, or GCP, cGMP, the Helsinki Declaration, the International
Council for Harmonization Guideline for Good Clinical Practice, applicable European Commission Directives on Clinical Trials, laws and
regulations applicable to clinical trials conducted in other territories, good laboratory practices, or GLP, which are regulations and
guidelines enforced by the FDA, the Competent Authorities of the Member States of the European Economic Area, or EEA, and comparable
regulatory authorities for all our product candidates in clinical development as well as rules and regulations regarding the collection
and use of personal data such as the GDPR.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Regulatory
authorities enforce these regulations through periodic inspections of study sponsors, principal investigators, study sites and other
contractors. If we or any of our CROs or vendors fail to comply with applicable regulations, including GCP and cGMP regulations, the
clinical data generated in our clinical studies may be deemed unreliable and the FDA, EMA or comparable regulatory authorities may require
us to perform additional clinical studies before approving our marketing applications. Our failure to comply with these regulations may
require us to repeat clinical studies, which would delay the regulatory approval process.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">If
any of our relationships with these third-party CROs or vendors terminate, we may not be able to enter into arrangements with alternative
CROs or vendors or do so on commercially reasonable terms. In addition, our CROs are not our employees, and, except for remedies available
to us under our agreements with such CROs, we cannot control whether or not they devote sufficient time and resources to our ongoing
clinical, nonclinical and preclinical programs. If CROs do not successfully carry out their contractual duties or obligations or meet
expected deadlines, if they need to be replaced or if the quality or accuracy of the clinical data they obtain is compromised due to
the failure to adhere to our clinical protocols, regulatory requirements or for other reasons, our clinical studies may be extended,
delayed or terminated, and we may not be able to obtain regulatory approval for or successfully commercialize our product candidates.
CROs may also generate higher costs than anticipated, which could adversely affect our results of operations and the commercial prospects
for our product candidates, increase our costs and delay our ability to generate revenue.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Replacing
or adding additional CROs involves additional cost and requires management time and focus. In addition, there is a natural transition
period when a new CRO commences work. As a result, delays occur, which can materially impact our ability to meet our desired clinical
development timelines. Though we carefully manage our relationships with our CROs, we may encounter similar challenges or delays in the
future, which could have a material adverse impact on our business, financial condition and prospects.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Independent
clinical investigators and CROs that we engage to conduct our clinical trials may not devote sufficient time or attention to our clinical
trials or be able to repeat their past success.</span></p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">We
expect to continue to depend on third parties, including independent clinical investigators and CROs, to conduct our clinical trials.
CROs may also assist us in the collection and analysis of data. There is a limited number of third-party service providers and vendors
that specialize or have the expertise required to achieve our business objectives. Identifying, qualifying and managing performance of
third-party service providers can be difficult, time consuming and cause delays in our development programs.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">These
investigators and CROs will not be our employees and we will not be able to control, other than through contract, the amount of resources,
including time, which they devote to our product candidates and clinical trials. If independent investigators or CROs fail to devote
sufficient resources to the development of our product candidates, or if their performance is substandard, it may delay or compromise
the prospects for approval and commercialization of any product candidates that we develop.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Investigators
for our clinical trials may serve as scientific advisors or consultants to us from time to time and receive compensation in connection
with such services. Under certain circumstances, we may be required to report some of these relationships to the FDA or other regulatory
authorities. The FDA or other regulatory authorities may conclude that a financial relationship between us and an investigator has created
a conflict of interest or otherwise affected interpretation of the study. The FDA or other regulatory authorities may therefore question
the integrity of the data generated at the applicable clinical trial site and the utility of the clinical trial itself may be jeopardized.
This could result in a delay in approval or rejection of our marketing applications by the FDA or other regulatory authorities, as the
case may be, and may ultimately lead to the denial of marketing approval of one or more of our product candidates.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 54; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">In
addition, the use of third-party service providers requires us to disclose our proprietary information to these parties, which could
increase the risk that this information will be misappropriated. Further, the FDA and other regulatory authorities require that we comply
with standards, commonly referred to as GCP, for conducting, recording and reporting clinical trials to assure that data and reported
results are credible and accurate and that the rights, integrity and confidentiality of trial subjects are protected. Failure of clinical
investigators or CROs to meet their obligations to us or comply with GCP procedures could adversely affect the clinical development of
our product candidates and harm our business.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">We
rely on a limited number of suppliers to provide the raw materials other than cord blood (serum and growth factor) needed to produce
our product candidates. We have a relationship with a single supplier, Miltenyi Biotec GmbH, for certain equipment (columns and beads)
necessary to create our product candidates.</span></p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">We
do not have any control over the availability of these raw materials or pieces of equipment. If we or our providers are unable to purchase
these raw materials or equipment on acceptable terms, at sufficient quality levels, or in adequate quantities, if at all, the development
and commercialization of our product candidates or any future product candidates, could be delayed or there could be a shortage in supply,
which could impair our ability to meet our development objectives for our product candidates or generate revenue from the sale of any
approved products.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Even
following our establishment of our own planned cGMP-compliant manufacturing capabilities, we intend to continue to rely on third-party
suppliers for these raw materials and pieces of equipment, which will expose us to risks including:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">failure
                                            of any supplier to become or maintain its status as a cGMP-compliant manufacturer of raw
                                            materials, which status is a prerequisite to our attainment of a BLA for omidubicel and our
                                            other product candidate&#894;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">termination
                                            or nonrenewal of supply or service agreements with third parties in a manner or at a time
                                            that is costly or damaging to us&#894; and</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">disruptions
                                            to the operations of our third-party suppliers and service providers caused by conditions
                                            unrelated to our business or operations, including the bankruptcy of the supplier or service
                                            provider.</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">We
rely on a single facility located in Kiryat Gat, Israel to manufacture omidubicel. Severe natural or other disaster, power outages or
disruption at this site could have a material adverse effect on our ability to manufacture sufficient commercial supply.</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-style: normal; font-weight: normal">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">After
the termination of the Services Agreement with Lonza and unless and until we establish an alternative supplier, we will be solely dependent
on our facility in Kiryat Gat, Israel for the manufacture of the commercial supply of omidubicel, if omidubicel is approved. We have
completed construction on the facility in Kiryat Gat and we are now working to qualify our manufacturing process and facility with the
FDA&#8217;s cGMP regulations. Severe natural or other disasters, power outages, ongoing or revived hostilities or other political or
economic factors could severely disrupt our manufacturing operations at our Kiryat Gat facility. If any event occurred that prevented
us from using all or a significant portion of this facility or otherwise disrupted operations, it may be difficult or, in certain cases,
impossible for us to continue manufacturing omidubicel for a substantial period of time in sufficient quantities, or at all. The disaster
recovery and business continuity plans we have in place currently are limited and are unlikely to prove adequate to guarantee a sufficient
continuation of supply in the event of a serious disaster or similar event. Although we intend to establish an alternative source supplier
or manufacturer for the commercial supply of omidubicel, we cannot guarantee that we will be able to establish an alternative source,
supplier or partner for the manufacturing of omidubicel at acceptable commercial terms, or at all.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 55; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Our
reliance on third parties requires us to share our trade secrets and other intellectual property, which increases the possibility that
a competitor will discover them or that our trade secrets and other intellectual property will be misappropriated or disclosed.</span></p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Because
we rely on third parties to provide us with the materials that we use to develop and manufacture our product candidates, we may, at times,
share trade secrets and other intellectual property with such third parties. We seek to protect our proprietary technology in part by
entering into confidentiality agreements and, if applicable, material transfer agreements, collaborative research agreements, consulting
agreements, or other similar agreements with our collaborators, advisors, employees and consultants prior to beginning research or disclosing
proprietary information. These agreements typically limit the rights of the third parties to use or disclose our confidential information,
such as trade secrets and intellectual property. Despite the contractual provisions employed when working with third parties, the need
to share trade secrets and other confidential information increases the risk that such trade secrets become known by our competitors,
are inadvertently incorporated into the technology of others, or are disclosed or used in violation of these agreements. Given that our
proprietary position is based, in part, on our know-how and trade secrets, a competitor&#8217;s discovery of our trade secrets or other
unauthorized use or disclosure would impair our competitive position and may have a material adverse effect on our business.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Despite
our efforts to protect our trade secrets, our competitors or other third parties may discover our trade secrets, either through breach
of these agreements, independent development or publication of information including our trade secrets by third parties. A competitor&#8217;s
or other third party&#8217;s discovery of our trade secrets would impair our competitive position and have an adverse impact on our business,
financial condition, results of operations and prospects.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">We
face a variety of challenges and uncertainties associated with our dependence on the availability of human umbilical cord blood units,
or CBUs, at cord blood banks for the manufacture of omidubicel.</span></p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">CBUs
are one of the raw materials for the manufacture of omidubicel. The CBUs currently used in the manufacture of omidubicel are procured
directly by the clinical cell processing facilities from cord blood banks, which hold more than 800,000 CBUs that have been donated,
processed and cryopreserved. However, the availability of CBUs for the manufacture of omidubicel depends on a number of regulatory, political,
economic and technical factors outside of our control, including:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">government
                                            policies relating to the regulation of CBUs for clinical use&#894;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">the
                                            availability of government funding for cord blood banks&#894;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">pregnancy
                                            and birth rates, which we expect to decline temporarily in response to the COVID-19 pandemic,
                                            and the willingness of mothers to consent to the donation of CBUs and the terms of such consent&#894;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">individual
                                            cord blood bank policies and practices relating to CBU acquisition and banking&#894;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">the
                                            pricing of CBUs&#894;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">the
                                            methods used in searching for and matching CBUs to patients, which involve emerging technology
                                            related to current and future CBU parameters that guide the selection of an appropriate CBU
                                            for transplantation&#894; and</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">methods
                                            for the procurement and shipment of CBUs and their handling and storage at clinical sites,
                                            any or all of which may have been complicated by public health policies aimed at slowing
                                            the spread of the COVID-19 virus.</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Additionally,
we do not have control over the types of CBUs used in the manufacture of omidubicel. We rely heavily on these clinical cell processing
facilities to procure CBUs from cord blood banks that are compliant with government regulations and within the current standard of care.
In addition, we may identify specific characteristics of CBUs, such as their volume and red blood cell content, that may limit their
ability to be used to manufacture omidubicel even though these CBUs may otherwise be suitable for use in allogeneic transplant. As a
result, the requirement for CBUs to meet our specifications may limit the potential inventory of CBUs eligible for use in the manufacture
of omidubicel. There is a large variability in the tests, methods and equipment utilized by cord blood banks in testing CBUs before storage.
This could result in CBUs that are found to be unsuitable for production after their arrival at the manufacturing site. In the United
States, cord blood banks are required to file a BLA and meet certain continued regulatory requirements in order to bank and provide CBUs
for transplantation. Despite these requirements, most of the cord blood banks in the United States are not licensed. While the FDA currently
allows CBUs from unlicensed cord blood banks to be used for transplantation and we have used CBUs from such facilities in the manufacture
of omidubicel for our clinical trials, the FDA may later prohibit the use of such CBUs for transplantation. Additionally, although CBUs
from non-U.S. cord blood banks, which are generally unlicensed, are currently available in the United States for use in transplantation
and we have used CBUs from non-U.S. cord blood banks in our clinical trials, we anticipate we will not be able to use cord blood from
non-U.S. cord blood banks for the manufacturing of omidubicel. Any inability to procure adequate supplies of CBUs will adversely impact
our ability to develop and commercialize omidubicel.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 56; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Risks
Related to Our Intellectual Property</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">If
we are unable to obtain, maintain or protect intellectual property rights related to any of our product candidates or any future product
candidates, we may not be able to compete effectively in our market.</span></p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">We
rely upon a combination of patents, trade secret protection and confidentiality agreements to protect the intellectual property related
to our technologies and product candidates. Our success depends in large part on our ability to obtain and maintain patent and other
intellectual property protection in the United States and in other countries with respect to our proprietary technology and product candidates.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">We
have sought to protect our proprietary position by filing patent applications in the United States and in other countries, with respect
to our novel technologies and product candidates, which are important to our business. Patent prosecution is expensive and time consuming.
We may not be able to prepare, file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely
manner or in all jurisdictions. It is also possible that we will fail to identify patentable aspects of our research and development
activities before it is too late to obtain patent protection.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Further,
the patent position of biopharmaceutical companies generally is highly uncertain and involves complex legal and factual questions for
which legal principles remain unsettled. This renders the patent prosecution process particularly expensive and time-consuming. There
is no assurance that all potentially relevant prior art relating to our patent applications has been found and that there are no material
defects in the form, preparation, or prosecution of our patent applications, which can invalidate a patent or prevent a patent from issuing
from a pending patent application. Even if patents do successfully issue, and even if such patents cover our product candidates, because
the issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability, our patents or pending patent applications
may be challenged in the courts or patent offices in the United States and abroad, which may result in such patents being narrowed, found
unenforceable or invalidated. For example, we may be subject to a third party pre-issuance submission of prior art to the United States
Patent and Trademark Office, or USPTO, or become involved in post-grant review procedures, oppositions, derivations, reexaminations,
inter parts review, or IPR, or interference proceedings, in the United States or elsewhere, challenging our patent rights or the patent
rights of others. An adverse determination in any such challenges may result in loss of exclusivity or in patent claims being narrowed,
invalidated or held unenforceable, in whole or in part, which could limit our ability to stop others from using or commercializing similar
or identical technology and products, or limit the duration of the patent protection of our technology and products. Furthermore, even
if they are unchallenged, our patent applications and any future patents may not adequately protect our intellectual property, provide
exclusivity for our product candidates, or prevent others from designing around our claims. Any of these outcomes could impair our ability
to prevent competition from third parties, which may have an adverse impact on our business.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">If
we cannot obtain and maintain effective patent rights for our product candidates, we may not be able to compete effectively and our business
and results of operations would be harmed.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">In
addition to the protection afforded by any patents that have been or may be granted, we rely on trade secret protection and confidentiality
agreements to protect proprietary know-how that is not patentable or that we elect not to patent, processes for which patents are difficult
to enforce and any other elements of our product candidate discovery and development processes that involve proprietary know-how, information
or technology that is not covered by patents. However, trade secrets can be difficult to protect. We seek to protect our proprietary
technology and processes, in part, by entering into confidentiality agreements with our employees, consultants, scientific advisors and
contractors. We also seek to preserve the integrity and confidentiality of our data, trade secrets and intellectual property by maintaining
the physical security of our premises and physical and electronic security of our information technology systems. Notwithstanding these
measures, organizations and systems, agreements or security measures may be breached, and we may not have adequate remedies for any breach.
In addition, our trade secrets and intellectual property may otherwise become known or be independently discovered by competitors. Although
we expect all our employees and consultants and other third parties who may be involved in the development of intellectual property for
us to assign their inventions to us, and all of our employees, consultants, advisors and any third parties who have access to our proprietary
knowhow, information, or technology to enter into confidentiality agreements, we cannot provide any assurances that we have entered into
such agreements with all applicable third parties or that all such agreements have been duly executed. Even if we have entered into such
agreements, we cannot assure you that our counterparties will comply with the terms of such agreements or that the assignment of intellectual
property rights under such agreements is self-executing. We may be forced to bring claims against third parties, or defend claims that
they may bring against us, to determine the ownership of what we regard as our intellectual property. If we fail in prosecuting or defending
any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights. Even if we are successful
in prosecuting or defending against such claims, litigation could result in substantial costs and be a distraction to our senior management
and scientific personnel.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 57; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">We
also cannot assure you that our trade secrets and other confidential proprietary information will not be disclosed or that competitors
will not otherwise gain access to our trade secrets or independently develop substantially equivalent information and techniques. Misappropriation
or unauthorized disclosure of our trade secrets and intellectual property could impair our competitive position and may have a material
adverse effect on our business. Additionally, if the steps taken to maintain our trade secrets and intellectual property are deemed inadequate,
we may have insufficient recourse against third parties for misappropriating the trade secret. Any of the foregoing could significantly
harm our business, results of operations and prospects.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Patent
reform legislation and rule changes could increase the uncertainties and costs surrounding the prosecution of our patent applications
and the enforcement or defense of any issued patents.</span></p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Our
ability to obtain patents is highly uncertain because, to date, some legal principles remain unsettled, there has not been a consistent
policy regarding the breadth or interpretation of claims allowed in patents in the United States and the specific content of patents
and patent applications that are necessary to support and interpret patent claims is highly uncertain due to the complex nature of the
relevant legal, scientific, and factual issues. Changes in either patent laws or interpretations of patent laws in the United States
and other countries may diminish the value of our intellectual property or narrow the scope of our patent protection.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">For
example, on September 16, 2011, the Leahy-Smith America Invents Act, or the Leahy-Smith Act, was signed into law. The Leahy-Smith Act
includes a number of significant changes to United States patent law. These include provisions that affect the way patent applications
will be prosecuted and may also affect patent litigation. The USPTO has developed new and untested regulations and procedures to govern
the full implementation of the Leahy-Smith Act and many of the substantive changes to patent law associated with the Leahy-Smith Act,
and in particular, the first to file provisions only became effective in March 2013. Prior to March 2013, in the United States, the first
to invent was entitled to the patent. As of March 2013, assuming the other requirements for patentability are met, the first to file
a patent application is generally entitled to the patent. Publications of discoveries in the scientific literature often lag behind the
actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until 18 months
after filing, or in some cases not at all. Therefore, we cannot be certain that we were the first to make the inventions claimed in our
patents or pending patent applications, or that we were the first to file for patent protection of such inventions. The Leahy-Smith Act
has also introduced procedures making it easier for third parties to challenge issued patents, as well as to intervene in the prosecution
of patent applications. Finally, the Leahy-Smith Act contains new statutory provisions that require the USPTO to issue new regulations
for their implementation, and it may take the courts years to interpret the provisions of the new statute.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">However,
the Leahy-Smith Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications
and the enforcement or defense of our issued patents. Further, the U.S. Supreme Court has ruled on several patent cases in recent years,
either narrowing the scope of patent protection available in certain circumstances or weakening the rights of patent owners in certain
situations. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events
has created uncertainty with respect to the value of patents, once obtained. Depending on actions by the U.S. Congress, the federal courts,
and the USPTO, the laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain
new patents or to enforce patents that we have owned or licensed or that we might obtain in the future. Any inability to obtain, enforce,
and defend patents covering our proprietary technologies would materially and adversely affect our business prospects and financial condition.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Similarly,
changes in patent laws and regulations in other countries or jurisdictions or changes in the governmental bodies that enforce them or
changes in how the relevant governmental authority enforces patent laws or regulations may weaken our ability to obtain new patents or
to enforce patents that we own or that we may obtain in the future. Further, the laws of some countries do not protect proprietary rights
to the same extent or in the same manner as the laws of the United States. As a result, we may encounter significant problems in protecting
and defending our intellectual property both in the United States and abroad. For example, if the issuance to us, in a given country,
of a patent covering an invention is not followed by the issuance, in other countries, of patents covering the same invention, or if
any judicial interpretation of the validity, enforceability, or scope of the claims, or the written description or enablement, in a patent
issued in one country is not similar to the interpretation given to the corresponding patent issued in another country, our ability to
protect our intellectual property in those countries may be limited. Changes in either patent laws or in interpretations of patent laws
in the United States and other countries may materially diminish the value of our intellectual property or narrow the scope of our patent
protection. Any of the foregoing could significantly harm our business, results of operations and prospects.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 58; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">If
our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest
and our business may be adversely affected.</span></p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Our
registered or unregistered trademarks or trade names may be challenged, infringed, circumvented or declared generic or determined to
be infringing on other marks. We may not be able to protect our rights to these trademarks and trade names, which we need to build name
recognition by potential partners or customers in our markets of interest. Over the long term, if we are unable to establish name recognition
based on our trademarks and trade names, then we may not be able to compete effectively and our business may be adversely affected. If
other entities use trademarks similar to ours in different jurisdictions, or have senior rights to ours, it could interfere with our
use of our current trademarks throughout the world.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Intellectual
property rights of third parties could adversely affect our ability to commercialize our product candidates, and we might be required
to litigate or obtain licenses from third parties in order to develop or market our product candidate. Such litigation or licenses could
be costly or not available on commercially reasonable terms.</span></p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">It
is inherently difficult to conclusively assess our freedom to operate without infringing on or otherwise violating third-party rights.
Our competitive position may suffer if patents issued to third parties or other third-party intellectual property rights cover our product
candidates or elements thereof, or our manufacturing or uses relevant to our development plans. In such cases, we may not be in a position
to develop or commercialize products or our product candidates unless we successfully pursue litigation to nullify or invalidate the
third-party intellectual property right concerned, or enter into a license agreement with the intellectual property right holder, if
available on commercially reasonable terms.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">There
may also be pending patent applications that if they result in issued patents, could be alleged to be infringed by our product candidates.
If such an infringement claim should be brought and be successful, we may be required to pay substantial damages, including treble damages
and attorneys&#8217; fees if we are found to have willfully infringed, we may be forced to cease the development and commercialization
of and otherwise abandon our product candidates, or we may need to seek a license from any patent holders. No assurances can be given
that a license will be available on commercially reasonable terms, if at all. Even if we were able to obtain such a license, it could
be granted on non-exclusive terms, thereby providing our competitors and other third parties access to the same technologies licensed
to us.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">It
is also possible that we have failed to identify relevant third-party patents or applications. For example, U.S. applications filed before
November 29, 2000 and certain U.S. applications filed after that date that will not be filed outside the U.S. remain confidential until
patents issue. Patent applications in the U.S. and elsewhere are published approximately 18 months after the earliest filing to which
priority is claimed, with such earliest filing date being commonly referred to as the priority date. Therefore, patent applications covering
our product candidates or platform technology could have been filed by others without our knowledge. Additionally, pending patent applications
which have been published can, subject to certain limitations, be later amended in a manner that could cover our platform technologies,
our product candidates or the use of our product candidates. Third-party intellectual property right holders may also actively bring
infringement claims against us. We cannot guarantee that we will be able to successfully defend, settle or otherwise resolve such infringement
claims. If we are unable to successfully settle future claims on terms acceptable to us, we may be required to engage in or continue
costly, unpredictable and time-consuming litigation and may be prevented from or experience substantial delays in pursuing the development
of and/or marketing of our product candidates. If we fail in any such dispute, in addition to being forced to pay damages, we may be
temporarily or permanently prohibited from commercializing our product candidates that are held to be infringing. We might, if possible,
also be forced to redesign our product candidates so that we no longer infringe the third-party intellectual property rights, which may
not be commercially feasible. Any of these events, even if we were ultimately to prevail, could require us to divert substantial financial
and management resources that we would otherwise be able to devote to our business and otherwise significantly harm our business, results
of operations and prospects.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 59; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Third-party
claims of intellectual property infringement may prevent or delay our development and commercialization efforts.</span></p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Our
commercial success depends in part on our avoiding infringing or otherwise violating the patents and proprietary rights of third parties.
There have been many lawsuits and other proceedings involving patent and other intellectual property rights in the biotechnology and
pharmaceutical industries, including patent infringement lawsuits, interferences, oppositions, post grant review, IPR, and reexamination
proceedings before the USPTO and corresponding non-U.S. patent offices. Numerous U.S. and non-U.S. issued patents and pending patent
applications, which are owned by third parties, exist in the fields in which we are developing product candidates. As the pharmaceutical
industry expands and more patents are issued, the risk increases that our product candidates may be subject to claims of infringement
of the patent rights of third parties or other intellectual property claims.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Third
parties may assert that we are employing their proprietary technology without authorization. There may be third-party patents or patent
applications with claims to materials, formulations, methods of manufacture, or methods for treatment related to the use or manufacture
of our product candidates. Because patent applications can take many years to issue, there may be currently pending patent applications
that may later result in issued patents that our product candidates may infringe. In addition, third parties may obtain patents in the
future and claim that use of our technologies infringes upon these patents. If any third-party patents were held by a court of competent
jurisdiction to cover the manufacturing process of any of our product candidates, any materials formed during the manufacturing process
or any final product itself, the holders of any such patents may be able to block our ability to commercialize such product candidates
unless we obtain a license under the applicable patents, or until such patents expire or are finally determined to be invalid or unenforceable.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Similarly,
if any third-party patents were held by a court of competent jurisdiction to cover aspects of our formulations, processes for manufacture,
or methods of use, the holders of any such patents may be able to block our ability to develop and commercialize the applicable product
candidate unless we obtain a license or until such patent expires or is finally determined to be invalid or unenforceable. In either
case, such a license may not be available on commercially reasonable terms or at all.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Parties
making claims against us may obtain injunctive or other equitable relief, which could effectively block our ability to further develop
and commercialize one or more of our product candidates. Defense of these claims, regardless of their merit, would involve substantial
litigation expense and would be a substantial diversion of employee resources from our business. In the event of a successful claim of
infringement against us, we may have to pay substantial damages, including treble damages and attorneys&#8217; fees for willful infringement,
pay royalties, redesign our infringing products or obtain one or more licenses from third parties, which may be impossible or require
substantial time and monetary expenditure.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Furthermore,
because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some
of our confidential information could be compromised by disclosure during this type of litigation. There could also be public announcements
of the results of hearings, motions, or other interim proceedings or developments. If securities analysts or investors perceive these
results to be negative, it could have a material adverse effect on the price of our ordinary shares. Any of the foregoing could significantly
harm our business, results of operations and prospects.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 60; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">We
may not be successful in obtaining or maintaining necessary rights to our product candidates through acquisitions and in-licenses.</span></p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Because
our programs may require the use of intellectual property or proprietary rights held by third parties, the growth of our business will
likely depend in part on our ability to acquire, in-license, or use these intellectual property and proprietary rights. In addition,
our product candidates may require specific formulations to work effectively and efficiently and the rights to these formulations may
be held by others. We may be unable to acquire or in-license any compositions, methods of use, processes, or other third-party intellectual
property rights from third parties that we identify as necessary for our product candidates. The licensing and acquisition of third-party
intellectual property rights is a competitive area, and a number of more established companies are also pursuing strategies to license
or acquire third-party intellectual property rights that we may consider attractive. These established companies may have a competitive
advantage over us due to their size, cash resources, and greater clinical development and commercialization capabilities. In addition,
the Indenture governing our Notes contain restrictions that may limit our ability to enter into acquisition or in-licensing agreements.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">For
example, we sometimes collaborate with academic institutions to accelerate our preclinical research or development under written agreements
with these institutions, some of which provide that the applicable institution will own certain rights in any technology developed thereunder.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Typically,
these institutions provide us with an option to negotiate a license to any of the institution&#8217;s rights in technology resulting
from the collaboration. Regardless of such option, we may be unable to negotiate a license within the specified timeframe or under terms
that are acceptable to us. If we are unable to do so, the institution may offer the intellectual property rights to other parties, potentially
blocking our ability to pursue our program.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">In
addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. We are also subject to certain
restrictions regarding obtaining licenses of third-party intellectual property pursuant to the terms of the indenture governing the Notes,
and we may be unable to license or acquire third-party intellectual property rights on terms that would allow us to make an appropriate
return on our investment. If we are unable to successfully obtain rights to required third-party intellectual property rights, we may
have to abandon development of that program and our business and financial condition could suffer.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">We
may be involved in lawsuits to protect or enforce our intellectual property, which could be expensive, time consuming and unsuccessful.</span></p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Competitors
may infringe, misappropriate or otherwise violate our intellectual property or that of our licensors that we may acquire in the future.
To counter infringement or unauthorized use, we may be required to file infringement claims, which can be expensive and time-consuming.
If we initiate legal proceedings against a third party to enforce a patent covering one of our product candidates, the defendant could
counterclaim that the patent covering our product or product candidate is invalid and/or unenforceable. In patent litigation in the United
States, defendant counterclaims alleging invalidity and/or unenforceability are common, and there are numerous grounds upon which a third
party can assert invalidity or unenforceability of a patent. In an infringement proceeding, a court may decide that a patent of ours
is not valid or is unenforceable, or may refuse to stop the other party from using the technology at issue on the grounds that our patents
do not cover the technology in question. Third parties may also raise similar claims before administrative bodies in the United States
or abroad, even outside the context of litigation. Such mechanisms include re-examination, post grant review, inter parties review, or
IPR, and equivalent proceedings in non-U.S. jurisdictions (e.g., opposition proceedings). Such proceedings could result in revocation
of or amendment to our patents in such a way that they no longer cover our product candidates. The outcome following legal assertions
of invalidity and unenforceability is unpredictable. With respect to the validity question, for example, we cannot be certain that there
is no invalidating prior art, of which we, our patent counsel, and the patent examiner were unaware during prosecution. If a defendant
were to prevail on a legal assertion of invalidity and/or unenforceability, we would lose at least part, and perhaps all, of the patent
protection on our product candidates. An adverse result in any litigation or defense proceedings could put one or more of our patents
at risk of being invalidated or interpreted narrowly, could put our patent applications at risk of not issuing and could have a material
adverse impact on our business.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Interference
proceedings provoked by third parties or brought by us may be necessary to determine the priority of inventions with respect to our patent
applications. An unfavorable outcome could require us to cease using the related technology or to attempt to license rights to it from
the prevailing party. Our business could be harmed if the prevailing party does not offer us a license on commercially reasonable terms.
Our defense of litigation or interference proceedings may fail and, even if successful, may result in substantial costs and distract
our management and other employees. We may not be able to prevent misappropriation of our intellectual property rights, particularly
in countries where the laws may not protect those rights as fully as in the United States.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 61; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Furthermore,
because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some
of our confidential information could be compromised by disclosure during this type of litigation. There could also be public announcements
of the results of hearings, motions, or other interim proceedings or developments. If securities analysts or investors perceive these
results to be negative, it could have a material adverse effect on the price of our ordinary shares. Any of the foregoing could significantly
harm our business, results of operations and prospects.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">We
may be subject to claims that our employees, consultants, or independent contractors have wrongfully used or disclosed confidential information
of third parties or that our employees have wrongfully used or disclosed alleged trade secrets of their former employers.</span></p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">We
employ individuals who were previously employed at universities or other biotechnology or pharmaceutical companies, including our competitors
or potential competitors. Although we try to ensure that our employees, consultants and independent contractors do not use the proprietary
information or know-how of others in their work for us, we may be subject to claims that we or our employees, consultants, or independent
contractors have inadvertently or otherwise used or disclosed intellectual property, including trade secrets or other proprietary information,
of any of our employees&#8217; former employers or other third parties. Litigation may be necessary to defend against these claims. If
we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel,
which could adversely impact our business. Even if we are successful in defending against such claims, litigation could result in substantial
costs and be a distraction to management and other employees. Any of the foregoing could significantly harm our business, results of
operations and prospects.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">We
may be subject to claims challenging the inventorship of our intellectual property.</span></p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">We
may be subject to claims that former employees, collaborators or other third parties have an interest in or right to compensation with
respect to our current patent and patent applications, future patents or other intellectual property as an inventor or co-inventor. For
example, we may have inventorship disputes arise from conflicting obligations of consultants or others who are involved in developing
our product candidates. Litigation may be necessary to defend against these and other claims challenging inventorship or claiming the
right to compensation. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual
property rights, such as exclusive ownership of, or right to use, valuable intellectual property. Such an outcome could have a material
adverse effect on our business. Even if we are successful in defending against such claims, litigation could result in substantial costs
and be a distraction to management and other employees. To the extent that our employees have not effectively waived the right to compensation
with respect to inventions that they helped create, they may be able to assert claims for compensation with respect to our future revenue.
As a result, we may receive less revenue from future products if such claims are successful which in turn could impact our future profitability,
business, results of operations and prospects.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">We
may become subject to claims for remuneration or royalties for assigned service invention rights by our employees, which could result
in litigation and adversely affect our business.</span></p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">A
significant portion of our intellectual property has been developed by our employees in the course of their employment for us. Under
the Israeli Patent Law, 5727-1967, or the Patent Law, inventions conceived by an employee in the course and as a result of or arising
from his or her employment with a company are regarded as &#8220;service inventions,&#8221; which belong to the employer, absent a specific
agreement between the employee and employer giving the employee service invention rights. The Patent Law also provides that if there
is no such agreement between an employer and an employee, the Israeli Compensation and Royalties Committee, or the Committee, a body
constituted under the Patent Law, shall determine whether the employee is entitled to remuneration for his inventions. Case law clarifies
that the right to receive consideration for &#8220;service inventions&#8221; can be waived by the employee and that in certain circumstances,
such waiver does not necessarily have to be explicit. The Committee will examine, on a case-by-case basis, the general contractual framework
between the parties, using interpretation rules of the general Israeli contract laws. Further, the Committee has not yet determined one
specific formula for calculating this remuneration (but rather uses the criteria specified in the Patent Law). Although we generally
enter into assignment-of-invention agreements with our employees pursuant to which such individuals assign to us all rights to any inventions
created in the scope of their employment or engagement with us, we may face claims demanding remuneration in consideration for assigned
inventions. As a consequence of such claims, we could be required to pay additional remuneration or royalties to our current and/or former
employees, or be forced to litigate such claims, which could negatively affect our business.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 62; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Obtaining
and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements
imposed by government patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.</span></p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Periodic
maintenance fees, renewal fees, annuity fees and various other government fees on patents and/or applications will be due to be paid
to the USPTO and various government patent agencies outside of the United States over the lifetime of our patents and/or applications
and any patent rights we may own or license in the future. We rely on our outside counsel or third-party service providers to pay these
fees due to the USPTO and non-U.S. patent agencies. The USPTO and various non-U.S. government patent agencies require compliance with
several procedural, documentary, fee payment and other similar provisions during the patent application process. We employ reputable
law firms and other professionals to help us comply. In many cases, an inadvertent lapse can be cured by payment of a late fee or by
other means in accordance with the applicable rules. There are situations, however, in which non-compliance can result in abandonment
or lapse of the patents or patent applications, resulting in partial or complete loss of patent rights in the relevant jurisdiction.
In such an event, potential competitors might be able to enter the market and this circumstance could harm our business.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">We
may enjoy only limited geographical protection with respect to certain patents and we may not be able to protect our intellectual property
rights throughout the world.</span></p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Filing
and prosecuting patent applications and defending patents covering our product candidates in all countries throughout the world would
be prohibitively expensive. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop
their own products and, further, may export otherwise infringing products to territories where we have patent protection, but enforcement
rights are not as strong as that in the United States. These products may compete with our product candidates, and our patents or other
intellectual property rights may not be effective or sufficient to prevent them from competing.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">In
addition, we may decide to abandon national and regional patent applications before grant. The examination of each national or regional
patent application is an independent proceeding. As a result, patent applications in the same family may issue as patents in some jurisdictions,
such as in the United States, but may issue as patents with claims of different scope or may even be refused in other jurisdictions.
It is also quite common that depending on the country, the scope of patent protection may vary for the same product candidate or technology.
The laws of some jurisdictions do not protect intellectual property rights to the same extent as the laws or rules and regulations in
the United States, and many companies have encountered significant difficulties in protecting and defending such rights in such jurisdictions.
The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets
and other intellectual property protection, which could make it difficult for us to stop the infringement of our patents or marketing
of competing products in violation of our proprietary rights generally. Proceedings to enforce our patent rights in other jurisdictions,
whether or not successful, could result in substantial costs and divert our efforts and attention from other aspects of our business,
could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing as patents,
and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate and the damages or other
remedies awarded, if any, may not be commercially meaningful.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Accordingly,
our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage
from the intellectual property that we develop or license. Furthermore, while we intend to protect our intellectual property rights in
our expected significant markets, we cannot ensure that we will be able to initiate or maintain similar efforts in all jurisdictions
in which we may wish to market our product candidates. Accordingly, our efforts to protect our intellectual property rights in such countries
may be inadequate, which may have an adverse effect on our ability to successfully commercialize our product candidates in all our expected
significant non-U.S. markets. If we encounter difficulties in protecting, or are otherwise precluded from effectively protecting, the
intellectual property rights important for our business in such jurisdictions, the value of these rights may be diminished and we may
face additional competition from others in those jurisdictions.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Some
countries also have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. In addition,
some countries limit the enforceability of patents against government agencies or government contractors. In those countries, the patent
owner may have limited remedies, which could materially diminish the value of such patents. If we are forced to grant a license to third
parties with respect to any patents relevant to our business, our competitive position may be impaired.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 63; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Patent
terms may be inadequate to protect our competitive position on our product candidates for an adequate amount of time.</span></p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Patents
have a limited lifespan. In the United States, if all maintenance fees are timely paid, the natural expiration of a patent is generally
20 years from its earliest U.S. non-provisional filing date. Various extensions may be available, but the life of a patent, and the protection
it affords, is limited. Even if patents covering our product candidates are obtained, once the patent life has expired for a product
candidate, we may be open to competition from competitive medications, including biosimilar and generic medications. Given the amount
of time required for the development, testing and regulatory review of new product candidates, patents protecting such product candidates
might expire before or shortly after such product candidates are commercialized. As a result, our patent portfolio may not provide us
with sufficient rights to exclude others from commercializing product candidates similar or identical to ours.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Depending
upon the timing, duration and conditions of any FDA marketing approval of our product candidates, one or more of our U.S. patents may
be eligible for limited patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984, referred to as
the Hatch-Waxman Amendments, and similar legislation in the European Union. The Hatch-Waxman Amendments permit a patent term extension
of up to five years for a patent covering an approved product as compensation for effective patent term lost during product development
and the FDA regulatory review process. However, we may not receive an extension if we fail to exercise due diligence during the testing
phase or regulatory review process, fail to apply within applicable deadlines, fail to apply prior to expiration of relevant patents
or otherwise fail to satisfy applicable requirements. Moreover, the length of the extension could be less than we request. Only one patent
per approved product can be extended, the extension cannot extend the total patent term beyond 14 years from approval and only those
claims covering the approved drug, a method for using it or a method for manufacturing it may be extended. If we are unable to obtain
patent term extension or the term of any such extension is less than we request, the period during which we can enforce our patent rights
for the applicable product candidate will be shortened and our competitors may obtain approval to market competing products sooner. As
a result, our revenue from applicable products could be reduced. Further, if this occurs, our competitors may take advantage of our investment
in development and trials by referencing our clinical and preclinical data and launch their product earlier than might otherwise be the
case, and our competitive position, business, financial condition, results of operations, and prospects could be materially harmed.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Intellectual
property rights do not necessarily address all potential threats to our competitive advantage.</span></p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">The
degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations
and may not adequately protect our business or permit us to maintain our competitive advantage. The following examples are illustrative:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">others
                                            may be able to make products that are similar to our product candidates but that are not
                                            covered by the claims of the patents that we own&#894;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">we
                                            might not have been the first to invent the inventions covered by our patents or the first
                                            to file patent applications covering our inventions&#894;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">others
                                            may independently develop similar or alternative technologies or duplicate any of our technologies
                                            without infringing our intellectual property rights&#894;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">it
                                            is possible that our pending patent applications will not lead to issued patents&#894;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">issued
                                            patents that we own may be held invalid or unenforceable as a result of legal challenges
                                            by our competitors&#894;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">issued
                                            patents that we own may not provide coverage for all aspects of our product candidates in
                                            all countries&#894;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">our
                                            competitors might conduct research and development activities in countries where we do not
                                            have patent rights and then use the information learned from such activities to develop competitive
                                            products for sale in our major commercial markets&#894;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">we
                                            may not develop additional proprietary technologies that are patentable&#894; and</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">the
                                            patents of others may have an adverse effect on our business.</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Should
any of these events occur, they could significantly harm our business, results of operations and prospects.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 64; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Risks
Related to Our Business Operations</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Our
future success depends in part on our ability to retain our senior management team and to attract, retain and motivate other qualified
personnel.</span></p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">We
are highly dependent on the members of our senior management team. The loss of their services without a proper replacement may adversely
impact the achievement of our objectives. Our employees may leave our employment at any time. Recruiting and retaining other qualified
employees, consultants and advisors for our business, including scientific and technical personnel, will also be critical to our success.
There is currently a shortage of skilled personnel in our industry, which is likely to continue for the foreseeable future. This is particularly
the case in Israel and Boston, Massachusetts, where our operations are focused and where there is a &#8220;war for talent&#8221; between
members in our industry. As a result, competition for skilled personnel is intense, and the turnover rate can be high. We may not be
able to attract and retain personnel on acceptable terms given the competition among numerous pharmaceutical companies for individuals
with similar skill sets. In addition, failure to succeed in preclinical or clinical studies may make it more challenging to recruit and
retain qualified personnel. The inability to recruit and retain qualified personnel, or the loss of the services of any members of our
senior management team without proper replacement, may impede the progress of our research, development and commercialization objectives.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">We
will need to expand our organization, and we may experience difficulties in managing this growth, which could disrupt our operations.</span></p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Our
future financial performance and our ability to commercialize product candidates and compete effectively will depend, in part, on our
ability to effectively manage any future growth. As our development and commercialization plans and strategies develop, we expect to
need additional managerial, operational, sales, marketing, financial and legal personnel. Our management may need to divert a disproportionate
amount of its attention away from our day-to-day activities and devote a substantial amount of time to managing these growth activities.
We may not be able to effectively manage the expansion of our operations, which may result in weaknesses in our infrastructure, operational
mistakes, loss of business opportunities, loss of employees and reduced productivity among remaining employees. Our expected growth could
require significant capital expenditures and may divert financial resources from other projects, such as the development of additional
product candidates. If our management is unable to effectively manage our growth, our expenses may increase more than expected, our ability
to generate and/or grow revenue could be reduced, and we may not be able to implement our business strategy.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Due
to our limited resources and access to capital, we must, and have in the past decided to, prioritize development of certain product candidates
over other potential candidates. These decisions may prove to have been wrong and may adversely affect our revenue.</span></p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Because
we have limited resources and access to capital to fund our operations, we must decide which product candidates to pursue and the amount
of resources to allocate to each. Our decisions concerning the allocation of research, collaboration, management and financial resources
toward particular product candidates may not lead to the development of viable commercial products and may divert resources away from
better opportunities. Similarly, our decisions to delay, terminate or collaborate with third parties in respect of certain product development
programs may also prove not to be optimal and could cause us to miss valuable opportunities. For instance, we made the decision to prioritize
the development of omidubicel for the treatment of hematologic malignancies over SCD because our hematologic malignancy program is at
a more advanced stage of development, while our sickle cell program remains exploratory. In addition, we are evaluating alternatives
for commercialization of omidubicel, if approved, which may include commercializing omidubicel ourselves or entering into potential strategic
alliances or licensing arrangements with pharmaceutical companies and other partners. If we make the decision to commercialize omidubicel
ourselves, we may have to significantly expand our commercial organization in time for omidubicel approval, which may jeopardize the
success of a timely commercial launch and may reduce or delay our anticipated revenue from sales of omidubicel. Commercializing omidubicel
ourselves will also require additional capital to fund an increase in workforce as well as operating expenses and capital expenses to
expand our manufacturing facility in Kiryat Gat, Israel. If we decide to enter into licensing arrangements or other forms of collaboration,
the potential for us to generate revenue from royalties on sales of such out-licensed products depends on the performance of our partners.
If our partners do not perform in the manner we expect, fail to fulfill their responsibilities in a timely manner or at all, if the FDA,
EMA or other similar regulatory authorities decline to grant a marketing authorization to them, or provide them with a restricted authorization,
if our agreements with them terminate, they abandon the collaboration or if the quality or accuracy of the clinical data they obtain
is compromised, the clinical development, regulatory approval and commercialization efforts related to our out-licensed product candidates
could be delayed or terminated, and it could become necessary for us to assume the responsibility at our own expense, or seek new partners
on reduced commercial terms, for the clinical development of such product candidates. If we make incorrect determinations regarding the
market potential of our product candidates or misread trends in the pharmaceutical industry, in particular for our lead product candidate,
our business, financial condition and results of operations could be materially adversely affected.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 65; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Business
disruptions could seriously harm our future revenue and financial condition and increase costs and expenses.</span></p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Our
operations and those of our third-party suppliers and collaborators could be subject to earthquakes, power shortages, telecommunications
failures, water shortages, floods, hurricanes or other extreme weather conditions, medical epidemics, labor disputes, war or other business
interruptions. Although we have limited business interruption insurance policies in place, any interruption could come with high costs
for us, as salaries and loan payments would usually continue. Moreover, any interruption could seriously harm one or more of our research,
development or manufacturing programs, the commercialization of any approved product or our clinical trial operations. For example, the
current COVID-19 pandemic has, at points, caused an interruption in our ongoing and planned clinical trials activities. In addition,
the initial timeline for submission of our BLA for omidubicel was delayed, in part, as a result of the impact of the COVID-19 pandemic
on our operations. Moreover, at the end of 2021 and into 2022, tensions between the United States and Russia escalated when Russia amassed
large numbers of military ground forces and support personnel on the Ukraine-Russia border and, in February 2022, Russia invaded Ukraine.
In response, North Atlantic Treaty Organization, or NATO has deployed additional military forces to Eastern Europe, including to Lithuania,
and the Biden administration implemented certain sanctions against Russia. The invasion of Ukraine and the retaliatory measures that
have been taken, or could be taken in the future, by the United States, NATO, and other countries have created global security concerns
that could result in a regional conflict and otherwise have a lasting impact on regional and global economies, any or all of which could
disrupt our supply chain, adversely affect our ability to conduct ongoing and future clinical trials of our product candidates or commercialize
our products. In addition, the conflict has had significant ramifications on global financial markets, which may adversely impact our
ability to raise capital on favorable terms or at all.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">We
may not be successful in our efforts to identify, discover or license additional product candidates.</span></p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Although
a substantial amount of our effort will focus on the continued clinical testing, potential approval and commercialization of omidubicel
and GDA-201, the success of our business also depends upon our ability to identify, discover or license additional product candidates,
including within our NK-cell pipeline. Our research programs or licensing efforts may fail to yield additional product candidates for
clinical development for a number of reasons, including but not limited to the following:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">our
                                            research or business development methodology or search criteria and process may be unsuccessful
                                            in identifying potential product candidates&#894;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">we
                                            may not be able or willing to assemble sufficient resources to acquire or discover additional
                                            product candidates&#894;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">our
                                            product candidates may not succeed in preclinical or clinical testing&#894;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">our
                                            product candidates may be shown to have harmful side effects or may have other characteristics
                                            that may make the products unmarketable or unlikely to receive marketing approval&#894;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">competitors
                                            may develop alternatives that render our product candidates obsolete or less attractive&#894;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">product
                                            candidates we develop may be covered by third parties&#8217; patents or other exclusive rights&#894;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">the
                                            market for a product candidate may change during our development program so that such product
                                            may become unprofitable to continue to develop&#894;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">a
                                            product candidate may not be capable of being produced in commercial quantities at an acceptable
                                            cost, or at all&#894; and</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">a
                                            product candidate may not be accepted as safe and effective by patients, the medical community,
                                            or third-party payers.</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">If
any of these events occur, we may be forced to abandon our development efforts for a program or programs, or we may not be able to identify,
license, or discover additional product candidates, which would have a material adverse effect on our business and could potentially
cause us to cease operations. Research programs to identify new product candidates require substantial technical, financial and human
resources. We may focus our efforts and resources on potential programs or product candidates that ultimately prove to be unsuccessful.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 66; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Our
business and operations would suffer in the event of computer system failures, cyber-attacks or a deficiency in our cybersecurity.</span></p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Despite
the implementation of security measures, our internal computer systems, and those of third parties on which we rely, are vulnerable to
damage from a variety of causes, including computer viruses, malware, intentional or accidental mistakes or errors by users with authorized
access to our computer systems, natural disasters, terrorism, war, telecommunication and electrical failures, cyber-attacks or cyber-intrusions
over the Internet, or attachments to emails. The risk of a security breach or disruption, particularly through cyber-attacks or cyber
intrusions, including by computer hackers, non-U.S. governments, extra-state actors and cyber terrorists, has generally increased as
the number, intensity and sophistication of attempted attacks and intrusions from around the world have increased. If such an event were
to occur and cause interruptions in our operations, it could result in a material disruption of our drug development programs. For example,
the loss or compromise of clinical trial data from completed or ongoing or planned clinical trials could result in delays in our regulatory
approval efforts and significantly increase our costs to recover or reproduce the data. To the extent that any disruption or security
breach was to result in a loss of or damage to our data or applications, or inappropriate disclosure of confidential or proprietary information,
we could incur material legal claims and liability, damage to our reputation, and the further development of our drug candidates could
be delayed. Further, any breach, loss or compromise of clinical study participant personal data may also subject us to civil fines and
penalties, including under GDPR and relevant member state law in the European Union, or, potentially, other relevant state and federal
privacy laws in the United States.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">In
the current environment, there are numerous and evolving risks to cybersecurity and privacy, including criminal hackers, hacktivists,
state-sponsored intrusions, industrial espionage, employee malfeasance and human or technological error. We may be subject to elevated
cybersecurity risk due to Russia&#8217;s invasion of Ukraine. High-profile security breaches at other companies and in government agencies
have increased in recent years, and security industry experts and government officials have warned about the risks of hackers and cyber-attacks
targeting businesses such as ours. Computer hackers and others routinely attempt to breach the security of technology products, services
and systems, and to fraudulently induce employees, customers, or others to disclose information or unwittingly provide access to systems
or data. We can provide no assurance that our current IT systems, software, or third party services, or any updates or upgrades thereto
will be fully protected against third-party intrusions, viruses, hacker attacks, information or data theft or other similar threats.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Legislative
or regulatory action in these areas is also evolving, and we may be unable to adapt our IT systems to accommodate these changes. We have
experienced and expect to continue to experience sophisticated attempted cyber-attacks of our IT networks. Although none of these attempted
cyber-attacks has had a material adverse impact on our operations or financial condition, we cannot guarantee that any such incidents
will not have such an impact in the future.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">We
incur significant costs as a result of operating as a public company in the United States, and our management is required to devote substantial
time to compliance initiatives.</span></p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">As
a public company whose ordinary shares are listed in the United States, we are subject to an extensive regulatory regime, requiring us,
among other things, to maintain various internal controls and facilities and to prepare and file periodic and current reports and statements,
including reports on the effectiveness of our internal control over financial reporting pursuant to Section 404 of the Sarbanes-Oxley
Act of 2002. Complying with these requirements is costly and time consuming. In the event that we are unable to demonstrate compliance
with our obligations as a public company in a timely manner, or are unable to produce timely or accurate financial statements, we may
be subject to sanctions or investigations by regulatory authorities, such as the SEC, or The Nasdaq Global Market, and investors may
lose confidence in our operating results and the price of our ordinary shares could decline.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Our
independent registered public accounting firm is not engaged to perform an audit of our internal control over financial reporting, and
as long as we remain an emerging growth company, as such term is defined in the Jumpstart Our Business Startups Act of 2012, or the JOBS
Act, we will be exempt from the requirement to have an independent registered public accounting firm perform such audit. Accordingly,
no such opinion was expressed or will be expressed any during any such period. Once we cease to qualify as an emerging growth company,
our independent registered public accounting firm will be required to attest to our management&#8217;s annual assessment of the effectiveness
of our internal controls over financial reporting, which will entail additional costs and expenses.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 67; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">International
expansion of our business exposes us to business, regulatory, political, operational, financial and economic risks associated with doing
business outside of the United States or Israel.</span></p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Other
than substantial operations in Israel (as further described below), we currently have limited international operations, but our business
strategy incorporates potentially significant international expansion, particularly in anticipation of approval of our product candidates.
We plan to retain sales representatives and third-party distributors and conduct physician, infectious disease specialist, hospital pharmacist
and patient association outreach activities, as well as clinical trials, outside of the United States, EU and Israel. Doing business
internationally involves a number of risks, including but not limited to:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">multiple,
                                            conflicting and changing laws and regulations such as privacy regulations, tax laws, export
                                            and import restrictions, employment laws, regulatory requirements and other governmental
                                            approvals, permits, and licenses&#894;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">failure
                                            by us to obtain regulatory approvals for the use of our product candidates in various countries&#894;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">additional
                                            potentially relevant third-party patent or other intellectual property rights&#894;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">complexities
                                            and difficulties in obtaining protection and enforcing our intellectual property&#894;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">difficulties
                                            in staffing and managing international operations&#894;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">complexities
                                            associated with managing multiple payer reimbursement regimes, government payers, price controls
                                            or patient self-pay systems&#894;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">limits
                                            in our ability to penetrate international markets&#894;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">financial
                                            risks, such as longer payment cycles, difficulty collecting accounts receivable, the impact
                                            of local and regional financial crises on demand and payment for our products and exposure
                                            to foreign currency exchange rate fluctuations&#894;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">natural
                                            disasters, political and economic instability, including wars, terrorism, and political unrest,
                                            outbreak of disease, boycotts, curtailment of trade, and other business restrictions&#894;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">certain
                                            expenses including, among others, expenses for travel, translation and insurance&#894; and</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">regulatory
                                            and compliance risks that relate to maintaining accurate information and control over sales
                                            and activities that may fall within the purview of the U.S. Foreign Corrupt Practices Act
                                            its books and records provisions, or its anti-bribery provisions.</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Any
of these factors could significantly harm our future international expansion and operations and, consequently, our results of operations.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">We
may be subject to extensive environmental, health and safety, and other laws and regulations in multiple jurisdictions.</span></p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Our
business involves the controlled use, directly or indirectly through our service providers, of hazardous materials, various biological
compounds and chemicals&#894; therefore, we, our agents and our service providers may be subject to various environmental, health and
safety laws and regulations, including those governing air emissions, water and wastewater discharges, noise emissions, the use, management
and disposal of hazardous, radioactive and biological materials and wastes and the cleanup of contaminated sites. The risk of accidental
contamination or injury from these materials cannot be eliminated. If an accident, spill or release of any regulated chemicals or substances
occurs, we could be held liable for resulting damages, including for investigation, remediation and monitoring of the contamination,
including natural resource damages, the costs of which could be substantial. We are also subject to numerous environmental, health and
workplace safety laws and regulations, including those governing laboratory procedures, exposure to blood-borne pathogens and the handling
of biohazardous materials and chemicals. Although we maintain workers&#8217; compensation insurance to cover the costs and expenses that
may be incurred because of injuries to our employees resulting from the use of these materials, this insurance may not provide adequate
coverage against potential liabilities. Additional or more stringent federal, state, local or non-U.S. laws and regulations affecting
our operations may be adopted in the future. We may incur substantial capital costs and operating expenses and may be required to obtain
consents to comply with any of these or certain other laws or regulations and the terms and conditions of any permits or licenses required
pursuant to such laws and regulations. For instance, we have undergone inspections and obtained approvals from various governmental agencies.
We hold a general business license from the City of Jerusalem that is valid until December 31, 2022.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 68; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">We
also hold a toxic substances permit from the Ministry of Environmental Protection (the Hazardous Material Division) and a Certificate
of GMP Compliance of a Manufacturer from the Israeli Ministry of Health - Pharmaceutical Administration. Failure to renew any of the
foregoing licenses and permits may harm our on-going and future operations. In addition, fines and penalties may be imposed for noncompliance
with environmental, health and safety and other laws and regulations or for the failure to have, or comply with the terms and conditions
of our business license, or required environmental or other permits or consents.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Our
employees and independent contractors may engage in misconduct or other improper activities, including noncompliance with regulatory
standards and requirements.</span></p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">We
are exposed to the risk of fraud or other misconduct by our employees and independent contractors. Misconduct by these parties could
include intentional failures to comply with FDA regulations, provide accurate information to the FDA, comply with manufacturing standards
we may establish, comply with federal and state healthcare fraud and abuse laws and regulations, report financial information or data
accurately or disclose unauthorized activities to us. In particular, sales, marketing and business arrangements in the healthcare industry
are subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing and other abusive practices.
These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission,
customer incentive programs and other business arrangements. Employee and independent contractor misconduct could also involve the improper
use of information obtained in the course of clinical trials, including individually identifiable information, creating fraudulent data
in our preclinical studies or clinical trials or illegal misappropriation of product candidates. If our operations are found to be in
violation of any of these laws, we may be subject to significant penalties, including civil, criminal and administrative penalties, damages,
fines, exclusion from government-funded healthcare programs, such as Medicare and Medicaid or similar programs in other countries or
jurisdictions, integrity oversight and reporting obligations to resolve allegations of non-compliance, disgorgement, imprisonment, contractual
damages, reputational harm, diminished profits and the curtailment or restructuring of our operations. It is not always possible to identify
and deter misconduct by employees and other third parties, and the precautions we take to detect and prevent this activity may not be
effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or
lawsuits stemming from a failure to be in compliance with such laws or regulations. Additionally, we are subject to the risk that a person
or government could allege such fraud or other misconduct, even if none occurred. If any such actions are instituted against us, and
we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business,
including the imposition of significant fines or other sanctions.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Under
current Israeli law, we may not be able to enforce employees&#8217; covenants not to compete and therefore may be unable to prevent our
competitors from benefiting from the expertise of some of our former employees.</span></p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">We
generally enter into non-competition agreements with our key employees, in most cases within the framework of their employment agreements.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">These
agreements prohibit our key employees, if they cease working for us, from competing directly with us or working for our competitors for
a limited period. Under applicable Israeli law, we may be unable to enforce these agreements or any part thereof. If we cannot enforce
our noncompetition agreements with our employees, then we may be unable to prevent our competitors from benefiting from the expertise
of our former employees, which could materially adversely affect our business, results of operations and ability to capitalize on our
proprietary information.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">We
are vulnerable to interest rate risk with respect to the grants received from the Israel Innovation Authority</span></p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Since
our incorporation, we have received grants from the IIA relating to various projects. We were members of Bereshit Consortium, sponsored
by IIA in which certain of our technologies were developed, such program does not require payments of royalties to the IIA, but all other
restrictions under the Innovation Law, such as local manufacturing obligations and know-how transfer limitations, as further detailed
hereunder, are applicable to the know how developed by us with the funding received in such consortium program. No royalties have been
paid to the IIA in respect of any grant. Our total outstanding obligation to the IIA, including the interest accrued through March 31,
2022, amounts to approximately $44.9 million.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">The
United Kingdom&#8217;s Financial Conduct Authority, which regulates the London Interbank Offered Rate, or LIBOR, announced that it will
no longer persuade or require banks to submit rates for LIBOR after January 1, 2022. The grants received from the IIA bear an annual
interest rate based on the 12-month LIBOR. Accordingly, there is considerable uncertainty regarding the interest accrued to the IIA grants.
While it is not currently possible to determine precisely whether, or to what extent, the withdrawal and replacement of LIBOR would affect
us, the implementation of alternative benchmark rates to LIBOR may increase our financial liabilities to the IIA. Management continues
to monitor the status and discussions regarding LIBOR. We are not yet able to reasonably estimate the expected impact. To date, the IIA
has not issued any clarification regarding an alternative interest to be used instead of the LIBOR.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 69; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Risks
Related to Commercialization of Our Product Candidates</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">We
do not have experience producing our product candidates at commercial levels or operating a cGMP manufacturing facility and may not obtain
the necessary regulatory approvals or produce our product candidates at the quality, quantities, locations and timing needed to support
commercialization.</span></p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">The
Israeli Ministry of Health issued a GMP certificate for our manufacturing facility at Kiryat Gat, Israel in July 2021 and we are working
to establish cGMP compliance under the FDA&#8217;s regulations. We do not have an extensive number of employees with the experience or
ability to manufacture our product candidates at commercial levels. We may encounter technical or scientific issues related to manufacturing
or development that we may be unable to resolve in a timely manner or with available funds. We also have not completed all of the characterization
and validation activities necessary for commercialization and regulatory approval of omidubicel. If we do not conduct all such necessary
activities in the second quarter of 2022, our commercialization efforts will be delayed.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">We
also may encounter problems hiring and retaining the experienced specialist scientific, quality control and manufacturing personnel needed
to operate our manufacturing process, which could result in delays in our production or difficulties in maintaining compliance with applicable
regulatory requirements. Any problems in our manufacturing process or facilities could make us a less attractive collaborator for potential
partners, including larger pharmaceutical companies, which could limit our access to additional attractive development programs. Problems
in our manufacturing process or facilities also could restrict our ability to meet market demand for our product candidates.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">If
the market opportunities for our product candidates are smaller than we believe they are, our revenue may be adversely affected, and
our business may suffer.</span></p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Our
projections of the number of people who have the potential to benefit from treatment with our product candidates are based on our beliefs
and estimates. These estimates have been derived from a variety of sources, including the scientific literature, surveys of clinics and
other market research, and may prove to be incorrect. Our target patient populations may be lower than expected, may not be otherwise
amenable to treatment with our product candidates or patients may become increasingly difficult to identify and access, all of which
would adversely affect our business, financial condition, results of operations and prospects. In addition, medical advances may reduce
our target markets. For example, new processes and advances in oral antibiotic medications or new operative procedures may limit the
need for localized delivery systems like our product candidates. Further, advances in treatments in the fields in which we are conducting
research programs that reduce side effects and have better deliverability to target organs may limit the market for our future product
candidates.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">We
currently have limited marketing and sales organization. If we are unable to establish adequate sales and marketing capabilities to support
the potential commercial launch of omidubicel or enter into agreements with third parties to market and sell omidubicel, if approved,
we may be unable to generate any product revenue.</span></p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Although
we have a chief commercial officer to lead our efforts to commercialize omidubicel should it receive regulatory approval and we decide
to commercialize omidubicel ourselves, we currently have a limited sales and marketing organization, and we have limited experience selling
and marketing our product candidates. To successfully commercialize any product candidates that may result from our development programs,
we will need to develop these capabilities, either on our own or with others. If omidubicel or any other product candidate receives regulatory
approval, we may establish a sales and marketing organization independently or by utilizing experienced third parties with technical
expertise and supporting distribution capabilities to commercialize our product candidates in major markets, all of which will be expensive,
difficult and time consuming. Any failure or delay in the development of our internal sales, marketing and distribution capabilities
or identification of appropriate strategic partnering would adversely impact our ability to commercialize our product candidates.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 70; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->68<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Further,
our initial estimate of the size of the required sales force may be materially more or less than the size of the sales force actually
required to effectively commercialize our product candidates. As such, we may be required to hire sales representatives and third-party
partners to adequately support the commercialization of our product candidates, or we may incur excess costs if we hire more sales representatives
than necessary. With respect to certain geographical markets, we may enter into collaborations with other entities to utilize their local
marketing and distribution capabilities, but we may be unable to enter into such agreements on favorable terms, if at all. We also may
enter into collaborations with large pharmaceutical companies to develop and commercialize product candidates. If our future collaborators
do not commit sufficient resources to develop and commercialize our future products, if any, and we are unable to develop the necessary
marketing capabilities on our own, we will be unable to generate sufficient product revenue to sustain our business. We may compete with
companies that currently have extensive and well-funded marketing and sales operations. Without an internal team or the support of a
third party to perform marketing and sales functions, we may be unable to compete successfully against these more established companies.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Our
efforts to educate the medical community, including physicians, hospital pharmacists and infectious disease specialists, and third-party
payers on the benefits of our product candidates may require significant resources and may never be successful. If any of our product
candidates are approved, but fail to achieve market acceptance among physicians, patients or third-party payers, we will not be able
to generate significant revenue from such product, which could have a material adverse effect on our business, financial condition, results
of operations and prospects.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Delays
in establishing and obtaining regulatory approval of our manufacturing process and facility or disruptions in our manufacturing process
may delay or disrupt our product development and commercialization efforts.</span></p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">We
are working to establish our own cGMP compliant manufacturing facility at Kiryat Gat, Israel. We have completed construction on the facility,
and we are now working to qualify our manufacturing process and facility with the FDA&#8217;s cGMP regulations. Before we can begin to
commercially manufacture omidubicel or any product candidate in our facility, we must pass a pre-approval inspection of our manufacturing
facility by the FDA before omidubicel or any product candidate can obtain marketing approval. A manufacturing authorization must also
be obtained from the appropriate regulatory authorities in the European Union, Israel and worldwide. Such manufacturing authorizations
must also be obtained for any third-party manufacturing facility and process. In order to obtain approval, we will need to ensure that
all our processes, methods and equipment are compliant with cGMP, and perform extensive audits of vendors, contract laboratories and
suppliers. If any of our vendors, contract laboratories or suppliers is found to be out of compliance with cGMP, we may experience delays
or disruptions in manufacturing while we work with these third parties to remedy the violation or while we work to identify suitable
replacement vendors. If we do not demonstrate to the satisfaction of the applicable regulator that our manufacturing facilities, or those
of our contract manufacturers, are in compliance with applicable requirements, we may be materially delayed in the development of our
product candidates, which would materially harm our business. The cGMP requirements govern quality control of the manufacturing process
and documentation policies and procedures. In complying with cGMP, we will be obligated to expend time, money and effort in production,
record keeping and quality control to assure that the product meets applicable specifications and other requirements. If we fail to comply
with these requirements, we would be subject to possible regulatory action and may not be permitted to sell any product candidate that
we may develop. While we continue to work to establish the cGMP compliance of our manufacturing facility at Kiryat Gat in Israel, we
do not have another long-term partner for the manufacturing of omidubicel.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Qualifying
our manufacturing facility is subject to other delays, including because of COVID-19 related shortages of labor and governmentally imposed
shut-downs. Unexpected problems in the qualification of our manufacturing facility may adversely impact our ability to provide supply
for the development and commercialization of omidubicel as well as our financial condition.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 71; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->69<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">If
we receive marketing approval for our product candidates, sales will be limited unless the product achieves broad market acceptance by
physicians, patients, third-party payers, hospital pharmacists and others in the medical community.</span></p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">The
commercial success of our product candidates will depend upon the acceptance of the product by the medical community, including physicians,
patients, healthcare payers and hospital personnel, including transplant teams and pharmacists. The degree of market acceptance of any
approved product will depend on a number of factors, including:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">the
                                            demonstration of clinical safety and efficacy of our product candidates in clinical trials&#894;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">the
                                            efficacy, potential and perceived advantages of our product candidates over alternative treatments&#894;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">the
                                            prevalence and severity of any adverse side effects&#894;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">product
                                            labeling or product insert requirements of the FDA or other regulatory authorities, including
                                            any limitations or warnings contained in a product&#8217;s approved labeling&#894;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">distribution
                                            and use restrictions imposed by the FDA or agreed to by us as part of a mandatory or voluntary
                                            risk management plan&#894;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">our
                                            ability to obtain third-party payer coverage and adequate reimbursement for our products&#894;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">the
                                            willingness of patients to pay for drugs out of pocket in the absence of third-party coverage&#894;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">the
                                            demonstration of the effectiveness of our product candidates in reducing the cost of treatment&#894;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">the
                                            strength of marketing and distribution support&#894;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">the
                                            timing of market introduction of competitive products&#894;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">the
                                            availability of products and their ability to meet market demand&#894; and</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">publicity
                                            concerning our product candidates or competing products and treatments.</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">There
are a number of alternatives to our product candidates, including stem cell transplantation using cells from matched related donors,
matched unrelated donors, haploidentical donors or unmodified umbilical cord blood. If our product candidates are approved but do not
achieve an adequate level of acceptance by physicians, patients, healthcare payers and hospital personnel, including transplant teams
and pharmacists, we may not generate sufficient revenue from the product, and we may not become or remain profitable. In addition, our
efforts to educate the medical community and third-party payers on the benefits of our product candidates may require significant resources
and may never be successful.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">It
may be difficult for us to profitably sell our product candidates if coverage and reimbursement for these products is limited by government
authorities and/or third-party payer policies.</span></p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Significant
uncertainty exists as to the coverage and reimbursement status of any product candidates for which we obtain regulatory approval. In
the United States and markets in other countries, sales of any products for which we receive regulatory approval for commercial sale
will depend, in part, on the extent to which third-party payers provide coverage, and establish adequate reimbursement levels, for such
products. In the United States, third-party payers include federal and state healthcare programs, private managed care providers, health
insurers and other organizations.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">The
process for determining whether a third-party payer will provide coverage for a product may be separate from the process for setting
the price of a product or for establishing the reimbursement rate that such a payer will pay for the product. Third-party payers may
limit coverage to specific products on an approved list, or also known as a formulary, which might not include all of the FDA-approved
products for a particular indication.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 72; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->70<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Third-party
payers are increasingly challenging the price, examining the medical necessity and reviewing the cost-effectiveness of medical products,
therapies and services, in addition to questioning their safety and efficacy.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">We
may need to conduct expensive pharmaco-economic studies in order to demonstrate the medical necessity and cost-effectiveness of our products,
in addition to the costs required to obtain the FDA approvals. Our product candidates may not be considered medically necessary or cost-effective.
Payer&#8217;s decision to provide coverage for a product does not imply that an adequate reimbursement rate will be approved. Further,
the determination of one payer to provide coverage for a product does not assure that other payers will also provide such coverage for
the product. Adequate third-party reimbursement may not be available to enable us to maintain price levels sufficient to realize an appropriate
return on our investment in product development.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Different
pricing and reimbursement schemes exist in other countries. In the EU, governments influence the price of pharmaceutical products through
their pricing and reimbursement rules and control of national health care systems that in some countries subsidize a large part of the
cost of those products for consumers. Some jurisdictions operate positive and negative list systems under which products may only be
marketed once a reimbursement price has been agreed. To obtain reimbursement or pricing approval, some of these countries may require
the completion of clinical trials that compare the cost-effectiveness of a particular product candidate to then available therapies.
Other EU member states allow companies to fix their own prices for medicines, but monitor and control company profits. The downward pressure
on health care costs has become very intense. As a result, increasingly high barriers are being erected to the entry of new products.
In addition, in some countries, cross-border imports from low-priced markets exert a commercial pressure on pricing within a country.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">The
marketability of any of our product candidates for which we receive regulatory approval for commercial sale may suffer if the government
and third-party payers fail to provide adequate coverage and reimbursement. In addition, emphasis on managed care in the United States
has increased and we expect will continue to increase the pressure on healthcare pricing. Coverage policies and third-party reimbursement
rates may change at any time. Even if favorable coverage and reimbursement status is attained for one or more products for which we receive
regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in the future.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">In
addition to any healthcare reform measures that may affect reimbursement, market acceptance and sales of our product candidates, if approved,
will depend on, in part, the extent to which the procedures utilizing our product candidates, performed by health care providers, will
be covered by third-party payers, such as government health care programs, commercial insurance and managed care organizations. In the
event health care providers and patients accept our product candidates as medically useful, cost effective and safe, there is uncertainty
on how exactly our products will be reimbursed. Third-party payers determine the extent to which new products will be covered as a benefit
under their plans and the level of reimbursement for any covered product or procedure that may utilize a covered product. Coverage will
be dependent on FDA-approval and other factors&#894; reimbursement may vary across payers which is a risk for our product candidates.
Establishment of reimbursement guidelines for products is difficult to predict at this time what third-party payers will decide with
respect to the coverage and reimbursement for our product candidates.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">A
primary trend in the U.S. healthcare industry and elsewhere has been cost containment, including price controls, restrictions on coverage
and reimbursement and requirements for substitution of less expensive products. Third-party payers decide which products and procedures
they will pay for and establish reimbursement and co-payment levels. Government and other third-party payers are increasingly challenging
the prices charged for health care products and procedures, examining the cost effectiveness of procedures, and the products used in
such procedures, in addition to their safety and efficacy, and payers limit coverage and reimbursement to the appropriate patient per
a products label. We cannot be sure that coverage will be available for our product candidates, if approved, or, if coverage is available,
the level of direct or indirect reimbursement.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">We
expect to experience pricing pressures in connection with the sale of any of our product candidates due to the trend toward managed healthcare,
the increasing influence of health maintenance organizations, and additional legislative changes. The downward pressure on healthcare
costs in general, particularly prescription drugs and other treatments, has become increasingly intense. As a result, high barriers exist
to the successful commercialization of new products. Further, the adoption and implementation of any future governmental cost containment
or other health reform initiative may result in additional downward pressure on the price that we may receive for any approved product.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 73; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->71<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Reimbursement
by a third-party payer may depend upon a number of factors including the third-party payer&#8217;s determination that use of a product
is:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">a
                                            covered benefit or part of a covered benefit under its health plan&#894;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">safe,
                                            effective and medically necessary&#894;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">appropriate
                                            for the specific patient&#894;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">cost-effective&#894;
                                            and</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">neither
                                            experimental nor investigational.</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">There
is significant uncertainty related to the insurance coverage and reimbursement of newly approved products. In the United States, the
principal decisions about reimbursement are typically made by The Centers for Medicare &amp; Medicaid Services, or CMS, an agency within
the U.S. Department of Health and Human Services, as CMS decides whether and to what extent products, and the procedures that utilize
such products, will be covered and reimbursed under Medicare. Private payers may follow CMS, but have their own methods and approval
processes for determining reimbursement for new products and the procedures that utilize such products. It is difficult to predict what
CMS as well as other payers will decide with respect to reimbursement for fundamentally novel products such as ours, as there is no body
of established practices and precedents for these new products.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">In
addition, under current Medicare hospital inpatient reimbursement policies CMS offers a process whereby manufacturers may apply for the
temporary New Technology Add-on Payment or NTAP program for a new medical technology when the applicable Diagnosis-Related Group, or
DRG, based inpatient prospective payment rate is inadequate to cover the cost of a new product. As part of our commercialization efforts,
we are evaluating the potential application for omidubicel to be eligible under the NTAP program. To obtain add-on payment, a technology
must be considered &#8220;new,&#8221; represent an advance in medical technology that substantially improves, relative to technologies
previously available, the diagnosis or treatment of Medicare beneficiaries, and data reflecting the cost of the new technology must not
yet be available in the data used to recalibrate the DRGs and the sponsor much show that admissions involving the furnishing of the technology
exceed cost thresholds established by CMS for each applicable DRG. If an application is approved, new technology add-on payments are
made to hospitals for no less than two years and no more than three years. We must demonstrate the safety and effectiveness of our technology
to the FDA in addition to meeting CMS&#8217;s requirements for the NTAP program before add-on payments can be made, and we cannot assure
that CMS will agree to provide such incremental payments for omidubicel or any of our other product candidates.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Obtaining
coverage and reimbursement approval for a product from a government or other third-party payer is a time-consuming and costly process
that could require us to provide supporting scientific, clinical and cost effectiveness data for the use of our products to the payer.
We may not be able to provide data sufficient to gain acceptance with respect to coverage and reimbursement. Further, no uniform policy
requirement for coverage and reimbursement exists among third-party payers in the United States. Similarly, health care providers enter
into participation agreements with third-party payers wherein reimbursement rates are negotiated. Therefore, coverage and reimbursement
can differ significantly from payer to payer and health care provider to health care provider. As a result, we cannot be sure that coverage
or adequate reimbursement will be available for our product candidates, if approved or procedures utilizing such products. Also, we cannot
be sure that reimbursement amounts will not reduce the demand for, or the price of, our future products. If reimbursement is not available,
or is available only to limited levels, we may not be able to commercialize our product candidates, or achieve profitably at all, even
if approved.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 74; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->72<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Our
business entails a significant risk of product liability and our ability to obtain sufficient insurance coverage could have a material
effect on our business, financial condition, results of operations or prospects.</span></p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Our
business exposes us to significant product liability risks inherent in the development, testing, manufacturing and marketing of therapeutic
treatments. Product liability claims could delay or prevent completion of our development programs. If we succeed in marketing products,
such claims could result in an FDA investigation of the safety and effectiveness of our products, our manufacturing processes and facilities
or our marketing programs and potentially a recall of our products or more serious enforcement action, limitations on the approved indications
for which they may be used or suspension or withdrawal of approvals. Regardless of the merits or eventual outcome, liability claims may
also result in decreased demand for our products, injury to our reputation, costs to defend the related litigation, a diversion of management&#8217;s
time and our resources, substantial monetary awards to trial participants or patients and a decline in our share price. We do not currently
have product liability insurance and do not anticipate obtaining product liability insurance until such time as we have received FDA
or other comparable authority approval for a product and there is a product that is being provided to patients outside of clinical trials.
Any insurance we have or may obtain may not provide sufficient coverage against potential liabilities. Furthermore, product liability
insurance is becoming increasingly expensive. As a result, we may be unable to obtain sufficient insurance at a reasonable cost to protect
us against losses caused by product liability claims that could have a material adverse effect on our business.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Risks
Related to Ownership of our Ordinary Shares</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Our
executive officers, directors and principal shareholders maintain the ability to exert significant control over matters submitted to
our shareholders for approval.</span></p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Certain
of our executive officers, directors and holders of more than 5% of our voting securities beneficially owned as of March 31, 2022 shares
that represent approximately 38.8% of our share capital. As a result, if these shareholders were to act together, they would be able
to control all matters submitted to our shareholders for approval, as well as our management and affairs. For example, these persons,
if they act together, would control the election of directors and approval of any merger, consolidation or sale of all or substantially
all our assets. This concentration of voting power could delay or prevent an acquisition of our company on terms that other shareholders
may desire or result in management of our company that our public shareholders disagree with.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
market price of our ordinary shares may fluctuate significantly, which could result in substantial losses by our investors.</span></p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">The
stock market in general, and the market for pharmaceutical companies in particular, has experienced extreme volatility that has often
been unrelated to the operating performance of particular companies. As a result of this volatility, you may not be able to sell your
ordinary shares at or above the initial public offering price. The following factors, in addition to other risk factors described in
this section, may have a significant impact on the market price of our ordinary shares:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">inability
                                            to obtain the approvals necessary to commence marketing of omidubicel or initiate further
                                            clinical trials of GDA-201&#894;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">unsatisfactory
                                            results of clinical trials&#894;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">announcements
                                            of regulatory approvals or the failure to obtain them, or specific label indications or patient
                                            populations for their use, or changes or delays in the regulatory review process&#894;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">announcements
                                            of therapeutic innovations or new products by us or our competitors&#894;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">adverse
                                            actions taken by regulatory agencies with respect to our clinical trials, manufacturing supply
                                            chain or sales and marketing activities&#894;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"></p><div>

</div><!-- Field: Page; Sequence: 75; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->73<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">changes
                                            or developments in laws or regulations, and payer reimbursement requirements applicable to
                                            any candidate product in any of our platforms&#894;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">any
                                            adverse changes to our relationship with manufacturers or suppliers, especially manufacturers
                                            of candidate products&#894;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">any
                                            intellectual property infringement, misappropriation or other actions in which we may become
                                            involved&#894;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">announcements
                                            concerning our competitors or the pharmaceutical industry in general&#894;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">achievement
                                            of expected product sales and profitability or our failure to meet expectations&#894;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">our
                                            commencement of, or involvement in, litigation&#894;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">any
                                            changes in our board of directors or management&#894; and</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">the
                                            other factors described in this &#8220;Risk Factors&#8221; section.</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">If
our quarterly operating results fall below the expectations of investors or securities analysts, the price of our ordinary shares could
decline substantially. Furthermore, any quarterly fluctuations in our operating results may, in turn, cause the price of our shares to
fluctuate substantially. We believe that quarterly comparisons of our financial results are not necessarily meaningful and should not
be relied upon as an indication of our future performance.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Further,
the stock market in general, the Nasdaq Global Market and the market for biotechnology companies in particular, have experienced extreme
price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of companies like ours,
including due to coordinate buying and selling activities and market manipulation. Broad market and industry factors may negatively affect
the market price of our ordinary shares regardless of our actual operating performance. In addition, a systemic decline in the financial
markets and related factors beyond our control may cause our share price to decline rapidly and unexpectedly. Price volatility of our
ordinary shares might be worse if the trading volume of our ordinary shares is low. In the past, following periods of market volatility,
shareholders have often instituted securities class action litigation. If we were involved in securities litigation, it could have a
substantial cost and divert resources and attention of management from our business, even if we are successful.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Sales
of a substantial number of shares of our ordinary shares in the public market, or the perception that these sales might occur, could
depress the market price of our ordinary shares and could impair our ability to raise capital through the sale of additional equity securities.
We are unable to predict the effect that sales may have on the prevailing market price of our ordinary shares. In addition, we have registered
all ordinary shares that we may issue under our equity compensation plans, and, as such, these shares can be freely sold in the public
market upon issuance.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Moreover,
the liquidity of our ordinary shares may be limited, not only in terms of the number of ordinary shares that can be bought and sold at
a given price, but by potential delays in the timing of executing transactions in our ordinary shares and a reduction in security analyst
and media&#8217;s coverage of our company, if any. These factors may result in lower prices for our ordinary shares than might otherwise
be obtained and could also result in a larger spread between the bid and ask prices for our ordinary shares. In addition, without a large
float, our ordinary shares will be less liquid than the stock of companies with broader public ownership and, as a result, the trading
prices of our ordinary shares may be more volatile. In the absence of an active public trading market, an investor may be unable to liquidate
its investment in our ordinary shares. Trading of a relatively small volume of our ordinary shares may have a greater impact on the trading
price of our ordinary shares than would be the case if our public float were larger. We cannot predict the prices at which our ordinary
shares will trade in the future.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 76; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->74<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">If
we are or become classified as a passive foreign investment company, our U.S. shareholders may suffer adverse tax consequences as a result.</span></p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Generally,
for any taxable year, if at least 75% of our gross income is passive income, or at least 50% of the value of our assets is attributable
to assets that produce passive income or are held for the production of passive income, including cash, we would be characterized as
a passive foreign investment company, or PFIC, for U.S. federal income tax purposes. For purposes of these tests, passive income includes
dividends, interest gains from commodities and securities transactions, the excess of gains over losses from the disposition of assets
which produce passive income (including amounts derived by reason of the temporary investment of funds raised in offerings of our shares)
and rents and royalties other than rents and royalties which are received from unrelated parties in connection with the active conduct
of a trade or business. If we are characterized as a PFIC, our U.S. shareholders may suffer adverse tax consequences, including having
gains realized on the sale of our ordinary shares treated as ordinary income, rather than capital gain, the loss of the preferential
rate applicable to dividends received on our ordinary shares by individuals who are U.S. holders, and having interest charges apply to
distributions by us and gains from the sales of our shares.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Our
status as a PFIC will depend on the nature and composition of our income and the nature, composition and value of our assets (which may
be determined based on the fair market value of each asset, with the value of goodwill and going concern value determined in large part
by reference to the market value of our common shares, which may be volatile). Based upon the value of our assets, including any goodwill,
and the nature and composition of our income and assets, we do not believe that we were classified as a PFIC for the taxable year ended
December 31, 2021. Because the determination of whether we are a PFIC for any taxable year is a factual determination made annually after
the end of each taxable year, there can be no assurance that we will not be considered a PFIC in any taxable year. Accordingly, our U.S.
counsel expresses no opinion with respect to our PFIC status for our taxable year ended December 31, 2021, and also expresses no opinion
with regard to our expectations regarding our PFIC status in the future.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">The
tax consequences that would apply if we are classified as a PFIC would also be different from those described above if a U.S. shareholder
were able to make a valid qualified electing fund, or QEF, election. At this time, we do not expect to provide U.S. shareholders with
the information necessary for a U.S. shareholder to make a QEF election. Prospective investors should assume that a QEF election will
not be available.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">If
a United States person is treated as owning at least 10% of our shares, such holder may be subject to adverse U.S. federal income tax
consequences.</span></p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">If
a United States person is treated as owning (directly, indirectly or constructively through the application of attribution rules) at
least 10% of the value or voting power of our shares, such person may be treated as a &#8220;United States shareholder&#8221; with respect
to each &#8220;controlled foreign corporation&#8221; in our group (if any). Because our group includes one or more U.S. subsidiaries,
certain of our current or future non-U.S. subsidiaries could be treated as controlled foreign corporations (regardless of whether we
are or are not treated as a controlled foreign corporation). A United States shareholder of a controlled foreign corporation may be required
to annually report and include in its U.S. taxable income its pro rata share of the controlled foreign corporation&#8217;s &#8220;Subpart
F income&#8221;, &#8220;global intangible low-taxed income&#8221; and investments in U.S. property, whether or not such controlled foreign
corporation makes any distributions. An individual that is a United States shareholder with respect to a controlled foreign corporation
generally would not be allowed certain tax deductions or foreign tax credits that would be allowed to a United States shareholder that
is a U.S. corporation. A failure to comply with these reporting obligations may subject you to significant monetary penalties and may
prevent the statute of limitations with respect to your U.S. federal income tax return for the year for which reporting was due from
starting. We cannot provide any assurances that we will assist investors in determining whether any of our current or future non-U.S.
subsidiaries are treated as a controlled foreign corporation or whether such investor is treated as a United States shareholder with
respect to any of such controlled foreign corporations or furnish to any United States shareholders information that may be necessary
to comply with the aforementioned reporting and tax paying obligations. A United States investor should consult their own advisors regarding
the potential application of these rules to its investment in the shares.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 77; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->75<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
intended tax effects of our corporate structure and intercompany arrangements depend on the application of the tax laws of various jurisdictions
and on how we operate our business.</span></p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Significant
judgment is required in evaluating our tax positions and determining our provision for income taxes. During the ordinary course of business,
there are many transactions and calculations for which the ultimate tax determination is uncertain. For example, our effective tax rates
could be adversely affected by changes in foreign currency exchange rates or by changes in the relevant tax, accounting and other laws,
regulations, principles and interpretations. As we intend to operate in numerous countries and taxing jurisdictions, the application
of tax laws can be subject to diverging and sometimes conflicting interpretations by tax authorities of these jurisdictions. It is not
uncommon for taxing authorities in different countries to have conflicting views, for instance, with respect to, among other things,
the manner in which the arm&#8217;s length standard is applied for transfer pricing purposes, or with respect to the valuation of intellectual
property.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">If
tax authorities in any of the countries in which we operate were to successfully challenge our transfer prices as not reflecting arms&#8217;
length transactions, they could require us to adjust our transfer prices and thereby reallocate our income to reflect these revised transfer
prices, which could result in a higher tax liability to us. In addition, if the country from which the income is reallocated does not
agree with the reallocation, both countries could tax the same income, potentially resulting in double taxation. If tax authorities were
to allocate income to a higher tax jurisdiction, subject our income to double taxation or assess interest and penalties, it would increase
our consolidated tax liability, which could adversely affect our financial condition, results of operations and cash flows. Similarly,
a tax authority could assert that we are subject to tax in a jurisdiction where we believe we have not established a taxable connection,
often referred to as a &#8220;permanent establishment&#8221; under international tax treaties, and such an assertion, if successful could
increase our expected tax liability in one or more jurisdictions.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Future
changes to tax laws could materially adversely affect our company and reduce net return to our shareholders</span></p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Tax
laws are dynamic and subject to change as new laws are passed and interpretations of the law are issued or applied. Such changes may
include (but are not limited to) the taxation of operating income, investment income, dividends received or (in the specific context
of withholding tax) dividends paid. We are unable to predict what tax reform may be proposed or enacted in the future or what effect
such changes would have on our business, but such changes, to the extent they are brought into tax legislation, regulations, policies
or practices, could affect our financial position and overall or effective tax rates in the future in countries where we have operations,
reduce post-tax returns to our shareholder, and increase the complexity, burden and cost of tax compliance.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The
tax benefits that are available to us require us to continue to meet various conditions and may be terminated or reduced in the future,
which could increase our costs and taxes.</span></p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Some
of our operations in Israel may entitle us to certain tax benefits under the Law for the Encouragement of Capital Investments, 5719-1959,
or the Investment Law, once we begin to produce revenue. If we do not meet the requirements for maintaining these benefits, they may
be reduced or cancelled and the relevant operations would be subject to Israeli corporate tax at the standard rate, which is set at 23%
in 2021 and thereafter. In addition to being subject to the standard corporate tax rate, we could be required to refund any tax benefits
that we will receive, plus interest and penalties thereon. Even if we continue to meet the relevant requirements, the tax benefits that
our current &#8220;Preferred Enterprise&#8221; is entitled to may not be continued in the future at their current levels or at all. If
these tax benefits were reduced or eliminated, the amount of taxes that we will pay would likely increase, as all our operations would
consequently be subject to corporate tax at the standard rate, which could adversely affect our results of operations. Additionally,
if we increase our activities outside of Israel, for example, by way of acquisitions, our increased activities may not be eligible for
inclusion in Israeli tax benefits programs.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">We
have never paid cash dividends on our share capital, and we do not anticipate paying any cash dividends in the foreseeable future.</span></p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">We
have never declared or paid cash dividends on our ordinary shares. We currently anticipate that we will retain future earnings for the
development, operation and expansion of our business and do not anticipate declaring or paying any cash dividends in the foreseeable
future. As a result, capital appreciation, if any, of our ordinary shares will be investors&#8217; sole source of gain for the foreseeable
future. In addition, Israeli law limits our ability to declare and pay dividends, and may subject our dividends to Israeli withholding
taxes.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 78; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->76<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">If
securities or industry analysts do not publish or cease publishing research or reports about us, our business or our market, or if they
adversely change their recommendations or publish negative reports regarding our business or our ordinary shares, our share price and
trading volume could be negatively impacted.</span></p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">The
trading market for our ordinary shares is influenced by the research and reports that industry or securities analysts publish about us,
our business, our market or our competitors. We do not have any control over these analysts, and we cannot provide any assurance that
analysts will continue to cover us or provide favorable coverage. If any of the analysts who cover us adversely change their recommendation
regarding our shares, or provide more favorable relative recommendations about our competitors, our share price would likely decline.
If any analyst who cover us were to cease coverage of our company or fail to regularly publish reports on us, we could lose visibility
in the financial markets, which in turn could cause our share price or trading volume to decline.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">We
are an emerging growth company and the reduced disclosure requirements applicable to emerging growth companies may make our ordinary
shares less attractive to investors.</span></p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">We
are an emerging growth company, as defined in the JOBS Act, and we may take advantage of certain exemptions from various requirements
that are applicable to other public companies that are not emerging growth companies. For as long as we remain an emerging growth company,
we are permitted and intend to rely on exemptions from certain disclosure requirements that are applicable to other public companies
that are not &#8220;emerging growth companies.&#8221; These exemptions include:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">being
                                            permitted to provide only two years of audited financial statements, in addition to any required
                                            unaudited condensed consolidated interim financial statements, with correspondingly&#894;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">not
                                            being required to comply with the auditor attestation requirements in the assessment of our
                                            internal control over financial reporting&#894;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">not
                                            being required to comply with any requirement that may be adopted by the Public Company Accounting
                                            Oversight Board regarding mandatory audit firm rotation or a supplement to the auditor&#8217;s
                                            report providing additional information about the audit and the financial statements&#894;</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">reduced
                                            disclosure obligations regarding executive compensation&#894; and</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.25in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">exemptions
                                            from the requirements of holding a nonbinding advisory vote on executive compensation and
                                            shareholder approval of any golden parachute payments not previously approved.</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">We
may take advantage of these provisions until such time that we are no longer an emerging growth company. We will cease to be an emerging
growth company upon the earlier to occur of: (1) the last day of our fiscal year following the fifth anniversary of the date of our October
2018 initial public offering; (2) the last day of the fiscal year in which we have total annual gross revenue of $1.07 billion or more&#894;
(2) the date on which we have issued more than $1.0 billion in nonconvertible debt during the previous three years&#894; or (4) the date
on which we are deemed to be a large accelerated filer under the rules of the SEC. We may choose to take advantage of some but not all
of these reduced burdens, and therefore the information that we provide holders of our ordinary shares may be different than the information
you might receive from other public companies in which you hold equity. In addition, Section 107 of the JOBS Act also provides that an
emerging growth company can take advantage of an extended transition period for complying with new or revised accounting standards applicable
to public companies. However, given that we currently report and expect to continue to report under IFRS as issued by the IASB, the extended
transition period available to emerging growth companies that report under GAAP is inapplicable to us.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">When
we are no longer deemed to be an emerging growth company, we will not be entitled to the exemptions provided in the JOBS Act discussed
above. We cannot predict if investors will find our ordinary shares less attractive as a result of our reliance on exemptions under the
JOBS Act. If some investors find our ordinary shares less attractive as a result, there may be a less active trading market for our ordinary
shares and our share price may be more volatile.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 79; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->77<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"><b><i>We
must meet the Nasdaq Global Market&#8217;s continued listing requirements and comply with the other Nasdaq rules, or we may risk delisting.
Delisting could negatively affect the price of our ordinary shares, which could make it more difficult for us to sell securities in a
financing and for you to sell your ordinary shares</i></b><i>.</i></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">We
are required to meet the continued listing requirements of the Nasdaq Global Market and comply with the other Nasdaq rules, including
those regarding director independence and independent committee requirements, minimum shareholders&#8217; equity, minimum share price
and certain other corporate governance requirements. If we do not meet these continued listing requirements, our ordinary shares could
be delisted. Delisting of our ordinary shares from the Nasdaq Global Market would cause us to pursue eligibility for trading on other
markets or exchanges, or on the pink sheets. In such case, our shareholders&#8217; ability to trade, or obtain quotations of the market
value of, our ordinary shares would be severely limited because of lower trading volumes and transaction delays. These factors could
contribute to lower prices and larger spreads in the bid and ask prices for our securities. There can be no assurance that our ordinary
shares, if delisted from the Nasdaq Global Market in the future, would be listed on a national securities exchange or quoted on a national
quotation service, the OTCBB or the pink sheets. Delisting from the Nasdaq Global Market, or even the issuance of a notice of potential
delisting, would also result in negative publicity, make it more difficult for us to raise additional capital, adversely affect the market
liquidity of our ordinary shares, reduce security analysts&#8217; coverage of us and diminish investor, supplier and employee confidence.
In addition, as a consequence of any such delisting, our share price could be negatively affected and our shareholders would likely find
it more difficult to sell, or to obtain accurate quotations as to the prices of, our ordinary shares.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Risks
Related to Israeli Law and Our Operations in Israel</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Significant
parts of our operations are located in Israel and, therefore, our results may be adversely affected by political, economic and military
conditions in Israel.</span></p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">We
have substantial operations in Israel, including our research and development facilities and our manufacturing facilities, that may be
influenced by regional instability and extreme military tension. Accordingly, political, economic and military conditions in Israel and
the surrounding region could directly affect our business. Any armed conflicts, political instability, terrorism, cyberattacks or any
other hostilities involving Israel or the interruption or curtailment of trade between Israel and its present trading partners could
affect adversely our operations.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Ongoing
and revived hostilities or other Israeli political or economic factors, could prevent or delay shipments of our products, harm our operations
and product development and cause any future sales to decrease. In the event that hostilities disrupt the ongoing operation of our facilities
or the airports and seaports on which we depend to import and export our supplies and products, our operations may be materially adverse
affected.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Our
operations may be disrupted as a result of the obligation of management or key personnel or consultants to perform military service.</span></p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Many
Israeli citizens are obligated to perform several days, and in some cases more, of annual military reserve duty each year until they
reach the age of 40 (or older, for reservists who are military officers or who have certain occupations) and, in the event of a military
conflict, may be called to active duty. In response to increases in terrorist activity, there have been periods of significant call-ups
of military reservists. It is possible that there will be military reserve duty call-ups in the future. Our operations could be disrupted
by such call-ups, which may include the call-up of members of our management. Such disruption could materially adversely affect our business,
financial condition and results of operations.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 80; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->78<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Because
we incur a portion of our expenses in currencies other than the U.S. dollar, our financial condition and results of operations may be
harmed by currency fluctuations and inflation.</span></p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">While
our reporting and functional currency is the U.S. dollar, we pay a meaningful portion of our expenses in NIS, Euros and other currencies.
All of the salaries of our employees, our general and administrative expenses (including rent for our real property facility in Israel),
and the fees that we pay to certain of our partners, are denominated in NIS. Certain of our suppliers are located in Europe and are paid
in Euros. As a result, we are exposed to the currency fluctuation risks relating to the denomination of our future expenses in U.S. dollars.
More specifically, if the U.S. dollar becomes devalued against the NIS or the Euro, our NIS- or Euro- denominated expenses will be greater
than anticipated when reported in U.S. dollars. Inflation in Israel compounds the adverse impact of such devaluation by further increasing
the amount of our Israeli expenses. Israeli inflation may also (in the future) outweigh the positive effect of any appreciation of the
U.S. dollar relative to the NIS, if, and to the extent that, it outpaces such appreciation or precedes such appreciation. The Israeli
rate of inflation did not have a material adverse effect on our financial condition during 2020 or 2021. Given our general lack of currency
hedging arrangements to protect us from fluctuations in the exchange rates of the NIS or the Euro and other non-U.S. currencies in relation
to the U.S. dollar (and/or from inflation of such non-U.S. currencies), we may be exposed to material adverse effects from such movements.
We cannot predict any future trends in the rate of inflation in Israel or in Europe or the rate of devaluation (if any) of the U.S. dollar
against the NIS or the Euro.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Provisions
of Israeli law and our amended and restated articles of association may delay, prevent or make undesirable an acquisition of all or a
significant portion of our shares or assets.</span></p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Certain
provisions of Israeli law and our amended and restated articles of association could have the effect of delaying or preventing a change
in control and may make it more difficult for a third-party to acquire us or for our shareholders to elect different individuals to our
board of directors, even if doing so would be beneficial to our shareholders, and may limit the price that investors may be willing to
pay in the future for our ordinary shares. For example, our amended and restated articles of association provide that our directors are
elected on a staggered basis, such that a potential acquirer cannot readily replace our entire board of directors at a single annual
general shareholder meeting. In addition, Israeli corporate law regulates mergers and requires that a tender offer be affected when more
than a specified percentage of shares in a company are purchased.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Further,
Israeli tax considerations may make potential transactions undesirable to us or to some of our shareholders whose country of residence
does not have a tax treaty with Israel granting tax relief to such shareholders from Israeli tax. With respect to certain mergers, Israeli
tax law may impose certain restrictions on future transactions, including with respect to dispositions of shares received as consideration,
for a period of two years from the date of the merger.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Furthermore,
under the Encouragement of Research, Development and Technological Innovation in the Industry Law 5744-1984 (formerly known as the Law
for the Encouragement of Research and Development in Industry 5744-1984), and the regulations and guidelines promulgated thereunder,
or the Innovation Law, to which we are subject due to our receipt of grants from the Israel Innovation Authority, or IIA (formerly known
as the Office of the Chief Scientist of the Ministry of Economy and Industry, or the OCS), a recipient of IIA grants such as us must
report to IIA regarding any change of control of our company or regarding any change in the holding of the means of control of our company
which results in any non- Israeli citizen or resident becoming an &#8220;interested party&#8221;, as defined in the Innovation Law, in
our company, and in the latter event, the non-Israeli citizen or resident will be required to execute an undertaking in favor of IIA,
in a form prescribed by IIA, acknowledging the restrictions imposed by such law and agreeing to abide by its terms.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></p><div>

</div><!-- Field: Page; Sequence: 81; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->79<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Investors
may have difficulties enforcing a U.S. judgment, including judgments based upon the civil liability provisions of the U.S. federal securities
laws against us, or our executive officers and directors or asserting U.S. securities laws claims in Israel.</span></p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Not
all our directors are residents of the United States and most our assets are located outside the United States. Service of process upon
us or our non-U.S. resident directors and enforcement of judgments obtained in the United States against us or our non-U.S. directors
may be difficult to obtain within the United States. We have been informed by our legal counsel in Israel that it may be difficult to
assert claims under U.S. securities laws in original actions instituted in Israel or obtain a judgment based on the civil liability provisions
of U.S. federal securities laws. Israeli courts may refuse to hear a claim based on a violation of U.S. securities laws against us or
our non-U.S. directors because Israel may not be the most appropriate forum to bring such a claim. In addition, even if an Israeli court
agrees to hear a claim, it may determine that Israeli law and not U.S. law is applicable to the claim. If U.S. law is found to be applicable,
the content of applicable U.S. law must be proved as a fact, which can be a time-consuming and costly process. Certain matters of procedure
will also be governed by Israeli law. There is little binding case law in Israel addressing the matters described above. Israeli courts
might not enforce judgments rendered outside Israel, which may make it difficult to collect on judgments rendered against us or our non-U.S.
directors.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Moreover,
among other reasons, including but not limited to, fraud or absence of due process, or the existence of a judgment which is at variance
with another judgment that was given in the same matter if a suit in the same matter between the same parties was pending before a court
or tribunal in Israel, an Israeli court will not enforce a non-Israeli judgment if it was given in a state whose laws do not provide
for the enforcement of judgments of Israeli courts (subject to exceptional cases) or if its enforcement is likely to prejudice the sovereignty
or security of the State of Israel.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Your
liabilities and responsibilities as a shareholder will be governed by Israeli law, which differs in some material respects from the U.S.
law that governs the liabilities and responsibilities of shareholders of U.S. corporations.</span></p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">We
are incorporated under Israeli law. The rights and responsibilities of holders of our ordinary shares are governed by our amended and
restated articles of association and the Israeli Companies Law 5759-1999, or Companies Law. These rights and responsibilities differ
in some respects from the rights and responsibilities of shareholders in typical U.S. corporations. In particular, pursuant to the Companies
Law each shareholder of an Israeli company has to act in good faith in exercising his or her rights and fulfilling his or her obligations
toward the company and other shareholders and to refrain from abusing his or her power in the company, including, among other things,
in voting at the general meeting of shareholders and class meetings, on amendments to a company&#8217;s articles of association, increases
in a company&#8217;s authorized share capital, mergers, and transactions requiring shareholders&#8217; approval under the Companies Law.
In addition, a controlling shareholder of an Israeli company or a shareholder who knows that it possesses the power to determine the
outcome of a shareholder vote or who has the power to appoint or prevent the appointment of a director or officer in the company, or
has other powers toward the company, has a duty of fairness toward the company. However, Israeli law does not define the substance of
this duty of fairness.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Because
Israeli corporate law has undergone extensive revision in recent years, there is little case law available to assist in understanding
the implications of these provisions that govern shareholder behavior.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><div><a id="a_014"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Item
2. Unregistered Sales of Equity Securities and Use of Proceeds.</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-weight: normal">None.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-weight: normal">&#160;</span></p><div>

</div><div><a id="a_015"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Item
3. Defaults Upon Senior Securities.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">None.</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><div><a id="a_016"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Item
4. Mine Safety Disclosures.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">None.</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><div><a id="a_017"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Item
5. Other Information.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">None.</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 82; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->80<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><div><a id="a_018"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif">Item
6. Exhibits.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">The
following exhibits are filed as part of this report:</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid; width: 10%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit <br/>
Number</b></span></td>
    <td style="text-align: center; width: 1%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 89%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Description</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify">
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">3.1</p></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1600847/000121390022014643/f10k2021ex3-1_gamidacell.htm">Articles of Association of the Registrant (incorporated by reference to Exhibit 3.1 to the Registrant&#8217;s Form 10-K (File No. 001-38716), filed with the SEC on March 24, 2022).</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1600847/000114036118039574/s002295x7_ex3-4.htm">Memorandum of Association of the Registrant (unofficial English translation from Hebrew original), as amended on September 14, 2006 (incorporated by reference to Exhibit 3.4 to the Registrant&#8217;s Form F-1 (File No. 333-227601), filed with the SEC on September 28, 2018).</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1600847/000121390022014643/f10k2021ex4-3_gamidacell.htm">Description of Securities (incorporated by reference to Exhibit 4.3 to the Registrant&#8217;s Form 10-K (File No. 001-38716), filed with the SEC on March 24, 2022).</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1600847/000121390022014643/f10k2021ex10-1_gamidacell.htm">Form of Indemnification Agreement (incorporated by reference to Exhibit 10.1 to the Registrant&#8217;s Form 10-K (File No. 001-38716), filed with the SEC on March 24, 2022).</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify">
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">31.1</p></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="f10q0322ex31-1_gamidacell.htm">Certification of Principal Executive Officer pursuant to Rules 13a-14(a) or 15d-14(a) under the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify">
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">31.2</p></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="f10q0322ex31-2_gamidacell.htm">Certification of Principal Financial Officer pursuant to Rules 13a-14(a) or 15d-14(a) under the Securities Exchange Act of 1934, as amended, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify">
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">32.1#</p></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="f10q0322ex32-1_gamidacell.htm">Certification of Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify">
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">32.2#</p></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="f10q0322ex32-2_gamidacell.htm">Certification of Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify">
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">101.INS</p></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Instance Document &#8211; The instance document does not appear in the interactive data file because its XBRL tags are embedded within the Inline XBRL document</span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.SCH</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Taxonomy Extension Schema Document</span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.CAL</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Taxonomy Extension Calculation Linkbase Document</span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.DEF</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Taxonomy Extension Definition Linkbase Document</span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.LAB</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Taxonomy Extension Label Linkbase Document</span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.PRE</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Inline XBRL Taxonomy Extension Presentation Linkbase Document</span></td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">104</span></td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The cover page from the Company&#8217;s Quarterly Report on Form 10-Q has been formatted in Inline XBRL</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top">
<td style="width: 0%"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">#</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif">The information
                                            in Exhibits 32.1 and 32.2 shall not be deemed &#8220;filed&#8221; for purposes of Section
                                            18 of the Exchange Act, or otherwise subject to the liabilities of that section, nor shall
                                            it be deemed incorporated by reference in any filing under the Securities Act or the Exchange
                                            Act (including this Quarterly Report), unless the Registrant specifically incorporates the
                                            foregoing information into those documents by reference.</span></td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"></p><div>

</div><!-- Field: Page; Sequence: 83; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->81<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><div><a id="a_019"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.1in; text-align: center"><span style="font-family: Times New Roman, Times, Serif">Signatures</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif">Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned thereunto duly authorized.</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td colspan="2" style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Gamida Cell Ltd.</b></span></td></tr>
  <tr>
    <td style="width: 60%">&#160;</td>
    <td style="vertical-align: bottom; width: 4%">&#160;</td>
    <td style="vertical-align: bottom; width: 36%">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">May 12, 2022</span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Julian Adams</span></td></tr>
  <tr>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Julian Adams</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Chief Executive Officer and Director
    <br/>
(Principal Executive Officer)</b></p></td></tr>
  <tr>
    <td>&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td></tr>
  <tr>
    <td style="vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">May 12, 2022</span></td>
    <td style="vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td style="border-bottom: black 1.5pt solid; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Shai Lankry</span></td></tr>
  <tr>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Shai Lankry</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Chief Financial Officer <br/>
(Principal
    Financial Officer and Principal Accounting Officer)</b></p></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>

</div><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif">82</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif">&#160;</span></p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 18pt"></p><div>


</div><div style="display: none"><ix:header>
<ix:hidden>
<ix:nonNumeric contextRef="c0" id="hidden-fact-0" name="dei:EntityTaxIdentificationNumber">00-0000000</ix:nonNumeric>
<ix:nonFraction contextRef="c2" id="hidden-fact-1" name="us-gaap:CommitmentsAndContingencies" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-2" name="us-gaap:CommitmentsAndContingencies" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c2" id="hidden-fact-3" name="us-gaap:TreasuryStockValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-4" name="us-gaap:TreasuryStockValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c9" id="hidden-fact-5" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-6" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c19" id="hidden-fact-7" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c20" id="hidden-fact-8" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-9" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c21" id="hidden-fact-10" name="us-gaap:TreasuryStockSharesRetired" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c20" id="hidden-fact-11" name="us-gaap:TreasuryStockValueAcquiredCostMethod" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-12" name="us-gaap:TreasuryStockValueAcquiredCostMethod" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c19" id="hidden-fact-13" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c24" id="hidden-fact-14" name="us-gaap:SharesOutstanding" unitRef="shares" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c33" id="hidden-fact-15" name="us-gaap:MoneyMarketFundsAtCarryingValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c35" id="hidden-fact-16" name="us-gaap:MoneyMarketFundsAtCarryingValue" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c32" id="hidden-fact-17" name="gmda:CorporateDebentures" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c34" id="hidden-fact-18" name="gmda:CorporateDebentures" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c32" id="hidden-fact-19" name="gmda:GovernmentDebentures" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c34" id="hidden-fact-20" name="gmda:GovernmentDebentures" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonNumeric contextRef="c0" name="dei:AmendmentFlag">false</ix:nonNumeric>
<ix:nonNumeric contextRef="c0" name="dei:CurrentFiscalYearEndDate">--12-31</ix:nonNumeric>
<ix:nonNumeric contextRef="c0" name="dei:DocumentFiscalPeriodFocus">Q1</ix:nonNumeric>
<ix:nonNumeric contextRef="c0" name="dei:EntityCentralIndexKey">0001600847</ix:nonNumeric>
</ix:hidden>
<ix:references><link:schemaRef xlink:href="gmda-20220331.xsd" xlink:type="simple"></link:schemaRef></ix:references>
<ix:resources xmlns="http://www.xbrl.org/2003/instance"><ix:relationship fromRefs="hidden-fact-3" toRefs="ix_0_footnote"></ix:relationship>
<ix:relationship fromRefs="hidden-fact-5 hidden-fact-6 hidden-fact-7 hidden-fact-8 hidden-fact-9 hidden-fact-10 hidden-fact-11 hidden-fact-12 hidden-fact-13 hidden-fact-14" toRefs="ix_1_footnote"></ix:relationship>
<xbrli:context id="c0">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001600847</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c1">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001600847</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-05-09</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c2">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001600847</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c3">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001600847</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c4">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001600847</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c5">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001600847</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c6">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001600847</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c7">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001600847</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c8">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001600847</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c9">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001600847</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c10">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001600847</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c11">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001600847</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c12">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001600847</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c13">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001600847</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c14">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001600847</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c15">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001600847</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c16">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001600847</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c17">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001600847</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c18">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001600847</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c19">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001600847</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c20">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001600847</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c21">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001600847</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c22">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001600847</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c23">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001600847</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c24">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001600847</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c25">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001600847</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrbGzSS2V9veXLez+Xl0dIVqXQZdaaX7U8iZ3lEvQVQ8yavTR5LGMAC/Y6xtwO1cV8d5LpXjJeLMk6eat28V4VVXVBSb2HOCKvVmZvuAbSKzXyDRkT12vtciTURxwLsQFoRiJcYRfObTSc0gbTBq++/nfodHvEU7EA/LrQkg0k4it0+ht+i+C+b89bqCog/XAhWFRbdZDsE8Wg==] CSR-->
  <xbrli:period>
    <xbrli:instant>2022-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c26">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001600847</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c27">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001600847</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c28">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001600847</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-02-02</xbrli:startDate>
    <xbrli:endDate>2021-02-16</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c29">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001600847</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-02-02</xbrli:startDate>
    <xbrli:endDate>2021-02-16</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c30">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001600847</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c31">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001600847</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c32">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001600847</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c33">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001600847</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c34">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001600847</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c35">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001600847</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c36">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001600847</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="pf0:RangeAxis">pf0:MinimumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c37">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001600847</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="pf0:RangeAxis">pf0:MaximumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c38">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001600847</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c39">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001600847</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c40">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001600847</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassCMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2014-11-23</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c41">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001600847</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">gmda:TwoZeroOneFourIsraelShareOptionPlanMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassCMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2014-11-23</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c42">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001600847</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2014-11-01</xbrli:startDate>
    <xbrli:endDate>2014-11-23</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c43">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001600847</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">gmda:TwoThousandSeventeenStockCompensationPlanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2017-01-23</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c44">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001600847</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">gmda:TwoThousandSeventeenStockCompensationPlanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2017-06-26</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c45">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001600847</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">gmda:TwoThousandSeventeenStockCompensationPlanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2017-12-28</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c46">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001600847</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">gmda:TwoThousandSeventeenStockCompensationPlanMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2022-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c47">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001600847</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="pf0:RangeAxis">pf0:MinimumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c48">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001600847</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="pf0:RangeAxis">pf0:MaximumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c49">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001600847</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="gmda:LossPerShareAxis">gmda:ForTheComputationOfDilutedLossMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2022-01-01</xbrli:startDate>
    <xbrli:endDate>2022-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c50">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001600847</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="gmda:LossPerShareAxis">gmda:ForTheComputationOfDilutedLossMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:unit id="shares">
  <xbrli:measure>xbrli:shares</xbrli:measure>
</xbrli:unit><xbrli:unit id="usd">
  <xbrli:measure>iso4217:USD</xbrli:measure>
</xbrli:unit><xbrli:unit id="ilsPershares">
  <xbrli:divide>
    <xbrli:unitNumerator>
      <xbrli:measure>iso4217:ILS</xbrli:measure>
    </xbrli:unitNumerator>
    <xbrli:unitDenominator>
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unitDenominator>
  </xbrli:divide>
</xbrli:unit><xbrli:unit id="usdPershares">
  <xbrli:divide>
    <xbrli:unitNumerator>
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unitNumerator>
    <xbrli:unitDenominator>
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unitDenominator>
  </xbrli:divide>
</xbrli:unit><xbrli:unit id="pure">
  <xbrli:measure>xbrli:pure</xbrli:measure>
</xbrli:unit></ix:resources></ix:header>

</div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>f10q0322ex31-1_gamidacell.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 31.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTIFICATION PURSUANT TO SECTION 302 OF SARBANES-OXLEY
ACT OF 2002</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">I, Julian Adams, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">1.</TD><TD STYLE="text-align: justify">I have reviewed this Quarterly Report on Form 10-Q of Gamida
Cell Ltd.;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">2.</TD><TD STYLE="text-align: justify">Based on my knowledge, this report does not contain any untrue
statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under
which such statements were made, not misleading with respect to the period covered by this report;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">3.</TD><TD STYLE="text-align: justify">Based on my knowledge, the financial statements, and other financial
information included in this report, fairly present in all material respects the financial condition, results of operations and cash
flows of the registrant as of, and for, the periods presented in this report;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">4.</TD><TD STYLE="text-align: justify">The registrant&rsquo;s other certifying officer(s) and I are
responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e))
and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">a.</TD><TD STYLE="text-align: justify">Designed such disclosure controls and procedures, or caused
such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant,
including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which
this report is being prepared;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">b.</TD><TD STYLE="text-align: justify">Designed such internal control over financial reporting or
caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurances regarding
the reliability of financial reporting in the preparation of financial statements for external purposes in accordance with generally
accepted accounting principles;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">c.</TD><TD STYLE="text-align: justify">Evaluated the effectiveness of the registrant&rsquo;s disclosure
controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures,
as of the end of the period covered by this report based on such evaluation;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">d.</TD><TD STYLE="text-align: justify">Disclosed in this report any change in the registrant&rsquo;s
internal control over financial reporting that occurred during the registrant&rsquo;s most recent fiscal quarter (the registrant&rsquo;s
fourth quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&rsquo;s
internal control over financial reporting; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">5.</TD><TD STYLE="text-align: justify">The registrant&rsquo;s other certifying officer(s) and I have
disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&rsquo;s auditors and the
Audit Committee of the registrant&rsquo;s Board of Directors (or persons performing the equivalent functions):</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">a.</TD><TD STYLE="text-align: justify">All significant deficiencies and material weaknesses in the
design or operation of internal control over financial reporting, which are reasonably likely to adversely affect the registrant&rsquo;s
ability to record, process, summarize and report financial information; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">b.</TD><TD STYLE="text-align: justify">Any fraud, whether or not material, that involves management
or other employees who have a significant role in the registrant&rsquo;s internal control over financial reporting.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Date: May 12, 2022</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="font-size: 10pt">/s/ Julian Adams</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%; border-top: black 1.5pt solid; font-size: 10pt">By:</TD>
    <TD STYLE="width: 35%; border-top: black 1.5pt solid; font-size: 10pt"><B>Julian Adams, Ph.D.</B></TD>
    <TD STYLE="width: 60%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">Title:</TD>
    <TD STYLE="font-size: 10pt">Chief Executive Officer</TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>f10q0322ex31-2_gamidacell.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 31.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTIFICATION PURSUANT TO SECTION 302 OF SARBANES-OXLEY
ACT OF 2002</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">I, Shai Lankry, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">1.</TD><TD STYLE="text-align: justify">I have reviewed this Quarterly Report on Form 10-Q of Gamida
Cell Ltd.;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">2.</TD><TD STYLE="text-align: justify">Based on my knowledge, this report does not contain any untrue
statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under
which such statements were made, not misleading with respect to the period covered by this report;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">3.</TD><TD STYLE="text-align: justify">Based on my knowledge, the financial statements, and other financial
information included in this report, fairly present in all material respects the financial condition, results of operations and cash
flows of the registrant as of, and for, the periods presented in this report;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">4.</TD><TD STYLE="text-align: justify">The registrant&rsquo;s other certifying officer(s) and I are
responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e))
and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">a.</TD><TD STYLE="text-align: justify">Designed such disclosure controls and procedures, or caused
such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant,
including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which
this report is being prepared;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">b.</TD><TD STYLE="text-align: justify">Designed such internal control over financial reporting or
caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurances regarding
the reliability of financial reporting in the preparation of financial statements for external purposes in accordance with generally
accepted accounting principles;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">c.</TD><TD STYLE="text-align: justify">Evaluated the effectiveness of the registrant&rsquo;s disclosure
controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures,
as of the end of the period covered by this report based on such evaluation;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">d.</TD><TD STYLE="text-align: justify">Disclosed in this report any change in the registrant&rsquo;s
internal control over financial reporting that occurred during the registrant&rsquo;s most recent fiscal quarter (the registrant&rsquo;s
fourth quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&rsquo;s
internal control over financial reporting; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">5.</TD><TD STYLE="text-align: justify">The registrant&rsquo;s other certifying officer(s) and I have
disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&rsquo;s auditors and the
Audit Committee of the registrant&rsquo;s Board of Directors (or persons performing the equivalent functions):</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">a.</TD><TD STYLE="text-align: justify">All significant deficiencies and material weaknesses in the
design or operation of internal control over financial reporting, which are reasonably likely to adversely affect the registrant&rsquo;s
ability to record, process, summarize and report financial information; and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">b.</TD><TD STYLE="text-align: justify">Any fraud, whether or not material, that involves management
or other employees who have a significant role in the registrant&rsquo;s internal control over financial reporting.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Date: May 12, 2022</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="font-size: 10pt">/s/ Shai Lankry</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-top: black 1.5pt solid; width: 5%; font-size: 10pt">By:</TD>
    <TD STYLE="border-top: black 1.5pt solid; width: 35%; font-size: 10pt"><B>Shai Lankry</B></TD>
    <TD STYLE="width: 60%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">Title:</TD>
    <TD STYLE="font-size: 10pt">Chief Financial Officer</TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>f10q0322ex32-1_gamidacell.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt -0.25in; text-align: right"><B>Exhibit 32.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTIFICATION PURSUANT TO </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>18 U.S.C. Section 1350, </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>AS ADOPTED PURSUANT TO </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with the Quarterly Report of Gamida
Cell Ltd. (the &ldquo;Company&rdquo;) on Form 10-Q for the period ended March 31, 2022 as filed with the Securities and Exchange Commission
on the date hereof (the &ldquo;Report&rdquo;), I, Julian Adams, Principal Executive Officer of the Company, certify, pursuant to 18 U.S.C.
Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">(1)</TD><TD STYLE="text-align: justify">The Report fully complies with the requirements of Section 13(a)
or 15(d) of the Securities Exchange Act of 1934; and</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">(2)</TD><TD STYLE="text-align: justify">The information contained in this Report fairly presents, in
all material respects, the financial condition and results of operations of the Company.</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Date: May 12, 2022</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">/s/ Julian Adams</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-top: black 1.5pt solid; width: 40%; font-size: 10pt"><B>Julian Adams, Ph.D.</B></TD>
    <TD STYLE="width: 60%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">Chief Executive Officer</TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>5
<FILENAME>f10q0322ex32-2_gamidacell.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 32.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CERTIFICATION PURSUANT TO </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>18 U.S.C. Section 1350, </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>AS ADOPTED PURSUANT TO </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with the Quarterly Report of Gamida
Cell Ltd. (the &ldquo;Company&rdquo;) on Form 10-Q for the period ended March 31, 2022 as filed with the Securities and Exchange Commission
on the date hereof (the &ldquo;Report&rdquo;), I, Shai Lankry, Principal Financial Officer of the Company, certify, pursuant to 18 U.S.C.
Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">(1)</TD><TD STYLE="text-align: justify">The Report fully complies with the requirements of Section 13(a)
or 15(d) of the Securities Exchange Act of 1934; and</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">(2)</TD><TD STYLE="text-align: justify">The information contained in this Report fairly presents, in
all material respects, the financial condition and results of operations of the Company.</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Date: May 12, 2022</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">/s/ Shai Lankry</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-top: black 1.5pt solid; width: 40%; font-size: 10pt"><B>Shai Lankry</B></TD>
    <TD STYLE="width: 60%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">Chief Financial Officer</TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>gmda-20220331.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Wed May 11 15:03:37 UTC 2022 -->
<xs:schema elementFormDefault="qualified" xmlns:srt-types="http://fasb.org/srt-types/2022" targetNamespace="http://www.gamidacell.com/20220331" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:us-types="http://fasb.org/us-types/2022" xmlns:gmda="http://www.gamidacell.com/20220331" xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:dtr="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xlink:type="simple" xlink:href="gmda-20220331_lab.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="gmda-20220331_pre.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="gmda-20220331_def.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="gmda-20220331_cal.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef"/>
      <link:roleType roleURI="http://www.gamidacell.com/role/ConsolidatedBalanceSheet" id="gmda_r_ConsolidatedBalanceSheet">
        <link:definition>001 - Statement - Condensed Consolidated Balance Sheets (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gamidacell.com/role/ConsolidatedBalanceSheet_Parentheticals" id="gmda_r_ConsolidatedBalanceSheet_Parentheticals">
        <link:definition>002 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parentheticals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gamidacell.com/role/ConsolidatedIncomeStatement" id="gmda_r_ConsolidatedIncomeStatement">
        <link:definition>003 - Statement - Condensed Consolidated Statements of Operation (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gamidacell.com/role/ShareholdersEquityType2or3" id="gmda_r_ShareholdersEquityType2or3">
        <link:definition>004 - Statement - Condensed Consolidated Statements of Changes in Shareholders&#8217; Equity (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gamidacell.com/role/ConsolidatedCashFlow" id="gmda_r_ConsolidatedCashFlow">
        <link:definition>005 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gamidacell.com/role/General" id="gmda_r_General">
        <link:definition>006 - Disclosure - General</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gamidacell.com/role/SignificantAccountingPolicies" id="gmda_r_SignificantAccountingPolicies">
        <link:definition>007 - Disclosure - Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gamidacell.com/role/Leases" id="gmda_r_Leases">
        <link:definition>008 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gamidacell.com/role/ConvertibleSeniorNotesNet" id="gmda_r_ConvertibleSeniorNotesNet">
        <link:definition>009 - Disclosure - Convertible Senior Notes, Net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gamidacell.com/role/FairValueMeasurements" id="gmda_r_FairValueMeasurements">
        <link:definition>010 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gamidacell.com/role/ContingentLiabilitiesandCommitments" id="gmda_r_ContingentLiabilitiesandCommitments">
        <link:definition>011 - Disclosure - Contingent Liabilities and Commitments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gamidacell.com/role/ShareholdersEquity" id="gmda_r_ShareholdersEquity">
        <link:definition>012 - Disclosure - Shareholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gamidacell.com/role/ShareBasedCompensation" id="gmda_r_ShareBasedCompensation">
        <link:definition>013 - Disclosure - Share-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gamidacell.com/role/BasicandDilutedNetLossPerShare" id="gmda_r_BasicandDilutedNetLossPerShare">
        <link:definition>014 - Disclosure - Basic and Diluted Net Loss Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gamidacell.com/role/AccountingPoliciesByPolicy" id="gmda_r_AccountingPoliciesByPolicy">
        <link:definition>015 - Disclosure - Accounting Policies, by Policy (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gamidacell.com/role/LeasesTables" id="gmda_r_LeasesTables">
        <link:definition>016 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gamidacell.com/role/ConvertibleSeniorNotesNetTables" id="gmda_r_ConvertibleSeniorNotesNetTables">
        <link:definition>017 - Disclosure - Convertible Senior Notes, Net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gamidacell.com/role/FairValueMeasurementsTables" id="gmda_r_FairValueMeasurementsTables">
        <link:definition>018 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gamidacell.com/role/ShareBasedCompensationTables" id="gmda_r_ShareBasedCompensationTables">
        <link:definition>019 - Disclosure - Share-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gamidacell.com/role/BasicandDilutedNetLossPerShareTables" id="gmda_r_BasicandDilutedNetLossPerShareTables">
        <link:definition>020 - Disclosure - Basic and Diluted Net Loss Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gamidacell.com/role/GeneralDetails" id="gmda_r_GeneralDetails">
        <link:definition>021 - Disclosure - General (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gamidacell.com/role/LeasesDetails" id="gmda_r_LeasesDetails">
        <link:definition>022 - Disclosure - Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gamidacell.com/role/ScheduleofoperatingleasecostsTable" id="gmda_r_ScheduleofoperatingleasecostsTable">
        <link:definition>023 - Disclosure - Leases (Details) - Schedule of operating lease costs</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrbGzSS2V9veXLez+Xl0dIVqXQZdaaX7U8iZ3lEvQVQ8yavTR5LGMAC/Y6xtwO1cV8d5LpXjJeLMk6eat28V4VVXVBSb2HOCKvVmZvuAbSKzXyDRkT12vtciTURxwLsQFoRiJcYRfObTSc0gbTBq++/nfodHvEU7EA/LrQkg0k4it0+ht+i+C+b8+UuUGeDG/qMiVwE4dvbs3g==] CSR-->
      <link:roleType roleURI="http://www.gamidacell.com/role/ScheduleofoperatingleasesTable" id="gmda_r_ScheduleofoperatingleasesTable">
        <link:definition>024 - Disclosure - Leases (Details) - Schedule of operating leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gamidacell.com/role/ScheduleofmaturitiesofleaseliabilitiesTable" id="gmda_r_ScheduleofmaturitiesofleaseliabilitiesTable">
        <link:definition>025 - Disclosure - Leases (Details) - Schedule of maturities of lease liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gamidacell.com/role/ConvertibleSeniorNotesNetDetails" id="gmda_r_ConvertibleSeniorNotesNetDetails">
        <link:definition>026 - Disclosure - Convertible Senior Notes, Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gamidacell.com/role/ScheduleofliabilityandequitycomponentsoftheconvertiblenotesTable" id="gmda_r_ScheduleofliabilityandequitycomponentsoftheconvertiblenotesTable">
        <link:definition>027 - Disclosure - Convertible Senior Notes, Net (Details) - Schedule of liability and equity components of the convertible notes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gamidacell.com/role/ScheduleoffairvalueofmoneymarketfundsandmarketablesecuritiesTable" id="gmda_r_ScheduleoffairvalueofmoneymarketfundsandmarketablesecuritiesTable">
        <link:definition>028 - Disclosure - Fair Value Measurements (Details) - Schedule of fair value of money market funds and marketable securities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gamidacell.com/role/ContingentLiabilitiesandCommitmentsDetails" id="gmda_r_ContingentLiabilitiesandCommitmentsDetails">
        <link:definition>029 - Disclosure - Contingent Liabilities and Commitments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gamidacell.com/role/ShareholdersEquityDetails" id="gmda_r_ShareholdersEquityDetails">
        <link:definition>030 - Disclosure - Shareholders' Equity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gamidacell.com/role/ShareBasedCompensationDetails" id="gmda_r_ShareBasedCompensationDetails">
        <link:definition>031 - Disclosure - Share-Based Compensation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gamidacell.com/role/ScheduleoffairvaluemeasurementofequitysettledshareoptionsTable" id="gmda_r_ScheduleoffairvaluemeasurementofequitysettledshareoptionsTable">
        <link:definition>032 - Disclosure - Share-Based Compensation (Details) - Schedule of fair value measurement of equity-settled share options</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gamidacell.com/role/ScheduleofstockoptionplansTable" id="gmda_r_ScheduleofstockoptionplansTable">
        <link:definition>033 - Disclosure - Share-Based Compensation (Details) - Schedule of stock option plans</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gamidacell.com/role/ScheduleofrestrictedsharesactivityTable" id="gmda_r_ScheduleofrestrictedsharesactivityTable">
        <link:definition>034 - Disclosure - Share-Based Compensation (Details) - Schedule of restricted shares activity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gamidacell.com/role/ScheduleofsharebasedcompensationexpenseTable" id="gmda_r_ScheduleofsharebasedcompensationexpenseTable">
        <link:definition>035 - Disclosure - Share-Based Compensation (Details) - Schedule of share-based compensation expense</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gamidacell.com/role/ScheduleofnumberofsharesandlossusedinthecomputationofnetlosspershareTable" id="gmda_r_ScheduleofnumberofsharesandlossusedinthecomputationofnetlosspershareTable">
        <link:definition>036 - Disclosure - Basic and Diluted Net Loss Per Share (Details) - Schedule of number of shares and loss used in the computation of net loss per share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gamidacell.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
        <link:definition>000 - Document - Document And Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-types/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://fasb.org/srt-types/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/sic/2022" schemaLocation="https://xbrl.sec.gov/sic/2022/sic-2022.xsd"/>
  <xs:element name="ScheduleOfOperatingLeaseCostsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="gmda_ScheduleOfOperatingLeaseCostsAbstract"/>
  <xs:element name="ScheduleOfOperatingLeasesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="gmda_ScheduleOfOperatingLeasesAbstract"/>
  <xs:element name="ScheduleOfMaturitiesOfLeaseLiabilitiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="gmda_ScheduleOfMaturitiesOfLeaseLiabilitiesAbstract"/>
  <xs:element name="DisclosureOfNotesAndOtherExplanatoryInformationsExplanatoryAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="gmda_DisclosureOfNotesAndOtherExplanatoryInformationsExplanatoryAbstract"/>
  <xs:element name="ScheduleOfLiabilityAndEquityComponentsOfTheConvertibleNotesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="gmda_ScheduleOfLiabilityAndEquityComponentsOfTheConvertibleNotesAbstract"/>
  <xs:element name="ScheduleOfFairValueOfMoneyMarketFundsAndMarketableSecuritiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="gmda_ScheduleOfFairValueOfMoneyMarketFundsAndMarketableSecuritiesAbstract"/>
  <xs:element name="ScheduleOfFairValueMeasurementOfEquitySettledShareOptionsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="gmda_ScheduleOfFairValueMeasurementOfEquitySettledShareOptionsAbstract"/>
  <xs:element name="ScheduleOfStockOptionPlansAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="gmda_ScheduleOfStockOptionPlansAbstract"/>
  <xs:element name="ScheduleOfRestrictedSharesActivityAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="gmda_ScheduleOfRestrictedSharesActivityAbstract"/>
  <xs:element name="ScheduleOfShareBasedCompensationExpenseAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="gmda_ScheduleOfShareBasedCompensationExpenseAbstract"/>
  <xs:element name="ScheduleOfNumberOfSharesAndLossUsedInTheComputationOfNetLossPerShareAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="gmda_ScheduleOfNumberOfSharesAndLossUsedInTheComputationOfNetLossPerShareAbstract"/>
  <xs:element name="LiabilityComponentAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="gmda_LiabilityComponentAbstract"/>
  <xs:element name="CashEquivalentsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="gmda_CashEquivalentsAbstract"/>
  <xs:element name="ResearchAndDevelopmentExpensesNet" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="gmda_ResearchAndDevelopmentExpensesNet"/>
  <xs:element name="CommercialExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="gmda_CommercialExpenses"/>
  <xs:element name="GeneralAndAdministrativeExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="gmda_GeneralAndAdministrativeExpenses"/>
  <xs:element name="IssuanceExpensesOnCredit" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="gmda_IssuanceExpensesOnCredit"/>
  <xs:element name="DisclosureOfNotesAndOtherExplanatoryInformationsExplanatoryTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="gmda_DisclosureOfNotesAndOtherExplanatoryInformationsExplanatoryTextBlock"/>
  <xs:element name="ConvertibleSeniorNotesPolicyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="gmda_ConvertibleSeniorNotesPolicyTextBlock"/>
  <xs:element name="ScheduleOfLiabilityAndEquityComponentConvertibleNotesTableTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="gmda_ScheduleOfLiabilityAndEquityComponentConvertibleNotesTableTextBlock"/>
  <xs:element name="ScheduleOfFairValueOfMoneyMarketFundsAndMarketableSecuritiesTableTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="gmda_ScheduleOfFairValueOfMoneyMarketFundsAndMarketableSecuritiesTableTextBlock"/>
  <xs:element name="LesseeOperatingLeaseLiabilityPaymentsDueYearSix" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="gmda_LesseeOperatingLeaseLiabilityPaymentsDueYearSix"/>
  <xs:element name="AmountOfPrincipal" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="gmda_AmountOfPrincipal"/>
  <xs:element name="UnamortizedIssuanceCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="gmda_UnamortizedIssuanceCosts"/>
  <xs:element name="NetIssuanceCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="gmda_NetIssuanceCosts"/>
  <xs:element name="NetCarryingAmountincludingAccruedInterest" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="gmda_NetCarryingAmountincludingAccruedInterest"/>
  <xs:element name="FairValueMeasurementsDetailsScheduleoffairvalueofmoneymarketfundsandmarketablesecuritiesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="gmda_FairValueMeasurementsDetailsScheduleoffairvalueofmoneymarketfundsandmarketablesecuritiesTable"/>
  <xs:element name="FairValueMeasurementsDetailsScheduleoffairvalueofmoneymarketfundsandmarketablesecuritiesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="gmda_FairValueMeasurementsDetailsScheduleoffairvalueofmoneymarketfundsandmarketablesecuritiesLineItems"/>
  <xs:element name="CorporateDebentures" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="gmda_CorporateDebentures"/>
  <xs:element name="GovernmentDebentures" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="gmda_GovernmentDebentures"/>
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrosses" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="gmda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrosses"/>
  <xs:element name="StockIssuedDuringPeriodSharesStockOptionesExercised" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="gmda_StockIssuedDuringPeriodSharesStockOptionesExercised"/>
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriods" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="gmda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriods"/>
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableInPeriod" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="gmda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableInPeriod"/>
  <xs:element name="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisableInPeriodWeightedAverageExercisePrice" type="dtr:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="gmda_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisableInPeriodWeightedAverageExercisePrice"/>
  <xs:element name="LossPerShareDomain" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="gmda_LossPerShareDomain"/>
  <xs:element name="BasicandDilutedNetLossPerShareDetailsScheduleofnumberofsharesandlossusedinthecomputationofnetlosspershareTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="gmda_BasicandDilutedNetLossPerShareDetailsScheduleofnumberofsharesandlossusedinthecomputationofnetlosspershareTable"/>
  <xs:element name="BasicandDilutedNetLossPerShareDetailsScheduleofnumberofsharesandlossusedinthecomputationofnetlosspershareLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="gmda_BasicandDilutedNetLossPerShareDetailsScheduleofnumberofsharesandlossusedinthecomputationofnetlosspershareLineItems"/>
  <xs:element name="WeightedAverageNumberOfSharesOutstandingBasicAndDiluted" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="gmda_WeightedAverageNumberOfSharesOutstandingBasicAndDiluted"/>
  <xs:element name="ResponseRatePercentage" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="gmda_ResponseRatePercentage"/>
  <xs:element name="ClinicalTrialOnOutcomes" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="gmda_ClinicalTrialOnOutcomes"/>
  <xs:element name="AccumulatedDeficit" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="gmda_AccumulatedDeficit"/>
  <xs:element name="ConvertibleSeniorNotesNetDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="gmda_ConvertibleSeniorNotesNetDetailsTable"/>
  <xs:element name="ConvertibleSeniorNotesNetDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="gmda_ConvertibleSeniorNotesNetDetailsLineItems"/>
  <xs:element name="PrincipalAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="gmda_PrincipalAmount"/>
  <xs:element name="AnnualInterestPercentage" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="gmda_AnnualInterestPercentage"/>
  <xs:element name="ExchangePricePercentage" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="gmda_ExchangePricePercentage"/>
  <xs:element name="ContingentLiabilitiesandCommitmentsDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="gmda_ContingentLiabilitiesandCommitmentsDetailsTable"/>
  <xs:element name="ContingentLiabilitiesandCommitmentsDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="gmda_ContingentLiabilitiesandCommitmentsDetailsLineItems"/>
  <xs:element name="ShareholdersEquityDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="gmda_ShareholdersEquityDetailsTable"/>
  <xs:element name="ShareholdersEquityDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="gmda_ShareholdersEquityDetailsLineItems"/>
  <xs:element name="UnderwritersDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="gmda_UnderwritersDescription"/>
  <xs:element name="ExpiryDate" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="gmda_ExpiryDate"/>
  <xs:element name="ShareBasedCompensationDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="gmda_ShareBasedCompensationDetailsTable"/>
  <xs:element name="ShareBasedCompensationDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="gmda_ShareBasedCompensationDetailsLineItems"/>
  <xs:element name="OrdinarySharesOutstandingPercentage" type="dtr:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="gmda_OrdinarySharesOutstandingPercentage"/>
  <xs:element name="LossPerShareAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:dimensionItem" id="gmda_LossPerShareAxis"/>
  <xs:element name="ForTheComputationOfDilutedLossMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="gmda_ForTheComputationOfDilutedLossMember"/>
  <xs:element name="TwoThousandSeventeenStockCompensationPlanMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="gmda_TwoThousandSeventeenStockCompensationPlanMember"/>
  <xs:element name="TwoZeroOneFourIsraelShareOptionPlanMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="gmda_TwoZeroOneFourIsraelShareOptionPlanMember"/>
  <xs:element name="DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="gmda_DocumentAndEntityInformationAbstract"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>7
<FILENAME>gmda-20220331_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Wed May 11 15:03:37 UTC 2022 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="gmda-20220331.xsd#gmda_r_ConsolidatedBalanceSheet" roleURI="http://www.gamidacell.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="gmda-20220331.xsd#gmda_r_ConsolidatedIncomeStatement" roleURI="http://www.gamidacell.com/role/ConsolidatedIncomeStatement"/>
  <roleRef xlink:type="simple" xlink:href="gmda-20220331.xsd#gmda_r_ConsolidatedCashFlow" roleURI="http://www.gamidacell.com/role/ConsolidatedCashFlow"/>
  <calculationLink xlink:type="extended" xlink:role="http://www.gamidacell.com/role/ConsolidatedBalanceSheet">
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_MarketableSecuritiesCurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsNoncurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedInvestmentsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedInvestmentsNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_RestrictedInvestmentsNoncurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLongTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLongTermInvestments"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_OtherLongTermInvestments" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsNoncurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NotesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayableCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_NotesPayableCurrent" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleLongTermNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleLongTermNotesPayable"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_ConvertibleLongTermNotesPayable" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesNoncurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TreasuryStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_TreasuryStockValue" order="4" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesCurrent" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesNoncurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrbGzSS2V9veXLez+Xl0dIVqXQZdaaX7U8iZ3lEvQVQ8yavTR5LGMAC/Y6xtwO1cV8d5LpXjJeLMk6eat28V4VVXVBSb2HOCKvVmZvuAbSKzXyDRkT12vtciTURxwLsQFoRiJcYRfObTSc0gbTBq++/nfodHvEU7EA/LrQkg0k4it0+ht+i+C+b8uIHzF430cQ+x4pepXcHzRQ==] CSR-->
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies" order="3" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="4" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.gamidacell.com/role/ConsolidatedIncomeStatement">
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <loc xlink:type="locator" xlink:label="gmda_ResearchAndDevelopmentExpensesNet" xlink:href="gmda-20220331.xsd#gmda_ResearchAndDevelopmentExpensesNet"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="gmda_ResearchAndDevelopmentExpensesNet" order="1" weight="-1"/>
    <loc xlink:type="locator" xlink:label="gmda_CommercialExpenses" xlink:href="gmda-20220331.xsd#gmda_CommercialExpenses"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="gmda_CommercialExpenses" order="2" weight="-1"/>
    <loc xlink:type="locator" xlink:label="gmda_GeneralAndAdministrativeExpenses" xlink:href="gmda-20220331.xsd#gmda_GeneralAndAdministrativeExpenses"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="gmda_GeneralAndAdministrativeExpenses" order="3" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_OperatingIncomeLoss" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_NonoperatingIncomeExpense" order="2" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.gamidacell.com/role/ConsolidatedCashFlow">
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetIncomeLoss" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_Depreciation" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostsAndExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_CostsAndExpenses" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" order="6" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" order="7" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPostemploymentObligations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPostemploymentObligations"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPostemploymentObligations" order="8" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableTrade" order="9" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" order="10" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="11" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="2" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities" order="3" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" order="4" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="2" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="3" weight="1"/>
  </calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>8
<FILENAME>gmda-20220331_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Wed May 11 15:03:37 UTC 2022 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <roleRef xlink:type="simple" xlink:href="gmda-20220331.xsd#gmda_r_ConsolidatedBalanceSheet" roleURI="http://www.gamidacell.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="gmda-20220331.xsd#gmda_r_ConsolidatedBalanceSheet_Parentheticals" roleURI="http://www.gamidacell.com/role/ConsolidatedBalanceSheet_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="gmda-20220331.xsd#gmda_r_ConsolidatedIncomeStatement" roleURI="http://www.gamidacell.com/role/ConsolidatedIncomeStatement"/>
  <roleRef xlink:type="simple" xlink:href="gmda-20220331.xsd#gmda_r_ShareholdersEquityType2or3" roleURI="http://www.gamidacell.com/role/ShareholdersEquityType2or3"/>
  <roleRef xlink:type="simple" xlink:href="gmda-20220331.xsd#gmda_r_ConsolidatedCashFlow" roleURI="http://www.gamidacell.com/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="gmda-20220331.xsd#gmda_r_General" roleURI="http://www.gamidacell.com/role/General"/>
  <roleRef xlink:type="simple" xlink:href="gmda-20220331.xsd#gmda_r_SignificantAccountingPolicies" roleURI="http://www.gamidacell.com/role/SignificantAccountingPolicies"/>
  <roleRef xlink:type="simple" xlink:href="gmda-20220331.xsd#gmda_r_Leases" roleURI="http://www.gamidacell.com/role/Leases"/>
  <roleRef xlink:type="simple" xlink:href="gmda-20220331.xsd#gmda_r_ConvertibleSeniorNotesNet" roleURI="http://www.gamidacell.com/role/ConvertibleSeniorNotesNet"/>
  <roleRef xlink:type="simple" xlink:href="gmda-20220331.xsd#gmda_r_FairValueMeasurements" roleURI="http://www.gamidacell.com/role/FairValueMeasurements"/>
  <roleRef xlink:type="simple" xlink:href="gmda-20220331.xsd#gmda_r_ContingentLiabilitiesandCommitments" roleURI="http://www.gamidacell.com/role/ContingentLiabilitiesandCommitments"/>
  <roleRef xlink:type="simple" xlink:href="gmda-20220331.xsd#gmda_r_ShareholdersEquity" roleURI="http://www.gamidacell.com/role/ShareholdersEquity"/>
  <roleRef xlink:type="simple" xlink:href="gmda-20220331.xsd#gmda_r_ShareBasedCompensation" roleURI="http://www.gamidacell.com/role/ShareBasedCompensation"/>
  <roleRef xlink:type="simple" xlink:href="gmda-20220331.xsd#gmda_r_BasicandDilutedNetLossPerShare" roleURI="http://www.gamidacell.com/role/BasicandDilutedNetLossPerShare"/>
  <roleRef xlink:type="simple" xlink:href="gmda-20220331.xsd#gmda_r_AccountingPoliciesByPolicy" roleURI="http://www.gamidacell.com/role/AccountingPoliciesByPolicy"/>
  <roleRef xlink:type="simple" xlink:href="gmda-20220331.xsd#gmda_r_LeasesTables" roleURI="http://www.gamidacell.com/role/LeasesTables"/>
  <roleRef xlink:type="simple" xlink:href="gmda-20220331.xsd#gmda_r_ConvertibleSeniorNotesNetTables" roleURI="http://www.gamidacell.com/role/ConvertibleSeniorNotesNetTables"/>
  <roleRef xlink:type="simple" xlink:href="gmda-20220331.xsd#gmda_r_FairValueMeasurementsTables" roleURI="http://www.gamidacell.com/role/FairValueMeasurementsTables"/>
  <roleRef xlink:type="simple" xlink:href="gmda-20220331.xsd#gmda_r_ShareBasedCompensationTables" roleURI="http://www.gamidacell.com/role/ShareBasedCompensationTables"/>
  <roleRef xlink:type="simple" xlink:href="gmda-20220331.xsd#gmda_r_BasicandDilutedNetLossPerShareTables" roleURI="http://www.gamidacell.com/role/BasicandDilutedNetLossPerShareTables"/>
  <roleRef xlink:type="simple" xlink:href="gmda-20220331.xsd#gmda_r_ScheduleofoperatingleasecostsTable" roleURI="http://www.gamidacell.com/role/ScheduleofoperatingleasecostsTable"/>
  <roleRef xlink:type="simple" xlink:href="gmda-20220331.xsd#gmda_r_ScheduleofoperatingleasesTable" roleURI="http://www.gamidacell.com/role/ScheduleofoperatingleasesTable"/>
  <roleRef xlink:type="simple" xlink:href="gmda-20220331.xsd#gmda_r_ScheduleofmaturitiesofleaseliabilitiesTable" roleURI="http://www.gamidacell.com/role/ScheduleofmaturitiesofleaseliabilitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="gmda-20220331.xsd#gmda_r_ScheduleofliabilityandequitycomponentsoftheconvertiblenotesTable" roleURI="http://www.gamidacell.com/role/ScheduleofliabilityandequitycomponentsoftheconvertiblenotesTable"/>
  <roleRef xlink:type="simple" xlink:href="gmda-20220331.xsd#gmda_r_ScheduleoffairvalueofmoneymarketfundsandmarketablesecuritiesTable" roleURI="http://www.gamidacell.com/role/ScheduleoffairvalueofmoneymarketfundsandmarketablesecuritiesTable"/>
  <roleRef xlink:type="simple" xlink:href="gmda-20220331.xsd#gmda_r_ScheduleoffairvaluemeasurementofequitysettledshareoptionsTable" roleURI="http://www.gamidacell.com/role/ScheduleoffairvaluemeasurementofequitysettledshareoptionsTable"/>
  <roleRef xlink:type="simple" xlink:href="gmda-20220331.xsd#gmda_r_ScheduleofstockoptionplansTable" roleURI="http://www.gamidacell.com/role/ScheduleofstockoptionplansTable"/>
  <roleRef xlink:type="simple" xlink:href="gmda-20220331.xsd#gmda_r_ScheduleofrestrictedsharesactivityTable" roleURI="http://www.gamidacell.com/role/ScheduleofrestrictedsharesactivityTable"/>
  <roleRef xlink:type="simple" xlink:href="gmda-20220331.xsd#gmda_r_ScheduleofsharebasedcompensationexpenseTable" roleURI="http://www.gamidacell.com/role/ScheduleofsharebasedcompensationexpenseTable"/>
  <roleRef xlink:type="simple" xlink:href="gmda-20220331.xsd#gmda_r_ScheduleofnumberofsharesandlossusedinthecomputationofnetlosspershareTable" roleURI="http://www.gamidacell.com/role/ScheduleofnumberofsharesandlossusedinthecomputationofnetlosspershareTable"/>
  <roleRef xlink:type="simple" xlink:href="gmda-20220331.xsd#gmda_r_GeneralDetails" roleURI="http://www.gamidacell.com/role/GeneralDetails"/>
  <roleRef xlink:type="simple" xlink:href="gmda-20220331.xsd#gmda_r_LeasesDetails" roleURI="http://www.gamidacell.com/role/LeasesDetails"/>
  <roleRef xlink:type="simple" xlink:href="gmda-20220331.xsd#gmda_r_ConvertibleSeniorNotesNetDetails" roleURI="http://www.gamidacell.com/role/ConvertibleSeniorNotesNetDetails"/>
  <roleRef xlink:type="simple" xlink:href="gmda-20220331.xsd#gmda_r_ContingentLiabilitiesandCommitmentsDetails" roleURI="http://www.gamidacell.com/role/ContingentLiabilitiesandCommitmentsDetails"/>
  <roleRef xlink:type="simple" xlink:href="gmda-20220331.xsd#gmda_r_ShareholdersEquityDetails" roleURI="http://www.gamidacell.com/role/ShareholdersEquityDetails"/>
  <roleRef xlink:type="simple" xlink:href="gmda-20220331.xsd#gmda_r_ShareBasedCompensationDetails" roleURI="http://www.gamidacell.com/role/ShareBasedCompensationDetails"/>
  <roleRef xlink:type="simple" xlink:href="gmda-20220331.xsd#DocumentAndEntityInformation" roleURI="http://www.gamidacell.com/role/DocumentAndEntityInformation"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all"/>
  <definitionLink xlink:type="extended" xlink:role="http://www.gamidacell.com/role/ConsolidatedBalanceSheet">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_MarketableSecuritiesCurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsNoncurrentAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsNoncurrentAbstract" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedInvestmentsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedInvestmentsNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_RestrictedInvestmentsNoncurrent" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLongTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLongTermInvestments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_OtherLongTermInvestments" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_AssetsNoncurrent" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NotesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayableCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_NotesPayableCurrent" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleLongTermNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleLongTermNotesPayable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_ConvertibleLongTermNotesPayable" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesNoncurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesNoncurrent" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TreasuryStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_TreasuryStockValue" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_StockholdersEquity" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.gamidacell.com/role/ConsolidatedBalanceSheet_Parentheticals">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquitySharesAuthorized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_TemporaryEquitySharesAuthorized" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TreasuryStockShares" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_TreasuryStockShares" order="5" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.gamidacell.com/role/ConsolidatedIncomeStatement">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <loc xlink:type="locator" xlink:label="gmda_ResearchAndDevelopmentExpensesNet" xlink:href="gmda-20220331.xsd#gmda_ResearchAndDevelopmentExpensesNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="gmda_ResearchAndDevelopmentExpensesNet" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="gmda_CommercialExpenses" xlink:href="gmda-20220331.xsd#gmda_CommercialExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="gmda_CommercialExpenses" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="gmda_GeneralAndAdministrativeExpenses" xlink:href="gmda-20220331.xsd#gmda_GeneralAndAdministrativeExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="gmda_GeneralAndAdministrativeExpenses" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NonoperatingIncomeExpense" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_ProfitLoss" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="7" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.gamidacell.com/role/ShareholdersEquityType2or3">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TreasuryStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_TreasuryStockMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TreasuryStockValueAcquiredCostMethod" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TreasuryStockSharesRetired" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockSharesRetired"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TreasuryStockSharesRetired" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EmployeeBenefitsAndShareBasedCompensation" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="10" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.gamidacell.com/role/ConsolidatedCashFlow">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_Depreciation" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostsAndExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_CostsAndExpenses" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPostemploymentObligations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPostemploymentObligations"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInPostemploymentObligations" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableTrade" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="gmda_IssuanceExpensesOnCredit" xlink:href="gmda-20220331.xsd#gmda_IssuanceExpensesOnCredit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="gmda_IssuanceExpensesOnCredit" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_InterestPaidNet" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.gamidacell.com/role/General">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.gamidacell.com/role/SignificantAccountingPolicies">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.gamidacell.com/role/Leases">
    <loc xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.gamidacell.com/role/ConvertibleSeniorNotesNet">
    <loc xlink:type="locator" xlink:label="gmda_DisclosureOfNotesAndOtherExplanatoryInformationsExplanatoryAbstract" xlink:href="gmda-20220331.xsd#gmda_DisclosureOfNotesAndOtherExplanatoryInformationsExplanatoryAbstract"/>
    <loc xlink:type="locator" xlink:label="gmda_DisclosureOfNotesAndOtherExplanatoryInformationsExplanatoryTextBlock" xlink:href="gmda-20220331.xsd#gmda_DisclosureOfNotesAndOtherExplanatoryInformationsExplanatoryTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gmda_DisclosureOfNotesAndOtherExplanatoryInformationsExplanatoryAbstract" xlink:to="gmda_DisclosureOfNotesAndOtherExplanatoryInformationsExplanatoryTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.gamidacell.com/role/FairValueMeasurements">
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.gamidacell.com/role/ContingentLiabilitiesandCommitments">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.gamidacell.com/role/ShareholdersEquity">
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.gamidacell.com/role/ShareBasedCompensation">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.gamidacell.com/role/BasicandDilutedNetLossPerShare">
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.gamidacell.com/role/AccountingPoliciesByPolicy">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="gmda_ConvertibleSeniorNotesPolicyTextBlock" xlink:href="gmda-20220331.xsd#gmda_ConvertibleSeniorNotesPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="gmda_ConvertibleSeniorNotesPolicyTextBlock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.gamidacell.com/role/LeasesTables">
    <loc xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeaseCostTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.gamidacell.com/role/ConvertibleSeniorNotesNetTables">
    <loc xlink:type="locator" xlink:label="gmda_DisclosureOfNotesAndOtherExplanatoryInformationsExplanatoryAbstract" xlink:href="gmda-20220331.xsd#gmda_DisclosureOfNotesAndOtherExplanatoryInformationsExplanatoryAbstract"/>
    <loc xlink:type="locator" xlink:label="gmda_ScheduleOfLiabilityAndEquityComponentConvertibleNotesTableTextBlock" xlink:href="gmda-20220331.xsd#gmda_ScheduleOfLiabilityAndEquityComponentConvertibleNotesTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gmda_DisclosureOfNotesAndOtherExplanatoryInformationsExplanatoryAbstract" xlink:to="gmda_ScheduleOfLiabilityAndEquityComponentConvertibleNotesTableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.gamidacell.com/role/FairValueMeasurementsTables">
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <loc xlink:type="locator" xlink:label="gmda_ScheduleOfFairValueOfMoneyMarketFundsAndMarketableSecuritiesTableTextBlock" xlink:href="gmda-20220331.xsd#gmda_ScheduleOfFairValueOfMoneyMarketFundsAndMarketableSecuritiesTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="gmda_ScheduleOfFairValueOfMoneyMarketFundsAndMarketableSecuritiesTableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.gamidacell.com/role/ShareBasedCompensationTables">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.gamidacell.com/role/BasicandDilutedNetLossPerShareTables">
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.gamidacell.com/role/ScheduleofoperatingleasecostsTable">
    <loc xlink:type="locator" xlink:label="gmda_ScheduleOfOperatingLeaseCostsAbstract" xlink:href="gmda-20220331.xsd#gmda_ScheduleOfOperatingLeaseCostsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gmda_ScheduleOfOperatingLeaseCostsAbstract" xlink:to="us-gaap_OperatingLeaseCost" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermLeaseCost"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gmda_ScheduleOfOperatingLeaseCostsAbstract" xlink:to="us-gaap_ShortTermLeaseCost" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCost"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gmda_ScheduleOfOperatingLeaseCostsAbstract" xlink:to="us-gaap_LeaseCost" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.gamidacell.com/role/ScheduleofoperatingleasesTable">
    <loc xlink:type="locator" xlink:label="gmda_ScheduleOfOperatingLeasesAbstract" xlink:href="gmda-20220331.xsd#gmda_ScheduleOfOperatingLeasesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gmda_ScheduleOfOperatingLeasesAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gmda_ScheduleOfOperatingLeasesAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.gamidacell.com/role/ScheduleofmaturitiesofleaseliabilitiesTable">
    <loc xlink:type="locator" xlink:label="gmda_ScheduleOfMaturitiesOfLeaseLiabilitiesAbstract" xlink:href="gmda-20220331.xsd#gmda_ScheduleOfMaturitiesOfLeaseLiabilitiesAbstract"/>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrbGzSS2V9veXLez+Xl0dIVqXQZdaaX7U8iZ3lEvQVQ8yavTR5LGMAC/Y6xtwO1cV8d5LpXjJeLMk6eat28V4VVXVBSb2HOCKvVmZvuAbSKzXyDRkT12vtciTURxwLsQFoRiJcYRfObTSc0gbTBq++/nfodHvEU7EA/LrQkg0k4it0+ht+i+C+b8NI2eXoURKIaciMFzRPFIaw==] CSR-->
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gmda_ScheduleOfMaturitiesOfLeaseLiabilitiesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gmda_ScheduleOfMaturitiesOfLeaseLiabilitiesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gmda_ScheduleOfMaturitiesOfLeaseLiabilitiesAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gmda_ScheduleOfMaturitiesOfLeaseLiabilitiesAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="gmda_LesseeOperatingLeaseLiabilityPaymentsDueYearSix" xlink:href="gmda-20220331.xsd#gmda_LesseeOperatingLeaseLiabilityPaymentsDueYearSix"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gmda_ScheduleOfMaturitiesOfLeaseLiabilitiesAbstract" xlink:to="gmda_LesseeOperatingLeaseLiabilityPaymentsDueYearSix" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gmda_LesseeOperatingLeaseLiabilityPaymentsDueYearSix" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gmda_LesseeOperatingLeaseLiabilityPaymentsDueYearSix" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gmda_LesseeOperatingLeaseLiabilityPaymentsDueYearSix" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PresentValueOfFutureMinimumLeasePaymentsSaleLeasebackTransactions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PresentValueOfFutureMinimumLeasePaymentsSaleLeasebackTransactions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gmda_LesseeOperatingLeaseLiabilityPaymentsDueYearSix" xlink:to="us-gaap_PresentValueOfFutureMinimumLeasePaymentsSaleLeasebackTransactions" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.gamidacell.com/role/ScheduleofliabilityandequitycomponentsoftheconvertiblenotesTable">
    <loc xlink:type="locator" xlink:label="gmda_ScheduleOfLiabilityAndEquityComponentsOfTheConvertibleNotesAbstract" xlink:href="gmda-20220331.xsd#gmda_ScheduleOfLiabilityAndEquityComponentsOfTheConvertibleNotesAbstract"/>
    <loc xlink:type="locator" xlink:label="gmda_AmountOfPrincipal" xlink:href="gmda-20220331.xsd#gmda_AmountOfPrincipal"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gmda_ScheduleOfLiabilityAndEquityComponentsOfTheConvertibleNotesAbstract" xlink:to="gmda_AmountOfPrincipal" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="gmda_UnamortizedIssuanceCosts" xlink:href="gmda-20220331.xsd#gmda_UnamortizedIssuanceCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gmda_ScheduleOfLiabilityAndEquityComponentsOfTheConvertibleNotesAbstract" xlink:to="gmda_UnamortizedIssuanceCosts" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="gmda_NetIssuanceCosts" xlink:href="gmda-20220331.xsd#gmda_NetIssuanceCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gmda_ScheduleOfLiabilityAndEquityComponentsOfTheConvertibleNotesAbstract" xlink:to="gmda_NetIssuanceCosts" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfFinancingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gmda_ScheduleOfLiabilityAndEquityComponentsOfTheConvertibleNotesAbstract" xlink:to="us-gaap_AmortizationOfFinancingCosts" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="gmda_NetCarryingAmountincludingAccruedInterest" xlink:href="gmda-20220331.xsd#gmda_NetCarryingAmountincludingAccruedInterest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gmda_ScheduleOfLiabilityAndEquityComponentsOfTheConvertibleNotesAbstract" xlink:to="gmda_NetCarryingAmountincludingAccruedInterest" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.gamidacell.com/role/ScheduleoffairvalueofmoneymarketfundsandmarketablesecuritiesTable">
    <loc xlink:type="locator" xlink:label="gmda_FairValueMeasurementsDetailsScheduleoffairvalueofmoneymarketfundsandmarketablesecuritiesLineItems" xlink:href="gmda-20220331.xsd#gmda_FairValueMeasurementsDetailsScheduleoffairvalueofmoneymarketfundsandmarketablesecuritiesLineItems"/>
    <loc xlink:type="locator" xlink:label="gmda_FairValueMeasurementsDetailsScheduleoffairvalueofmoneymarketfundsandmarketablesecuritiesTable" xlink:href="gmda-20220331.xsd#gmda_FairValueMeasurementsDetailsScheduleoffairvalueofmoneymarketfundsandmarketablesecuritiesTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="gmda_FairValueMeasurementsDetailsScheduleoffairvalueofmoneymarketfundsandmarketablesecuritiesLineItems" xlink:to="gmda_FairValueMeasurementsDetailsScheduleoffairvalueofmoneymarketfundsandmarketablesecuritiesTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="gmda_FairValueMeasurementsDetailsScheduleoffairvalueofmoneymarketfundsandmarketablesecuritiesTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="gmda_CashEquivalentsAbstract" xlink:href="gmda-20220331.xsd#gmda_CashEquivalentsAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gmda_FairValueMeasurementsDetailsScheduleoffairvalueofmoneymarketfundsandmarketablesecuritiesLineItems" xlink:to="gmda_CashEquivalentsAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MoneyMarketFundsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsAtCarryingValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gmda_CashEquivalentsAbstract" xlink:to="us-gaap_MoneyMarketFundsAtCarryingValue" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gmda_FairValueMeasurementsDetailsScheduleoffairvalueofmoneymarketfundsandmarketablesecuritiesLineItems" xlink:to="us-gaap_MarketableSecuritiesAbstract" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="gmda_CorporateDebentures" xlink:href="gmda-20220331.xsd#gmda_CorporateDebentures"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MarketableSecuritiesAbstract" xlink:to="gmda_CorporateDebentures" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="gmda_GovernmentDebentures" xlink:href="gmda-20220331.xsd#gmda_GovernmentDebentures"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MarketableSecuritiesAbstract" xlink:to="gmda_GovernmentDebentures" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueNetAssetLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueNetAssetLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MarketableSecuritiesAbstract" xlink:to="us-gaap_FairValueNetAssetLiability" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.gamidacell.com/role/ScheduleoffairvaluemeasurementofequitysettledshareoptionsTable">
    <loc xlink:type="locator" xlink:label="gmda_ScheduleOfFairValueMeasurementOfEquitySettledShareOptionsAbstract" xlink:href="gmda-20220331.xsd#gmda_ScheduleOfFairValueMeasurementOfEquitySettledShareOptionsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gmda_ScheduleOfFairValueMeasurementOfEquitySettledShareOptionsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gmda_ScheduleOfFairValueMeasurementOfEquitySettledShareOptionsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gmda_ScheduleOfFairValueMeasurementOfEquitySettledShareOptionsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gmda_ScheduleOfFairValueMeasurementOfEquitySettledShareOptionsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.gamidacell.com/role/ScheduleofstockoptionplansTable">
    <loc xlink:type="locator" xlink:label="gmda_ScheduleOfStockOptionPlansAbstract" xlink:href="gmda-20220331.xsd#gmda_ScheduleOfStockOptionPlansAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gmda_ScheduleOfStockOptionPlansAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gmda_ScheduleOfStockOptionPlansAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="gmda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrosses" xlink:href="gmda-20220331.xsd#gmda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrosses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gmda_ScheduleOfStockOptionPlansAbstract" xlink:to="gmda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrosses" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gmda_ScheduleOfStockOptionPlansAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="gmda_StockIssuedDuringPeriodSharesStockOptionesExercised" xlink:href="gmda-20220331.xsd#gmda_StockIssuedDuringPeriodSharesStockOptionesExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gmda_ScheduleOfStockOptionPlansAbstract" xlink:to="gmda_StockIssuedDuringPeriodSharesStockOptionesExercised" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gmda_ScheduleOfStockOptionPlansAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="gmda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriods" xlink:href="gmda-20220331.xsd#gmda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriods"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gmda_ScheduleOfStockOptionPlansAbstract" xlink:to="gmda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriods" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gmda_ScheduleOfStockOptionPlansAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gmda_ScheduleOfStockOptionPlansAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gmda_ScheduleOfStockOptionPlansAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="gmda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableInPeriod" xlink:href="gmda-20220331.xsd#gmda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableInPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gmda_ScheduleOfStockOptionPlansAbstract" xlink:to="gmda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableInPeriod" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="gmda_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisableInPeriodWeightedAverageExercisePrice" xlink:href="gmda-20220331.xsd#gmda_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisableInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gmda_ScheduleOfStockOptionPlansAbstract" xlink:to="gmda_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisableInPeriodWeightedAverageExercisePrice" order="11" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.gamidacell.com/role/ScheduleofrestrictedsharesactivityTable">
    <loc xlink:type="locator" xlink:label="gmda_ScheduleOfRestrictedSharesActivityAbstract" xlink:href="gmda-20220331.xsd#gmda_ScheduleOfRestrictedSharesActivityAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gmda_ScheduleOfRestrictedSharesActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gmda_ScheduleOfRestrictedSharesActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gmda_ScheduleOfRestrictedSharesActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gmda_ScheduleOfRestrictedSharesActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gmda_ScheduleOfRestrictedSharesActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodIntrinsicValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gmda_ScheduleOfRestrictedSharesActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodIntrinsicValue" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gmda_ScheduleOfRestrictedSharesActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gmda_ScheduleOfRestrictedSharesActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue" order="7" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.gamidacell.com/role/ScheduleofsharebasedcompensationexpenseTable">
    <loc xlink:type="locator" xlink:label="gmda_ScheduleOfShareBasedCompensationExpenseAbstract" xlink:href="gmda-20220331.xsd#gmda_ScheduleOfShareBasedCompensationExpenseAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gmda_ScheduleOfShareBasedCompensationExpenseAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostsAndExpensesRelatedParty" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpensesRelatedParty"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gmda_ScheduleOfShareBasedCompensationExpenseAbstract" xlink:to="us-gaap_CostsAndExpensesRelatedParty" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gmda_ScheduleOfShareBasedCompensationExpenseAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gmda_ScheduleOfShareBasedCompensationExpenseAbstract" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.gamidacell.com/role/ScheduleofnumberofsharesandlossusedinthecomputationofnetlosspershareTable">
    <loc xlink:type="locator" xlink:label="gmda_BasicandDilutedNetLossPerShareDetailsScheduleofnumberofsharesandlossusedinthecomputationofnetlosspershareLineItems" xlink:href="gmda-20220331.xsd#gmda_BasicandDilutedNetLossPerShareDetailsScheduleofnumberofsharesandlossusedinthecomputationofnetlosspershareLineItems"/>
    <loc xlink:type="locator" xlink:label="gmda_BasicandDilutedNetLossPerShareDetailsScheduleofnumberofsharesandlossusedinthecomputationofnetlosspershareTable" xlink:href="gmda-20220331.xsd#gmda_BasicandDilutedNetLossPerShareDetailsScheduleofnumberofsharesandlossusedinthecomputationofnetlosspershareTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="gmda_BasicandDilutedNetLossPerShareDetailsScheduleofnumberofsharesandlossusedinthecomputationofnetlosspershareLineItems" xlink:to="gmda_BasicandDilutedNetLossPerShareDetailsScheduleofnumberofsharesandlossusedinthecomputationofnetlosspershareTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="gmda_LossPerShareAxis" xlink:href="gmda-20220331.xsd#gmda_LossPerShareAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="gmda_BasicandDilutedNetLossPerShareDetailsScheduleofnumberofsharesandlossusedinthecomputationofnetlosspershareTable" xlink:to="gmda_LossPerShareAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="gmda_LossPerShareDomain" xlink:href="gmda-20220331.xsd#gmda_LossPerShareDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="gmda_LossPerShareAxis" xlink:to="gmda_LossPerShareDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="gmda_LossPerShareDomain_0" xlink:href="gmda-20220331.xsd#gmda_LossPerShareDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="gmda_LossPerShareAxis" xlink:to="gmda_LossPerShareDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="gmda_ForTheComputationOfDilutedLossMember" xlink:href="gmda-20220331.xsd#gmda_ForTheComputationOfDilutedLossMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gmda_LossPerShareDomain" xlink:to="gmda_ForTheComputationOfDilutedLossMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="gmda_WeightedAverageNumberOfSharesOutstandingBasicAndDiluted" xlink:href="gmda-20220331.xsd#gmda_WeightedAverageNumberOfSharesOutstandingBasicAndDiluted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gmda_BasicandDilutedNetLossPerShareDetailsScheduleofnumberofsharesandlossusedinthecomputationofnetlosspershareLineItems" xlink:to="gmda_WeightedAverageNumberOfSharesOutstandingBasicAndDiluted" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gmda_BasicandDilutedNetLossPerShareDetailsScheduleofnumberofsharesandlossusedinthecomputationofnetlosspershareLineItems" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.gamidacell.com/role/GeneralDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="gmda_ResponseRatePercentage" xlink:href="gmda-20220331.xsd#gmda_ResponseRatePercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="gmda_ResponseRatePercentage" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="gmda_ClinicalTrialOnOutcomes" xlink:href="gmda-20220331.xsd#gmda_ClinicalTrialOnOutcomes"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="gmda_ClinicalTrialOnOutcomes" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="gmda_AccumulatedDeficit" xlink:href="gmda-20220331.xsd#gmda_AccumulatedDeficit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="gmda_AccumulatedDeficit" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentsAndCash" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsAndCash"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InvestmentsAndCash" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NumberOfOperatingSegments" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.gamidacell.com/role/LeasesDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.gamidacell.com/role/ConvertibleSeniorNotesNetDetails">
    <loc xlink:type="locator" xlink:label="gmda_ConvertibleSeniorNotesNetDetailsLineItems" xlink:href="gmda-20220331.xsd#gmda_ConvertibleSeniorNotesNetDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="gmda_ConvertibleSeniorNotesNetDetailsTable" xlink:href="gmda-20220331.xsd#gmda_ConvertibleSeniorNotesNetDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="gmda_ConvertibleSeniorNotesNetDetailsLineItems" xlink:to="gmda_ConvertibleSeniorNotesNetDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="gmda_ConvertibleSeniorNotesNetDetailsTable" xlink:to="us-gaap_ShortTermDebtTypeAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleNotesPayableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleNotesPayableMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="us-gaap_ConvertibleNotesPayableMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="gmda_PrincipalAmount" xlink:href="gmda-20220331.xsd#gmda_PrincipalAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gmda_ConvertibleSeniorNotesNetDetailsLineItems" xlink:to="gmda_PrincipalAmount" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="gmda_AnnualInterestPercentage" xlink:href="gmda-20220331.xsd#gmda_AnnualInterestPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gmda_ConvertibleSeniorNotesNetDetailsLineItems" xlink:to="gmda_AnnualInterestPercentage" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentConvertibleConversionDate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleConversionDate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gmda_ConvertibleSeniorNotesNetDetailsLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleConversionDate" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleNotesPayable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gmda_ConvertibleSeniorNotesNetDetailsLineItems" xlink:to="us-gaap_ConvertibleNotesPayable" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquitySharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gmda_ConvertibleSeniorNotesNetDetailsLineItems" xlink:to="us-gaap_TemporaryEquitySharesIssued" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleNotesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleNotesPayableCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gmda_ConvertibleSeniorNotesNetDetailsLineItems" xlink:to="us-gaap_ConvertibleNotesPayableCurrent" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gmda_ConvertibleSeniorNotesNetDetailsLineItems" xlink:to="us-gaap_SharePrice" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gmda_ConvertibleSeniorNotesNetDetailsLineItems" xlink:to="us-gaap_DebtInstrumentRedemptionPricePercentage" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="gmda_ExchangePricePercentage" xlink:href="gmda-20220331.xsd#gmda_ExchangePricePercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gmda_ConvertibleSeniorNotesNetDetailsLineItems" xlink:to="gmda_ExchangePricePercentage" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gmda_ConvertibleSeniorNotesNetDetailsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateBasisForEffectiveRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateBasisForEffectiveRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gmda_ConvertibleSeniorNotesNetDetailsLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateBasisForEffectiveRate" order="11" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.gamidacell.com/role/ContingentLiabilitiesandCommitmentsDetails">
    <loc xlink:type="locator" xlink:label="gmda_ContingentLiabilitiesandCommitmentsDetailsLineItems" xlink:href="gmda-20220331.xsd#gmda_ContingentLiabilitiesandCommitmentsDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="gmda_ContingentLiabilitiesandCommitmentsDetailsTable" xlink:href="gmda-20220331.xsd#gmda_ContingentLiabilitiesandCommitmentsDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="gmda_ContingentLiabilitiesandCommitmentsDetailsLineItems" xlink:to="gmda_ContingentLiabilitiesandCommitmentsDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="gmda_ContingentLiabilitiesandCommitmentsDetailsTable" xlink:to="srt_RangeAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember_0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RoyaltyGuaranteesCommitmentsAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RoyaltyGuaranteesCommitmentsAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gmda_ContingentLiabilitiesandCommitmentsDetailsLineItems" xlink:to="us-gaap_RoyaltyGuaranteesCommitmentsAmount" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BorrowingsUnderGuaranteedInvestmentAgreements" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BorrowingsUnderGuaranteedInvestmentAgreements"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gmda_ContingentLiabilitiesandCommitmentsDetailsLineItems" xlink:to="us-gaap_BorrowingsUnderGuaranteedInvestmentAgreements" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GrantsReceivableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrantsReceivableCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gmda_ContingentLiabilitiesandCommitmentsDetailsLineItems" xlink:to="us-gaap_GrantsReceivableCurrent" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RoyaltyExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RoyaltyExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gmda_ContingentLiabilitiesandCommitmentsDetailsLineItems" xlink:to="us-gaap_RoyaltyExpense" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfAdvanceRoyalty" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfAdvanceRoyalty"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gmda_ContingentLiabilitiesandCommitmentsDetailsLineItems" xlink:to="us-gaap_AmortizationOfAdvanceRoyalty" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeForwardInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeForwardInterestRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gmda_ContingentLiabilitiesandCommitmentsDetailsLineItems" xlink:to="us-gaap_DerivativeForwardInterestRate" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gmda_ContingentLiabilitiesandCommitmentsDetailsLineItems" xlink:to="us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GrantsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrantsReceivable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gmda_ContingentLiabilitiesandCommitmentsDetailsLineItems" xlink:to="us-gaap_GrantsReceivable" order="8" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.gamidacell.com/role/ShareholdersEquityDetails">
    <loc xlink:type="locator" xlink:label="gmda_ShareholdersEquityDetailsLineItems" xlink:href="gmda-20220331.xsd#gmda_ShareholdersEquityDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="gmda_ShareholdersEquityDetailsTable" xlink:href="gmda-20220331.xsd#gmda_ShareholdersEquityDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="gmda_ShareholdersEquityDetailsLineItems" xlink:to="gmda_ShareholdersEquityDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="gmda_ShareholdersEquityDetailsTable" xlink:to="us-gaap_InvestmentTypeAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentTypeCategorizationMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentTypeCategorizationMember_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestorMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestorMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_InvestorMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_WarrantMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="gmda_UnderwritersDescription" xlink:href="gmda-20220331.xsd#gmda_UnderwritersDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gmda_ShareholdersEquityDetailsLineItems" xlink:to="gmda_UnderwritersDescription" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="gmda_ExpiryDate" xlink:href="gmda-20220331.xsd#gmda_ExpiryDate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gmda_ShareholdersEquityDetailsLineItems" xlink:to="gmda_ExpiryDate" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gmda_ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.gamidacell.com/role/ShareBasedCompensationDetails">
    <loc xlink:type="locator" xlink:label="gmda_ShareBasedCompensationDetailsLineItems" xlink:href="gmda-20220331.xsd#gmda_ShareBasedCompensationDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="gmda_ShareBasedCompensationDetailsTable" xlink:href="gmda-20220331.xsd#gmda_ShareBasedCompensationDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="gmda_ShareBasedCompensationDetailsLineItems" xlink:to="gmda_ShareBasedCompensationDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="gmda_ShareBasedCompensationDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="gmda_ShareBasedCompensationDetailsTable" xlink:to="srt_RangeAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember_0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="gmda_ShareBasedCompensationDetailsTable" xlink:to="us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis" xlink:to="us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis" xlink:to="us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="gmda_TwoZeroOneFourIsraelShareOptionPlanMember" xlink:href="gmda-20220331.xsd#gmda_TwoZeroOneFourIsraelShareOptionPlanMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain" xlink:to="gmda_TwoZeroOneFourIsraelShareOptionPlanMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="gmda_TwoThousandSeventeenStockCompensationPlanMember" xlink:href="gmda-20220331.xsd#gmda_TwoThousandSeventeenStockCompensationPlanMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain" xlink:to="gmda_TwoThousandSeventeenStockCompensationPlanMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonClassCMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassCMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_CommonClassCMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gmda_ShareBasedCompensationDetailsLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPNumberOfAllocatedShares" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOwnershipPlanESOPNumberOfAllocatedShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gmda_ShareBasedCompensationDetailsLineItems" xlink:to="us-gaap_EmployeeStockOwnershipPlanESOPNumberOfAllocatedShares" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPNumberOfSuspenseShares" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOwnershipPlanESOPNumberOfSuspenseShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gmda_ShareBasedCompensationDetailsLineItems" xlink:to="us-gaap_EmployeeStockOwnershipPlanESOPNumberOfSuspenseShares" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gmda_ShareBasedCompensationDetailsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gmda_ShareBasedCompensationDetailsLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="gmda_OrdinarySharesOutstandingPercentage" xlink:href="gmda-20220331.xsd#gmda_OrdinarySharesOutstandingPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gmda_ShareBasedCompensationDetailsLineItems" xlink:to="gmda_OrdinarySharesOutstandingPercentage" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gmda_ShareBasedCompensationDetailsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="gmda_ShareBasedCompensationDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" order="8" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.gamidacell.com/role/DocumentAndEntityInformation">
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationLineItems"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationTable" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCurrentReportingStatus" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntitySmallBusiness" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityShellCompany" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityExTransitionPeriod" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityExTransitionPeriod" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentQuarterlyReport" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentTransitionReport" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityTaxIdentificationNumber" order="21" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" order="22" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" order="23" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince" order="24" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" order="25" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" order="26" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" order="27" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_Security12bTitle" order="28" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SecurityExchangeName" order="29" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityInteractiveDataCurrent" order="30" xbrldt:closed="true"/>
  </definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>gmda-20220331_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Wed May 11 15:03:37 UTC 2022 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  <labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Statement of Financial Position [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsNoncurrent_lbl" xml:lang="en-US">Total non-current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_AssetsNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Total assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total current liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesNoncurrent_lbl" xml:lang="en-US">Total non-current liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_LiabilitiesNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total Shareholders&#8217; Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_lbl0" xml:lang="en-US">Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_lbl1" xml:lang="en-US">Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Total Liabilities and Shareholders&#8217; Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Income Statement [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Total operating loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US">Loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US">Statement of Stockholders&apos; Equity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Balance (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_lbl0" xml:lang="en-US">Balance (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of Cash Flows [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash used in operating activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net cash provided by (used in) investing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash provided by financing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" xml:lang="en-US">Increase (decrease) in cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xml:lang="en-US">Cash and cash equivalents at beginning of period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl0" xml:lang="en-US">Cash and cash equivalents at end of period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Accounting Policies [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeasesAbstract_lbl" xml:lang="en-US">Leases [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeasesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="gmda_ScheduleOfOperatingLeaseCostsAbstract" xlink:href="gmda-20220331.xsd#gmda_ScheduleOfOperatingLeaseCostsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmda_ScheduleOfOperatingLeaseCostsAbstract_lbl" xml:lang="en-US">Schedule of operating lease costs [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmda_ScheduleOfOperatingLeaseCostsAbstract" xlink:to="gmda_ScheduleOfOperatingLeaseCostsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="gmda_ScheduleOfOperatingLeasesAbstract" xlink:href="gmda-20220331.xsd#gmda_ScheduleOfOperatingLeasesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmda_ScheduleOfOperatingLeasesAbstract_lbl" xml:lang="en-US">Schedule of operating leases [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmda_ScheduleOfOperatingLeasesAbstract" xlink:to="gmda_ScheduleOfOperatingLeasesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="gmda_ScheduleOfMaturitiesOfLeaseLiabilitiesAbstract" xlink:href="gmda-20220331.xsd#gmda_ScheduleOfMaturitiesOfLeaseLiabilitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmda_ScheduleOfMaturitiesOfLeaseLiabilitiesAbstract_lbl" xml:lang="en-US">Schedule of maturities of lease liabilities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmda_ScheduleOfMaturitiesOfLeaseLiabilitiesAbstract" xlink:to="gmda_ScheduleOfMaturitiesOfLeaseLiabilitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="gmda_DisclosureOfNotesAndOtherExplanatoryInformationsExplanatoryAbstract" xlink:href="gmda-20220331.xsd#gmda_DisclosureOfNotesAndOtherExplanatoryInformationsExplanatoryAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmda_DisclosureOfNotesAndOtherExplanatoryInformationsExplanatoryAbstract_lbl" xml:lang="en-US">Disclosure Of Notes And Other Explanatory Informations Explanatory [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmda_DisclosureOfNotesAndOtherExplanatoryInformationsExplanatoryAbstract" xlink:to="gmda_DisclosureOfNotesAndOtherExplanatoryInformationsExplanatoryAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="gmda_ScheduleOfLiabilityAndEquityComponentsOfTheConvertibleNotesAbstract" xlink:href="gmda-20220331.xsd#gmda_ScheduleOfLiabilityAndEquityComponentsOfTheConvertibleNotesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmda_ScheduleOfLiabilityAndEquityComponentsOfTheConvertibleNotesAbstract_lbl" xml:lang="en-US">Schedule of liability and equity components of the convertible notes [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmda_ScheduleOfLiabilityAndEquityComponentsOfTheConvertibleNotesAbstract" xlink:to="gmda_ScheduleOfLiabilityAndEquityComponentsOfTheConvertibleNotesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xml:lang="en-US">Fair Value Disclosures [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="gmda_ScheduleOfFairValueOfMoneyMarketFundsAndMarketableSecuritiesAbstract" xlink:href="gmda-20220331.xsd#gmda_ScheduleOfFairValueOfMoneyMarketFundsAndMarketableSecuritiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmda_ScheduleOfFairValueOfMoneyMarketFundsAndMarketableSecuritiesAbstract_lbl" xml:lang="en-US">Schedule of fair value of money market funds and marketable securities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmda_ScheduleOfFairValueOfMoneyMarketFundsAndMarketableSecuritiesAbstract" xlink:to="gmda_ScheduleOfFairValueOfMoneyMarketFundsAndMarketableSecuritiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteAbstract_lbl" xml:lang="en-US">Stockholders&apos; Equity Note [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="gmda_ScheduleOfFairValueMeasurementOfEquitySettledShareOptionsAbstract" xlink:href="gmda-20220331.xsd#gmda_ScheduleOfFairValueMeasurementOfEquitySettledShareOptionsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmda_ScheduleOfFairValueMeasurementOfEquitySettledShareOptionsAbstract_lbl" xml:lang="en-US">Schedule of fair value measurement of equity-settled share options [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmda_ScheduleOfFairValueMeasurementOfEquitySettledShareOptionsAbstract" xlink:to="gmda_ScheduleOfFairValueMeasurementOfEquitySettledShareOptionsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="gmda_ScheduleOfStockOptionPlansAbstract" xlink:href="gmda-20220331.xsd#gmda_ScheduleOfStockOptionPlansAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmda_ScheduleOfStockOptionPlansAbstract_lbl" xml:lang="en-US">Schedule of stock option plans [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmda_ScheduleOfStockOptionPlansAbstract" xlink:to="gmda_ScheduleOfStockOptionPlansAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Amount of options and restricted share unites, beginning balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl0" xml:lang="en-US">Amount of options and restricted share unites, ending balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, beginning balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Weighted average exercise price, ending balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl0"/>
    <loc xlink:type="locator" xlink:label="gmda_ScheduleOfRestrictedSharesActivityAbstract" xlink:href="gmda-20220331.xsd#gmda_ScheduleOfRestrictedSharesActivityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmda_ScheduleOfRestrictedSharesActivityAbstract_lbl" xml:lang="en-US">Schedule of restricted shares activity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmda_ScheduleOfRestrictedSharesActivityAbstract" xlink:to="gmda_ScheduleOfRestrictedSharesActivityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US">Amount of restricted shares and restricted shares units, Unvested beginning</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl0" xml:lang="en-US">Amount of restricted shares and restricted shares units, Unvested ending</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue_lbl" xml:lang="en-US">Weighted average grant date fair value, Unvested beginning</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue_lbl0" xml:lang="en-US">Weighted average grant date fair value, Unvested ending</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue_lbl0"/>
    <loc xlink:type="locator" xlink:label="gmda_ScheduleOfShareBasedCompensationExpenseAbstract" xlink:href="gmda-20220331.xsd#gmda_ScheduleOfShareBasedCompensationExpenseAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmda_ScheduleOfShareBasedCompensationExpenseAbstract_lbl" xml:lang="en-US">Schedule of share-based compensation expense [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmda_ScheduleOfShareBasedCompensationExpenseAbstract" xlink:to="gmda_ScheduleOfShareBasedCompensationExpenseAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xml:lang="en-US">Earnings Per Share [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="gmda_ScheduleOfNumberOfSharesAndLossUsedInTheComputationOfNetLossPerShareAbstract" xlink:href="gmda-20220331.xsd#gmda_ScheduleOfNumberOfSharesAndLossUsedInTheComputationOfNetLossPerShareAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmda_ScheduleOfNumberOfSharesAndLossUsedInTheComputationOfNetLossPerShareAbstract_lbl" xml:lang="en-US">Schedule of number of shares and loss used in the computation of net loss per share [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmda_ScheduleOfNumberOfSharesAndLossUsedInTheComputationOfNetLossPerShareAbstract" xlink:to="gmda_ScheduleOfNumberOfSharesAndLossUsedInTheComputationOfNetLossPerShareAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="gmda_LossPerShareAxis" xlink:href="gmda-20220331.xsd#gmda_LossPerShareAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gmda_LossPerShareAxis_lbl" xml:lang="en-US">Loss Per Share [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmda_LossPerShareAxis" xlink:to="gmda_LossPerShareAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityExTransitionPeriod" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Entity Ex Transition Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Current assets:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MarketableSecuritiesCurrent_lbl" xml:lang="en-US">Marketable securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesCurrent" xlink:to="us-gaap_MarketableSecuritiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US">Prepaid expenses and other current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsNoncurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsNoncurrentAbstract_lbl" xml:lang="en-US">Non-current assets:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_AssetsNoncurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedInvestmentsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedInvestmentsNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedInvestmentsNoncurrent_lbl" xml:lang="en-US">Restricted deposits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedInvestmentsNoncurrent" xlink:to="us-gaap_RestrictedInvestmentsNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property, plant and equipment, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Operating lease right-of-use assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLongTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLongTermInvestments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherLongTermInvestments_lbl" xml:lang="en-US">Severance pay fund</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLongTermInvestments" xlink:to="us-gaap_OtherLongTermInvestments_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US">Other long-term assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">Liabilities and Shareholders&#8217; Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Current liabilities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Trade payables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xml:lang="en-US">Employees and payroll accruals</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Operating lease liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NotesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayableCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NotesPayableCurrent_lbl" xml:lang="en-US">Accrued interest of convertible senior notes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayableCurrent" xlink:to="us-gaap_NotesPayableCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued expenses and other current liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xml:lang="en-US">Non-current liabilities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleLongTermNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleLongTermNotesPayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConvertibleLongTermNotesPayable_lbl" xml:lang="en-US">Convertible senior notes, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleLongTermNotesPayable" xlink:to="us-gaap_ConvertibleLongTermNotesPayable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAccruedLiabilitiesNoncurrent_lbl" xml:lang="en-US">Accrued severance pay</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesNoncurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Long-term operating lease liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">Contingent liabilities and commitments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">Shareholders&#8217; equity:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Ordinary shares NIS 0.01 par value; 150,000,000 shares authorized at March 31, 2022 (unaudited) and December 31, 2021; 60,021,415 and 59,970,389 shares issued at March 31, 2022 (unaudited) and December 31, 2021, respectively; 59,946,298 and 59,970,389 shares outstanding as of March 31, 2022 (unaudited) and December 31, 2021, respectively</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Ordinary shares par value (in New Shekels per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Ordinary shares authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Ordinary shares Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Ordinary shares outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TreasuryStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TreasuryStockValue_lbl" xml:lang="en-US">Treasury ordinary shares of NIS 0.01 par value; 75,117 and 0 shares at March 31, 2022 (unaudited) and December 31, 2021 respectively.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockValue" xlink:to="us-gaap_TreasuryStockValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquitySharesAuthorized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TemporaryEquitySharesAuthorized_lbl" xml:lang="en-US">Treasury ordinary shares par value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesAuthorized" xlink:to="us-gaap_TemporaryEquitySharesAuthorized_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TreasuryStockShares" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TreasuryStockShares_lbl" xml:lang="en-US">Treasury ordinary shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockShares" xlink:to="us-gaap_TreasuryStockShares_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xml:lang="en-US">Additional paid-in capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US">Accumulated deficit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl"/>
    <loc xlink:type="locator" xlink:label="gmda_ResearchAndDevelopmentExpensesNet" xlink:href="gmda-20220331.xsd#gmda_ResearchAndDevelopmentExpensesNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gmda_ResearchAndDevelopmentExpensesNet_lbl" xml:lang="en-US">Research and development expenses, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmda_ResearchAndDevelopmentExpensesNet" xlink:to="gmda_ResearchAndDevelopmentExpensesNet_lbl"/>
    <loc xlink:type="locator" xlink:label="gmda_CommercialExpenses" xlink:href="gmda-20220331.xsd#gmda_CommercialExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gmda_CommercialExpenses_lbl" xml:lang="en-US">Commercial expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmda_CommercialExpenses" xlink:to="gmda_CommercialExpenses_lbl"/>
    <loc xlink:type="locator" xlink:label="gmda_GeneralAndAdministrativeExpenses" xlink:href="gmda-20220331.xsd#gmda_GeneralAndAdministrativeExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gmda_GeneralAndAdministrativeExpenses_lbl" xml:lang="en-US">General and administrative expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmda_GeneralAndAdministrativeExpenses" xlink:to="gmda_GeneralAndAdministrativeExpenses_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">Net loss per share attributable to ordinary shareholders, basic and diluted (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">Weighted average number of shares used in computing net loss per share attributable to ordinary shareholders, basic and diluted (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures_lbl" xml:lang="en-US">Grant of restricted shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" xml:lang="en-US">Grant of restricted shares (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US">Exercise of options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Exercise of options (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensation_lbl" xml:lang="en-US">Share-based compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:to="us-gaap_EmployeeBenefitsAndShareBasedCompensation_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TreasuryStockValueAcquiredCostMethod_lbl" xml:lang="en-US">Treasury shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:to="us-gaap_TreasuryStockValueAcquiredCostMethod_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TreasuryStockSharesRetired" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockSharesRetired"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TreasuryStockSharesRetired_lbl" xml:lang="en-US">Treasury shares (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockSharesRetired" xlink:to="us-gaap_TreasuryStockSharesRetired_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Cash Flows From Operating Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustment to reconcile loss to net cash used in operating activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US">Depreciation of property, plant and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostsAndExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CostsAndExpenses_lbl" xml:lang="en-US">Financing expense (income), net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_CostsAndExpenses_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Share-based compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl" xml:lang="en-US">Amortization of issuance costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xml:lang="en-US">Operating lease right-of-use assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xml:lang="en-US">Operating lease liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPostemploymentObligations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPostemploymentObligations"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInPostemploymentObligations_lbl" xml:lang="en-US">Accrued severance pay, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPostemploymentObligations" xlink:to="us-gaap_IncreaseDecreaseInPostemploymentObligations_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade_lbl" xml:lang="en-US">Increase (decrease) in trade payables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableTrade_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US">Decrease in accrued expenses and current liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">Cash Flows From Investing Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl" xml:lang="en-US">Proceeds from maturity of marketable securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">Cash Flows From Financing Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US">Proceeds from exercise of options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Proceeds from issuance of convertible senior notes, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xml:lang="en-US">Significant non-cash transactions:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="gmda_IssuanceExpensesOnCredit" xlink:href="gmda-20220331.xsd#gmda_IssuanceExpensesOnCredit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gmda_IssuanceExpensesOnCredit_lbl" xml:lang="en-US">Issuance expenses on credit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmda_IssuanceExpensesOnCredit" xlink:to="gmda_IssuanceExpensesOnCredit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" xml:lang="en-US">Purchase of property, plant and equipment on credit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">Supplemental disclosures of cash flow information:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US">Cash paid for interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">Financial expenses, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US">Increase in prepaid expenses and other assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Purchase of property, plant and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities_lbl" xml:lang="en-US">Purchase of marketable securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireMarketableSecurities" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_lbl" xml:lang="en-US">Proceeds from restricted deposits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:to="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Ordinary shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional paid-in capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl0" xml:lang="en-US">Additional Paid-in Capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Accumulated deficit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TreasuryStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TreasuryStockMember_lbl" xml:lang="en-US">Treasury shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockMember" xlink:to="us-gaap_TreasuryStockMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xml:lang="en-US">GENERAL</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">SIGNIFICANT ACCOUNTING POLICIES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xml:lang="en-US">LEASES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xml:lang="en-US">Schedule of operating lease costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostTableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseCost_lbl" xml:lang="en-US">Operating lease costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermLeaseCost"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShortTermLeaseCost_lbl" xml:lang="en-US">Short-term lease costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermLeaseCost" xlink:to="us-gaap_ShortTermLeaseCost_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCost"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeaseCost_lbl" xml:lang="en-US">Total lease costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_LeaseCost_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock_lbl" xml:lang="en-US">Schedule of operating leases</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock" xlink:to="us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US">Weighted average remaining lease term (in years)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US">Weighted average discount rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US">Schedule of maturities of lease liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US">2022</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xml:lang="en-US">2023</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_lbl" xml:lang="en-US">2024</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_lbl" xml:lang="en-US">2025</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_lbl"/>
    <loc xlink:type="locator" xlink:label="gmda_LesseeOperatingLeaseLiabilityPaymentsDueYearSix" xlink:href="gmda-20220331.xsd#gmda_LesseeOperatingLeaseLiabilityPaymentsDueYearSix"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gmda_LesseeOperatingLeaseLiabilityPaymentsDueYearSix_lbl" xml:lang="en-US">2026</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmda_LesseeOperatingLeaseLiabilityPaymentsDueYearSix" xlink:to="gmda_LesseeOperatingLeaseLiabilityPaymentsDueYearSix_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xml:lang="en-US">Thereafter</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US">Total undiscounted lease payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PresentValueOfFutureMinimumLeasePaymentsSaleLeasebackTransactions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PresentValueOfFutureMinimumLeasePaymentsSaleLeasebackTransactions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PresentValueOfFutureMinimumLeasePaymentsSaleLeasebackTransactions_lbl" xml:lang="en-US">Present value of lease liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PresentValueOfFutureMinimumLeasePaymentsSaleLeasebackTransactions" xlink:to="us-gaap_PresentValueOfFutureMinimumLeasePaymentsSaleLeasebackTransactions_lbl"/>
    <loc xlink:type="locator" xlink:label="gmda_DisclosureOfNotesAndOtherExplanatoryInformationsExplanatoryTextBlock" xlink:href="gmda-20220331.xsd#gmda_DisclosureOfNotesAndOtherExplanatoryInformationsExplanatoryTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gmda_DisclosureOfNotesAndOtherExplanatoryInformationsExplanatoryTextBlock_lbl" xml:lang="en-US">CONVERTIBLE SENIOR NOTES, NET</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmda_DisclosureOfNotesAndOtherExplanatoryInformationsExplanatoryTextBlock" xlink:to="gmda_DisclosureOfNotesAndOtherExplanatoryInformationsExplanatoryTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="gmda_ScheduleOfLiabilityAndEquityComponentConvertibleNotesTableTextBlock" xlink:href="gmda-20220331.xsd#gmda_ScheduleOfLiabilityAndEquityComponentConvertibleNotesTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gmda_ScheduleOfLiabilityAndEquityComponentConvertibleNotesTableTextBlock_lbl" xml:lang="en-US">Schedule of liability and equity components of the convertible notes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmda_ScheduleOfLiabilityAndEquityComponentConvertibleNotesTableTextBlock" xlink:to="gmda_ScheduleOfLiabilityAndEquityComponentConvertibleNotesTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="gmda_LiabilityComponentAbstract" xlink:href="gmda-20220331.xsd#gmda_LiabilityComponentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gmda_LiabilityComponentAbstract_lbl" xml:lang="en-US">Liability component:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmda_LiabilityComponentAbstract" xlink:to="gmda_LiabilityComponentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="gmda_AmountOfPrincipal" xlink:href="gmda-20220331.xsd#gmda_AmountOfPrincipal"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gmda_AmountOfPrincipal_lbl" xml:lang="en-US">Principal amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmda_AmountOfPrincipal" xlink:to="gmda_AmountOfPrincipal_lbl"/>
    <loc xlink:type="locator" xlink:label="gmda_UnamortizedIssuanceCosts" xlink:href="gmda-20220331.xsd#gmda_UnamortizedIssuanceCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gmda_UnamortizedIssuanceCosts_lbl" xml:lang="en-US">Issuance costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmda_UnamortizedIssuanceCosts" xlink:to="gmda_UnamortizedIssuanceCosts_lbl"/>
    <loc xlink:type="locator" xlink:label="gmda_NetIssuanceCosts" xlink:href="gmda-20220331.xsd#gmda_NetIssuanceCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gmda_NetIssuanceCosts_lbl" xml:lang="en-US">Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmda_NetIssuanceCosts" xlink:to="gmda_NetIssuanceCosts_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfFinancingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AmortizationOfFinancingCosts_lbl" xml:lang="en-US">Amortized issuance costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfFinancingCosts" xlink:to="us-gaap_AmortizationOfFinancingCosts_lbl"/>
    <loc xlink:type="locator" xlink:label="gmda_NetCarryingAmountincludingAccruedInterest" xlink:href="gmda-20220331.xsd#gmda_NetCarryingAmountincludingAccruedInterest"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gmda_NetCarryingAmountincludingAccruedInterest_lbl" xml:lang="en-US">Net carrying amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmda_NetCarryingAmountincludingAccruedInterest" xlink:to="gmda_NetCarryingAmountincludingAccruedInterest_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US">FAIR VALUE MEASUREMENTS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="gmda_ScheduleOfFairValueOfMoneyMarketFundsAndMarketableSecuritiesTableTextBlock" xlink:href="gmda-20220331.xsd#gmda_ScheduleOfFairValueOfMoneyMarketFundsAndMarketableSecuritiesTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gmda_ScheduleOfFairValueOfMoneyMarketFundsAndMarketableSecuritiesTableTextBlock_lbl" xml:lang="en-US">Schedule of fair value of money market funds and marketable securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmda_ScheduleOfFairValueOfMoneyMarketFundsAndMarketableSecuritiesTableTextBlock" xlink:to="gmda_ScheduleOfFairValueOfMoneyMarketFundsAndMarketableSecuritiesTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="gmda_CashEquivalentsAbstract" xlink:href="gmda-20220331.xsd#gmda_CashEquivalentsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gmda_CashEquivalentsAbstract_lbl" xml:lang="en-US">Cash equivalents:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmda_CashEquivalentsAbstract" xlink:to="gmda_CashEquivalentsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MoneyMarketFundsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsAtCarryingValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MoneyMarketFundsAtCarryingValue_lbl" xml:lang="en-US">Money market funds</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsAtCarryingValue" xlink:to="us-gaap_MoneyMarketFundsAtCarryingValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MarketableSecuritiesAbstract_lbl" xml:lang="en-US">Marketable securities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesAbstract" xlink:to="us-gaap_MarketableSecuritiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="gmda_CorporateDebentures" xlink:href="gmda-20220331.xsd#gmda_CorporateDebentures"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gmda_CorporateDebentures_lbl" xml:lang="en-US">Corporate debentures</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmda_CorporateDebentures" xlink:to="gmda_CorporateDebentures_lbl"/>
    <loc xlink:type="locator" xlink:label="gmda_GovernmentDebentures" xlink:href="gmda-20220331.xsd#gmda_GovernmentDebentures"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gmda_GovernmentDebentures_lbl" xml:lang="en-US">Government debentures</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmda_GovernmentDebentures" xlink:to="gmda_GovernmentDebentures_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueNetAssetLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueNetAssetLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueNetAssetLiability_lbl" xml:lang="en-US">Total assets measured at fair value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueNetAssetLiability" xlink:to="us-gaap_FairValueNetAssetLiability_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">CONTINGENT LIABILITIES AND COMMITMENTS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">SHAREHOLDERS&apos; EQUITY</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US">SHARE-BASED COMPENSATION</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US">Schedule of fair value measurement of equity-settled share options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Dividend yield</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US">Expected volatility of the share prices</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US">Risk-free interest rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Expected term (in years)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of stock option plans</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="gmda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrosses" xlink:href="gmda-20220331.xsd#gmda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrosses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gmda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrosses_lbl" xml:lang="en-US">Amount of options and restricted share unites, Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrosses" xlink:to="gmda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrosses_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, Forfeited</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, Expired</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="gmda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableInPeriod" xlink:href="gmda-20220331.xsd#gmda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableInPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gmda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableInPeriod_lbl" xml:lang="en-US">Amount of options and restricted share unites, Exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableInPeriod" xlink:to="gmda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableInPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="gmda_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisableInPeriodWeightedAverageExercisePrice" xlink:href="gmda-20220331.xsd#gmda_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisableInPeriodWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gmda_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisableInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, Exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmda_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisableInPeriodWeightedAverageExercisePrice" xlink:to="gmda_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisableInPeriodWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of restricted shares activity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Amount of restricted shares and restricted shares units, Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue_lbl" xml:lang="en-US">Weighted average grant date fair value, Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodIntrinsicValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodIntrinsicValue_lbl" xml:lang="en-US">Weighted average grant date fair value, Vested</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodIntrinsicValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue_lbl" xml:lang="en-US">Weighted average grant date fair value, Forfeited</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xml:lang="en-US">Schedule of share-based compensation expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development expenses, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostsAndExpensesRelatedParty" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpensesRelatedParty"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CostsAndExpensesRelatedParty_lbl" xml:lang="en-US">Commercial expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostsAndExpensesRelatedParty" xlink:to="us-gaap_CostsAndExpensesRelatedParty_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administrative expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Total share-based compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US">BASIC AND DILUTED NET LOSS PER SHARE</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xml:lang="en-US">Schedule of number of shares and loss used in the computation of net loss per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="gmda_WeightedAverageNumberOfSharesOutstandingBasicAndDiluted" xlink:href="gmda-20220331.xsd#gmda_WeightedAverageNumberOfSharesOutstandingBasicAndDiluted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gmda_WeightedAverageNumberOfSharesOutstandingBasicAndDiluted_lbl" xml:lang="en-US">Weighted number of shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmda_WeightedAverageNumberOfSharesOutstandingBasicAndDiluted" xlink:to="gmda_WeightedAverageNumberOfSharesOutstandingBasicAndDiluted_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_lbl" xml:lang="en-US">Net loss attributable to equity holders of the Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US">Less: Imputed interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="gmda_StockIssuedDuringPeriodSharesStockOptionesExercised" xlink:href="gmda-20220331.xsd#gmda_StockIssuedDuringPeriodSharesStockOptionesExercised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="gmda_StockIssuedDuringPeriodSharesStockOptionesExercised_lbl" xml:lang="en-US">Amount of options and restricted share unites, Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmda_StockIssuedDuringPeriodSharesStockOptionesExercised" xlink:to="gmda_StockIssuedDuringPeriodSharesStockOptionesExercised_lbl"/>
    <loc xlink:type="locator" xlink:label="gmda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriods" xlink:href="gmda-20220331.xsd#gmda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriods"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="gmda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriods_lbl" xml:lang="en-US">Amount of options and restricted share unites, Forfeited</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriods" xlink:to="gmda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriods_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" xml:lang="en-US">Amount of options and restricted share unites, Expired</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xml:lang="en-US">Amount of restricted shares and restricted shares units, Vested</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US">Amount of restricted shares and restricted shares units, Forfeited</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl"/>
    <loc xlink:type="locator" xlink:label="gmda_ForTheComputationOfDilutedLossMember" xlink:href="gmda-20220331.xsd#gmda_ForTheComputationOfDilutedLossMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gmda_ForTheComputationOfDilutedLossMember_lbl" xml:lang="en-US">For the computation of diluted loss [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmda_ForTheComputationOfDilutedLossMember" xlink:to="gmda_ForTheComputationOfDilutedLossMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermDebtTypeAxis_lbl" xml:lang="en-US">Short-Term Debt, Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US">Statistical Measurement [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentTypeAxis_lbl" xml:lang="en-US">Investment Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US">Class of Stock [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_lbl" xml:lang="en-US">Employee Stock Ownership Plan (ESOP) Name [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis" xlink:to="us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="gmda_ResponseRatePercentage" xlink:href="gmda-20220331.xsd#gmda_ResponseRatePercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gmda_ResponseRatePercentage_lbl" xml:lang="en-US">Response rate percentage, description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmda_ResponseRatePercentage" xlink:to="gmda_ResponseRatePercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="gmda_ClinicalTrialOnOutcomes" xlink:href="gmda-20220331.xsd#gmda_ClinicalTrialOnOutcomes"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gmda_ClinicalTrialOnOutcomes_lbl" xml:lang="en-US">Clinical trial on outcomes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmda_ClinicalTrialOnOutcomes" xlink:to="gmda_ClinicalTrialOnOutcomes_lbl"/>
    <loc xlink:type="locator" xlink:label="gmda_AccumulatedDeficit" xlink:href="gmda-20220331.xsd#gmda_AccumulatedDeficit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gmda_AccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmda_AccumulatedDeficit" xlink:to="gmda_AccumulatedDeficit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentsAndCash" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsAndCash"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InvestmentsAndCash_lbl" xml:lang="en-US">Cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsAndCash" xlink:to="us-gaap_InvestmentsAndCash_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xml:lang="en-US">Operating segment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_lbl" xml:lang="en-US">Lease term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:to="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_lbl"/>
    <loc xlink:type="locator" xlink:label="gmda_PrincipalAmount" xlink:href="gmda-20220331.xsd#gmda_PrincipalAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gmda_PrincipalAmount_lbl" xml:lang="en-US">Aggregate principal amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmda_PrincipalAmount" xlink:to="gmda_PrincipalAmount_lbl"/>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrbGzSS2V9veXLez+Xl0dIVqXQZdaaX7U8iZ3lEvQVQ8yavTR5LGMAC/Y6xtwO1cV8d5LpXjJeLMk6eat28V4VVXVBSb2HOCKvVmZvuAbSKzXyDRkT12vtciTURxwLsQFoRiJcYRfObTSc0gbTBq++/nfodHvEU7EA/LrQkg0k4it0+ht+i+C+b8cuG4bNt+Fpq7Go9dQP/G8Q==] CSR-->
    <loc xlink:type="locator" xlink:label="gmda_AnnualInterestPercentage" xlink:href="gmda-20220331.xsd#gmda_AnnualInterestPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gmda_AnnualInterestPercentage_lbl" xml:lang="en-US">Annual interest percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmda_AnnualInterestPercentage" xlink:to="gmda_AnnualInterestPercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentConvertibleConversionDate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleConversionDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentConvertibleConversionDate_lbl" xml:lang="en-US">Maturity date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleConversionDate" xlink:to="us-gaap_DebtInstrumentConvertibleConversionDate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleNotesPayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConvertibleNotesPayable_lbl" xml:lang="en-US">Convertible notes payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleNotesPayable" xlink:to="us-gaap_ConvertibleNotesPayable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquitySharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TemporaryEquitySharesIssued_lbl" xml:lang="en-US">Ordinary shares (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesIssued" xlink:to="us-gaap_TemporaryEquitySharesIssued_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleNotesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleNotesPayableCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConvertibleNotesPayableCurrent_lbl" xml:lang="en-US">Principal amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleNotesPayableCurrent" xlink:to="us-gaap_ConvertibleNotesPayableCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US">Exchange price (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentRedemptionPricePercentage_lbl" xml:lang="en-US">Repurchase price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:to="us-gaap_DebtInstrumentRedemptionPricePercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="gmda_ExchangePricePercentage" xlink:href="gmda-20220331.xsd#gmda_ExchangePricePercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gmda_ExchangePricePercentage_lbl" xml:lang="en-US">Exchange price percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmda_ExchangePricePercentage" xlink:to="gmda_ExchangePricePercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock_lbl" xml:lang="en-US">Convertible notes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" xlink:to="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateBasisForEffectiveRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateBasisForEffectiveRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentInterestRateBasisForEffectiveRate_lbl" xml:lang="en-US">Effective interest rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateBasisForEffectiveRate" xlink:to="us-gaap_DebtInstrumentInterestRateBasisForEffectiveRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RoyaltyGuaranteesCommitmentsAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RoyaltyGuaranteesCommitmentsAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RoyaltyGuaranteesCommitmentsAmount_lbl" xml:lang="en-US">Bank guarantees amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RoyaltyGuaranteesCommitmentsAmount" xlink:to="us-gaap_RoyaltyGuaranteesCommitmentsAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BorrowingsUnderGuaranteedInvestmentAgreements" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BorrowingsUnderGuaranteedInvestmentAgreements"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BorrowingsUnderGuaranteedInvestmentAgreements_lbl" xml:lang="en-US">Investment center grant amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BorrowingsUnderGuaranteedInvestmentAgreements" xlink:to="us-gaap_BorrowingsUnderGuaranteedInvestmentAgreements_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GrantsReceivableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrantsReceivableCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GrantsReceivableCurrent_lbl" xml:lang="en-US">Aggregate amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrantsReceivableCurrent" xlink:to="us-gaap_GrantsReceivableCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RoyaltyExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RoyaltyExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RoyaltyExpense_lbl" xml:lang="en-US">Royalty-bearing grants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RoyaltyExpense" xlink:to="us-gaap_RoyaltyExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfAdvanceRoyalty" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfAdvanceRoyalty"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AmortizationOfAdvanceRoyalty_lbl" xml:lang="en-US">Non-royalty-bearing grants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfAdvanceRoyalty" xlink:to="us-gaap_AmortizationOfAdvanceRoyalty_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeForwardInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeForwardInterestRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DerivativeForwardInterestRate_lbl" xml:lang="en-US">Royalties rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeForwardInterestRate" xlink:to="us-gaap_DerivativeForwardInterestRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction_lbl" xml:lang="en-US">Percentage of interest rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction" xlink:to="us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GrantsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrantsReceivable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GrantsReceivable_lbl" xml:lang="en-US">Total grants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrantsReceivable" xlink:to="us-gaap_GrantsReceivable_lbl"/>
    <loc xlink:type="locator" xlink:label="gmda_UnderwritersDescription" xlink:href="gmda-20220331.xsd#gmda_UnderwritersDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gmda_UnderwritersDescription_lbl" xml:lang="en-US">Underwriters description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmda_UnderwritersDescription" xlink:to="gmda_UnderwritersDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="gmda_ExpiryDate" xlink:href="gmda-20220331.xsd#gmda_ExpiryDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gmda_ExpiryDate_lbl" xml:lang="en-US">Expire date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmda_ExpiryDate" xlink:to="gmda_ExpiryDate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_lbl" xml:lang="en-US">Granted Warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xml:lang="en-US">Nominal per share value (in New Shekels per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPNumberOfAllocatedShares" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOwnershipPlanESOPNumberOfAllocatedShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPNumberOfAllocatedShares_lbl" xml:lang="en-US">Ordinary shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOwnershipPlanESOPNumberOfAllocatedShares" xlink:to="us-gaap_EmployeeStockOwnershipPlanESOPNumberOfAllocatedShares_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPNumberOfSuspenseShares" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOwnershipPlanESOPNumberOfSuspenseShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPNumberOfSuspenseShares_lbl" xml:lang="en-US">Ordinary shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOwnershipPlanESOPNumberOfSuspenseShares" xlink:to="us-gaap_EmployeeStockOwnershipPlanESOPNumberOfSuspenseShares_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Options vest period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US">Number of shares reserved for issuance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl"/>
    <loc xlink:type="locator" xlink:label="gmda_OrdinarySharesOutstandingPercentage" xlink:href="gmda-20220331.xsd#gmda_OrdinarySharesOutstandingPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gmda_OrdinarySharesOutstandingPercentage_lbl" xml:lang="en-US">Ordinary shares outstanding percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmda_OrdinarySharesOutstandingPercentage" xlink:to="gmda_OrdinarySharesOutstandingPercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Grant date fair value per share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xml:lang="en-US">Share-based compensation non-vested (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Use of estimates</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl"/>
    <loc xlink:type="locator" xlink:label="gmda_ConvertibleSeniorNotesPolicyTextBlock" xlink:href="gmda-20220331.xsd#gmda_ConvertibleSeniorNotesPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gmda_ConvertibleSeniorNotesPolicyTextBlock_lbl" xml:lang="en-US">Convertible senior notes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmda_ConvertibleSeniorNotesPolicyTextBlock" xlink:to="gmda_ConvertibleSeniorNotesPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Basic and diluted net loss per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleNotesPayableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleNotesPayableMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConvertibleNotesPayableMember_lbl" xml:lang="en-US">Convertible Notes Payable [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleNotesPayableMember" xlink:to="us-gaap_ConvertibleNotesPayableMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ConvertibleNotesPayableMember_lbl0" xml:lang="en-US">Convertible Notes [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleNotesPayableMember" xlink:to="us-gaap_ConvertibleNotesPayableMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestorMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestorMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InvestorMember_lbl" xml:lang="en-US">2017 Investor [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestorMember" xlink:to="us-gaap_InvestorMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US">Warrant [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonClassCMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassCMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonClassCMember_lbl" xml:lang="en-US">Ordinary C Share [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonClassCMember" xlink:to="us-gaap_CommonClassCMember_lbl"/>
    <loc xlink:type="locator" xlink:label="gmda_TwoZeroOneFourIsraelShareOptionPlanMember" xlink:href="gmda-20220331.xsd#gmda_TwoZeroOneFourIsraelShareOptionPlanMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gmda_TwoZeroOneFourIsraelShareOptionPlanMember_lbl" xml:lang="en-US">2014 Israel Share Option Plan [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmda_TwoZeroOneFourIsraelShareOptionPlanMember" xlink:to="gmda_TwoZeroOneFourIsraelShareOptionPlanMember_lbl"/>
    <loc xlink:type="locator" xlink:label="gmda_TwoThousandSeventeenStockCompensationPlanMember" xlink:href="gmda-20220331.xsd#gmda_TwoThousandSeventeenStockCompensationPlanMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="gmda_TwoThousandSeventeenStockCompensationPlanMember_lbl" xml:lang="en-US">2017 Share Incentive Plan [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmda_TwoThousandSeventeenStockCompensationPlanMember" xlink:to="gmda_TwoThousandSeventeenStockCompensationPlanMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US">Equity Component [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="gmda_FairValueMeasurementsDetailsScheduleoffairvalueofmoneymarketfundsandmarketablesecuritiesTable" xlink:href="gmda-20220331.xsd#gmda_FairValueMeasurementsDetailsScheduleoffairvalueofmoneymarketfundsandmarketablesecuritiesTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmda_FairValueMeasurementsDetailsScheduleoffairvalueofmoneymarketfundsandmarketablesecuritiesTable_lbl" xml:lang="en-US">Fair Value Measurements (Details) - Schedule of fair value of money market funds and marketable securities [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmda_FairValueMeasurementsDetailsScheduleoffairvalueofmoneymarketfundsandmarketablesecuritiesTable" xlink:to="gmda_FairValueMeasurementsDetailsScheduleoffairvalueofmoneymarketfundsandmarketablesecuritiesTable_lbl"/>
    <loc xlink:type="locator" xlink:label="gmda_FairValueMeasurementsDetailsScheduleoffairvalueofmoneymarketfundsandmarketablesecuritiesLineItems" xlink:href="gmda-20220331.xsd#gmda_FairValueMeasurementsDetailsScheduleoffairvalueofmoneymarketfundsandmarketablesecuritiesLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmda_FairValueMeasurementsDetailsScheduleoffairvalueofmoneymarketfundsandmarketablesecuritiesLineItems_lbl" xml:lang="en-US">Fair Value Measurements (Details) - Schedule of fair value of money market funds and marketable securities [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmda_FairValueMeasurementsDetailsScheduleoffairvalueofmoneymarketfundsandmarketablesecuritiesLineItems" xlink:to="gmda_FairValueMeasurementsDetailsScheduleoffairvalueofmoneymarketfundsandmarketablesecuritiesLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="gmda_LossPerShareDomain" xlink:href="gmda-20220331.xsd#gmda_LossPerShareDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmda_LossPerShareDomain_lbl" xml:lang="en-US">LossPerShare [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmda_LossPerShareDomain" xlink:to="gmda_LossPerShareDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="gmda_BasicandDilutedNetLossPerShareDetailsScheduleofnumberofsharesandlossusedinthecomputationofnetlosspershareTable" xlink:href="gmda-20220331.xsd#gmda_BasicandDilutedNetLossPerShareDetailsScheduleofnumberofsharesandlossusedinthecomputationofnetlosspershareTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmda_BasicandDilutedNetLossPerShareDetailsScheduleofnumberofsharesandlossusedinthecomputationofnetlosspershareTable_lbl" xml:lang="en-US">Basic and Diluted Net Loss Per Share (Details) - Schedule of number of shares and loss used in the computation of net loss per share [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmda_BasicandDilutedNetLossPerShareDetailsScheduleofnumberofsharesandlossusedinthecomputationofnetlosspershareTable" xlink:to="gmda_BasicandDilutedNetLossPerShareDetailsScheduleofnumberofsharesandlossusedinthecomputationofnetlosspershareTable_lbl"/>
    <loc xlink:type="locator" xlink:label="gmda_BasicandDilutedNetLossPerShareDetailsScheduleofnumberofsharesandlossusedinthecomputationofnetlosspershareLineItems" xlink:href="gmda-20220331.xsd#gmda_BasicandDilutedNetLossPerShareDetailsScheduleofnumberofsharesandlossusedinthecomputationofnetlosspershareLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmda_BasicandDilutedNetLossPerShareDetailsScheduleofnumberofsharesandlossusedinthecomputationofnetlosspershareLineItems_lbl" xml:lang="en-US">Basic and Diluted Net Loss Per Share (Details) - Schedule of number of shares and loss used in the computation of net loss per share [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmda_BasicandDilutedNetLossPerShareDetailsScheduleofnumberofsharesandlossusedinthecomputationofnetlosspershareLineItems" xlink:to="gmda_BasicandDilutedNetLossPerShareDetailsScheduleofnumberofsharesandlossusedinthecomputationofnetlosspershareLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermDebtTypeDomain_lbl" xml:lang="en-US">Short-Term Debt, Type [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtTypeDomain" xlink:to="us-gaap_ShortTermDebtTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="gmda_ConvertibleSeniorNotesNetDetailsTable" xlink:href="gmda-20220331.xsd#gmda_ConvertibleSeniorNotesNetDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmda_ConvertibleSeniorNotesNetDetailsTable_lbl" xml:lang="en-US">Convertible Senior Notes, Net (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmda_ConvertibleSeniorNotesNetDetailsTable" xlink:to="gmda_ConvertibleSeniorNotesNetDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="gmda_ConvertibleSeniorNotesNetDetailsLineItems" xlink:href="gmda-20220331.xsd#gmda_ConvertibleSeniorNotesNetDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmda_ConvertibleSeniorNotesNetDetailsLineItems_lbl" xml:lang="en-US">Convertible Senior Notes, Net (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmda_ConvertibleSeniorNotesNetDetailsLineItems" xlink:to="gmda_ConvertibleSeniorNotesNetDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeMember_lbl" xml:lang="en-US">Statistical Measurement [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl"/>
    <loc xlink:type="locator" xlink:label="gmda_ContingentLiabilitiesandCommitmentsDetailsTable" xlink:href="gmda-20220331.xsd#gmda_ContingentLiabilitiesandCommitmentsDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmda_ContingentLiabilitiesandCommitmentsDetailsTable_lbl" xml:lang="en-US">Contingent Liabilities and Commitments (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmda_ContingentLiabilitiesandCommitmentsDetailsTable" xlink:to="gmda_ContingentLiabilitiesandCommitmentsDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="gmda_ContingentLiabilitiesandCommitmentsDetailsLineItems" xlink:href="gmda-20220331.xsd#gmda_ContingentLiabilitiesandCommitmentsDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmda_ContingentLiabilitiesandCommitmentsDetailsLineItems_lbl" xml:lang="en-US">Contingent Liabilities and Commitments (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmda_ContingentLiabilitiesandCommitmentsDetailsLineItems" xlink:to="gmda_ContingentLiabilitiesandCommitmentsDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentTypeCategorizationMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentTypeCategorizationMember_lbl" xml:lang="en-US">Investments [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_InvestmentTypeCategorizationMember_lbl"/>
    <loc xlink:type="locator" xlink:label="gmda_ShareholdersEquityDetailsTable" xlink:href="gmda-20220331.xsd#gmda_ShareholdersEquityDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmda_ShareholdersEquityDetailsTable_lbl" xml:lang="en-US">Shareholders&apos; Equity (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmda_ShareholdersEquityDetailsTable" xlink:to="gmda_ShareholdersEquityDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="gmda_ShareholdersEquityDetailsLineItems" xlink:href="gmda-20220331.xsd#gmda_ShareholdersEquityDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmda_ShareholdersEquityDetailsLineItems_lbl" xml:lang="en-US">Shareholders&apos; Equity (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmda_ShareholdersEquityDetailsLineItems" xlink:to="gmda_ShareholdersEquityDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfStockDomain_lbl" xml:lang="en-US">Class of Stock [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain_lbl" xml:lang="en-US">Employee Stock Ownership Plan (ESOP), Plan [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain" xlink:to="us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="gmda_ShareBasedCompensationDetailsTable" xlink:href="gmda-20220331.xsd#gmda_ShareBasedCompensationDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmda_ShareBasedCompensationDetailsTable_lbl" xml:lang="en-US">Share-Based Compensation (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmda_ShareBasedCompensationDetailsTable" xlink:to="gmda_ShareBasedCompensationDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="gmda_ShareBasedCompensationDetailsLineItems" xlink:href="gmda-20220331.xsd#gmda_ShareBasedCompensationDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmda_ShareBasedCompensationDetailsLineItems_lbl" xml:lang="en-US">Share-Based Compensation (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmda_ShareBasedCompensationDetailsLineItems" xlink:to="gmda_ShareBasedCompensationDetailsLineItems_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmda_AccumulatedDeficit_lbl0" xml:lang="en-US">Accumulated deficit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmda_AccumulatedDeficit" xlink:to="gmda_AccumulatedDeficit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmda_AmountOfPrincipal_lbl0" xml:lang="en-US">Principal amount.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmda_AmountOfPrincipal" xlink:to="gmda_AmountOfPrincipal_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmda_AnnualInterestPercentage_lbl0" xml:lang="en-US">Annual Interest Percentage.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmda_AnnualInterestPercentage" xlink:to="gmda_AnnualInterestPercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmda_ClinicalTrialOnOutcomes_lbl0" xml:lang="en-US">Clinical trial on outcomes.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmda_ClinicalTrialOnOutcomes" xlink:to="gmda_ClinicalTrialOnOutcomes_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmda_CommercialExpenses_lbl0" xml:lang="en-US">Amount of commercial expenses.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmda_CommercialExpenses" xlink:to="gmda_CommercialExpenses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmda_CorporateDebentures_lbl0" xml:lang="en-US">Amount of corporate debentures.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmda_CorporateDebentures" xlink:to="gmda_CorporateDebentures_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmda_DisclosureOfNotesAndOtherExplanatoryInformationsExplanatoryTextBlock_lbl0" xml:lang="en-US">The disclosure of notes and other explanatory information as part of a complete set of financial statements.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmda_DisclosureOfNotesAndOtherExplanatoryInformationsExplanatoryTextBlock" xlink:to="gmda_DisclosureOfNotesAndOtherExplanatoryInformationsExplanatoryTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmda_GeneralAndAdministrativeExpenses_lbl0" xml:lang="en-US">General and administrative expenses.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmda_GeneralAndAdministrativeExpenses" xlink:to="gmda_GeneralAndAdministrativeExpenses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmda_GovernmentDebentures_lbl0" xml:lang="en-US">Amount of government debentures.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmda_GovernmentDebentures" xlink:to="gmda_GovernmentDebentures_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmda_IssuanceExpensesOnCredit_lbl0" xml:lang="en-US">Issuance expenses on credit.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmda_IssuanceExpensesOnCredit" xlink:to="gmda_IssuanceExpensesOnCredit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmda_LesseeOperatingLeaseLiabilityPaymentsDueYearSix_lbl0" xml:lang="en-US">Amount of lessee&apos;s undiscounted obligation for lease payment for operating lease to be paid in Sixth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmda_LesseeOperatingLeaseLiabilityPaymentsDueYearSix" xlink:to="gmda_LesseeOperatingLeaseLiabilityPaymentsDueYearSix_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmda_NetCarryingAmountincludingAccruedInterest_lbl0" xml:lang="en-US">It represents of net carrying amount including accrued interest.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmda_NetCarryingAmountincludingAccruedInterest" xlink:to="gmda_NetCarryingAmountincludingAccruedInterest_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmda_NetIssuanceCosts_lbl0" xml:lang="en-US">The amount of net issuance costs.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmda_NetIssuanceCosts" xlink:to="gmda_NetIssuanceCosts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmda_PrincipalAmount_lbl0" xml:lang="en-US">It represents of principal amount.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmda_PrincipalAmount" xlink:to="gmda_PrincipalAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmda_ResearchAndDevelopmentExpensesNet_lbl0" xml:lang="en-US">Research and development expenses, net.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmda_ResearchAndDevelopmentExpensesNet" xlink:to="gmda_ResearchAndDevelopmentExpensesNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmda_ResponseRatePercentage_lbl0" xml:lang="en-US">Response rate percentage., description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmda_ResponseRatePercentage" xlink:to="gmda_ResponseRatePercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmda_ScheduleOfLiabilityAndEquityComponentConvertibleNotesTableTextBlock_lbl0" xml:lang="en-US">Schedule Of Liability And Equity Components Convertible Notes Table Text Block.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmda_ScheduleOfLiabilityAndEquityComponentConvertibleNotesTableTextBlock" xlink:to="gmda_ScheduleOfLiabilityAndEquityComponentConvertibleNotesTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableInPeriod_lbl0" xml:lang="en-US">Number of options or other stock instruments for which the right to exercisable has lapsed under the terms of the plan agreements.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableInPeriod" xlink:to="gmda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableInPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriods_lbl0" xml:lang="en-US">Amount of options, Forfeited.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriods" xlink:to="gmda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriods_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrosses_lbl0" xml:lang="en-US">Amount of options, Granted.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrosses" xlink:to="gmda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrosses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmda_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisableInPeriodWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that exercisable.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmda_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisableInPeriodWeightedAverageExercisePrice" xlink:to="gmda_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisableInPeriodWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmda_StockIssuedDuringPeriodSharesStockOptionesExercised_lbl0" xml:lang="en-US">Stock issued during period shares stock options exercised.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmda_StockIssuedDuringPeriodSharesStockOptionesExercised" xlink:to="gmda_StockIssuedDuringPeriodSharesStockOptionesExercised_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmda_UnamortizedIssuanceCosts_lbl0" xml:lang="en-US">It represents of unamortized discount.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmda_UnamortizedIssuanceCosts" xlink:to="gmda_UnamortizedIssuanceCosts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmda_UnderwritersDescription_lbl0" xml:lang="en-US">The description related to underwriters description.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmda_UnderwritersDescription" xlink:to="gmda_UnderwritersDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="gmda_WeightedAverageNumberOfSharesOutstandingBasicAndDiluted_lbl0" xml:lang="en-US">Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmda_WeightedAverageNumberOfSharesOutstandingBasicAndDiluted" xlink:to="gmda_WeightedAverageNumberOfSharesOutstandingBasicAndDiluted_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableInPeriod_lbl1" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableInPeriod</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableInPeriod" xlink:to="gmda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableInPeriod_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmda_CashEquivalentsAbstract_lbl0" xml:lang="en-US">CashEquivalentsAbstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmda_CashEquivalentsAbstract" xlink:to="gmda_CashEquivalentsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrosses_lbl1" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrosses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrosses" xlink:to="gmda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrosses_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmda_ClinicalTrialOnOutcomes_lbl1" xml:lang="en-US">ClinicalTrialOnOutcomes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmda_ClinicalTrialOnOutcomes" xlink:to="gmda_ClinicalTrialOnOutcomes_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmda_GeneralAndAdministrativeExpenses_lbl1" xml:lang="en-US">GeneralAndAdministrativeExpenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmda_GeneralAndAdministrativeExpenses" xlink:to="gmda_GeneralAndAdministrativeExpenses_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmda_LesseeOperatingLeaseLiabilityPaymentsDueYearSix_lbl1" xml:lang="en-US">LesseeOperatingLeaseLiabilityPaymentsDueYearSix</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmda_LesseeOperatingLeaseLiabilityPaymentsDueYearSix" xlink:to="gmda_LesseeOperatingLeaseLiabilityPaymentsDueYearSix_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmda_AccumulatedDeficit_lbl1" xml:lang="en-US">AccumulatedDeficit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmda_AccumulatedDeficit" xlink:to="gmda_AccumulatedDeficit_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmda_GovernmentDebentures_lbl1" xml:lang="en-US">GovernmentDebentures</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmda_GovernmentDebentures" xlink:to="gmda_GovernmentDebentures_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmda_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisableInPeriodWeightedAverageExercisePrice_lbl1" xml:lang="en-US">ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisableInPeriodWeightedAverageExercisePrice</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmda_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisableInPeriodWeightedAverageExercisePrice" xlink:to="gmda_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisableInPeriodWeightedAverageExercisePrice_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmda_ExchangePricePercentage_lbl0" xml:lang="en-US">ExchangePricePercentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmda_ExchangePricePercentage" xlink:to="gmda_ExchangePricePercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmda_AmountOfPrincipal_lbl1" xml:lang="en-US">AmountOfPrincipal</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmda_AmountOfPrincipal" xlink:to="gmda_AmountOfPrincipal_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmda_NetCarryingAmountincludingAccruedInterest_lbl1" xml:lang="en-US">NetCarryingAmountincludingAccruedInterest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmda_NetCarryingAmountincludingAccruedInterest" xlink:to="gmda_NetCarryingAmountincludingAccruedInterest_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmda_PrincipalAmount_lbl1" xml:lang="en-US">PrincipalAmount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmda_PrincipalAmount" xlink:to="gmda_PrincipalAmount_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmda_StockIssuedDuringPeriodSharesStockOptionesExercised_lbl1" xml:lang="en-US">StockIssuedDuringPeriodSharesStockOptionesExercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmda_StockIssuedDuringPeriodSharesStockOptionesExercised" xlink:to="gmda_StockIssuedDuringPeriodSharesStockOptionesExercised_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmda_OrdinarySharesOutstandingPercentage_lbl0" xml:lang="en-US">OrdinarySharesOutstandingPercentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmda_OrdinarySharesOutstandingPercentage" xlink:to="gmda_OrdinarySharesOutstandingPercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmda_TwoZeroOneFourIsraelShareOptionPlanMember_lbl0" xml:lang="en-US">TwoZeroOneFourIsraelShareOptionPlanMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmda_TwoZeroOneFourIsraelShareOptionPlanMember" xlink:to="gmda_TwoZeroOneFourIsraelShareOptionPlanMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmda_ScheduleOfFairValueOfMoneyMarketFundsAndMarketableSecuritiesTableTextBlock_lbl0" xml:lang="en-US">ScheduleOfFairValueOfMoneyMarketFundsAndMarketableSecuritiesTableTextBlock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmda_ScheduleOfFairValueOfMoneyMarketFundsAndMarketableSecuritiesTableTextBlock" xlink:to="gmda_ScheduleOfFairValueOfMoneyMarketFundsAndMarketableSecuritiesTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmda_ExpiryDate_lbl0" xml:lang="en-US">ExpiryDate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmda_ExpiryDate" xlink:to="gmda_ExpiryDate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmda_NetIssuanceCosts_lbl1" xml:lang="en-US">NetIssuanceCosts</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmda_NetIssuanceCosts" xlink:to="gmda_NetIssuanceCosts_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriods_lbl1" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriods</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriods" xlink:to="gmda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriods_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmda_IssuanceExpensesOnCredit_lbl1" xml:lang="en-US">IssuanceExpensesOnCredit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmda_IssuanceExpensesOnCredit" xlink:to="gmda_IssuanceExpensesOnCredit_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmda_WeightedAverageNumberOfSharesOutstandingBasicAndDiluted_lbl1" xml:lang="en-US">WeightedAverageNumberOfSharesOutstandingBasicAndDiluted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmda_WeightedAverageNumberOfSharesOutstandingBasicAndDiluted" xlink:to="gmda_WeightedAverageNumberOfSharesOutstandingBasicAndDiluted_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmda_ForTheComputationOfDilutedLossMember_lbl0" xml:lang="en-US">ForTheComputationOfDilutedLossMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmda_ForTheComputationOfDilutedLossMember" xlink:to="gmda_ForTheComputationOfDilutedLossMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmda_CommercialExpenses_lbl1" xml:lang="en-US">CommercialExpenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmda_CommercialExpenses" xlink:to="gmda_CommercialExpenses_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmda_AnnualInterestPercentage_lbl1" xml:lang="en-US">AnnualInterestPercentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmda_AnnualInterestPercentage" xlink:to="gmda_AnnualInterestPercentage_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmda_CorporateDebentures_lbl1" xml:lang="en-US">CorporateDebentures</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmda_CorporateDebentures" xlink:to="gmda_CorporateDebentures_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmda_ResponseRatePercentage_lbl1" xml:lang="en-US">ResponseRatePercentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmda_ResponseRatePercentage" xlink:to="gmda_ResponseRatePercentage_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmda_UnderwritersDescription_lbl1" xml:lang="en-US">UnderwritersDescription</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmda_UnderwritersDescription" xlink:to="gmda_UnderwritersDescription_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmda_ResearchAndDevelopmentExpensesNet_lbl1" xml:lang="en-US">ResearchAndDevelopmentExpensesNet</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmda_ResearchAndDevelopmentExpensesNet" xlink:to="gmda_ResearchAndDevelopmentExpensesNet_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmda_DisclosureOfNotesAndOtherExplanatoryInformationsExplanatoryTextBlock_lbl1" xml:lang="en-US">DisclosureOfNotesAndOtherExplanatoryInformationsExplanatoryTextBlock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmda_DisclosureOfNotesAndOtherExplanatoryInformationsExplanatoryTextBlock" xlink:to="gmda_DisclosureOfNotesAndOtherExplanatoryInformationsExplanatoryTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmda_LiabilityComponentAbstract_lbl0" xml:lang="en-US">LiabilityComponentAbstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmda_LiabilityComponentAbstract" xlink:to="gmda_LiabilityComponentAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmda_ConvertibleSeniorNotesPolicyTextBlock_lbl0" xml:lang="en-US">ConvertibleSeniorNotesPolicyTextBlock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmda_ConvertibleSeniorNotesPolicyTextBlock" xlink:to="gmda_ConvertibleSeniorNotesPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmda_TwoThousandSeventeenStockCompensationPlanMember_lbl0" xml:lang="en-US">TwoThousandSeventeenStockCompensationPlanMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmda_TwoThousandSeventeenStockCompensationPlanMember" xlink:to="gmda_TwoThousandSeventeenStockCompensationPlanMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmda_LossPerShareAxis_lbl0" xml:lang="en-US">LossPerShareAxis</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmda_LossPerShareAxis" xlink:to="gmda_LossPerShareAxis_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmda_ScheduleOfLiabilityAndEquityComponentConvertibleNotesTableTextBlock_lbl1" xml:lang="en-US">ScheduleOfLiabilityAndEquityComponentConvertibleNotesTableTextBlock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmda_ScheduleOfLiabilityAndEquityComponentConvertibleNotesTableTextBlock" xlink:to="gmda_ScheduleOfLiabilityAndEquityComponentConvertibleNotesTableTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="gmda_UnamortizedIssuanceCosts_lbl1" xml:lang="en-US">UnamortizedIssuanceCosts</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="gmda_UnamortizedIssuanceCosts" xlink:to="gmda_UnamortizedIssuanceCosts_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl0" xml:lang="en-US">Earnings Per Share, Basic</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl0" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl0" xml:lang="en-US">Research and Development Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodIntrinsicValue_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Intrinsic Value, Amount Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodIntrinsicValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleNotesPayable_lbl0" xml:lang="en-US">Convertible Notes Payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleNotesPayable" xlink:to="us-gaap_ConvertibleNotesPayable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_lbl0" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Diluted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentRedemptionPricePercentage_lbl0" xml:lang="en-US">Debt Instrument, Redemption Price, Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:to="us-gaap_DebtInstrumentRedemptionPricePercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeForwardInterestRate_lbl0" xml:lang="en-US">Derivative, Forward Interest Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeForwardInterestRate" xlink:to="us-gaap_DerivativeForwardInterestRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl0" xml:lang="en-US">Commitments and Contingencies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl0" xml:lang="en-US">Entity Small Business</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfAdvanceRoyalty_lbl0" xml:lang="en-US">Amortization of Advance Royalty</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfAdvanceRoyalty" xlink:to="us-gaap_AmortizationOfAdvanceRoyalty_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl0" xml:lang="en-US">Entity File Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl0" xml:lang="en-US">Entity Address, City or Town</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl0" xml:lang="en-US">Assets [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl0" xml:lang="en-US">Operating Lease, Liability, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_lbl0" xml:lang="en-US">Liabilities, Noncurrent [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl0" xml:lang="en-US">Common Stock, Value, Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfFinancingCosts_lbl0" xml:lang="en-US">Amortization of Debt Issuance Costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfFinancingCosts" xlink:to="us-gaap_AmortizationOfFinancingCosts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl0" xml:lang="en-US">Entity Filer Category</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl0" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPNumberOfSuspenseShares_lbl0" xml:lang="en-US">Employee Stock Ownership Plan (ESOP), Number of Suspense Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOwnershipPlanESOPNumberOfSuspenseShares" xlink:to="us-gaap_EmployeeStockOwnershipPlanESOPNumberOfSuspenseShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesNoncurrent_lbl0" xml:lang="en-US">Liabilities, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_LiabilitiesNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProfitLoss_lbl0" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaidNet_lbl0" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl0" xml:lang="en-US">Stockholders&apos; Equity Attributable to Parent [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl0" xml:lang="en-US">Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TreasuryStockValue_lbl0" xml:lang="en-US">Treasury Stock, Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockValue" xlink:to="us-gaap_TreasuryStockValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateBasisForEffectiveRate_lbl0" xml:lang="en-US">Debt Instrument, Interest Rate, Basis for Effective Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateBasisForEffectiveRate" xlink:to="us-gaap_DebtInstrumentInterestRateBasisForEffectiveRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TreasuryStockSharesRetired_lbl0" xml:lang="en-US">Treasury Stock, Shares, Retired</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockSharesRetired" xlink:to="us-gaap_TreasuryStockSharesRetired_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl0" xml:lang="en-US">Stockholders&apos; Equity Note Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl0" xml:lang="en-US">Entity Address, State or Province</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl0" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl0" xml:lang="en-US">Local Phone Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl0" xml:lang="en-US">Increase (Decrease) in Operating Lease Liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostsAndExpenses_lbl0" xml:lang="en-US">Costs and Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_CostsAndExpenses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl0" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NumberOfOperatingSegments_lbl0" xml:lang="en-US">Number of Operating Segments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl0" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl0" xml:lang="en-US">Lessee, Operating Leases [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl0" xml:lang="en-US">Other Assets, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl0" xml:lang="en-US">Retained Earnings [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_lbl0" xml:lang="en-US">Lessee, Operating Lease, Remaining Lease Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:to="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl0" xml:lang="en-US">Document Transition Report</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl0" xml:lang="en-US">Fair Value Disclosures [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl0" xml:lang="en-US">Amortization of Debt Issuance Costs and Discounts</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TreasuryStockShares_lbl0" xml:lang="en-US">Treasury Stock, Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockShares" xlink:to="us-gaap_TreasuryStockShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NotesPayableCurrent_lbl0" xml:lang="en-US">Notes Payable, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayableCurrent" xlink:to="us-gaap_NotesPayableCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl0" xml:lang="en-US">Accounts Payable, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade_lbl0" xml:lang="en-US">Increase (Decrease) in Accounts Payable, Trade</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableTrade_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl0" xml:lang="en-US">Entity Shell Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl0" xml:lang="en-US">Maximum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Intrinsic Value, Amount Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl0" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl0" xml:lang="en-US">Significant Accounting Policies [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl0" xml:lang="en-US">Common Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl0" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl0" xml:lang="en-US">Entity Incorporation, State or Country Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl0" xml:lang="en-US">Security Exchange Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl0" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl0" xml:lang="en-US">Entity Address, Address Line One</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl0" xml:lang="en-US">Minimum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl0" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl0" xml:lang="en-US">Common Stock, Shares, Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl0" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Depreciation_lbl0" xml:lang="en-US">Depreciation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl0" xml:lang="en-US">Prepaid Expense and Other Assets, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl0" xml:lang="en-US">Additional Paid in Capital, Common Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl0" xml:lang="en-US">Title of 12(b) Security</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl1" xml:lang="en-US">Additional Paid-in Capital [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PresentValueOfFutureMinimumLeasePaymentsSaleLeasebackTransactions_lbl0" xml:lang="en-US">Present Value of Future Minimum Lease Payments, Sale Leaseback Transactions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PresentValueOfFutureMinimumLeasePaymentsSaleLeasebackTransactions" xlink:to="us-gaap_PresentValueOfFutureMinimumLeasePaymentsSaleLeasebackTransactions_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl0" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl0" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, after Year Five</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensation_lbl0" xml:lang="en-US">Employee Benefits and Share-Based Compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:to="us-gaap_EmployeeBenefitsAndShareBasedCompensation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl0" xml:lang="en-US">Property, Plant and Equipment, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl0" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction_lbl0" xml:lang="en-US">Sale of Stock, Percentage of Ownership after Transaction</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction" xlink:to="us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl0" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl0" xml:lang="en-US">Sale of Stock, Price Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPNumberOfAllocatedShares_lbl0" xml:lang="en-US">Employee Stock Ownership Plan (ESOP), Number of Allocated Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOwnershipPlanESOPNumberOfAllocatedShares" xlink:to="us-gaap_EmployeeStockOwnershipPlanESOPNumberOfAllocatedShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl0" xml:lang="en-US">Entity Registrant Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermLeaseCost_lbl0" xml:lang="en-US">Short-Term Lease, Cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermLeaseCost" xlink:to="us-gaap_ShortTermLeaseCost_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantMember_lbl0" xml:lang="en-US">Warrant [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl0" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl0" xml:lang="en-US">Employee-related Liabilities, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleNotesPayableCurrent_lbl0" xml:lang="en-US">Convertible Notes Payable, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleNotesPayableCurrent" xlink:to="us-gaap_ConvertibleNotesPayableCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl0" xml:lang="en-US">City Area Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCost_lbl0" xml:lang="en-US">Lease, Cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_LeaseCost_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl0" xml:lang="en-US">Amendment Flag</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl0" xml:lang="en-US">Noncash Investing and Financing Items [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl0" xml:lang="en-US">Operating Income (Loss)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl0" xml:lang="en-US">Entity Central Index Key</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TreasuryStockMember_lbl0" xml:lang="en-US">Treasury Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockMember" xlink:to="us-gaap_TreasuryStockMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Intrinsic Value, Amount Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl0" xml:lang="en-US">Liabilities, Current [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl0" xml:lang="en-US">Nonoperating Income (Expense)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestorMember_lbl0" xml:lang="en-US">Investor [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestorMember" xlink:to="us-gaap_InvestorMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentConvertibleConversionDate_lbl0" xml:lang="en-US">Debt Instrument, Convertible, Conversion Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleConversionDate" xlink:to="us-gaap_DebtInstrumentConvertibleConversionDate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquitySharesAuthorized_lbl0" xml:lang="en-US">Temporary Equity, Shares Authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesAuthorized" xlink:to="us-gaap_TemporaryEquitySharesAuthorized_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl0" xml:lang="en-US">Other Accrued Liabilities, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl0" xml:lang="en-US">Gain (Loss) on Disposition of Property Plant Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedInvestmentsNoncurrent_lbl0" xml:lang="en-US">Restricted Investments, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedInvestmentsNoncurrent" xlink:to="us-gaap_RestrictedInvestmentsNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures_lbl0" xml:lang="en-US">Stock Issued During Period, Value, Restricted Stock Award, Forfeitures</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl0" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueNetAssetLiability_lbl0" xml:lang="en-US">Fair Value, Net Asset (Liability)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueNetAssetLiability" xlink:to="us-gaap_FairValueNetAssetLiability_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_lbl0" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Four Years</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLongTermInvestments_lbl0" xml:lang="en-US">Other Long-Term Investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLongTermInvestments" xlink:to="us-gaap_OtherLongTermInvestments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl1" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl0" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharePrice_lbl0" xml:lang="en-US">Share Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl0" xml:lang="en-US">Liabilities and Equity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseCost_lbl0" xml:lang="en-US">Operating Lease, Cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GrantsReceivableCurrent_lbl0" xml:lang="en-US">Grants Receivable, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrantsReceivableCurrent" xlink:to="us-gaap_GrantsReceivableCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl0" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TreasuryStockValueAcquiredCostMethod_lbl0" xml:lang="en-US">Treasury Stock, Value, Acquired, Cost Method</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:to="us-gaap_TreasuryStockValueAcquiredCostMethod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl0" xml:lang="en-US">Assets, Current [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl0" xml:lang="en-US">Current Fiscal Year End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl0" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl0" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl0" xml:lang="en-US">Common Stock, Shares Authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MoneyMarketFundsAtCarryingValue_lbl0" xml:lang="en-US">Money Market Funds, at Carrying Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsAtCarryingValue" xlink:to="us-gaap_MoneyMarketFundsAtCarryingValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl0" xml:lang="en-US">Earnings Per Share [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl2" xml:lang="en-US">Stockholders&apos; Equity Attributable to Parent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl0" xml:lang="en-US">Entity Ex Transition Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl0" xml:lang="en-US">Proceeds from Stock Options Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl0" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl0" xml:lang="en-US">Liabilities and Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MarketableSecuritiesCurrent_lbl0" xml:lang="en-US">Marketable Securities, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesCurrent" xlink:to="us-gaap_MarketableSecuritiesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_lbl0" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Five Years</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonClassCMember_lbl0" xml:lang="en-US">Common Class C [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonClassCMember" xlink:to="us-gaap_CommonClassCMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RoyaltyExpense_lbl0" xml:lang="en-US">Royalty Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RoyaltyExpense" xlink:to="us-gaap_RoyaltyExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl0" xml:lang="en-US">General and Administrative Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl0" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl0" xml:lang="en-US">Liabilities, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsNoncurrentAbstract_lbl0" xml:lang="en-US">Assets, Noncurrent [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_AssetsNoncurrentAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_lbl0" xml:lang="en-US">Payments to Acquire Businesses, Net of Cash Acquired</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:to="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl0" xml:lang="en-US">Assets, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl0" xml:lang="en-US">Document Fiscal Year Focus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl0" xml:lang="en-US">Entity Emerging Growth Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl0" xml:lang="en-US">Entity Tax Identification Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl0" xml:lang="en-US">Entity Address, Postal Zip Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl0" xml:lang="en-US">Document Type</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl0" xml:lang="en-US">Common Stock, Shares, Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl0" xml:lang="en-US">Entity Current Reporting Status</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl0" xml:lang="en-US">Proceeds from Sale and Maturity of Marketable Securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl0" xml:lang="en-US">Lease, Cost [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostTableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl0" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl0" xml:lang="en-US">Document Fiscal Period Focus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl0" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl0" xml:lang="en-US">Entity Interactive Data Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl0" xml:lang="en-US">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsNoncurrent_lbl0" xml:lang="en-US">Assets, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_AssetsNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPostemploymentObligations_lbl0" xml:lang="en-US">Increase (Decrease) in Postemployment Obligations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPostemploymentObligations" xlink:to="us-gaap_IncreaseDecreaseInPostemploymentObligations_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl0" xml:lang="en-US">Proceeds from Issuance of Common Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleNotesPayableMember_lbl1" xml:lang="en-US">Convertible Notes Payable [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleNotesPayableMember" xlink:to="us-gaap_ConvertibleNotesPayableMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAccruedLiabilitiesNoncurrent_lbl0" xml:lang="en-US">Other Accrued Liabilities, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesNoncurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleLongTermNotesPayable_lbl0" xml:lang="en-US">Convertible Notes Payable, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleLongTermNotesPayable" xlink:to="us-gaap_ConvertibleLongTermNotesPayable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_lbl0" xml:lang="en-US">Net Income (Loss) Attributable to Parent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RoyaltyGuaranteesCommitmentsAmount_lbl0" xml:lang="en-US">Royalty Guarantees, Commitments, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RoyaltyGuaranteesCommitmentsAmount" xlink:to="us-gaap_RoyaltyGuaranteesCommitmentsAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl0" xml:lang="en-US">Document Quarterly Report</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostsAndExpensesRelatedParty_lbl0" xml:lang="en-US">Costs and Expenses, Related Party</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostsAndExpensesRelatedParty" xlink:to="us-gaap_CostsAndExpensesRelatedParty_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl0" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl0" xml:lang="en-US">Trading Symbol</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock_lbl0" xml:lang="en-US">Proceeds from Issuance of Redeemable Convertible Preferred Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" xlink:to="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue_lbl1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instrument Other than Option, Nonvested, Intrinsic Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl0" xml:lang="en-US">Operating Lease, Right-of-Use Asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_lbl1" xml:lang="en-US">Shares, Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MarketableSecuritiesAbstract_lbl0" xml:lang="en-US">Marketable Securities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesAbstract" xlink:to="us-gaap_MarketableSecuritiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl0" xml:lang="en-US">Document Period End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities_lbl0" xml:lang="en-US">Payments to Acquire Marketable Securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireMarketableSecurities" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl0" xml:lang="en-US">Operating Lease, Liability, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TemporaryEquitySharesIssued_lbl0" xml:lang="en-US">Temporary Equity, Shares Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesIssued" xlink:to="us-gaap_TemporaryEquitySharesIssued_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GrantsReceivable_lbl0" xml:lang="en-US">Grants Receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrantsReceivable" xlink:to="us-gaap_GrantsReceivable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl0" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BorrowingsUnderGuaranteedInvestmentAgreements_lbl0" xml:lang="en-US">Borrowings under Guaranteed Investment Agreements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BorrowingsUnderGuaranteedInvestmentAgreements" xlink:to="us-gaap_BorrowingsUnderGuaranteedInvestmentAgreements_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl0" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock_lbl0" xml:lang="en-US">Lessee, Operating Lease, Disclosure [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock" xlink:to="us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentsAndCash_lbl0" xml:lang="en-US">Investments and Cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsAndCash" xlink:to="us-gaap_InvestmentsAndCash_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementScenarioAxis_lbl" xml:lang="en-US">Scenario [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_StatementScenarioAxis_lbl"/>
  </labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>gmda-20220331_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Wed May 11 15:03:37 UTC 2022 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="gmda-20220331.xsd#gmda_r_ConsolidatedBalanceSheet" roleURI="http://www.gamidacell.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="gmda-20220331.xsd#gmda_r_ConsolidatedBalanceSheet_Parentheticals" roleURI="http://www.gamidacell.com/role/ConsolidatedBalanceSheet_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="gmda-20220331.xsd#gmda_r_ConsolidatedIncomeStatement" roleURI="http://www.gamidacell.com/role/ConsolidatedIncomeStatement"/>
  <roleRef xlink:type="simple" xlink:href="gmda-20220331.xsd#gmda_r_ShareholdersEquityType2or3" roleURI="http://www.gamidacell.com/role/ShareholdersEquityType2or3"/>
  <roleRef xlink:type="simple" xlink:href="gmda-20220331.xsd#gmda_r_ConsolidatedCashFlow" roleURI="http://www.gamidacell.com/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="gmda-20220331.xsd#gmda_r_General" roleURI="http://www.gamidacell.com/role/General"/>
  <roleRef xlink:type="simple" xlink:href="gmda-20220331.xsd#gmda_r_SignificantAccountingPolicies" roleURI="http://www.gamidacell.com/role/SignificantAccountingPolicies"/>
  <roleRef xlink:type="simple" xlink:href="gmda-20220331.xsd#gmda_r_Leases" roleURI="http://www.gamidacell.com/role/Leases"/>
  <roleRef xlink:type="simple" xlink:href="gmda-20220331.xsd#gmda_r_ConvertibleSeniorNotesNet" roleURI="http://www.gamidacell.com/role/ConvertibleSeniorNotesNet"/>
  <roleRef xlink:type="simple" xlink:href="gmda-20220331.xsd#gmda_r_FairValueMeasurements" roleURI="http://www.gamidacell.com/role/FairValueMeasurements"/>
  <roleRef xlink:type="simple" xlink:href="gmda-20220331.xsd#gmda_r_ContingentLiabilitiesandCommitments" roleURI="http://www.gamidacell.com/role/ContingentLiabilitiesandCommitments"/>
  <roleRef xlink:type="simple" xlink:href="gmda-20220331.xsd#gmda_r_ShareholdersEquity" roleURI="http://www.gamidacell.com/role/ShareholdersEquity"/>
  <roleRef xlink:type="simple" xlink:href="gmda-20220331.xsd#gmda_r_ShareBasedCompensation" roleURI="http://www.gamidacell.com/role/ShareBasedCompensation"/>
  <roleRef xlink:type="simple" xlink:href="gmda-20220331.xsd#gmda_r_BasicandDilutedNetLossPerShare" roleURI="http://www.gamidacell.com/role/BasicandDilutedNetLossPerShare"/>
  <roleRef xlink:type="simple" xlink:href="gmda-20220331.xsd#gmda_r_AccountingPoliciesByPolicy" roleURI="http://www.gamidacell.com/role/AccountingPoliciesByPolicy"/>
  <roleRef xlink:type="simple" xlink:href="gmda-20220331.xsd#gmda_r_LeasesTables" roleURI="http://www.gamidacell.com/role/LeasesTables"/>
  <roleRef xlink:type="simple" xlink:href="gmda-20220331.xsd#gmda_r_ConvertibleSeniorNotesNetTables" roleURI="http://www.gamidacell.com/role/ConvertibleSeniorNotesNetTables"/>
  <roleRef xlink:type="simple" xlink:href="gmda-20220331.xsd#gmda_r_FairValueMeasurementsTables" roleURI="http://www.gamidacell.com/role/FairValueMeasurementsTables"/>
  <roleRef xlink:type="simple" xlink:href="gmda-20220331.xsd#gmda_r_ShareBasedCompensationTables" roleURI="http://www.gamidacell.com/role/ShareBasedCompensationTables"/>
  <roleRef xlink:type="simple" xlink:href="gmda-20220331.xsd#gmda_r_BasicandDilutedNetLossPerShareTables" roleURI="http://www.gamidacell.com/role/BasicandDilutedNetLossPerShareTables"/>
  <roleRef xlink:type="simple" xlink:href="gmda-20220331.xsd#gmda_r_ScheduleofoperatingleasecostsTable" roleURI="http://www.gamidacell.com/role/ScheduleofoperatingleasecostsTable"/>
  <roleRef xlink:type="simple" xlink:href="gmda-20220331.xsd#gmda_r_ScheduleofoperatingleasesTable" roleURI="http://www.gamidacell.com/role/ScheduleofoperatingleasesTable"/>
  <roleRef xlink:type="simple" xlink:href="gmda-20220331.xsd#gmda_r_ScheduleofmaturitiesofleaseliabilitiesTable" roleURI="http://www.gamidacell.com/role/ScheduleofmaturitiesofleaseliabilitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="gmda-20220331.xsd#gmda_r_ScheduleofliabilityandequitycomponentsoftheconvertiblenotesTable" roleURI="http://www.gamidacell.com/role/ScheduleofliabilityandequitycomponentsoftheconvertiblenotesTable"/>
  <roleRef xlink:type="simple" xlink:href="gmda-20220331.xsd#gmda_r_ScheduleoffairvalueofmoneymarketfundsandmarketablesecuritiesTable" roleURI="http://www.gamidacell.com/role/ScheduleoffairvalueofmoneymarketfundsandmarketablesecuritiesTable"/>
  <roleRef xlink:type="simple" xlink:href="gmda-20220331.xsd#gmda_r_ScheduleoffairvaluemeasurementofequitysettledshareoptionsTable" roleURI="http://www.gamidacell.com/role/ScheduleoffairvaluemeasurementofequitysettledshareoptionsTable"/>
  <roleRef xlink:type="simple" xlink:href="gmda-20220331.xsd#gmda_r_ScheduleofstockoptionplansTable" roleURI="http://www.gamidacell.com/role/ScheduleofstockoptionplansTable"/>
  <roleRef xlink:type="simple" xlink:href="gmda-20220331.xsd#gmda_r_ScheduleofrestrictedsharesactivityTable" roleURI="http://www.gamidacell.com/role/ScheduleofrestrictedsharesactivityTable"/>
  <roleRef xlink:type="simple" xlink:href="gmda-20220331.xsd#gmda_r_ScheduleofsharebasedcompensationexpenseTable" roleURI="http://www.gamidacell.com/role/ScheduleofsharebasedcompensationexpenseTable"/>
  <roleRef xlink:type="simple" xlink:href="gmda-20220331.xsd#gmda_r_ScheduleofnumberofsharesandlossusedinthecomputationofnetlosspershareTable" roleURI="http://www.gamidacell.com/role/ScheduleofnumberofsharesandlossusedinthecomputationofnetlosspershareTable"/>
  <roleRef xlink:type="simple" xlink:href="gmda-20220331.xsd#gmda_r_GeneralDetails" roleURI="http://www.gamidacell.com/role/GeneralDetails"/>
  <roleRef xlink:type="simple" xlink:href="gmda-20220331.xsd#gmda_r_LeasesDetails" roleURI="http://www.gamidacell.com/role/LeasesDetails"/>
  <roleRef xlink:type="simple" xlink:href="gmda-20220331.xsd#gmda_r_ConvertibleSeniorNotesNetDetails" roleURI="http://www.gamidacell.com/role/ConvertibleSeniorNotesNetDetails"/>
  <roleRef xlink:type="simple" xlink:href="gmda-20220331.xsd#gmda_r_ContingentLiabilitiesandCommitmentsDetails" roleURI="http://www.gamidacell.com/role/ContingentLiabilitiesandCommitmentsDetails"/>
  <roleRef xlink:type="simple" xlink:href="gmda-20220331.xsd#gmda_r_ShareholdersEquityDetails" roleURI="http://www.gamidacell.com/role/ShareholdersEquityDetails"/>
  <roleRef xlink:type="simple" xlink:href="gmda-20220331.xsd#gmda_r_ShareBasedCompensationDetails" roleURI="http://www.gamidacell.com/role/ShareBasedCompensationDetails"/>
  <roleRef xlink:type="simple" xlink:href="gmda-20220331.xsd#DocumentAndEntityInformation" roleURI="http://www.gamidacell.com/role/DocumentAndEntityInformation"/>
  <presentationLink xlink:type="extended" xlink:role="http://www.gamidacell.com/role/ConsolidatedBalanceSheet">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_MarketableSecuritiesCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsNoncurrentAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsNoncurrentAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RestrictedInvestmentsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedInvestmentsNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_RestrictedInvestmentsNoncurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLongTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLongTermInvestments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_OtherLongTermInvestments" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_AssetsNoncurrent" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NotesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayableCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_NotesPayableCurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleLongTermNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleLongTermNotesPayable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_ConvertibleLongTermNotesPayable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesNoncurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesNoncurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TreasuryStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_TreasuryStockValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_StockholdersEquity" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.gamidacell.com/role/ConsolidatedBalanceSheet_Parentheticals">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquitySharesAuthorized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_TemporaryEquitySharesAuthorized" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TreasuryStockShares" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_TreasuryStockShares" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.gamidacell.com/role/ConsolidatedIncomeStatement">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <loc xlink:type="locator" xlink:label="ResearchAndDevelopmentExpensesNet" xlink:href="gmda-20220331.xsd#gmda_ResearchAndDevelopmentExpensesNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="ResearchAndDevelopmentExpensesNet" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CommercialExpenses" xlink:href="gmda-20220331.xsd#gmda_CommercialExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="CommercialExpenses" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="GeneralAndAdministrativeExpenses" xlink:href="gmda-20220331.xsd#gmda_GeneralAndAdministrativeExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="GeneralAndAdministrativeExpenses" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NonoperatingIncomeExpense" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_ProfitLoss" order="5.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.gamidacell.com/role/ShareholdersEquityType2or3">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_CommonStockMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_RetainedEarningsMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TreasuryStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_TreasuryStockMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="4.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TreasuryStockValueAcquiredCostMethod" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TreasuryStockSharesRetired" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockSharesRetired"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TreasuryStockSharesRetired" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeBenefitsAndShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeBenefitsAndShareBasedCompensation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EmployeeBenefitsAndShareBasedCompensation" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity_0" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesOutstanding_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding_0" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.gamidacell.com/role/ConsolidatedCashFlow">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_Depreciation" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostsAndExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_CostsAndExpenses" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AmortizationOfFinancingCostsAndDiscounts" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPostemploymentObligations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPostemploymentObligations"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInPostemploymentObligations" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="7.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableTrade" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_0" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IssuanceExpensesOnCredit" xlink:href="gmda-20220331.xsd#gmda_IssuanceExpensesOnCredit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="IssuanceExpensesOnCredit" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_InterestPaidNet" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.gamidacell.com/role/General">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.gamidacell.com/role/SignificantAccountingPolicies">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.gamidacell.com/role/Leases">
    <loc xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.gamidacell.com/role/ConvertibleSeniorNotesNet">
    <loc xlink:type="locator" xlink:label="DisclosureOfNotesAndOtherExplanatoryInformationsExplanatoryAbstract" xlink:href="gmda-20220331.xsd#gmda_DisclosureOfNotesAndOtherExplanatoryInformationsExplanatoryAbstract"/>
    <loc xlink:type="locator" xlink:label="DisclosureOfNotesAndOtherExplanatoryInformationsExplanatoryTextBlock" xlink:href="gmda-20220331.xsd#gmda_DisclosureOfNotesAndOtherExplanatoryInformationsExplanatoryTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfNotesAndOtherExplanatoryInformationsExplanatoryAbstract" xlink:to="DisclosureOfNotesAndOtherExplanatoryInformationsExplanatoryTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.gamidacell.com/role/FairValueMeasurements">
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.gamidacell.com/role/ContingentLiabilitiesandCommitments">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.gamidacell.com/role/ShareholdersEquity">
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.gamidacell.com/role/ShareBasedCompensation">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.gamidacell.com/role/BasicandDilutedNetLossPerShare">
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.gamidacell.com/role/AccountingPoliciesByPolicy">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ConvertibleSeniorNotesPolicyTextBlock" xlink:href="gmda-20220331.xsd#gmda_ConvertibleSeniorNotesPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ConvertibleSeniorNotesPolicyTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.gamidacell.com/role/LeasesTables">
    <loc xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeaseCostTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.gamidacell.com/role/ConvertibleSeniorNotesNetTables">
    <loc xlink:type="locator" xlink:label="DisclosureOfNotesAndOtherExplanatoryInformationsExplanatoryAbstract" xlink:href="gmda-20220331.xsd#gmda_DisclosureOfNotesAndOtherExplanatoryInformationsExplanatoryAbstract"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfLiabilityAndEquityComponentConvertibleNotesTableTextBlock" xlink:href="gmda-20220331.xsd#gmda_ScheduleOfLiabilityAndEquityComponentConvertibleNotesTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfNotesAndOtherExplanatoryInformationsExplanatoryAbstract" xlink:to="ScheduleOfLiabilityAndEquityComponentConvertibleNotesTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.gamidacell.com/role/FairValueMeasurementsTables">
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfFairValueOfMoneyMarketFundsAndMarketableSecuritiesTableTextBlock" xlink:href="gmda-20220331.xsd#gmda_ScheduleOfFairValueOfMoneyMarketFundsAndMarketableSecuritiesTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="ScheduleOfFairValueOfMoneyMarketFundsAndMarketableSecuritiesTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.gamidacell.com/role/ShareBasedCompensationTables">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.gamidacell.com/role/BasicandDilutedNetLossPerShareTables">
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.gamidacell.com/role/ScheduleofoperatingleasecostsTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfOperatingLeaseCostsAbstract" xlink:href="gmda-20220331.xsd#gmda_ScheduleOfOperatingLeaseCostsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOperatingLeaseCostsAbstract" xlink:to="us-gaap_OperatingLeaseCost" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermLeaseCost"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOperatingLeaseCostsAbstract" xlink:to="us-gaap_ShortTermLeaseCost" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCost"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOperatingLeaseCostsAbstract" xlink:to="us-gaap_LeaseCost" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.gamidacell.com/role/ScheduleofoperatingleasesTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfOperatingLeasesAbstract" xlink:href="gmda-20220331.xsd#gmda_ScheduleOfOperatingLeasesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOperatingLeasesAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOperatingLeasesAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.gamidacell.com/role/ScheduleofmaturitiesofleaseliabilitiesTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfMaturitiesOfLeaseLiabilitiesAbstract" xlink:href="gmda-20220331.xsd#gmda_ScheduleOfMaturitiesOfLeaseLiabilitiesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrbGzSS2V9veXLez+Xl0dIVqXQZdaaX7U8iZ3lEvQVQ8yavTR5LGMAC/Y6xtwO1cV8d5LpXjJeLMk6eat28V4VVXVBSb2HOCKvVmZvuAbSKzXyDRkT12vtciTURxwLsQFoRiJcYRfObTSc0gbTBq++/nfodHvEU7EA/LrQkg0k4it0+ht+i+C+b8aTLZ5yhk2mNNFbC3YZimnQ==] CSR-->
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfMaturitiesOfLeaseLiabilitiesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfMaturitiesOfLeaseLiabilitiesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfMaturitiesOfLeaseLiabilitiesAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfMaturitiesOfLeaseLiabilitiesAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDueYearSix" xlink:href="gmda-20220331.xsd#gmda_LesseeOperatingLeaseLiabilityPaymentsDueYearSix"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfMaturitiesOfLeaseLiabilitiesAbstract" xlink:to="LesseeOperatingLeaseLiabilityPaymentsDueYearSix" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDueYearSix" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDueYearSix" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDueYearSix" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PresentValueOfFutureMinimumLeasePaymentsSaleLeasebackTransactions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PresentValueOfFutureMinimumLeasePaymentsSaleLeasebackTransactions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDueYearSix" xlink:to="us-gaap_PresentValueOfFutureMinimumLeasePaymentsSaleLeasebackTransactions" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.gamidacell.com/role/ScheduleofliabilityandequitycomponentsoftheconvertiblenotesTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfLiabilityAndEquityComponentsOfTheConvertibleNotesAbstract" xlink:href="gmda-20220331.xsd#gmda_ScheduleOfLiabilityAndEquityComponentsOfTheConvertibleNotesAbstract"/>
    <loc xlink:type="locator" xlink:label="AmountOfPrincipal" xlink:href="gmda-20220331.xsd#gmda_AmountOfPrincipal"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfLiabilityAndEquityComponentsOfTheConvertibleNotesAbstract" xlink:to="AmountOfPrincipal" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="UnamortizedIssuanceCosts" xlink:href="gmda-20220331.xsd#gmda_UnamortizedIssuanceCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfLiabilityAndEquityComponentsOfTheConvertibleNotesAbstract" xlink:to="UnamortizedIssuanceCosts" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NetIssuanceCosts" xlink:href="gmda-20220331.xsd#gmda_NetIssuanceCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfLiabilityAndEquityComponentsOfTheConvertibleNotesAbstract" xlink:to="NetIssuanceCosts" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfFinancingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfLiabilityAndEquityComponentsOfTheConvertibleNotesAbstract" xlink:to="us-gaap_AmortizationOfFinancingCosts" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NetCarryingAmountincludingAccruedInterest" xlink:href="gmda-20220331.xsd#gmda_NetCarryingAmountincludingAccruedInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfLiabilityAndEquityComponentsOfTheConvertibleNotesAbstract" xlink:to="NetCarryingAmountincludingAccruedInterest" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.gamidacell.com/role/ScheduleoffairvalueofmoneymarketfundsandmarketablesecuritiesTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfFairValueOfMoneyMarketFundsAndMarketableSecuritiesAbstract" xlink:href="gmda-20220331.xsd#gmda_ScheduleOfFairValueOfMoneyMarketFundsAndMarketableSecuritiesAbstract"/>
    <loc xlink:type="locator" xlink:label="FairValueMeasurementsDetailsScheduleoffairvalueofmoneymarketfundsandmarketablesecuritiesTable" xlink:href="gmda-20220331.xsd#gmda_FairValueMeasurementsDetailsScheduleoffairvalueofmoneymarketfundsandmarketablesecuritiesTable"/>
    <loc xlink:type="locator" xlink:label="FairValueMeasurementsDetailsScheduleoffairvalueofmoneymarketfundsandmarketablesecuritiesLineItems" xlink:href="gmda-20220331.xsd#gmda_FairValueMeasurementsDetailsScheduleoffairvalueofmoneymarketfundsandmarketablesecuritiesLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFairValueOfMoneyMarketFundsAndMarketableSecuritiesAbstract" xlink:to="FairValueMeasurementsDetailsScheduleoffairvalueofmoneymarketfundsandmarketablesecuritiesTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueMeasurementsDetailsScheduleoffairvalueofmoneymarketfundsandmarketablesecuritiesTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueInputsLevel1Member" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueInputsLevel2Member" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueMeasurementsDetailsScheduleoffairvalueofmoneymarketfundsandmarketablesecuritiesTable" xlink:to="FairValueMeasurementsDetailsScheduleoffairvalueofmoneymarketfundsandmarketablesecuritiesLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="CashEquivalentsAbstract" xlink:href="gmda-20220331.xsd#gmda_CashEquivalentsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueMeasurementsDetailsScheduleoffairvalueofmoneymarketfundsandmarketablesecuritiesLineItems" xlink:to="CashEquivalentsAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MoneyMarketFundsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsAtCarryingValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CashEquivalentsAbstract" xlink:to="us-gaap_MoneyMarketFundsAtCarryingValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueMeasurementsDetailsScheduleoffairvalueofmoneymarketfundsandmarketablesecuritiesLineItems" xlink:to="us-gaap_MarketableSecuritiesAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CorporateDebentures" xlink:href="gmda-20220331.xsd#gmda_CorporateDebentures"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesAbstract" xlink:to="CorporateDebentures" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="GovernmentDebentures" xlink:href="gmda-20220331.xsd#gmda_GovernmentDebentures"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesAbstract" xlink:to="GovernmentDebentures" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueNetAssetLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueNetAssetLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesAbstract" xlink:to="us-gaap_FairValueNetAssetLiability" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.gamidacell.com/role/ScheduleoffairvaluemeasurementofequitysettledshareoptionsTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfFairValueMeasurementOfEquitySettledShareOptionsAbstract" xlink:href="gmda-20220331.xsd#gmda_ScheduleOfFairValueMeasurementOfEquitySettledShareOptionsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFairValueMeasurementOfEquitySettledShareOptionsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFairValueMeasurementOfEquitySettledShareOptionsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFairValueMeasurementOfEquitySettledShareOptionsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFairValueMeasurementOfEquitySettledShareOptionsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.gamidacell.com/role/ScheduleofstockoptionplansTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfStockOptionPlansAbstract" xlink:href="gmda-20220331.xsd#gmda_ScheduleOfStockOptionPlansAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionPlansAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionPlansAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrosses" xlink:href="gmda-20220331.xsd#gmda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrosses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionPlansAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrosses" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionPlansAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="StockIssuedDuringPeriodSharesStockOptionesExercised" xlink:href="gmda-20220331.xsd#gmda_StockIssuedDuringPeriodSharesStockOptionesExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionPlansAbstract" xlink:to="StockIssuedDuringPeriodSharesStockOptionesExercised" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionPlansAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriods" xlink:href="gmda-20220331.xsd#gmda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriods"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionPlansAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriods" order="6.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionPlansAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionPlansAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" order="8.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionPlansAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionPlansAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionPlansAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableInPeriod" xlink:href="gmda-20220331.xsd#gmda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableInPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionPlansAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableInPeriod" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisableInPeriodWeightedAverageExercisePrice" xlink:href="gmda-20220331.xsd#gmda_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisableInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionPlansAbstract" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisableInPeriodWeightedAverageExercisePrice" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.gamidacell.com/role/ScheduleofrestrictedsharesactivityTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfRestrictedSharesActivityAbstract" xlink:href="gmda-20220331.xsd#gmda_ScheduleOfRestrictedSharesActivityAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfRestrictedSharesActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfRestrictedSharesActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfRestrictedSharesActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfRestrictedSharesActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfRestrictedSharesActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodIntrinsicValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfRestrictedSharesActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodIntrinsicValue" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfRestrictedSharesActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="6.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfRestrictedSharesActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfRestrictedSharesActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_0" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue_0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfRestrictedSharesActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue_0" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.gamidacell.com/role/ScheduleofsharebasedcompensationexpenseTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfShareBasedCompensationExpenseAbstract" xlink:href="gmda-20220331.xsd#gmda_ScheduleOfShareBasedCompensationExpenseAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareBasedCompensationExpenseAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CostsAndExpensesRelatedParty" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpensesRelatedParty"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareBasedCompensationExpenseAbstract" xlink:to="us-gaap_CostsAndExpensesRelatedParty" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareBasedCompensationExpenseAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareBasedCompensationExpenseAbstract" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.gamidacell.com/role/ScheduleofnumberofsharesandlossusedinthecomputationofnetlosspershareTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfNumberOfSharesAndLossUsedInTheComputationOfNetLossPerShareAbstract" xlink:href="gmda-20220331.xsd#gmda_ScheduleOfNumberOfSharesAndLossUsedInTheComputationOfNetLossPerShareAbstract"/>
    <loc xlink:type="locator" xlink:label="BasicandDilutedNetLossPerShareDetailsScheduleofnumberofsharesandlossusedinthecomputationofnetlosspershareTable" xlink:href="gmda-20220331.xsd#gmda_BasicandDilutedNetLossPerShareDetailsScheduleofnumberofsharesandlossusedinthecomputationofnetlosspershareTable"/>
    <loc xlink:type="locator" xlink:label="BasicandDilutedNetLossPerShareDetailsScheduleofnumberofsharesandlossusedinthecomputationofnetlosspershareLineItems" xlink:href="gmda-20220331.xsd#gmda_BasicandDilutedNetLossPerShareDetailsScheduleofnumberofsharesandlossusedinthecomputationofnetlosspershareLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfNumberOfSharesAndLossUsedInTheComputationOfNetLossPerShareAbstract" xlink:to="BasicandDilutedNetLossPerShareDetailsScheduleofnumberofsharesandlossusedinthecomputationofnetlosspershareTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="LossPerShareAxis" xlink:href="gmda-20220331.xsd#gmda_LossPerShareAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BasicandDilutedNetLossPerShareDetailsScheduleofnumberofsharesandlossusedinthecomputationofnetlosspershareTable" xlink:to="LossPerShareAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ForTheComputationOfDilutedLossMember" xlink:href="gmda-20220331.xsd#gmda_ForTheComputationOfDilutedLossMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LossPerShareAxis" xlink:to="ForTheComputationOfDilutedLossMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BasicandDilutedNetLossPerShareDetailsScheduleofnumberofsharesandlossusedinthecomputationofnetlosspershareTable" xlink:to="BasicandDilutedNetLossPerShareDetailsScheduleofnumberofsharesandlossusedinthecomputationofnetlosspershareLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="WeightedAverageNumberOfSharesOutstandingBasicAndDiluted" xlink:href="gmda-20220331.xsd#gmda_WeightedAverageNumberOfSharesOutstandingBasicAndDiluted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BasicandDilutedNetLossPerShareDetailsScheduleofnumberofsharesandlossusedinthecomputationofnetlosspershareLineItems" xlink:to="WeightedAverageNumberOfSharesOutstandingBasicAndDiluted" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="BasicandDilutedNetLossPerShareDetailsScheduleofnumberofsharesandlossusedinthecomputationofnetlosspershareLineItems" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.gamidacell.com/role/GeneralDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="ResponseRatePercentage" xlink:href="gmda-20220331.xsd#gmda_ResponseRatePercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ResponseRatePercentage" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ClinicalTrialOnOutcomes" xlink:href="gmda-20220331.xsd#gmda_ClinicalTrialOnOutcomes"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ClinicalTrialOnOutcomes" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AccumulatedDeficit" xlink:href="gmda-20220331.xsd#gmda_AccumulatedDeficit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="AccumulatedDeficit" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentsAndCash" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsAndCash"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InvestmentsAndCash" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NumberOfOperatingSegments" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.gamidacell.com/role/LeasesDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.gamidacell.com/role/ConvertibleSeniorNotesNetDetails">
    <loc xlink:type="locator" xlink:label="DisclosureOfNotesAndOtherExplanatoryInformationsExplanatoryAbstract" xlink:href="gmda-20220331.xsd#gmda_DisclosureOfNotesAndOtherExplanatoryInformationsExplanatoryAbstract"/>
    <loc xlink:type="locator" xlink:label="ConvertibleSeniorNotesNetDetailsTable" xlink:href="gmda-20220331.xsd#gmda_ConvertibleSeniorNotesNetDetailsTable"/>
    <loc xlink:type="locator" xlink:label="ConvertibleSeniorNotesNetDetailsLineItems" xlink:href="gmda-20220331.xsd#gmda_ConvertibleSeniorNotesNetDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfNotesAndOtherExplanatoryInformationsExplanatoryAbstract" xlink:to="ConvertibleSeniorNotesNetDetailsTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleSeniorNotesNetDetailsTable" xlink:to="us-gaap_ShortTermDebtTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ShortTermDebtTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleNotesPayableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleNotesPayableMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtTypeAxis" xlink:to="us-gaap_ConvertibleNotesPayableMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleSeniorNotesNetDetailsTable" xlink:to="ConvertibleSeniorNotesNetDetailsLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="PrincipalAmount" xlink:href="gmda-20220331.xsd#gmda_PrincipalAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleSeniorNotesNetDetailsLineItems" xlink:to="PrincipalAmount" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AnnualInterestPercentage" xlink:href="gmda-20220331.xsd#gmda_AnnualInterestPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleSeniorNotesNetDetailsLineItems" xlink:to="AnnualInterestPercentage" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentConvertibleConversionDate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleConversionDate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleSeniorNotesNetDetailsLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleConversionDate" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleNotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleNotesPayable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleSeniorNotesNetDetailsLineItems" xlink:to="us-gaap_ConvertibleNotesPayable" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TemporaryEquitySharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquitySharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleSeniorNotesNetDetailsLineItems" xlink:to="us-gaap_TemporaryEquitySharesIssued" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertibleNotesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleNotesPayableCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleSeniorNotesNetDetailsLineItems" xlink:to="us-gaap_ConvertibleNotesPayableCurrent" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleSeniorNotesNetDetailsLineItems" xlink:to="us-gaap_SharePrice" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleSeniorNotesNetDetailsLineItems" xlink:to="us-gaap_DebtInstrumentRedemptionPricePercentage" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExchangePricePercentage" xlink:href="gmda-20220331.xsd#gmda_ExchangePricePercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleSeniorNotesNetDetailsLineItems" xlink:to="ExchangePricePercentage" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleSeniorNotesNetDetailsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentInterestRateBasisForEffectiveRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateBasisForEffectiveRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConvertibleSeniorNotesNetDetailsLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateBasisForEffectiveRate" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.gamidacell.com/role/ContingentLiabilitiesandCommitmentsDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="ContingentLiabilitiesandCommitmentsDetailsTable" xlink:href="gmda-20220331.xsd#gmda_ContingentLiabilitiesandCommitmentsDetailsTable"/>
    <loc xlink:type="locator" xlink:label="ContingentLiabilitiesandCommitmentsDetailsLineItems" xlink:href="gmda-20220331.xsd#gmda_ContingentLiabilitiesandCommitmentsDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="ContingentLiabilitiesandCommitmentsDetailsTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ContingentLiabilitiesandCommitmentsDetailsTable" xlink:to="srt_RangeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ContingentLiabilitiesandCommitmentsDetailsTable" xlink:to="ContingentLiabilitiesandCommitmentsDetailsLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RoyaltyGuaranteesCommitmentsAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RoyaltyGuaranteesCommitmentsAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ContingentLiabilitiesandCommitmentsDetailsLineItems" xlink:to="us-gaap_RoyaltyGuaranteesCommitmentsAmount" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BorrowingsUnderGuaranteedInvestmentAgreements" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BorrowingsUnderGuaranteedInvestmentAgreements"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ContingentLiabilitiesandCommitmentsDetailsLineItems" xlink:to="us-gaap_BorrowingsUnderGuaranteedInvestmentAgreements" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GrantsReceivableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrantsReceivableCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ContingentLiabilitiesandCommitmentsDetailsLineItems" xlink:to="us-gaap_GrantsReceivableCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RoyaltyExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RoyaltyExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ContingentLiabilitiesandCommitmentsDetailsLineItems" xlink:to="us-gaap_RoyaltyExpense" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AmortizationOfAdvanceRoyalty" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfAdvanceRoyalty"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ContingentLiabilitiesandCommitmentsDetailsLineItems" xlink:to="us-gaap_AmortizationOfAdvanceRoyalty" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DerivativeForwardInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeForwardInterestRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ContingentLiabilitiesandCommitmentsDetailsLineItems" xlink:to="us-gaap_DerivativeForwardInterestRate" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ContingentLiabilitiesandCommitmentsDetailsLineItems" xlink:to="us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GrantsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrantsReceivable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ContingentLiabilitiesandCommitmentsDetailsLineItems" xlink:to="us-gaap_GrantsReceivable" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.gamidacell.com/role/ShareholdersEquityDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <loc xlink:type="locator" xlink:label="ShareholdersEquityDetailsTable" xlink:href="gmda-20220331.xsd#gmda_ShareholdersEquityDetailsTable"/>
    <loc xlink:type="locator" xlink:label="ShareholdersEquityDetailsLineItems" xlink:href="gmda-20220331.xsd#gmda_ShareholdersEquityDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="ShareholdersEquityDetailsTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsTable" xlink:to="us-gaap_InvestmentTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentTypeCategorizationMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestorMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestorMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestorMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_WarrantMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsTable" xlink:to="ShareholdersEquityDetailsLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="UnderwritersDescription" xlink:href="gmda-20220331.xsd#gmda_UnderwritersDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="UnderwritersDescription" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExpiryDate" xlink:href="gmda-20220331.xsd#gmda_ExpiryDate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="ExpiryDate" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.gamidacell.com/role/ShareBasedCompensationDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationDetailsTable" xlink:href="gmda-20220331.xsd#gmda_ShareBasedCompensationDetailsTable"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationDetailsLineItems" xlink:href="gmda-20220331.xsd#gmda_ShareBasedCompensationDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="ShareBasedCompensationDetailsTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonClassCMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassCMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_CommonClassCMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationDetailsTable" xlink:to="srt_RangeAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationDetailsTable" xlink:to="us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis" xlink:to="us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="TwoZeroOneFourIsraelShareOptionPlanMember" xlink:href="gmda-20220331.xsd#gmda_TwoZeroOneFourIsraelShareOptionPlanMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis" xlink:to="TwoZeroOneFourIsraelShareOptionPlanMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="TwoThousandSeventeenStockCompensationPlanMember" xlink:href="gmda-20220331.xsd#gmda_TwoThousandSeventeenStockCompensationPlanMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis" xlink:to="TwoThousandSeventeenStockCompensationPlanMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationDetailsTable" xlink:to="ShareBasedCompensationDetailsLineItems" order="4.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationDetailsLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPNumberOfAllocatedShares" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOwnershipPlanESOPNumberOfAllocatedShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationDetailsLineItems" xlink:to="us-gaap_EmployeeStockOwnershipPlanESOPNumberOfAllocatedShares" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPNumberOfSuspenseShares" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOwnershipPlanESOPNumberOfSuspenseShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationDetailsLineItems" xlink:to="us-gaap_EmployeeStockOwnershipPlanESOPNumberOfSuspenseShares" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationDetailsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationDetailsLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OrdinarySharesOutstandingPercentage" xlink:href="gmda-20220331.xsd#gmda_OrdinarySharesOutstandingPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationDetailsLineItems" xlink:to="OrdinarySharesOutstandingPercentage" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationDetailsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.gamidacell.com/role/DocumentAndEntityInformation">
    <loc xlink:type="locator" xlink:label="DocumentAndEntityInformationAbstract" xlink:href="gmda-20220331.xsd#gmda_DocumentAndEntityInformationAbstract"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationTable" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationTable"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentInformationTable" order="1.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationLineItems" order="1.0"/>
    <loc xlink:type="locator" xlink:label="dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCurrentReportingStatus" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntitySmallBusiness" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityShellCompany" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityExTransitionPeriod" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityExTransitionPeriod" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentQuarterlyReport" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentTransitionReport" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityTaxIdentificationNumber" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" order="24.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" order="25.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" order="26.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_Security12bTitle" order="27.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SecurityExchangeName" order="28.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityInteractiveDataCurrent" order="29.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140194444168456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document And Entity Information - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>May 09, 2022</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">GAMIDA CELL LTD.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">GMDA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59,946,298<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001600847<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38716<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">L3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">00-0000000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">116 Huntington Avenue<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Boston<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02116<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(617)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">892-9080<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Ordinary Shares, par value NIS 0.01 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140194446221224">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 42,057<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 55,892<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">27,661<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">40,034<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">2,994<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">2,688<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">72,712<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">98,614<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsNoncurrentAbstract', window );"><strong>Non-current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedInvestmentsNoncurrent', window );">Restricted deposits</a></td>
<td class="nump">3,893<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">3,961<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">37,533<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">35,180<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">6,722<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">7,236<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLongTermInvestments', window );">Severance pay fund</a></td>
<td class="nump">2,046<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">2,148<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other long-term assets</a></td>
<td class="nump">1,632<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,647<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsNoncurrent', window );">Total non-current assets</a></td>
<td class="nump">51,826<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">50,172<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">124,538<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">148,786<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Trade payables</a></td>
<td class="nump">4,346<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">8,272<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Employees and payroll accruals</a></td>
<td class="nump">4,119<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">4,957<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities</a></td>
<td class="nump">2,596<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">2,699<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Accrued interest of convertible senior notes</a></td>
<td class="nump">551<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,640<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">8,866<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">7,865<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">20,478<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">25,433<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Non-current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleLongTermNotesPayable', window );">Convertible senior notes, net</a></td>
<td class="nump">71,607<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">71,417<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesNoncurrent', window );">Accrued severance pay</a></td>
<td class="nump">2,327<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">2,396<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term operating lease liabilities</a></td>
<td class="nump">5,142<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">5,603<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">Total non-current liabilities</a></td>
<td class="nump">79,076<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">79,416<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Contingent liabilities and commitments</a></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Shareholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Ordinary shares NIS 0.01 par value; 150,000,000 shares authorized at March 31, 2022 (unaudited) and December 31, 2021; 60,021,415 and 59,970,389 shares issued at March 31, 2022 (unaudited) and December 31, 2021, respectively; 59,946,298 and 59,970,389 shares outstanding as of March 31, 2022 (unaudited) and December 31, 2021, respectively</a></td>
<td class="nump">169<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">169<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Treasury ordinary shares of NIS 0.01 par value; 75,117 and 0 shares at March 31, 2022 (unaudited) and December 31, 2021 respectively.</a></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">382,495<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">381,225<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated deficit</a></td>
<td class="num">(357,680)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(337,457)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Shareholders&#8217; Equity</a></td>
<td class="nump">24,984<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">43,937<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total Liabilities and Shareholders&#8217; Equity</a></td>
<td class="nump">$ 124,538<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 148,786<span></span>
</td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">represents an amount lower than $1.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleLongTermNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of long-term debt (with maturities initially due after one year or beyond the operating cycle if longer) identified as Convertible Notes Payable, excluding current portion. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleLongTermNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(26))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLongTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term investments classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.1(f))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLongTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedInvestmentsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the noncurrent portion of investments which are not defined as or included in marketable (debt, equity, or other) securities that are pledged or subject to withdrawal restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL6242262-115580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=127002003&amp;loc=SL6242269-115581<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedInvestmentsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23315-112656<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140194446246664">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Unaudited) (Parentheticals) - &#8362; / shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Ordinary shares par value (in New Shekels per share)</a></td>
<td class="nump">&#8362; 0.01<span></span>
</td>
<td class="nump">&#8362; 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Ordinary shares authorized</a></td>
<td class="nump">150,000,000<span></span>
</td>
<td class="nump">150,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ordinary shares Issued</a></td>
<td class="nump">60,021,415<span></span>
</td>
<td class="nump">59,970,389<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ordinary shares outstanding</a></td>
<td class="nump">59,946,298<span></span>
</td>
<td class="nump">59,970,389<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Treasury ordinary shares par value</a></td>
<td class="nump">0.01<span></span>
</td>
<td class="nump">0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockShares', window );">Treasury ordinary shares</a></td>
<td class="nump">75,117<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140194444134296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operation (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gmda_ResearchAndDevelopmentExpensesNet', window );">Research and development expenses, net</a></td>
<td class="nump">$ 11,305<span></span>
</td>
<td class="nump">$ 11,360<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gmda_CommercialExpenses', window );">Commercial expenses</a></td>
<td class="nump">3,879<span></span>
</td>
<td class="nump">4,231<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gmda_GeneralAndAdministrativeExpenses', window );">General and administrative expenses</a></td>
<td class="nump">4,139<span></span>
</td>
<td class="nump">3,513<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Total operating loss</a></td>
<td class="nump">19,323<span></span>
</td>
<td class="nump">19,104<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Financial expenses, net</a></td>
<td class="nump">900<span></span>
</td>
<td class="nump">82<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Loss</a></td>
<td class="nump">$ 20,223<span></span>
</td>
<td class="nump">$ 19,186<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share attributable to ordinary shareholders, basic and diluted (in Dollars per share)</a></td>
<td class="nump">$ 0.34<span></span>
</td>
<td class="nump">$ 0.32<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average number of shares used in computing net loss per share attributable to ordinary shareholders, basic and diluted (in Shares)</a></td>
<td class="nump">59,474,366<span></span>
</td>
<td class="nump">59,122,973<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gmda_CommercialExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of commercial expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gmda_CommercialExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gmda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gmda_GeneralAndAdministrativeExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>General and administrative expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gmda_GeneralAndAdministrativeExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gmda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gmda_ResearchAndDevelopmentExpensesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research and development expenses, net.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gmda_ResearchAndDevelopmentExpensesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gmda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140194444293624">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Changes in Shareholders&#8217; Equity (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2"><div>Ordinary shares</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Accumulated deficit</div></th>
<th class="th"><div>Treasury shares</div></th>
<th class="th"><sup>[1]</sup></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2020</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 166<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 376,369<span></span>
</td>
<td class="num">$ (247,664)<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="nump">$ 128,871<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Dec. 31, 2020</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">59,000,153<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures', window );">Grant of restricted shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Grant of restricted shares (in Shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">159,134<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of options</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 1<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">501<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="nump">502<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of options (in Shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">247,685<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeBenefitsAndShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">913<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="nump">913<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(19,186)<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="num">(19,186)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2021</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 167<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">377,783<span></span>
</td>
<td class="num">(266,850)<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="nump">111,100<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Mar. 31, 2021</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">59,406,972<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2021</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 169<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">381,225<span></span>
</td>
<td class="num">(337,457)<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="nump">43,937<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Dec. 31, 2021</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">59,970,389<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures', window );">Grant of restricted shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Grant of restricted shares (in Shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,600<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Treasury shares</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesRetired', window );">Treasury shares (in Shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(75,117)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of options</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">76<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="nump">76<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of options (in Shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">47,426<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeBenefitsAndShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,194<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="nump">1,194<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(20,223)<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="num">(20,223)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Mar. 31, 2022</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 169<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 382,495<span></span>
</td>
<td class="num">$ (357,680)<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
<td class="nump">$ 24,984<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Mar. 31, 2022</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">59,946,298<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="8"></td></tr>
<tr><td colspan="8"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Represents an amount lower than $1.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeBenefitsAndShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for employee benefit and equity-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeBenefitsAndShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock related to Restricted Stock Awards forfeited during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockSharesRetired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common and preferred stock retired from treasury during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockSharesRetired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValueAcquiredCostMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValueAcquiredCostMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140194445423256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash Flows From Operating Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Loss</a></td>
<td class="num">$ (20,223)<span></span>
</td>
<td class="num">$ (19,186)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustment to reconcile loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation of property, plant and equipment</a></td>
<td class="nump">112<span></span>
</td>
<td class="nump">98<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Financing expense (income), net</a></td>
<td class="num">(1,172)<span></span>
</td>
<td class="nump">220<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">1,194<span></span>
</td>
<td class="nump">913<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Amortization of issuance costs</a></td>
<td class="nump">191<span></span>
</td>
<td class="nump">323<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Operating lease right-of-use assets</a></td>
<td class="nump">562<span></span>
</td>
<td class="nump">516<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="num">(613)<span></span>
</td>
<td class="num">(929)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPostemploymentObligations', window );">Accrued severance pay, net</a></td>
<td class="nump">33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Increase in prepaid expenses and other assets</a></td>
<td class="num">(889)<span></span>
</td>
<td class="num">(515)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableTrade', window );">Increase (decrease) in trade payables</a></td>
<td class="num">(3,927)<span></span>
</td>
<td class="nump">907<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Decrease in accrued expenses and current liabilities</a></td>
<td class="num">(996)<span></span>
</td>
<td class="num">(3,192)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(25,728)<span></span>
</td>
<td class="num">(20,845)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash Flows From Investing Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property, plant and equipment</a></td>
<td class="num">(723)<span></span>
</td>
<td class="num">(2,806)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Purchase of marketable securities</a></td>
<td class="num">(2,086)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities', window );">Proceeds from maturity of marketable securities</a></td>
<td class="nump">14,126<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Proceeds from restricted deposits</a></td>
<td class="nump">500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by (used in) investing activities</a></td>
<td class="nump">11,817<span></span>
</td>
<td class="num">(2,806)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash Flows From Financing Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of options</a></td>
<td class="nump">76<span></span>
</td>
<td class="nump">502<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of convertible senior notes, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70,777<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">76<span></span>
</td>
<td class="nump">71,279<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect', window );">Increase (decrease) in cash and cash equivalents</a></td>
<td class="num">(13,835)<span></span>
</td>
<td class="nump">47,628<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash and cash equivalents at beginning of period</a></td>
<td class="nump">55,892<span></span>
</td>
<td class="nump">127,170<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash and cash equivalents at end of period</a></td>
<td class="nump">42,057<span></span>
</td>
<td class="nump">174,798<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Significant non-cash transactions:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gmda_IssuanceExpensesOnCredit', window );">Issuance expenses on credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">235<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Purchase of property, plant and equipment on credit</a></td>
<td class="nump">1,160<span></span>
</td>
<td class="nump">$ 216<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosures of cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="nump">$ 2,203<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gmda_IssuanceExpensesOnCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance expenses on credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gmda_IssuanceExpensesOnCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gmda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69F<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495745-112612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableTrade">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableTrade</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPostemploymentObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the current portion of the liability that represents various benefits due to former or inactive employees, their beneficiaries, and covered dependents after employment but before retirement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPostemploymentObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for purchase of marketable security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140194449506696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>General<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">GENERAL</a></td>
<td class="text"><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2cm; text-align: justify; text-indent: -2cm">NOTE 1:- GENERAL</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2cm; text-align: justify; text-indent: 0cm">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.75in"/><td style="width: 0.5in; text-align: left"><span style="font-size: 10pt">a.</span></td><td style="text-align: justify">Gamida
                                            Cell Ltd. (the &#8220;Company&#8221;), founded in 1998, is an advanced cell therapy company
                                            committed to cures for blood cancers and serious hematologic diseases. The Company harnesses
                                            its cell expansion platform to create therapies with the potential to redefine standards
                                            of care in areas of serious medical need</td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3cm; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top">
<td style="width: 0.75in"/><td style="width: 0.5in">b.</td><td style="text-align: justify">The Company has leveraged its NAM platform,
                                            or nicotinamide cell expansion technology platform, to develop a pipeline of product candidates
                                            designed to address the limitations of other cell therapies. The Company&#8217;s proprietary
                                            technology allows for the proliferation and enhancement of donor cells, which allows for
                                            maintenance of the cells&#8217; functional therapeutic characteristics, providing a potential
                                            treatment alternative for patients.</td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3cm; text-align: justify; text-indent: -1cm">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The lead product candidate, omidubicel,
is an advanced cell therapy in development as a potential life-saving treatment option for patients in need of a bone marrow transplant
(BMT). In May 2020, the Company reported that omidubicel met its primary endpoint in an international, randomized, multi-center Phase
3 clinical study in 125 patients with high-risk hematologic malignancies undergoing bone marrow transplant and who had no available matched
donor. The study evaluated the safety and efficacy of omidubicel compared to standard umbilical cord blood. BMT with a graft derived
from bone marrow or peripheral blood cells of a matched donor is currently the standard of care treatment for many of these patients,
but there is a significant unmet need for patients who cannot find a fully matched donor.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3cm; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">In October 2021, the complete results
from the Company&#8217;s pivotal Phase 3 clinical study of omidubicel in 125 patients with various hematologic malignancies were published
in the peer-reviewed medical journal Blood. The trial achieved its primary endpoint of time to neutrophil engraftment as well as all
three of the prespecified secondary endpoints. These secondary endpoints were the proportion of patients who achieved platelet engraftment
by day 42, the proportion of patients with grade 2 or grade 3 bacterial or invasive fungal infections in the first 100 days following
transplant, and the number of days alive and out of the hospital in the first 100 days following transplant. All three secondary endpoints
demonstrated statistical significance in an intent-to-treat analysis.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3cm; text-align: justify; text-indent: 0cm">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Omidubicel is the first bone marrow
transplant product to receive Breakthrough Therapy Designation from the U.S. Food and Drug Administration and has received orphan drug
designation in the U.S. and in Europe.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3cm; text-align: justify; text-indent: 0cm">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">In addition to omidubicel, the Company
is developing GDA-201, an investigational natural killer (&#8220;NK&#8221;) cell-based cancer immunotherapy that is intended to be used
in combination with standard-of-care therapeutic antibodies, as well as other product candidates in the Company&#8217;s NK cell pipeline.
NK cells have potent anti-tumor properties and have the advantage over other oncology cell therapies of not requiring genetic matching,
potentially enabling NK cells to serve as a universal donor-based therapy when combined with certain antibodies. GDA-201 is currently
in an investigator-sponsored Phase 1/2 study for the treatment of relapsed or refractory non-Hodgkin lymphoma (NHL). Data from the 35
patients in the Phase 1/2 study demonstrated that GDA-201 was clinically active and generally well tolerated. Among the 19 patients with
NHL, 13 complete responses and one partial response were observed, with an overall response rate of 74% and a complete response rate
of 68%.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3cm; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">At the December 2021 Annual Meeting
of America Society of Hematology, the Company reported two-year follow-up data from this clinical trial on outcomes and cytokine biomarkers
associated with survival. The data demonstrated a median duration of response of 16 months (range 5-36 months), an overall survival at
two years of 78% (95% CI, 51%&#8211;91%) and a safety profile similar to that reported previously.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3cm; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top">
<td style="width: 0.75in"/><td style="width: 0.5in">c.</td><td style="text-align: justify">Basis of presentation of the financial
                                            statements:</td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3cm; text-align: justify; text-indent: 0cm">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The accompanying unaudited condensed
consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States
of America (&#8220;U.S. GAAP&#8221;) for interim financial information and in accordance with the instructions to Form 10-Q and Article
10 of Regulation S-X promulgated by the U.S Securities and Exchange Commission (the &#8220;SEC&#8221;). Certain information or footnote
disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted, pursuant
to the rules and regulations of the SEC for interim financial reporting. Accordingly, they do not include all the information and footnotes
necessary for a complete presentation of financial position, results of operations, or cash flows. In the opinion of management, the
accompanying unaudited condensed consolidated financial statements include all adjustments, consisting of a normal recurring nature,
which are necessary for a fair presentation of the financial position, operating results and cash flows for the periods presented.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3cm; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The accompanying unaudited condensed
consolidated financial statements should be read in conjunction with the Company&#8217;s Annual Report on Form 10-K as of December 31,
2021 filed with the SEC on March 24, 2022. The interim period results do not necessarily indicate the results that may be expected for
any other interim period or for the full fiscal year.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3cm; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Prior to 2021, the Company prepared
its financial statements in accordance with International Financial Reporting Standards (IFRS), as issued by the International Accounting
Standards Board (IASB), as permitted in the United States based on the Company&#8217;s qualification as a &#8220;foreign private issuer&#8221;
under the rules and regulations of the SEC. In connection with the loss of the Company&#8217;s status as a foreign private issuer effective
on January 1, 2022, the Company, as a domestic filer, prepared its consolidated financial statements in accordance with U.S. GAAP.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3cm; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.75in"/><td style="width: 0.5in; text-align: left">d.</td><td style="text-align: justify">The Company continues to devote substantially all of its efforts toward
research and development activities. In the course of such activities, the Company has sustained operating losses and expects such losses
to continue in the foreseeable future. The Company's accumulated deficit as of March&#160;31, 2022 was $357,680 and negative cash flows
from operating activities during the three-month period ended March 31, 2022 was $25,728. The Company is planning to finance its operations
from its existing and future working capital resources and to continue to evaluate additional sources of capital and financing. However,
there is no assurance that additional capital and/or financing will be available to the Company, and even if available, whether it will
be on terms acceptable to the Company or in amounts required. The Company believes that its existing capital resources will be adequate
to satisfy its expected liquidity requirements for at least twelve months from the issuance of the condensed consolidated financial statements.</td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3cm; text-align: justify; text-indent: -1cm"><b>&#160;</b></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top">
<td style="width: 0.75in"/><td style="width: 0.5in">e.</td><td style="text-align: justify">The Company has a wholly owned U.S. subsidiary, Gamida Cell Inc. (the &#8220;Subsidiary&#8221;), which was incorporated in 2000, under the laws of the State of Delaware. The Company has one operating segment and reporting unit.</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI https://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI https://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140194449506696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text"><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0cm">NOTE 2:- SIGNIFICANT ACCOUNTING
POLICIES</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top">
<td style="width: 0.75in"/><td style="width: 0.5in">a.</td><td>Use of estimates:</td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3cm; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The preparation of condensed financial
statements in conformity with U.S. GAAP requires management to make estimates, judgments and assumptions that affect the amounts reported
in the consolidated financial statements and accompanying notes. The Company&#8217;s management believes that the estimates, judgment
and assumptions used are reasonable based upon information available at the time they are made. These estimates, judgments and assumptions
can affect the reported amounts of assets and liabilities at the dates of the consolidated financial statements, and the reported amount
of expenses during the reporting periods. Actual results could differ from those estimates.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top">
<td style="width: 0.75in"/><td style="width: 0.5in">b.</td><td>Convertible senior notes:</td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.85pt; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The Company accounts for its convertible
senior notes in accordance with ASC 470-20 &#8220;Debt with Conversion and Other Options&#8221;. The Company early adopted ASU 2020-06
using the modified retrospective approach. The convertible senior notes are accounted for as a single liability measured at its amortized
cost, as no other embedded features require bifurcation and recognition as derivatives according to ASC 815-40.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top">
<td style="width: 0.75in"/><td style="width: 0.5in">c.</td><td>Basic and diluted net loss per share:</td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 88.85pt; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The Company computes net loss per
share using the&#160;two-class&#160;method required for participating securities. The&#160;two-class&#160;method requires income available
to ordinary shareholders for the period to be allocated between ordinary shares and participating securities based upon their respective
rights to receive dividends as if all income for the period had been distributed. The Company considers its restricted shares to be participating
securities as the holders of the restricted shares would be entitled to dividends that would be distributed to the holders of ordinary
shares, on a&#160;pro-rata&#160;basis. These participating securities do not contractually require the holders of such shares to participate
in the Company&#8217;s losses. As such, net loss for the periods presented was not allocated to the Company&#8217;s participating securities.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 84.45pt; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The Company&#8217;s basic net loss
per share is calculated by dividing net loss attributable to ordinary shareholders by the weighted-average number of shares of ordinary
shares outstanding for the period, without consideration of potentially dilutive securities. The diluted net loss per share is calculated
by giving effect to all potentially dilutive securities outstanding for the period using the treasury share method or the&#160;if-converted&#160;method
based on the nature of such securities. Diluted net loss per share is the same as basic net loss per share in periods when the effects
of potentially dilutive ordinary shares are anti-dilutive.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140194446555176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">LEASES</a></td>
<td class="text"><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0cm">NOTE 3:-	LEASES</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 74.7pt; text-align: justify; text-indent: 0cm"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The Company entered into operating
leases primarily for its production plant, and its laboratories and offices. The leases have remaining lease terms of up&#160;to&#160;six
years, and the Company does not assume renewals in its determination of the lease term unless the renewals are considered as reasonably
certain at lease commencement.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2cm; text-align: justify; text-indent: 0cm">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The components of operating lease
costs were as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3cm 0pt 0; text-align: justify; text-indent: 0cm">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; padding-left: 0pt; text-indent: 0pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Three months ended<br/>
    March 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; padding-left: 0pt; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2022</b></span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2021</b></span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0pt; text-indent: 0pt">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: 0pt; padding-left: 0pt">Operating lease costs</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">636</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">585</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: 0pt; padding-left: 0pt">Short-term lease costs</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">24</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">60</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: 0pt; padding-left: 0pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: 0pt; padding-left: 0pt">Total lease costs</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">660</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">645</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3cm"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Supplemental balance sheet information
related to operating leases is as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3cm 0pt 0; text-align: justify; text-indent: 0cm">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Three months<br/>

    ended<br/>
    March 31,<br/>
 2022</td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="width: 88%; text-indent: -8.5pt; padding-left: 11.35pt">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Weighted average remaining lease term (in years)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4.12</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Weighted average discount rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2.56</td><td style="text-align: left">%</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3cm 0pt 0; text-align: justify; text-indent: 0cm">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">Maturities of lease liabilities were
as follows<span style="font-family: Times New Roman, Times, Serif">:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3cm 0pt 0; text-align: center; text-indent: 0cm">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0pt; white-space: nowrap; text-align: left; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Three months<br/>

    ended <br/> March 31,<br/>
 2022</td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0pt; text-align: left">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left; padding-left: 0pt">2022</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">2,042</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0pt">2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,742</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0pt">2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,748</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0pt">2025</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,316</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0pt">2026</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">790</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt">Thereafter</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">613</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0pt; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0pt">Total undiscounted lease payments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8,251</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt">Less: Imputed interest</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(513</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; padding-left: 0pt">Present value of lease liabilities</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">7,738</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI https://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140194449527672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Senior Notes, Net<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gmda_DisclosureOfNotesAndOtherExplanatoryInformationsExplanatoryAbstract', window );"><strong>Disclosure Of Notes And Other Explanatory Informations Explanatory [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gmda_DisclosureOfNotesAndOtherExplanatoryInformationsExplanatoryTextBlock', window );">CONVERTIBLE SENIOR NOTES, NET</a></td>
<td class="text"><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2cm; text-align: justify; text-indent: -2cm">NOTE 4: CONVERTIBLE
SENIOR NOTES, NET</p><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2cm; text-align: justify; text-indent: -2cm">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">On February 16,
2021, the Subsidiary issued convertible senior notes (the &#8220;Convertible Notes&#8221;) due in 2026, in the aggregate principal amount
of $75 million, pursuant to an Indenture between the Company, the Subsidiary, and Wilmington Savings Fund Society, FSB, dated February
16, 2021 (the &#8220;Indenture&#8221;). The Convertible Notes bear interest payable semiannually in arrears, at a rate of 5.875% per
year. The Convertible Notes will mature on February 15, 2026, unless earlier converted, redeemed or repurchased in accordance with their
terms.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2cm 0pt 1.25in; text-align: justify; text-indent: 0.25in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">Subject to the provisions
of the Indenture, the holders of the Convertible Notes have the right, prior to the close of business on the second scheduled trading
day immediately preceding February 15, 2026, to convert any Convertible Notes or portion thereof that is $1,000 or an integral multiple
thereof, into the Company&#8217;s ordinary shares at an initial conversion rate of 56.3063 shares per $1,000 principal amount of Convertible
Notes (equivalent to an exchange price of $17.76 per share). The conversion rate is subject to adjustment in specified events.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 4cm 0pt 1.25in; text-align: justify; text-indent: 0.25in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">Upon the occurrence
of a fundamental change (as defined in the Indenture), holders of the Convertible Notes may require the Company to repurchase for cash
all or a portion of their Convertible Notes, in multiples of $1,000 principal amount, at a repurchase price equal to 100% of the principal
amount of the Convertible Notes, plus any accrued and unpaid interest, if any, to, but excluding, interest accrued after the date of
such repurchase notice. If certain fundamental changes referred to as make-whole fundamental changes occur, the conversion rate for the
Convertible Notes may be increased.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 4cm 0pt 1.25in; text-align: justify; text-indent: 0.25in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">Subject to the provisions
of the Indenture, the Subsidiary may redeem for cash all or a portion of the Convertible Notes for cash, at its option, at a redemption
price equal to 100% of the principal amount of the Convertible Notes to be redeemed, plus accrued and unpaid interest on the notes to
be redeemed, if the last reported closing price of the Company&#8217;s ordinary shares has been at least 130% of the exchange price then
in effect for at least 20 trading days during any 30 consecutive trading day period, and in the event of certain tax law changes.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0cm">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">The Convertible
Notes are accounted for as a single liability measured at its amortized cost, as no other embedded features require bifurcation and recognition
as derivatives according to ASC 815-40.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2cm; text-align: justify; text-indent: 0cm">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Three months<br/>
 ended<br/>
    March 31,<br/>
 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: right">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Liability component:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">Principal amount</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">75,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; text-align: left">Issuance costs</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(4,223</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">70,777</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Amortized issuance costs</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">830</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Net carrying amount</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">71,607</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2cm; text-align: justify; text-indent: -2cm">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The total issuance costs of the Convertible
Notes amounted to $4,223 and are amortized to interest expense at an annual effective interest rate of 7.37%, over the term of the Convertible
Notes.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gmda_DisclosureOfNotesAndOtherExplanatoryInformationsExplanatoryAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gmda_DisclosureOfNotesAndOtherExplanatoryInformationsExplanatoryAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gmda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gmda_DisclosureOfNotesAndOtherExplanatoryInformationsExplanatoryTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of notes and other explanatory information as part of a complete set of financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gmda_DisclosureOfNotesAndOtherExplanatoryInformationsExplanatoryTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gmda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140194446476072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">FAIR VALUE MEASUREMENTS</a></td>
<td class="text"><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2cm; text-align: justify; text-indent: -2cm">NOTE 5:	FAIR
VALUE MEASUREMENTS</p><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2cm; text-align: justify; text-indent: -2cm">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The following tables present the fair
value of money market funds and marketable securities as of March 31, 2022 and December 31, 2021:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0pt; text-indent: 0pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">March 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0pt; text-indent: 0pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Level 1</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Level 2</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Level 1</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Level 2</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; text-indent: 0pt; padding-left: 0pt">Cash equivalents:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 28%; text-align: left; text-indent: 0pt; padding-left: 0pt">Money market funds</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">36,581</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-15">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">36,581</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">51,021</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-16">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">51,021</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: 0pt; padding-left: 0pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; text-indent: 0pt; padding-left: 0pt">Marketable securities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: 0pt; padding-left: 0pt">Corporate debentures</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-17">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">13,389</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">13,389</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-18">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">19,605</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">19,605</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: 0pt; padding-left: 0pt">Government debentures</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-19">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">14,272</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">14,272</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-20">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">20,429</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">20,429</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: 0pt; padding-left: 0pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: 0pt; padding-left: 0pt">Total assets measured at fair value</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">36,581</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">27,661</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">64,242</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">51,021</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">40,034</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">91,055</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140194446427032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Contingent Liabilities and Commitments<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">CONTINGENT LIABILITIES AND COMMITMENTS</a></td>
<td class="text"><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2cm; text-align: justify; text-indent: -2cm">NOTE 6:	CONTINGENT
LIABILITIES AND COMMITMENTS</p><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2cm; text-align: justify; text-indent: -2cm">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top">
<td style="width: 0.75in"/><td style="width: 0.5in">a.</td><td style="text-align: justify">Legal proceedings:</td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2cm; text-align: justify; text-indent: 0cm">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0cm">From time to time
the Company or its subsidiaries may be involved in legal proceedings and/or litigation arising in the ordinary course of business. While
the outcome of these matters cannot be predicted with certainty, the Company does not believe it will have a material effect on its consolidated
financial position, results of operations, or cash flows.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2cm; text-align: justify; text-indent: 0cm">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top">
<td style="width: 0.75in"/><td style="width: 0.5in">b.</td><td style="text-align: justify">Bank guarantees:</td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2cm; text-align: justify; text-indent: 0cm">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0cm">As of March 31,
2022, the Company obtained bank guarantees in the amount of $3,266, primarily in connection with an Investment Center grant of up to
$3,106 expected to be received in 2022 which requires a bank guarantee in order to ensure the fulfillment of the grant terms.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 74.7pt; text-align: justify"><b>&#160;</b></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top">
<td style="width: 0.75in"/><td style="width: 0.5in">c.</td><td>Government grants:</td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2cm; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0cm">The Company has received grants from the IIA to finance its research
and development programs in Israel, through which the Company received IIA participation payments in the aggregate amount of $37.3 million
through March 31, 2022, of which $34.7 million is royalty-bearing grants and $2.6 million is non-royalty-bearing grants. In return, the
Company is committed to pay IIA royalties at a rate of&#160;3-3.5%&#160;of future sales of the developed products, up to 100%of the amount
of grants received plus interest at LIBOR rate. Through March&#160;31, 2022, no royalties have been paid or accrued. The Company&#8217;s
contingent royalty liability to the IIA at March&#160;31, 2022, including grants received by the Company and the associated LIBOR interest
on all such grants totaled to $44.9 million.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI https://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI https://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140194446587384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">SHAREHOLDERS' EQUITY</a></td>
<td class="text"><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2cm; text-align: justify; text-indent: -2cm">NOTE 7:	SHAREHOLDERS'
EQUITY</p><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2cm; text-align: justify; text-indent: -2cm">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top">
<td style="width: 0.75in"/><td style="width: 0.5in"><span style="font-weight: normal">a.</span></td><td style="text-align: justify"><span style="font-weight: normal">Ordinary
                                            shares:</span></td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2cm; text-align: justify; text-indent: -2cm"><span style="font-weight: normal">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0cm">Subject to the Company&#8217;s
amended and restated Articles of Association, the holders of the Company&#8217;s ordinary shares have the right to receive notices to
attend and vote in general meetings of the Company&#8217;s shareholders, and the right to share in dividends and other distributions
upon liquidation<span style="font-family: Times New Roman, Times, Serif">.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2cm; text-align: justify; text-indent: 0cm">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top">
<td style="width: 0.75in"/><td style="width: 0.5in">b.</td><td style="text-align: justify">Warrants to investors:</td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2cm; text-align: justify; text-indent: 0cm">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0cm">As part of its 2017
investment round, the Company granted certain investors 4,323,978 warrants that will expire in July 2022. As of March 31, 2022, 1,010,466
of such warrants have been exercised into the Company&#8217;s ordinary shares.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI https://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126731327&amp;loc=SL126733271-114008<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140194446470888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">SHARE-BASED COMPENSATION</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 8:	SHARE-BASED COMPENSATION</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3cm; text-align: justify; text-indent: -1cm">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top">
<td style="width: 0.75in"/><td style="width: 0.5in">a.</td><td style="text-align: justify">Option plans:</td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 74.7pt; text-align: justify; text-indent: 0cm">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0cm">On November 23,
2014, the Company&#8217;s Board of Directors approved, subject to the approval of the shareholders, creation of the Company&#8217;s ordinary
C share class, with nominal value NIS 0.01 per share and classification of 1,500,000 ordinary shares for such class of shares, whereby
1,152,044 of such shares were allocated to the Company&#8217;s employees under the amended 2014 Israel Share Option Plan (the &#8220;2014
Plan&#8221;). The exercise price of the options granted under the 2014 Plan may not be less than the nominal value of the shares into
which the options are exercised. The options vest primarily over three years. There are no cash settlement alternatives. On December
29, 2014, the Company&#8217;s shareholders ratified and approved the aforesaid actions.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3cm; text-align: justify; text-indent: 0cm">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0cm">On January 23, 2017,
the Company&#8217;s Board of Directors approved the Company&#8217;s 2017 Share Incentive Plan (the &#8220;2017 Plan&#8221; and together
with the 2014 Plan, the &#8220;Option Plans&#8221;), and the subsequent grant of options to the Company&#8217;s employees, officers and
directors. Pursuant to the 2017 Plan, the Company initially reserved for issuance 312,867 ordinary shares, nominal value NIS 0.01 each.
On February 28, 2017, the Company&#8217;s shareholders approved the 2017 Plan.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0cm">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0cm">The 2017 Plan provides
for the grant of awards, including options, restricted shares and restricted share units to the Company&#8217;s directors, employees,
officers, consultants and advisors.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0cm">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0cm">On June 26, 2017
and on December 28, 2017, the Company&#8217;s Board of Directors approved the reservation of 463,384 and 559,764 additional ordinary
shares, respectively, for issuance under the 2017 Plan (totaling, including previous plans, an aggregate of 1,338,015 ordinary Shares).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0cm">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">On February 25, 2021 and November
17, 2021, the board of directors and shareholders, respectively, approved an amendment and restatement of the 2017 Plan. The 2017 Plan,
as amended, also contains an &#8220;evergreen&#8221; provision, which provides for an automatic allotment of ordinary shares to be added
every year to the pool of ordinary shares available for grant under the 2017 Plan. Under the evergreen provision, on January 1 of each
year (beginning January 1, 2022), the number of ordinary shares available under the 2017 Plan automatically increases by the lesser of
the following: (i) 4% of our outstanding ordinary shares on the last day of the immediately preceding year; and (ii) an amount determined
in advance of January 1 by the board of directors.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3cm; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0cm">The Company estimates
the fair value of stock options granted using the binominal option-pricing model. The option-pricing model requires a number of assumptions,
of which the most significant are the expected stock price volatility and the expected option term.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0cm">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0cm">Expected volatility
was calculated based upon the Company&#8217;s historical share price and historical volatilities of similar entities in the related sector
index. The expected term of the options granted is derived from output of the option valuation model and represents the period of time
that options granted are expected to be outstanding. The risk-free interest rate is based on the yield from U.S. treasury bonds with
an equivalent term. The Company has historically not paid dividends and has no foreseeable plans to pay dividends.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0cm">The following table
lists the inputs to the binomial option-pricing model used for the fair value measurement of equity-settled share options for the above
Options Plans as of March 31, 2022:&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4cm; text-align: justify; text-indent: -1cm">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Three months<br/>

    ended <br/>
    March 31,<br/>
 2022</td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left; text-indent: -11.35pt; padding-left: 14.15pt">Dividend yield</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">0</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -11.35pt; padding-left: 14.15pt">Expected volatility of the share prices</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">66</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -11.35pt; padding-left: 14.15pt">Risk-free interest rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.8</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -11.35pt; padding-left: 14.15pt">Expected term (in years)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8</td><td style="text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3cm">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0cm">Based on the above
inputs, the fair value of the options was determined to be $1.71 - $1.85 per option at the grant date.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 74.7pt; text-align: justify; text-indent: 0cm">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top">
<td style="width: 0.75in"/><td style="width: 0.5in">b.</td><td style="text-align: justify">The following table summarizes the number
                                            of options granted to employees under the Option Plans as of March 31, 2022 and related information:</td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3cm; text-align: justify; text-indent: -1cm">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0pt; text-indent: 0pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Amount</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>of</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>options</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Weighted</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>average</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>exercise</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>price</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0pt; text-indent: 0pt">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-indent: 0pt; padding-left: 0pt">Balance as of December 31, 2021</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">4,411,424</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">6.01</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: 0pt; padding-left: 0pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: 0pt; padding-left: 0pt">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,181,100</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2.93</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: 0pt; padding-left: 0pt">Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(47,426</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.60</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: 0pt; padding-left: 0pt">Forfeited</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(301,215</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6.74</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; text-indent: 0pt; padding-left: 0pt">Expired</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(18,349</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">6.70</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: 0pt; padding-left: 0pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt; text-indent: 0pt; padding-left: 0pt">Balance as of March 31, 2022</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">5,225,534</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">5.31</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: 0pt; padding-left: 0pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt; text-indent: 0pt; padding-left: 0pt">Exercisable as of March 31, 2022</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">2,417,453</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right">5.90</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3cm">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0cm">As of March 31,
2022, there are $11,848 of total unrecognized costs related to share-based compensation that are expected to be recognized over a period
of up to four years.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3cm; text-align: justify; text-indent: 0cm">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top">
<td style="width: 0.75in"/><td style="width: 0.5in"><span style="font-family: Times New Roman, Times, Serif">c.</span></td><td style="text-align: justify">A summary of restricted shares and restricted share units activity
as of March&#160;31, 2022 is as follows:</td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 74.7pt 0pt 0; text-align: justify; text-indent: 0cm">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0pt; text-indent: 0pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Amount of</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>restricted
                                            shares and restricted shares units</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Weighted</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>average</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>grant
                                            date<br/>
 fair value</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0pt; text-indent: 0pt">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-indent: 0pt; padding-left: 0pt">Unvested as of December 31, 2021</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">531,477</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">5.48</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: 0pt; padding-left: 0pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: 0pt; padding-left: 0pt">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">937,300</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2.93</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: 0pt; padding-left: 0pt">Vested</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(42,911</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9.46</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-indent: 0pt; padding-left: 0pt">Forfeited</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(75,117</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">6.26</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: 0pt; padding-left: 0pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt; text-indent: 0pt; padding-left: 0pt">Unvested as of March 31, 2022</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">1,350,749</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right">3.54</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top">
<td style="width: 0.75in"/><td style="width: 0.5in"><span style="font-size: 10pt">d.</span></td><td style="text-align: justify">The
                                            total share-based compensation expense related to all of the Company's equity-based awards,
                                            recognized for the three months ended March 31, 2022 and 2021 is comprised as follows:</td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0pt; text-indent: 0pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Three months ended<br/>
    March 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0pt; text-indent: 0pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0pt; text-indent: 0pt">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: 0pt; padding-left: 0pt">Research and development expenses, net</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">465</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">311</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: 0pt; padding-left: 0pt">Commercial expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">290</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">171</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: 0pt; padding-left: 0pt">General and administrative expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">439</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">431</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: 0pt; padding-left: 0pt">Total share-based compensation</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,194</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">913</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140194446526248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basic and Diluted Net Loss Per Share<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">BASIC AND DILUTED NET LOSS PER SHARE</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 9:	BASIC AND DILUTED NET LOSS PER SHARE</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3cm; text-align: justify; text-indent: -1cm">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0cm"><span style="font-weight: normal">Basic
net loss per ordinary share is computed by dividing net loss for each reporting period by the weighted-average number of ordinary shares
outstanding during each year. Diluted net loss per ordinary share is computed by dividing net loss for each reporting period by the weighted
average number of ordinary shares outstanding during the period, plus dilutive potential ordinary shares considered outstanding during
the period, in accordance with ASC No. 260-10 &#8220;Earnings Per Share&#8221;. The Company experienced a loss as of March 31, 2022;
hence all potentially dilutive ordinary shares were excluded due to their anti-dilutive effect.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3cm; text-align: justify; text-indent: -1cm">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in">Details of the number
of shares and loss used in the computation of loss per share:</p><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3cm; text-align: justify; text-indent: -2cm">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Three months ended March 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="text-align: center; font-weight: bold; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted number of shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Net loss attributable to equity holders of
                                                                                 the Company</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted number of shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Net loss attributable to equity holders of
                                                                                 the Company</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="width: 52%; text-indent: -8.5pt; padding-left: 11.35pt">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -8.5pt; padding-left: 11.35pt">For the computation of basic and diluted
    loss</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">59,474,366</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">20,223</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">59,122,973</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">19,186</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI https://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140194446944264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounting Policies, by Policy (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of estimates</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top">
<td style="width: 0.75in"/><td style="width: 0.5in">a.</td><td>Use of estimates:</td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3cm; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The preparation of condensed financial
statements in conformity with U.S. GAAP requires management to make estimates, judgments and assumptions that affect the amounts reported
in the consolidated financial statements and accompanying notes. The Company&#8217;s management believes that the estimates, judgment
and assumptions used are reasonable based upon information available at the time they are made. These estimates, judgments and assumptions
can affect the reported amounts of assets and liabilities at the dates of the consolidated financial statements, and the reported amount
of expenses during the reporting periods. Actual results could differ from those estimates.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gmda_ConvertibleSeniorNotesPolicyTextBlock', window );">Convertible senior notes</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top">
<td style="width: 0.75in"/><td style="width: 0.5in">b.</td><td>Convertible senior notes:</td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.85pt; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The Company accounts for its convertible
senior notes in accordance with ASC 470-20 &#8220;Debt with Conversion and Other Options&#8221;. The Company early adopted ASU 2020-06
using the modified retrospective approach. The convertible senior notes are accounted for as a single liability measured at its amortized
cost, as no other embedded features require bifurcation and recognition as derivatives according to ASC 815-40.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Basic and diluted net loss per share</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top">
<td style="width: 0.75in"/><td style="width: 0.5in">c.</td><td>Basic and diluted net loss per share:</td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 88.85pt; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The Company computes net loss per
share using the&#160;two-class&#160;method required for participating securities. The&#160;two-class&#160;method requires income available
to ordinary shareholders for the period to be allocated between ordinary shares and participating securities based upon their respective
rights to receive dividends as if all income for the period had been distributed. The Company considers its restricted shares to be participating
securities as the holders of the restricted shares would be entitled to dividends that would be distributed to the holders of ordinary
shares, on a&#160;pro-rata&#160;basis. These participating securities do not contractually require the holders of such shares to participate
in the Company&#8217;s losses. As such, net loss for the periods presented was not allocated to the Company&#8217;s participating securities.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 84.45pt; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify">The Company&#8217;s basic net loss
per share is calculated by dividing net loss attributable to ordinary shareholders by the weighted-average number of shares of ordinary
shares outstanding for the period, without consideration of potentially dilutive securities. The diluted net loss per share is calculated
by giving effect to all potentially dilutive securities outstanding for the period using the treasury share method or the&#160;if-converted&#160;method
based on the nature of such securities. Diluted net loss per share is the same as basic net loss per share in periods when the effects
of potentially dilutive ordinary shares are anti-dilutive.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gmda_ConvertibleSeniorNotesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gmda_ConvertibleSeniorNotesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gmda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140194447662264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Schedule of operating lease costs</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; padding-left: 0pt; text-indent: 0pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Three months ended<br/>
    March 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; padding-left: 0pt; text-indent: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2022</b></span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>2021</b></span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0pt; text-indent: 0pt">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: 0pt; padding-left: 0pt">Operating lease costs</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">636</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">585</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: 0pt; padding-left: 0pt">Short-term lease costs</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">24</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">60</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: 0pt; padding-left: 0pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: 0pt; padding-left: 0pt">Total lease costs</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">660</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">645</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3cm"><b>&#160;</b></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock', window );">Schedule of operating leases</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Three months<br/>

    ended<br/>
    March 31,<br/>
 2022</td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="width: 88%; text-indent: -8.5pt; padding-left: 11.35pt">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Weighted average remaining lease term (in years)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4.12</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Weighted average discount rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2.56</td><td style="text-align: left">%</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3cm 0pt 0; text-align: justify; text-indent: 0cm">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of maturities of lease liabilities</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0pt; white-space: nowrap; text-align: left; font-weight: bold">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Three months<br/>

    ended <br/> March 31,<br/>
 2022</td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0pt; text-align: left">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left; padding-left: 0pt">2022</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">2,042</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0pt">2023</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,742</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0pt">2024</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,748</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0pt">2025</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,316</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0pt">2026</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">790</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt">Thereafter</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">613</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0pt; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0pt">Total undiscounted lease payments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8,251</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt">Less: Imputed interest</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(513</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; padding-left: 0pt">Present value of lease liabilities</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">7,738</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for lessee's operating leases. Includes, but is not limited to, description of lessee's operating lease, existence and terms of renewal or purchase options and escalation clauses, restrictions imposed by lease, such as those concerning dividends, additional debt, and further leasing, rent holidays, rent concessions, or leasehold improvement incentives and unusual provisions or conditions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123406913&amp;loc=d3e41499-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124440162&amp;loc=d3e12069-110248<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123406913&amp;loc=d3e41502-112717<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123389372&amp;loc=d3e36991-112694<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123403562&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140194446415608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Senior Notes, Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gmda_DisclosureOfNotesAndOtherExplanatoryInformationsExplanatoryAbstract', window );"><strong>Disclosure Of Notes And Other Explanatory Informations Explanatory [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gmda_ScheduleOfLiabilityAndEquityComponentConvertibleNotesTableTextBlock', window );">Schedule of liability and equity components of the convertible notes</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Three months<br/>
 ended<br/>
    March 31,<br/>
 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: right">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Liability component:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">Principal amount</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">75,000</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; text-align: left">Issuance costs</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(4,223</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">70,777</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Amortized issuance costs</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">830</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Net carrying amount</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">71,607</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2cm; text-align: justify; text-indent: -2cm">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gmda_DisclosureOfNotesAndOtherExplanatoryInformationsExplanatoryAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gmda_DisclosureOfNotesAndOtherExplanatoryInformationsExplanatoryAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gmda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gmda_ScheduleOfLiabilityAndEquityComponentConvertibleNotesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Liability And Equity Components Convertible Notes Table Text Block.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gmda_ScheduleOfLiabilityAndEquityComponentConvertibleNotesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gmda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140194446516408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gmda_ScheduleOfFairValueOfMoneyMarketFundsAndMarketableSecuritiesTableTextBlock', window );">Schedule of fair value of money market funds and marketable securities</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0pt; text-indent: 0pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">March 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0pt; text-indent: 0pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Level 1</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Level 2</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Level 1</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Level 2</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="font-weight: bold; text-align: left; text-indent: 0pt; padding-left: 0pt">Cash equivalents:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 28%; text-align: left; text-indent: 0pt; padding-left: 0pt">Money market funds</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">36,581</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-15">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">36,581</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">51,021</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-16">-</div></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">51,021</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: 0pt; padding-left: 0pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; text-indent: 0pt; padding-left: 0pt">Marketable securities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: 0pt; padding-left: 0pt">Corporate debentures</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-17">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">13,389</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">13,389</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-18">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">19,605</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">19,605</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: 0pt; padding-left: 0pt">Government debentures</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-19">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">14,272</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">14,272</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-20">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">20,429</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">20,429</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: 0pt; padding-left: 0pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: 0pt; padding-left: 0pt">Total assets measured at fair value</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">36,581</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">27,661</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">64,242</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">51,021</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">40,034</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">91,055</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gmda_ScheduleOfFairValueOfMoneyMarketFundsAndMarketableSecuritiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gmda_ScheduleOfFairValueOfMoneyMarketFundsAndMarketableSecuritiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gmda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140194449419592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of fair value measurement of equity-settled share options</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Three months<br/>

    ended <br/>
    March 31,<br/>
 2022</td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left; text-indent: -11.35pt; padding-left: 14.15pt">Dividend yield</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">0</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -11.35pt; padding-left: 14.15pt">Expected volatility of the share prices</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">66</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -11.35pt; padding-left: 14.15pt">Risk-free interest rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.8</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -11.35pt; padding-left: 14.15pt">Expected term (in years)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8</td><td style="text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3cm">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of stock option plans</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0pt; text-indent: 0pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Amount</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>of</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>options</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Weighted</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>average</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>exercise</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>price</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0pt; text-indent: 0pt">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-indent: 0pt; padding-left: 0pt">Balance as of December 31, 2021</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">4,411,424</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">6.01</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: 0pt; padding-left: 0pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: 0pt; padding-left: 0pt">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,181,100</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2.93</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: 0pt; padding-left: 0pt">Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(47,426</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.60</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: 0pt; padding-left: 0pt">Forfeited</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(301,215</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6.74</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt; text-indent: 0pt; padding-left: 0pt">Expired</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(18,349</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">6.70</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: 0pt; padding-left: 0pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt; text-indent: 0pt; padding-left: 0pt">Balance as of March 31, 2022</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">5,225,534</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">5.31</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: 0pt; padding-left: 0pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt; text-indent: 0pt; padding-left: 0pt">Exercisable as of March 31, 2022</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">2,417,453</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right">5.90</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3cm">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock', window );">Schedule of restricted shares activity</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0pt; text-indent: 0pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Amount of</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>restricted
                                            shares and restricted shares units</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Weighted</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>average</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>grant
                                            date<br/>
 fair value</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0pt; text-indent: 0pt">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-indent: 0pt; padding-left: 0pt">Unvested as of December 31, 2021</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">531,477</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">5.48</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: 0pt; padding-left: 0pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: 0pt; padding-left: 0pt">Granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">937,300</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2.93</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: 0pt; padding-left: 0pt">Vested</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(42,911</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">9.46</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-indent: 0pt; padding-left: 0pt">Forfeited</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(75,117</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">6.26</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: 0pt; padding-left: 0pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt; text-indent: 0pt; padding-left: 0pt">Unvested as of March 31, 2022</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">1,350,749</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">$</td><td style="padding-bottom: 4pt; text-align: right">3.54</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of share-based compensation expense</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0pt; text-indent: 0pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Three months ended<br/>
    March 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0pt; text-indent: 0pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0pt; text-indent: 0pt">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; text-indent: 0pt; padding-left: 0pt">Research and development expenses, net</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">465</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">311</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: 0pt; padding-left: 0pt">Commercial expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">290</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">171</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: 0pt; padding-left: 0pt">General and administrative expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">439</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">431</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: 0pt; padding-left: 0pt">Total share-based compensation</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,194</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">913</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140194446495192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basic and Diluted Net Loss Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of number of shares and loss used in the computation of net loss per share</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Three months ended March 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="text-align: center; font-weight: bold; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted number of shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Net loss attributable to equity holders of
                                                                                 the Company</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted number of shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Net loss attributable to equity holders of
                                                                                 the Company</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="width: 52%; text-indent: -8.5pt; padding-left: 11.35pt">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -8.5pt; padding-left: 11.35pt">For the computation of basic and diluted
    loss</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">59,474,366</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">20,223</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">59,122,973</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">19,186</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140194446307320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>General (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gmda_ResponseRatePercentage', window );">Response rate percentage, description</a></td>
<td class="text">Among the 19 patients with
NHL, 13 complete responses and one partial response were observed, with an overall response rate of 74% and a complete response rate
of 68%.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gmda_ClinicalTrialOnOutcomes', window );">Clinical trial on outcomes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The data demonstrated a median duration of response of 16 months (range 5-36 months), an overall survival at
two years of 78% (95% CI, 51%&#8211;91%) and a safety profile similar to that reported previously.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gmda_AccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="nump">$ 357,680<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsAndCash', window );">Cash</a></td>
<td class="nump">$ 25,728<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Operating segment</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gmda_AccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated deficit</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gmda_AccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gmda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gmda_ClinicalTrialOnOutcomes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Clinical trial on outcomes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gmda_ClinicalTrialOnOutcomes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gmda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gmda_ResponseRatePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Response rate percentage., description</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gmda_ResponseRatePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gmda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsAndCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of investments and unrestricted cash as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.1,2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsAndCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140194446419928">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases (Details)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm', window );">Lease term</a></td>
<td class="text">6 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRemainingLeaseTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140194446276488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Details) - Schedule of operating lease costs - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gmda_ScheduleOfOperatingLeaseCostsAbstract', window );"><strong>Schedule of operating lease costs [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease costs</a></td>
<td class="nump">$ 636<span></span>
</td>
<td class="nump">$ 585<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermLeaseCost', window );">Short-term lease costs</a></td>
<td class="nump">24<span></span>
</td>
<td class="nump">60<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total lease costs</a></td>
<td class="nump">$ 660<span></span>
</td>
<td class="nump">$ 645<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gmda_ScheduleOfOperatingLeaseCostsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gmda_ScheduleOfOperatingLeaseCostsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gmda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term lease cost, excluding expense for lease with term of one month or less.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140194446587384">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases (Details) - Schedule of operating leases<br></strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gmda_ScheduleOfOperatingLeasesAbstract', window );"><strong>Schedule of operating leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term (in years)</a></td>
<td class="text">4 years 1 month 13 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted average discount rate</a></td>
<td class="nump">2.56%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gmda_ScheduleOfOperatingLeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gmda_ScheduleOfOperatingLeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gmda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140194446079064">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases (Details) - Schedule of maturities of lease liabilities<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gmda_ScheduleOfMaturitiesOfLeaseLiabilitiesAbstract', window );"><strong>Schedule of maturities of lease liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2022</a></td>
<td class="nump">$ 2,042<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2023</a></td>
<td class="nump">1,742<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears', window );">2024</a></td>
<td class="nump">1,748<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears', window );">2025</a></td>
<td class="nump">1,316<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gmda_LesseeOperatingLeaseLiabilityPaymentsDueYearSix', window );">2026</a></td>
<td class="nump">790<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">613<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total undiscounted lease payments</a></td>
<td class="nump">8,251<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: Imputed interest</a></td>
<td class="num">(513)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PresentValueOfFutureMinimumLeasePaymentsSaleLeasebackTransactions', window );">Present value of lease liabilities</a></td>
<td class="nump">$ 7,738<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gmda_LesseeOperatingLeaseLiabilityPaymentsDueYearSix">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in Sixth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gmda_LesseeOperatingLeaseLiabilityPaymentsDueYearSix</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gmda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gmda_ScheduleOfMaturitiesOfLeaseLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gmda_ScheduleOfMaturitiesOfLeaseLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gmda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406913&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123403562&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406913&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123403562&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PresentValueOfFutureMinimumLeasePaymentsSaleLeasebackTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of minimum lease payments for sale-leaseback transactions accounted for using the deposit method or as a financing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123386454&amp;loc=d3e45280-112737<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PresentValueOfFutureMinimumLeasePaymentsSaleLeasebackTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140194444513704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Senior Notes, Net (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Feb. 16, 2021</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gmda_ConvertibleSeniorNotesNetDetailsLineItems', window );"><strong>Convertible Senior Notes, Net (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gmda_AnnualInterestPercentage', window );">Annual interest percentage</a></td>
<td class="nump">5.875%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionDate', window );">Maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Feb. 15,  2026<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayable', window );">Convertible notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Ordinary shares (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56.3063<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayableCurrent', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Exchange price (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17.76<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentage', window );">Repurchase price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gmda_ExchangePricePercentage', window );">Exchange price percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock', window );">Convertible notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,223<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateBasisForEffectiveRate', window );">Effective interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7.37%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember', window );">Convertible Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gmda_ConvertibleSeniorNotesNetDetailsLineItems', window );"><strong>Convertible Senior Notes, Net (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gmda_PrincipalAmount', window );">Aggregate principal amount</a></td>
<td class="nump">$ 75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayableCurrent', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentage', window );">Repurchase price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gmda_AnnualInterestPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Annual Interest Percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gmda_AnnualInterestPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gmda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gmda_ConvertibleSeniorNotesNetDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gmda_ConvertibleSeniorNotesNetDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gmda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gmda_ExchangePricePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gmda_ExchangePricePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gmda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gmda_PrincipalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>It represents of principal amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gmda_PrincipalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gmda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, carrying value as of the balance sheet date of a written promise to pay a note, initially due after one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=120401414&amp;loc=d3e603758-122996<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleNotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the portion of long-term debt due within one year or the operating cycle if longer identified as Convertible Notes Payable. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleNotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date debt instrument can be converted into equity, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateBasisForEffectiveRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of any adjustments made to the stated rate to determine the effective rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateBasisForEffectiveRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPricePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage price of original principal amount of debt at which debt can be redeemed by the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph e<br> -URI https://asc.fasb.org/extlink&amp;oid=123599511&amp;loc=d3e64711-112823<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPricePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of callable preferred stock which is identified as being convertible to another type of financial security at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140194449650456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Senior Notes, Net (Details) - Schedule of liability and equity components of the convertible notes<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gmda_ScheduleOfLiabilityAndEquityComponentsOfTheConvertibleNotesAbstract', window );"><strong>Schedule of liability and equity components of the convertible notes [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gmda_AmountOfPrincipal', window );">Principal amount</a></td>
<td class="nump">$ 75,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gmda_UnamortizedIssuanceCosts', window );">Issuance costs</a></td>
<td class="num">(4,223)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gmda_NetIssuanceCosts', window );">Net</a></td>
<td class="nump">70,777<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortized issuance costs</a></td>
<td class="nump">830<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gmda_NetCarryingAmountincludingAccruedInterest', window );">Net carrying amount</a></td>
<td class="nump">$ 71,607<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gmda_AmountOfPrincipal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Principal amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gmda_AmountOfPrincipal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gmda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gmda_NetCarryingAmountincludingAccruedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>It represents of net carrying amount including accrued interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gmda_NetCarryingAmountincludingAccruedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gmda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gmda_NetIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gmda_NetIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gmda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gmda_ScheduleOfLiabilityAndEquityComponentsOfTheConvertibleNotesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gmda_ScheduleOfLiabilityAndEquityComponentsOfTheConvertibleNotesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gmda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gmda_UnamortizedIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>It represents of unamortized discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gmda_UnamortizedIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gmda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140194444549960">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements (Details) - Schedule of fair value of money market funds and marketable securities - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gmda_CashEquivalentsAbstract', window );"><strong>Cash equivalents:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MoneyMarketFundsAtCarryingValue', window );">Money market funds</a></td>
<td class="nump">$ 36,581<span></span>
</td>
<td class="nump">$ 51,021<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesAbstract', window );"><strong>Marketable securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gmda_CorporateDebentures', window );">Corporate debentures</a></td>
<td class="nump">13,389<span></span>
</td>
<td class="nump">19,605<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gmda_GovernmentDebentures', window );">Government debentures</a></td>
<td class="nump">14,272<span></span>
</td>
<td class="nump">20,429<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiability', window );">Total assets measured at fair value</a></td>
<td class="nump">64,242<span></span>
</td>
<td class="nump">91,055<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Fair Value, Inputs, Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gmda_CashEquivalentsAbstract', window );"><strong>Cash equivalents:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MoneyMarketFundsAtCarryingValue', window );">Money market funds</a></td>
<td class="nump">36,581<span></span>
</td>
<td class="nump">51,021<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesAbstract', window );"><strong>Marketable securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gmda_CorporateDebentures', window );">Corporate debentures</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gmda_GovernmentDebentures', window );">Government debentures</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiability', window );">Total assets measured at fair value</a></td>
<td class="nump">36,581<span></span>
</td>
<td class="nump">51,021<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Fair Value, Inputs, Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gmda_CashEquivalentsAbstract', window );"><strong>Cash equivalents:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MoneyMarketFundsAtCarryingValue', window );">Money market funds</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesAbstract', window );"><strong>Marketable securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gmda_CorporateDebentures', window );">Corporate debentures</a></td>
<td class="nump">13,389<span></span>
</td>
<td class="nump">19,605<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gmda_GovernmentDebentures', window );">Government debentures</a></td>
<td class="nump">14,272<span></span>
</td>
<td class="nump">20,429<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueNetAssetLiability', window );">Total assets measured at fair value</a></td>
<td class="nump">$ 27,661<span></span>
</td>
<td class="nump">$ 40,034<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gmda_CashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gmda_CashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gmda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gmda_CorporateDebentures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of corporate debentures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gmda_CorporateDebentures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gmda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gmda_GovernmentDebentures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of government debentures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gmda_GovernmentDebentures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gmda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueNetAssetLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of asset after deduction of liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueNetAssetLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MoneyMarketFundsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Investment in short-term money-market instruments (such as commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and so forth) which are highly liquid (that is, readily convertible to known amounts of cash) and so near their maturity that they present an insignificant risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify as cash equivalents by definition. Original maturity means an original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three-years ago does not become a cash equivalent when its remaining maturity is three months.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MoneyMarketFundsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140194444556184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Contingent Liabilities and Commitments (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gmda_ContingentLiabilitiesandCommitmentsDetailsLineItems', window );"><strong>Contingent Liabilities and Commitments (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RoyaltyGuaranteesCommitmentsAmount', window );">Bank guarantees amount</a></td>
<td class="nump">$ 3,266<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BorrowingsUnderGuaranteedInvestmentAgreements', window );">Investment center grant amount</a></td>
<td class="nump">3,106<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrantsReceivableCurrent', window );">Aggregate amount</a></td>
<td class="nump">37,300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RoyaltyExpense', window );">Royalty-bearing grants</a></td>
<td class="nump">34,700<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfAdvanceRoyalty', window );">Non-royalty-bearing grants</a></td>
<td class="nump">$ 2,600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction', window );">Percentage of interest rate</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrantsReceivable', window );">Total grants</a></td>
<td class="nump">$ 44,900<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gmda_ContingentLiabilitiesandCommitmentsDetailsLineItems', window );"><strong>Contingent Liabilities and Commitments (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeForwardInterestRate', window );">Royalties rate</a></td>
<td class="nump">3.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gmda_ContingentLiabilitiesandCommitmentsDetailsLineItems', window );"><strong>Contingent Liabilities and Commitments (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeForwardInterestRate', window );">Royalties rate</a></td>
<td class="nump">0.50%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gmda_ContingentLiabilitiesandCommitmentsDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gmda_ContingentLiabilitiesandCommitmentsDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gmda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfAdvanceRoyalty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The expense charged against earnings for the periodic recognition of the advance royalties. These royalties are paid in one accounting period, but are deducted from earnings over time through amortization. For example, royalties that are required to be paid in advance of production from a mineral, oil, or gas property and amortized over the period of right to produce these items.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfAdvanceRoyalty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BorrowingsUnderGuaranteedInvestmentAgreements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the sum of the obligations to contract holders to provide to them an agreed upon rate of return pursuant to the terms of the underlying contract. These contracts represent lending by the contract holders to the entity in return for a guaranteed (primarily fixed) interest rate until maturity, unless called earlier if the contracts provide that option to the contract holders (usually institutions). There is little or no insurance risk for the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.14)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BorrowingsUnderGuaranteedInvestmentAgreements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeForwardInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stated rate on an interest rate forward or futures contract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeForwardInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrantsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of amounts due under the terms of governmental, corporate, or foundation grants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrantsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrantsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of amounts due under the terms of governmental, corporate, or foundation grants. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrantsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RoyaltyExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyGuaranteesCommitmentsAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount the entity has committed to make for future royalty guarantees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6473578&amp;loc=d3e63223-108013<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RoyaltyGuaranteesCommitmentsAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of subsidiary's or equity investee's stock owned by parent company after stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140194446205080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2022 </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gmda_ShareholdersEquityDetailsLineItems', window );"><strong>Shareholders' Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gmda_UnderwritersDescription', window );">Underwriters description</a></td>
<td class="text">Subject to the Company&#8217;s
amended and restated Articles of Association, the holders of the Company&#8217;s ordinary shares have the right to receive notices to
attend and vote in general meetings of the Company&#8217;s shareholders, and the right to share in dividends and other distributions
upon liquidation.&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gmda_ExpiryDate', window );">Expire date</a></td>
<td class="text">As part of its 2017
investment round, the Company granted certain investors 4,323,978 warrants that will expire in July 2022.<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_InvestorMember', window );">2017 Investor [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gmda_ShareholdersEquityDetailsLineItems', window );"><strong>Shareholders' Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted', window );">Granted Warrants</a></td>
<td class="nump">4,323,978<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gmda_ShareholdersEquityDetailsLineItems', window );"><strong>Shareholders' Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted', window );">Granted Warrants</a></td>
<td class="nump">1,010,466<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gmda_ExpiryDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gmda_ExpiryDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gmda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gmda_ShareholdersEquityDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gmda_ShareholdersEquityDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gmda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gmda_UnderwritersDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description related to underwriters description.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gmda_UnderwritersDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gmda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net number of non-option equity instruments granted to participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_InvestorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_InvestorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140194441203112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Nov. 23, 2014 </div>
<div>&#8362; / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 28, 2017 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 26, 2017 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 23, 2017 </div>
<div>&#8362; / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gmda_ShareBasedCompensationDetailsLineItems', window );"><strong>Share-Based Compensation (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Options vest period</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gmda_OrdinarySharesOutstandingPercentage', window );">Ordinary shares outstanding percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Share-based compensation non-vested (in Dollars) | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,848<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis=gmda_TwoThousandSeventeenStockCompensationPlanMember', window );">2017 Share Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gmda_ShareBasedCompensationDetailsLineItems', window );"><strong>Share-Based Compensation (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Nominal per share value (in New Shekels per share) | &#8362; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8362; 0.01<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Number of shares reserved for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,338,015<span></span>
</td>
<td class="nump">559,764<span></span>
</td>
<td class="nump">463,384<span></span>
</td>
<td class="nump">312,867<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gmda_ShareBasedCompensationDetailsLineItems', window );"><strong>Share-Based Compensation (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue', window );">Grant date fair value per share (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.71<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gmda_ShareBasedCompensationDetailsLineItems', window );"><strong>Share-Based Compensation (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue', window );">Grant date fair value per share (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.85<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassCMember', window );">Ordinary C Share [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gmda_ShareBasedCompensationDetailsLineItems', window );"><strong>Share-Based Compensation (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Nominal per share value (in New Shekels per share) | &#8362; / shares</a></td>
<td class="nump">&#8362; 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeStockOwnershipPlanESOPNumberOfAllocatedShares', window );">Ordinary shares</a></td>
<td class="nump">1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassCMember', window );">Ordinary C Share [Member] | 2014 Israel Share Option Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gmda_ShareBasedCompensationDetailsLineItems', window );"><strong>Share-Based Compensation (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeStockOwnershipPlanESOPNumberOfSuspenseShares', window );">Ordinary shares issued</a></td>
<td class="nump">1,152,044<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gmda_OrdinarySharesOutstandingPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gmda_OrdinarySharesOutstandingPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gmda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gmda_ShareBasedCompensationDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gmda_ShareBasedCompensationDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gmda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeStockOwnershipPlanESOPNumberOfAllocatedShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The shares or units in an ESOP trust that have been assigned to individual participant accounts based on a known formula. IRS rules require allocations to be nondiscriminatory generally based on compensation, length of service, or a combination of both. For any particular participant such shares or units may be vested, unvested, or partially vested.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 40<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=109244661&amp;loc=d3e17540-113929<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeStockOwnershipPlanESOPNumberOfAllocatedShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeStockOwnershipPlanESOPNumberOfSuspenseShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Shares contributed to the ESOP that have not yet been released, committed to be released, or allocated to participant accounts. Suspense shares generally collateralize ESOP debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 40<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=109244661&amp;loc=d3e17540-113929<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeStockOwnershipPlanESOPNumberOfSuspenseShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of options vested.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis=gmda_TwoThousandSeventeenStockCompensationPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis=gmda_TwoThousandSeventeenStockCompensationPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis=gmda_TwoZeroOneFourIsraelShareOptionPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis=gmda_TwoZeroOneFourIsraelShareOptionPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140194446238136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation (Details) - Schedule of fair value measurement of equity-settled share options<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gmda_ScheduleOfFairValueMeasurementOfEquitySettledShareOptionsAbstract', window );"><strong>Schedule of fair value measurement of equity-settled share options [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility of the share prices</a></td>
<td class="nump">66.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">1.80%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">8 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gmda_ScheduleOfFairValueMeasurementOfEquitySettledShareOptionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gmda_ScheduleOfFairValueMeasurementOfEquitySettledShareOptionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gmda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140194444278104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation (Details) - Schedule of stock option plans<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gmda_ScheduleOfStockOptionPlansAbstract', window );"><strong>Schedule of stock option plans [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Amount of options and restricted share unites, beginning balance | shares</a></td>
<td class="nump">4,411,424<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, beginning balance | $ / shares</a></td>
<td class="nump">$ 6.01<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gmda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrosses', window );">Amount of options and restricted share unites, Granted | shares</a></td>
<td class="nump">1,181,100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, Granted | $ / shares</a></td>
<td class="nump">$ 2.93<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gmda_StockIssuedDuringPeriodSharesStockOptionesExercised', window );">Amount of options and restricted share unites, Exercised | shares</a></td>
<td class="num">(47,426)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, Exercised | $ / shares</a></td>
<td class="nump">$ 1.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gmda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriods', window );">Amount of options and restricted share unites, Forfeited | shares</a></td>
<td class="num">(301,215)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, Forfeited | $ / shares</a></td>
<td class="nump">$ 6.74<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Amount of options and restricted share unites, Expired | shares</a></td>
<td class="num">(18,349)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, Expired | $ / shares</a></td>
<td class="nump">$ 6.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Amount of options and restricted share unites, ending balance | shares</a></td>
<td class="nump">5,225,534<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, ending balance | $ / shares</a></td>
<td class="nump">$ 5.31<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gmda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableInPeriod', window );">Amount of options and restricted share unites, Exercisable | shares</a></td>
<td class="nump">2,417,453<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gmda_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisableInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, Exercisable | $ / shares</a></td>
<td class="nump">$ 5.9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gmda_ScheduleOfStockOptionPlansAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gmda_ScheduleOfStockOptionPlansAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gmda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gmda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercisable has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gmda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gmda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gmda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of options, Forfeited.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gmda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gmda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gmda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of options, Granted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gmda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gmda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gmda_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisableInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gmda_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisableInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gmda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gmda_StockIssuedDuringPeriodSharesStockOptionesExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period shares stock options exercised.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gmda_StockIssuedDuringPeriodSharesStockOptionesExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gmda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140194446065400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation (Details) - Schedule of restricted shares activity<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gmda_ScheduleOfRestrictedSharesActivityAbstract', window );"><strong>Schedule of restricted shares activity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Amount of restricted shares and restricted shares units, Unvested beginning | shares</a></td>
<td class="nump">531,477<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue', window );">Weighted average grant date fair value, Unvested beginning | $ / shares</a></td>
<td class="nump">$ 5.48<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Amount of restricted shares and restricted shares units, Granted | shares</a></td>
<td class="nump">937,300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue', window );">Weighted average grant date fair value, Granted | $ / shares</a></td>
<td class="nump">$ 2.93<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Amount of restricted shares and restricted shares units, Vested | shares</a></td>
<td class="num">(42,911)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodIntrinsicValue', window );">Weighted average grant date fair value, Vested | $ / shares</a></td>
<td class="nump">$ 9.46<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Amount of restricted shares and restricted shares units, Forfeited | shares</a></td>
<td class="num">(75,117)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue', window );">Weighted average grant date fair value, Forfeited | $ / shares</a></td>
<td class="nump">$ 6.26<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Amount of restricted shares and restricted shares units, Unvested ending | shares</a></td>
<td class="nump">1,350,749<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue', window );">Weighted average grant date fair value, Unvested ending | $ / shares</a></td>
<td class="nump">$ 3.54<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gmda_ScheduleOfRestrictedSharesActivityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gmda_ScheduleOfRestrictedSharesActivityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gmda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average intrinsic value of award forfeited under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average intrinsic value of award granted under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average intrinsic value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average intrinsic value of award vested under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140194449673544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation (Details) - Schedule of share-based compensation expense - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gmda_ScheduleOfShareBasedCompensationExpenseAbstract', window );"><strong>Schedule of share-based compensation expense [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expenses, net</a></td>
<td class="nump">$ 465<span></span>
</td>
<td class="nump">$ 311<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpensesRelatedParty', window );">Commercial expenses</a></td>
<td class="nump">290<span></span>
</td>
<td class="nump">171<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">439<span></span>
</td>
<td class="nump">431<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation</a></td>
<td class="nump">$ 1,194<span></span>
</td>
<td class="nump">$ 913<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gmda_ScheduleOfShareBasedCompensationExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gmda_ScheduleOfShareBasedCompensationExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gmda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Costs of sales and operating expenses for the period incurred from transactions with related parties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm140194446316680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basic and Diluted Net Loss Per Share (Details) - Schedule of number of shares and loss used in the computation of net loss per share - For the computation of diluted loss [Member] - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gmda_BasicandDilutedNetLossPerShareDetailsScheduleofnumberofsharesandlossusedinthecomputationofnetlosspershareLineItems', window );"><strong>Basic and Diluted Net Loss Per Share (Details) - Schedule of number of shares and loss used in the computation of net loss per share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_gmda_WeightedAverageNumberOfSharesOutstandingBasicAndDiluted', window );">Weighted number of shares</a></td>
<td class="nump">59,474,366<span></span>
</td>
<td class="nump">59,122,973<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted', window );">Net loss attributable to equity holders of the Company</a></td>
<td class="nump">$ 20,223<span></span>
</td>
<td class="nump">$ 19,186<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gmda_BasicandDilutedNetLossPerShareDetailsScheduleofnumberofsharesandlossusedinthecomputationofnetlosspershareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gmda_BasicandDilutedNetLossPerShareDetailsScheduleofnumberofsharesandlossusedinthecomputationofnetlosspershareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gmda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gmda_WeightedAverageNumberOfSharesOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gmda_WeightedAverageNumberOfSharesOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>gmda_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1930-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1930-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1930-109256<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1930-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_gmda_LossPerShareAxis=gmda_ForTheComputationOfDilutedLossMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">gmda_LossPerShareAxis=gmda_ForTheComputationOfDilutedLossMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>f10q0322_gamidacell_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:gmda="http://www.gamidacell.com/20220331"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:pf0="http://fasb.org/srt/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="gmda-20220331.xsd" xlink:type="simple"/>
    <context id="c0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600847</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600847</identifier>
        </entity>
        <period>
            <instant>2022-05-09</instant>
        </period>
    </context>
    <context id="c2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600847</identifier>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="c3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600847</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600847</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="c5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600847</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600847</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600847</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600847</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600847</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="c10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600847</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="c11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600847</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="c12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600847</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="c13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600847</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="c14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600847</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="c15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600847</identifier>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="c16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600847</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600847</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600847</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600847</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600847</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600847</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600847</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600847</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="c24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600847</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="c25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600847</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="c26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600847</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="c27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600847</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600847</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-02</startDate>
            <endDate>2021-02-16</endDate>
        </period>
    </context>
    <context id="c29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600847</identifier>
        </entity>
        <period>
            <startDate>2021-02-02</startDate>
            <endDate>2021-02-16</endDate>
        </period>
    </context>
    <context id="c30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600847</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="c31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600847</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:ConvertibleNotesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c32">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600847</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="c33">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600847</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="c34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600847</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600847</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c36">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600847</identifier>
            <segment>
                <xbrldi:explicitMember dimension="pf0:RangeAxis">pf0:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="c37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600847</identifier>
            <segment>
                <xbrldi:explicitMember dimension="pf0:RangeAxis">pf0:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="c38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600847</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600847</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600847</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2014-11-23</instant>
        </period>
    </context>
    <context id="c41">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600847</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">gmda:TwoZeroOneFourIsraelShareOptionPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2014-11-23</instant>
        </period>
    </context>
    <context id="c42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600847</identifier>
        </entity>
        <period>
            <startDate>2014-11-01</startDate>
            <endDate>2014-11-23</endDate>
        </period>
    </context>
    <context id="c43">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600847</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">gmda:TwoThousandSeventeenStockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-01-23</instant>
        </period>
    </context>
    <context id="c44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600847</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">gmda:TwoThousandSeventeenStockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-06-26</instant>
        </period>
    </context>
    <context id="c45">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600847</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">gmda:TwoThousandSeventeenStockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-28</instant>
        </period>
    </context>
    <context id="c46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600847</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">gmda:TwoThousandSeventeenStockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="c47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600847</identifier>
            <segment>
                <xbrldi:explicitMember dimension="pf0:RangeAxis">pf0:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600847</identifier>
            <segment>
                <xbrldi:explicitMember dimension="pf0:RangeAxis">pf0:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600847</identifier>
            <segment>
                <xbrldi:explicitMember dimension="gmda:LossPerShareAxis">gmda:ForTheComputationOfDilutedLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001600847</identifier>
            <segment>
                <xbrldi:explicitMember dimension="gmda:LossPerShareAxis">gmda:ForTheComputationOfDilutedLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="ilsPershares">
        <divide>
            <unitNumerator>
                <measure>iso4217:ILS</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="usdPershares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="pure">
        <measure>pure</measure>
    </unit>
    <dei:DocumentType contextRef="c0">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport contextRef="c0">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate contextRef="c0">2022-03-31</dei:DocumentPeriodEndDate>
    <dei:DocumentFiscalYearFocus contextRef="c0">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport contextRef="c0">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="c0">001-38716</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="c0">GAMIDA CELL LTD.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c0">L3</dei:EntityIncorporationStateCountryCode>
    <dei:EntityAddressAddressLine1 contextRef="c0">116 Huntington Avenue</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="c0">Boston</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c0">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c0">02116</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c0">(617)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c0">892-9080</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="c0">Ordinary Shares, par value NIS 0.01 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c0">GMDA</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c0">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus contextRef="c0">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="c0">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="c0">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="c0">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="c0">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="c0">false</dei:EntityExTransitionPeriod>
    <dei:EntityShellCompany contextRef="c0">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding contextRef="c1" decimals="INF" unitRef="shares">59946298</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c2" decimals="-3" unitRef="usd">42057000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c3" decimals="-3" unitRef="usd">55892000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent contextRef="c2" decimals="-3" unitRef="usd">27661000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent contextRef="c3" decimals="-3" unitRef="usd">40034000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c2" decimals="-3" unitRef="usd">2994000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c3" decimals="-3" unitRef="usd">2688000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c2" decimals="-3" unitRef="usd">72712000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c3" decimals="-3" unitRef="usd">98614000</us-gaap:AssetsCurrent>
    <us-gaap:RestrictedInvestmentsNoncurrent contextRef="c2" decimals="-3" unitRef="usd">3893000</us-gaap:RestrictedInvestmentsNoncurrent>
    <us-gaap:RestrictedInvestmentsNoncurrent contextRef="c3" decimals="-3" unitRef="usd">3961000</us-gaap:RestrictedInvestmentsNoncurrent>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c2" decimals="-3" unitRef="usd">37533000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c3" decimals="-3" unitRef="usd">35180000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c2" decimals="-3" unitRef="usd">6722000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c3" decimals="-3" unitRef="usd">7236000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherLongTermInvestments contextRef="c2" decimals="-3" unitRef="usd">2046000</us-gaap:OtherLongTermInvestments>
    <us-gaap:OtherLongTermInvestments contextRef="c3" decimals="-3" unitRef="usd">2148000</us-gaap:OtherLongTermInvestments>
    <us-gaap:OtherAssetsNoncurrent contextRef="c2" decimals="-3" unitRef="usd">1632000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent contextRef="c3" decimals="-3" unitRef="usd">1647000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:AssetsNoncurrent contextRef="c2" decimals="-3" unitRef="usd">51826000</us-gaap:AssetsNoncurrent>
    <us-gaap:AssetsNoncurrent contextRef="c3" decimals="-3" unitRef="usd">50172000</us-gaap:AssetsNoncurrent>
    <us-gaap:Assets contextRef="c2" decimals="-3" unitRef="usd">124538000</us-gaap:Assets>
    <us-gaap:Assets contextRef="c3" decimals="-3" unitRef="usd">148786000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent contextRef="c2" decimals="-3" unitRef="usd">4346000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="c3" decimals="-3" unitRef="usd">8272000</us-gaap:AccountsPayableCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="c2" decimals="-3" unitRef="usd">4119000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="c3" decimals="-3" unitRef="usd">4957000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c2" decimals="-3" unitRef="usd">2596000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c3" decimals="-3" unitRef="usd">2699000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:NotesPayableCurrent contextRef="c2" decimals="-3" unitRef="usd">551000</us-gaap:NotesPayableCurrent>
    <us-gaap:NotesPayableCurrent contextRef="c3" decimals="-3" unitRef="usd">1640000</us-gaap:NotesPayableCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="c2" decimals="-3" unitRef="usd">8866000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="c3" decimals="-3" unitRef="usd">7865000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c2" decimals="-3" unitRef="usd">20478000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c3" decimals="-3" unitRef="usd">25433000</us-gaap:LiabilitiesCurrent>
    <us-gaap:ConvertibleLongTermNotesPayable contextRef="c2" decimals="-3" unitRef="usd">71607000</us-gaap:ConvertibleLongTermNotesPayable>
    <us-gaap:ConvertibleLongTermNotesPayable contextRef="c3" decimals="-3" unitRef="usd">71417000</us-gaap:ConvertibleLongTermNotesPayable>
    <us-gaap:OtherAccruedLiabilitiesNoncurrent contextRef="c2" decimals="-3" unitRef="usd">2327000</us-gaap:OtherAccruedLiabilitiesNoncurrent>
    <us-gaap:OtherAccruedLiabilitiesNoncurrent contextRef="c3" decimals="-3" unitRef="usd">2396000</us-gaap:OtherAccruedLiabilitiesNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c2" decimals="-3" unitRef="usd">5142000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c3" decimals="-3" unitRef="usd">5603000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:LiabilitiesNoncurrent contextRef="c2" decimals="-3" unitRef="usd">79076000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent contextRef="c3" decimals="-3" unitRef="usd">79416000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:CommonStockParOrStatedValuePerShare contextRef="c2" decimals="2" unitRef="ilsPershares">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare contextRef="c3" decimals="2" unitRef="ilsPershares">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="c2" decimals="INF" unitRef="shares">150000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="c3" decimals="INF" unitRef="shares">150000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued contextRef="c2" decimals="INF" unitRef="shares">60021415</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued contextRef="c3" decimals="INF" unitRef="shares">59970389</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="c2" decimals="INF" unitRef="shares">59946298</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding contextRef="c3" decimals="INF" unitRef="shares">59970389</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue contextRef="c2" decimals="-3" unitRef="usd">169000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="c3" decimals="-3" unitRef="usd">169000</us-gaap:CommonStockValue>
    <us-gaap:TemporaryEquitySharesAuthorized contextRef="c2" decimals="INF" unitRef="shares">0.01</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesAuthorized contextRef="c3" decimals="INF" unitRef="shares">0.01</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TreasuryStockShares contextRef="c2" decimals="INF" unitRef="shares">75117</us-gaap:TreasuryStockShares>
    <us-gaap:TreasuryStockShares contextRef="c3" decimals="INF" unitRef="shares">0</us-gaap:TreasuryStockShares>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="c2" decimals="-3" unitRef="usd">382495000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="c3" decimals="-3" unitRef="usd">381225000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c2" decimals="-3" unitRef="usd">-357680000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c3" decimals="-3" unitRef="usd">-337457000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquity contextRef="c2" decimals="-3" unitRef="usd">24984000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c3" decimals="-3" unitRef="usd">43937000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c2" decimals="-3" unitRef="usd">124538000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c3" decimals="-3" unitRef="usd">148786000</us-gaap:LiabilitiesAndStockholdersEquity>
    <gmda:ResearchAndDevelopmentExpensesNet contextRef="c0" decimals="-3" unitRef="usd">11305000</gmda:ResearchAndDevelopmentExpensesNet>
    <gmda:ResearchAndDevelopmentExpensesNet contextRef="c4" decimals="-3" unitRef="usd">11360000</gmda:ResearchAndDevelopmentExpensesNet>
    <gmda:CommercialExpenses contextRef="c0" decimals="-3" unitRef="usd">3879000</gmda:CommercialExpenses>
    <gmda:CommercialExpenses contextRef="c4" decimals="-3" unitRef="usd">4231000</gmda:CommercialExpenses>
    <gmda:GeneralAndAdministrativeExpenses contextRef="c0" decimals="-3" unitRef="usd">4139000</gmda:GeneralAndAdministrativeExpenses>
    <gmda:GeneralAndAdministrativeExpenses contextRef="c4" decimals="-3" unitRef="usd">3513000</gmda:GeneralAndAdministrativeExpenses>
    <us-gaap:OperatingIncomeLoss contextRef="c0" decimals="-3" unitRef="usd">-19323000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c4" decimals="-3" unitRef="usd">-19104000</us-gaap:OperatingIncomeLoss>
    <us-gaap:NonoperatingIncomeExpense contextRef="c0" decimals="-3" unitRef="usd">-900000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c4" decimals="-3" unitRef="usd">-82000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:ProfitLoss contextRef="c0" decimals="-3" unitRef="usd">-20223000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c4" decimals="-3" unitRef="usd">-19186000</us-gaap:ProfitLoss>
    <us-gaap:EarningsPerShareBasic contextRef="c0" decimals="2" unitRef="usdPershares">0.34</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic contextRef="c4" decimals="2" unitRef="usdPershares">0.32</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c0" decimals="INF" unitRef="shares">59474366</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c4" decimals="INF" unitRef="shares">59122973</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:SharesOutstanding contextRef="c5" decimals="INF" unitRef="shares">59000153</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c5" decimals="-3" unitRef="usd">166000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c6" decimals="-3" unitRef="usd">376369000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c7" decimals="-3" unitRef="usd">-247664000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c8" decimals="-3" unitRef="usd">128871000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross contextRef="c9" decimals="INF" unitRef="shares">159134</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="c9" decimals="INF" unitRef="shares">247685</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c9" decimals="-3" unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c10" decimals="-3" unitRef="usd">501000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c4" decimals="-3" unitRef="usd">502000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:EmployeeBenefitsAndShareBasedCompensation contextRef="c10" decimals="-3" unitRef="usd">913000</us-gaap:EmployeeBenefitsAndShareBasedCompensation>
    <us-gaap:EmployeeBenefitsAndShareBasedCompensation contextRef="c4" decimals="-3" unitRef="usd">913000</us-gaap:EmployeeBenefitsAndShareBasedCompensation>
    <us-gaap:NetIncomeLoss contextRef="c11" decimals="-3" unitRef="usd">-19186000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c4" decimals="-3" unitRef="usd">-19186000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding contextRef="c12" decimals="INF" unitRef="shares">59406972</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c12" decimals="-3" unitRef="usd">167000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c13" decimals="-3" unitRef="usd">377783000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c14" decimals="-3" unitRef="usd">-266850000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c15" decimals="-3" unitRef="usd">111100000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding contextRef="c16" decimals="INF" unitRef="shares">59970389</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c16" decimals="-3" unitRef="usd">169000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c17" decimals="-3" unitRef="usd">381225000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c18" decimals="-3" unitRef="usd">-337457000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c3" decimals="-3" unitRef="usd">43937000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross contextRef="c19" decimals="INF" unitRef="shares">3600</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:TreasuryStockSharesRetired contextRef="c19" decimals="INF" unitRef="shares">-75117</us-gaap:TreasuryStockSharesRetired>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="c19" decimals="INF" unitRef="shares">47426</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c20" decimals="-3" unitRef="usd">76000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c0" decimals="-3" unitRef="usd">76000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:EmployeeBenefitsAndShareBasedCompensation contextRef="c20" decimals="-3" unitRef="usd">1194000</us-gaap:EmployeeBenefitsAndShareBasedCompensation>
    <us-gaap:EmployeeBenefitsAndShareBasedCompensation contextRef="c0" decimals="-3" unitRef="usd">1194000</us-gaap:EmployeeBenefitsAndShareBasedCompensation>
    <us-gaap:NetIncomeLoss contextRef="c22" decimals="-3" unitRef="usd">-20223000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c0" decimals="-3" unitRef="usd">-20223000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding contextRef="c23" decimals="INF" unitRef="shares">59946298</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c23" decimals="-3" unitRef="usd">169000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c25" decimals="-3" unitRef="usd">382495000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c26" decimals="-3" unitRef="usd">-357680000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c2" decimals="-3" unitRef="usd">24984000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss contextRef="c0" decimals="-3" unitRef="usd">-20223000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c4" decimals="-3" unitRef="usd">-19186000</us-gaap:NetIncomeLoss>
    <us-gaap:Depreciation contextRef="c0" decimals="-3" unitRef="usd">112000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c4" decimals="-3" unitRef="usd">98000</us-gaap:Depreciation>
    <us-gaap:CostsAndExpenses contextRef="c0" decimals="-3" unitRef="usd">-1172000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses contextRef="c4" decimals="-3" unitRef="usd">220000</us-gaap:CostsAndExpenses>
    <us-gaap:ShareBasedCompensation contextRef="c0" decimals="-3" unitRef="usd">1194000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c4" decimals="-3" unitRef="usd">913000</us-gaap:ShareBasedCompensation>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts contextRef="c0" decimals="-3" unitRef="usd">191000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts contextRef="c4" decimals="-3" unitRef="usd">323000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability contextRef="c0" decimals="-3" unitRef="usd">562000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability contextRef="c4" decimals="-3" unitRef="usd">516000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability contextRef="c0" decimals="-3" unitRef="usd">-613000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability contextRef="c4" decimals="-3" unitRef="usd">-929000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInPostemploymentObligations contextRef="c0" decimals="-3" unitRef="usd">33000</us-gaap:IncreaseDecreaseInPostemploymentObligations>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c0" decimals="-3" unitRef="usd">889000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c4" decimals="-3" unitRef="usd">515000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableTrade contextRef="c0" decimals="-3" unitRef="usd">-3927000</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
    <us-gaap:IncreaseDecreaseInAccountsPayableTrade contextRef="c4" decimals="-3" unitRef="usd">907000</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="c0" decimals="-3" unitRef="usd">-996000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="c4" decimals="-3" unitRef="usd">-3192000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c0" decimals="-3" unitRef="usd">-25728000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c4" decimals="-3" unitRef="usd">-20845000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c0" decimals="-3" unitRef="usd">723000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c4" decimals="-3" unitRef="usd">2806000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireMarketableSecurities contextRef="c0" decimals="-3" unitRef="usd">2086000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities contextRef="c0" decimals="-3" unitRef="usd">14126000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired contextRef="c0" decimals="-3" unitRef="usd">-500000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c0" decimals="-3" unitRef="usd">11817000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c4" decimals="-3" unitRef="usd">-2806000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="c0" decimals="-3" unitRef="usd">76000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="c4" decimals="-3" unitRef="usd">502000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c4" decimals="-3" unitRef="usd">70777000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c0" decimals="-3" unitRef="usd">76000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c4" decimals="-3" unitRef="usd">71279000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect contextRef="c0" decimals="-3" unitRef="usd">-13835000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect contextRef="c4" decimals="-3" unitRef="usd">47628000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="c3" decimals="-3" unitRef="usd">55892000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="c8" decimals="-3" unitRef="usd">127170000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="c2" decimals="-3" unitRef="usd">42057000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="c15" decimals="-3" unitRef="usd">174798000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <gmda:IssuanceExpensesOnCredit contextRef="c4" decimals="-3" unitRef="usd">235000</gmda:IssuanceExpensesOnCredit>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment contextRef="c0" decimals="-3" unitRef="usd">1160000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment contextRef="c4" decimals="-3" unitRef="usd">216000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:InterestPaidNet contextRef="c0" decimals="-3" unitRef="usd">2203000</us-gaap:InterestPaidNet>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="c0">&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2cm; text-align: justify; text-indent: -2cm"&gt;NOTE 1:- GENERAL&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2cm; text-align: justify; text-indent: 0cm"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.75in"/&gt;&lt;td style="width: 0.5in; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;a.&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;Gamida
                                            Cell Ltd. (the &#x201c;Company&#x201d;), founded in 1998, is an advanced cell therapy company
                                            committed to cures for blood cancers and serious hematologic diseases. The Company harnesses
                                            its cell expansion platform to create therapies with the potential to redefine standards
                                            of care in areas of serious medical need&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3cm; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.75in"/&gt;&lt;td style="width: 0.5in"&gt;b.&lt;/td&gt;&lt;td style="text-align: justify"&gt;The Company has leveraged its NAM platform,
                                            or nicotinamide cell expansion technology platform, to develop a pipeline of product candidates
                                            designed to address the limitations of other cell therapies. The Company&#x2019;s proprietary
                                            technology allows for the proliferation and enhancement of donor cells, which allows for
                                            maintenance of the cells&#x2019; functional therapeutic characteristics, providing a potential
                                            treatment alternative for patients.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3cm; text-align: justify; text-indent: -1cm"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The lead product candidate, omidubicel,
is an advanced cell therapy in development as a potential life-saving treatment option for patients in need of a bone marrow transplant
(BMT). In May 2020, the Company reported that omidubicel met its primary endpoint in an international, randomized, multi-center Phase
3 clinical study in 125 patients with high-risk hematologic malignancies undergoing bone marrow transplant and who had no available matched
donor. The study evaluated the safety and efficacy of omidubicel compared to standard umbilical cord blood. BMT with a graft derived
from bone marrow or peripheral blood cells of a matched donor is currently the standard of care treatment for many of these patients,
but there is a significant unmet need for patients who cannot find a fully matched donor.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3cm; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;In October 2021, the complete results
from the Company&#x2019;s pivotal Phase 3 clinical study of omidubicel in 125 patients with various hematologic malignancies were published
in the peer-reviewed medical journal Blood. The trial achieved its primary endpoint of time to neutrophil engraftment as well as all
three of the prespecified secondary endpoints. These secondary endpoints were the proportion of patients who achieved platelet engraftment
by day 42, the proportion of patients with grade 2 or grade 3 bacterial or invasive fungal infections in the first 100 days following
transplant, and the number of days alive and out of the hospital in the first 100 days following transplant. All three secondary endpoints
demonstrated statistical significance in an intent-to-treat analysis.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3cm; text-align: justify; text-indent: 0cm"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;Omidubicel is the first bone marrow
transplant product to receive Breakthrough Therapy Designation from the U.S. Food and Drug Administration and has received orphan drug
designation in the U.S. and in Europe.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3cm; text-align: justify; text-indent: 0cm"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;In addition to omidubicel, the Company
is developing GDA-201, an investigational natural killer (&#x201c;NK&#x201d;) cell-based cancer immunotherapy that is intended to be used
in combination with standard-of-care therapeutic antibodies, as well as other product candidates in the Company&#x2019;s NK cell pipeline.
NK cells have potent anti-tumor properties and have the advantage over other oncology cell therapies of not requiring genetic matching,
potentially enabling NK cells to serve as a universal donor-based therapy when combined with certain antibodies. GDA-201 is currently
in an investigator-sponsored Phase 1/2 study for the treatment of relapsed or refractory non-Hodgkin lymphoma (NHL). Data from the 35
patients in the Phase 1/2 study demonstrated that GDA-201 was clinically active and generally well tolerated. Among the 19 patients with
NHL, 13 complete responses and one partial response were observed, with an overall response rate of 74% and a complete response rate
of 68%.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3cm; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;At the December 2021 Annual Meeting
of America Society of Hematology, the Company reported two-year follow-up data from this clinical trial on outcomes and cytokine biomarkers
associated with survival. The data demonstrated a median duration of response of 16 months (range 5-36 months), an overall survival at
two years of 78% (95% CI, 51%&#x2013;91%) and a safety profile similar to that reported previously.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3cm; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.75in"/&gt;&lt;td style="width: 0.5in"&gt;c.&lt;/td&gt;&lt;td style="text-align: justify"&gt;Basis of presentation of the financial
                                            statements:&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3cm; text-align: justify; text-indent: 0cm"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The accompanying unaudited condensed
consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States
of America (&#x201c;U.S. GAAP&#x201d;) for interim financial information and in accordance with the instructions to Form 10-Q and Article
10 of Regulation S-X promulgated by the U.S Securities and Exchange Commission (the &#x201c;SEC&#x201d;). Certain information or footnote
disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted, pursuant
to the rules and regulations of the SEC for interim financial reporting. Accordingly, they do not include all the information and footnotes
necessary for a complete presentation of financial position, results of operations, or cash flows. In the opinion of management, the
accompanying unaudited condensed consolidated financial statements include all adjustments, consisting of a normal recurring nature,
which are necessary for a fair presentation of the financial position, operating results and cash flows for the periods presented.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3cm; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The accompanying unaudited condensed
consolidated financial statements should be read in conjunction with the Company&#x2019;s Annual Report on Form 10-K as of December 31,
2021 filed with the SEC on March 24, 2022. The interim period results do not necessarily indicate the results that may be expected for
any other interim period or for the full fiscal year.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3cm; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;Prior to 2021, the Company prepared
its financial statements in accordance with International Financial Reporting Standards (IFRS), as issued by the International Accounting
Standards Board (IASB), as permitted in the United States based on the Company&#x2019;s qualification as a &#x201c;foreign private issuer&#x201d;
under the rules and regulations of the SEC. In connection with the loss of the Company&#x2019;s status as a foreign private issuer effective
on January 1, 2022, the Company, as a domestic filer, prepared its consolidated financial statements in accordance with U.S. GAAP.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3cm; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.75in"/&gt;&lt;td style="width: 0.5in; text-align: left"&gt;d.&lt;/td&gt;&lt;td style="text-align: justify"&gt;The Company continues to devote substantially all of its efforts toward
research and development activities. In the course of such activities, the Company has sustained operating losses and expects such losses
to continue in the foreseeable future. The Company's accumulated deficit as of March&#160;31, 2022 was $357,680 and negative cash flows
from operating activities during the three-month period ended March 31, 2022 was $25,728. The Company is planning to finance its operations
from its existing and future working capital resources and to continue to evaluate additional sources of capital and financing. However,
there is no assurance that additional capital and/or financing will be available to the Company, and even if available, whether it will
be on terms acceptable to the Company or in amounts required. The Company believes that its existing capital resources will be adequate
to satisfy its expected liquidity requirements for at least twelve months from the issuance of the condensed consolidated financial statements.&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3cm; text-align: justify; text-indent: -1cm"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.75in"/&gt;&lt;td style="width: 0.5in"&gt;e.&lt;/td&gt;&lt;td style="text-align: justify"&gt;The Company has a wholly owned U.S. subsidiary, Gamida Cell Inc. (the &#x201c;Subsidiary&#x201d;), which was incorporated in 2000, under the laws of the State of Delaware. The Company has one operating segment and reporting unit.&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <gmda:ResponseRatePercentage contextRef="c0">Among the 19 patients with
NHL, 13 complete responses and one partial response were observed, with an overall response rate of 74% and a complete response rate
of 68%.</gmda:ResponseRatePercentage>
    <gmda:ClinicalTrialOnOutcomes contextRef="c27">The data demonstrated a median duration of response of 16 months (range 5-36 months), an overall survival at
two years of 78% (95% CI, 51%&#x2013;91%) and a safety profile similar to that reported previously.</gmda:ClinicalTrialOnOutcomes>
    <gmda:AccumulatedDeficit contextRef="c2" decimals="-3" unitRef="usd">357680000</gmda:AccumulatedDeficit>
    <us-gaap:InvestmentsAndCash contextRef="c2" decimals="-3" unitRef="usd">25728000</us-gaap:InvestmentsAndCash>
    <us-gaap:NumberOfOperatingSegments contextRef="c0" decimals="0" unitRef="pure">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="c0">&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0cm"&gt;NOTE 2:- SIGNIFICANT ACCOUNTING
POLICIES&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.75in"/&gt;&lt;td style="width: 0.5in"&gt;a.&lt;/td&gt;&lt;td&gt;Use of estimates:&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3cm; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The preparation of condensed financial
statements in conformity with U.S. GAAP requires management to make estimates, judgments and assumptions that affect the amounts reported
in the consolidated financial statements and accompanying notes. The Company&#x2019;s management believes that the estimates, judgment
and assumptions used are reasonable based upon information available at the time they are made. These estimates, judgments and assumptions
can affect the reported amounts of assets and liabilities at the dates of the consolidated financial statements, and the reported amount
of expenses during the reporting periods. Actual results could differ from those estimates.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.75in"/&gt;&lt;td style="width: 0.5in"&gt;b.&lt;/td&gt;&lt;td&gt;Convertible senior notes:&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.85pt; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The Company accounts for its convertible
senior notes in accordance with ASC 470-20 &#x201c;Debt with Conversion and Other Options&#x201d;. The Company early adopted ASU 2020-06
using the modified retrospective approach. The convertible senior notes are accounted for as a single liability measured at its amortized
cost, as no other embedded features require bifurcation and recognition as derivatives according to ASC 815-40.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.75in"/&gt;&lt;td style="width: 0.5in"&gt;c.&lt;/td&gt;&lt;td&gt;Basic and diluted net loss per share:&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 88.85pt; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The Company computes net loss per
share using the&#160;two-class&#160;method required for participating securities. The&#160;two-class&#160;method requires income available
to ordinary shareholders for the period to be allocated between ordinary shares and participating securities based upon their respective
rights to receive dividends as if all income for the period had been distributed. The Company considers its restricted shares to be participating
securities as the holders of the restricted shares would be entitled to dividends that would be distributed to the holders of ordinary
shares, on a&#160;pro-rata&#160;basis. These participating securities do not contractually require the holders of such shares to participate
in the Company&#x2019;s losses. As such, net loss for the periods presented was not allocated to the Company&#x2019;s participating securities.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 84.45pt; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The Company&#x2019;s basic net loss
per share is calculated by dividing net loss attributable to ordinary shareholders by the weighted-average number of shares of ordinary
shares outstanding for the period, without consideration of potentially dilutive securities. The diluted net loss per share is calculated
by giving effect to all potentially dilutive securities outstanding for the period using the treasury share method or the&#160;if-converted&#160;method
based on the nature of such securities. Diluted net loss per share is the same as basic net loss per share in periods when the effects
of potentially dilutive ordinary shares are anti-dilutive.&lt;/p&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:UseOfEstimates contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.75in"/&gt;&lt;td style="width: 0.5in"&gt;a.&lt;/td&gt;&lt;td&gt;Use of estimates:&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3cm; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The preparation of condensed financial
statements in conformity with U.S. GAAP requires management to make estimates, judgments and assumptions that affect the amounts reported
in the consolidated financial statements and accompanying notes. The Company&#x2019;s management believes that the estimates, judgment
and assumptions used are reasonable based upon information available at the time they are made. These estimates, judgments and assumptions
can affect the reported amounts of assets and liabilities at the dates of the consolidated financial statements, and the reported amount
of expenses during the reporting periods. Actual results could differ from those estimates.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:UseOfEstimates>
    <gmda:ConvertibleSeniorNotesPolicyTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.75in"/&gt;&lt;td style="width: 0.5in"&gt;b.&lt;/td&gt;&lt;td&gt;Convertible senior notes:&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 70.85pt; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The Company accounts for its convertible
senior notes in accordance with ASC 470-20 &#x201c;Debt with Conversion and Other Options&#x201d;. The Company early adopted ASU 2020-06
using the modified retrospective approach. The convertible senior notes are accounted for as a single liability measured at its amortized
cost, as no other embedded features require bifurcation and recognition as derivatives according to ASC 815-40.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</gmda:ConvertibleSeniorNotesPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.75in"/&gt;&lt;td style="width: 0.5in"&gt;c.&lt;/td&gt;&lt;td&gt;Basic and diluted net loss per share:&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 88.85pt; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The Company computes net loss per
share using the&#160;two-class&#160;method required for participating securities. The&#160;two-class&#160;method requires income available
to ordinary shareholders for the period to be allocated between ordinary shares and participating securities based upon their respective
rights to receive dividends as if all income for the period had been distributed. The Company considers its restricted shares to be participating
securities as the holders of the restricted shares would be entitled to dividends that would be distributed to the holders of ordinary
shares, on a&#160;pro-rata&#160;basis. These participating securities do not contractually require the holders of such shares to participate
in the Company&#x2019;s losses. As such, net loss for the periods presented was not allocated to the Company&#x2019;s participating securities.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 84.45pt; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The Company&#x2019;s basic net loss
per share is calculated by dividing net loss attributable to ordinary shareholders by the weighted-average number of shares of ordinary
shares outstanding for the period, without consideration of potentially dilutive securities. The diluted net loss per share is calculated
by giving effect to all potentially dilutive securities outstanding for the period using the treasury share method or the&#160;if-converted&#160;method
based on the nature of such securities. Diluted net loss per share is the same as basic net loss per share in periods when the effects
of potentially dilutive ordinary shares are anti-dilutive.&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:LesseeOperatingLeasesTextBlock contextRef="c0">&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0cm"&gt;NOTE 3:-	LEASES&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 74.7pt; text-align: justify; text-indent: 0cm"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The Company entered into operating
leases primarily for its production plant, and its laboratories and offices. The leases have remaining lease terms of up&#160;to&#160;six
years, and the Company does not assume renewals in its determination of the lease term unless the renewals are considered as reasonably
certain at lease commencement.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2cm; text-align: justify; text-indent: 0cm"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The components of operating lease
costs were as follows:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3cm 0pt 0; text-align: justify; text-indent: 0cm"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; padding-left: 0pt; text-indent: 0pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Three months ended&lt;br/&gt;
    March 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; padding-left: 0pt; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2022&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-left: 0pt; text-indent: 0pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; text-indent: 0pt; padding-left: 0pt"&gt;Operating lease costs&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;636&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;585&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: 0pt; padding-left: 0pt"&gt;Short-term lease costs&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;24&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;60&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: 0pt; padding-left: 0pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; text-indent: 0pt; padding-left: 0pt"&gt;Total lease costs&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;660&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;645&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3cm"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;Supplemental balance sheet information
related to operating leases is as follows:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3cm 0pt 0; text-align: justify; text-indent: 0cm"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Three months&lt;br/&gt;

    ended&lt;br/&gt;
    March 31,&lt;br/&gt;
 2022&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="width: 88%; text-indent: -8.5pt; padding-left: 11.35pt"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Weighted average remaining lease term (in years)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4.12&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;Weighted average discount rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2.56&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3cm 0pt 0; text-align: justify; text-indent: 0cm"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;Maturities of lease liabilities were
as follows&lt;span style="font-family: Times New Roman, Times, Serif"&gt;:&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3cm 0pt 0; text-align: center; text-indent: 0cm"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-left: 0pt; white-space: nowrap; text-align: left; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Three months&lt;br/&gt;

    ended &lt;br/&gt; March 31,&lt;br/&gt;
 2022&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-left: 0pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left; padding-left: 0pt"&gt;2022&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2,042&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-left: 0pt"&gt;2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,742&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 0pt"&gt;2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,748&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-left: 0pt"&gt;2025&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,316&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 0pt"&gt;2026&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;790&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt"&gt;Thereafter&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;613&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-left: 0pt"&gt;Total undiscounted lease payments&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8,251&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt"&gt;Less: Imputed interest&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(513&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-left: 0pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; padding-left: 0pt"&gt;Present value of lease liabilities&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;7,738&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:LesseeOperatingLeaseRemainingLeaseTerm contextRef="c2">P6Y</us-gaap:LesseeOperatingLeaseRemainingLeaseTerm>
    <us-gaap:LeaseCostTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; padding-left: 0pt; text-indent: 0pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Three months ended&lt;br/&gt;
    March 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; padding-left: 0pt; text-indent: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2022&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-left: 0pt; text-indent: 0pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; text-indent: 0pt; padding-left: 0pt"&gt;Operating lease costs&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;636&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;585&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: 0pt; padding-left: 0pt"&gt;Short-term lease costs&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;24&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;60&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: 0pt; padding-left: 0pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; text-indent: 0pt; padding-left: 0pt"&gt;Total lease costs&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;660&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;645&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3cm"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost contextRef="c0" decimals="-3" unitRef="usd">636000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost contextRef="c4" decimals="-3" unitRef="usd">585000</us-gaap:OperatingLeaseCost>
    <us-gaap:ShortTermLeaseCost contextRef="c0" decimals="-3" unitRef="usd">24000</us-gaap:ShortTermLeaseCost>
    <us-gaap:ShortTermLeaseCost contextRef="c4" decimals="-3" unitRef="usd">60000</us-gaap:ShortTermLeaseCost>
    <us-gaap:LeaseCost contextRef="c0" decimals="-3" unitRef="usd">660000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost contextRef="c4" decimals="-3" unitRef="usd">645000</us-gaap:LeaseCost>
    <us-gaap:OperatingLeasesOfLesseeDisclosureTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Three months&lt;br/&gt;

    ended&lt;br/&gt;
    March 31,&lt;br/&gt;
 2022&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="width: 88%; text-indent: -8.5pt; padding-left: 11.35pt"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Weighted average remaining lease term (in years)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4.12&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;Weighted average discount rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2.56&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 3cm 0pt 0; text-align: justify; text-indent: 0cm"&gt;&#160;&lt;/p&gt;</us-gaap:OperatingLeasesOfLesseeDisclosureTextBlock>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c2">P4Y1M13D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="c2" decimals="4" unitRef="pure">0.0256</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-left: 0pt; white-space: nowrap; text-align: left; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Three months&lt;br/&gt;

    ended &lt;br/&gt; March 31,&lt;br/&gt;
 2022&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-left: 0pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left; padding-left: 0pt"&gt;2022&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2,042&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-left: 0pt"&gt;2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,742&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 0pt"&gt;2024&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,748&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-left: 0pt"&gt;2025&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,316&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 0pt"&gt;2026&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;790&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt"&gt;Thereafter&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;613&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-left: 0pt"&gt;Total undiscounted lease payments&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8,251&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt"&gt;Less: Imputed interest&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(513&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-left: 0pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; padding-left: 0pt"&gt;Present value of lease liabilities&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;7,738&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo contextRef="c2" decimals="-3" unitRef="usd">2042000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree contextRef="c2" decimals="-3" unitRef="usd">1742000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears contextRef="c2" decimals="-3" unitRef="usd">1748000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFiveYears contextRef="c2" decimals="-3" unitRef="usd">1316000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFiveYears>
    <gmda:LesseeOperatingLeaseLiabilityPaymentsDueYearSix contextRef="c2" decimals="-3" unitRef="usd">790000</gmda:LesseeOperatingLeaseLiabilityPaymentsDueYearSix>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive contextRef="c2" decimals="-3" unitRef="usd">613000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue contextRef="c2" decimals="-3" unitRef="usd">8251000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount contextRef="c2" decimals="-3" unitRef="usd">513000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:PresentValueOfFutureMinimumLeasePaymentsSaleLeasebackTransactions contextRef="c2" decimals="-3" unitRef="usd">7738000</us-gaap:PresentValueOfFutureMinimumLeasePaymentsSaleLeasebackTransactions>
    <gmda:DisclosureOfNotesAndOtherExplanatoryInformationsExplanatoryTextBlock contextRef="c0">&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2cm; text-align: justify; text-indent: -2cm"&gt;NOTE 4: CONVERTIBLE
SENIOR NOTES, NET&lt;/p&gt;&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2cm; text-align: justify; text-indent: -2cm"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;On February 16,
2021, the Subsidiary issued convertible senior notes (the &#x201c;Convertible Notes&#x201d;) due in 2026, in the aggregate principal amount
of $75 million, pursuant to an Indenture between the Company, the Subsidiary, and Wilmington Savings Fund Society, FSB, dated February
16, 2021 (the &#x201c;Indenture&#x201d;). The Convertible Notes bear interest payable semiannually in arrears, at a rate of 5.875% per
year. The Convertible Notes will mature on February 15, 2026, unless earlier converted, redeemed or repurchased in accordance with their
terms.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2cm 0pt 1.25in; text-align: justify; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;Subject to the provisions
of the Indenture, the holders of the Convertible Notes have the right, prior to the close of business on the second scheduled trading
day immediately preceding February 15, 2026, to convert any Convertible Notes or portion thereof that is $1,000 or an integral multiple
thereof, into the Company&#x2019;s ordinary shares at an initial conversion rate of 56.3063 shares per $1,000 principal amount of Convertible
Notes (equivalent to an exchange price of $17.76 per share). The conversion rate is subject to adjustment in specified events.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 4cm 0pt 1.25in; text-align: justify; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;Upon the occurrence
of a fundamental change (as defined in the Indenture), holders of the Convertible Notes may require the Company to repurchase for cash
all or a portion of their Convertible Notes, in multiples of $1,000 principal amount, at a repurchase price equal to 100% of the principal
amount of the Convertible Notes, plus any accrued and unpaid interest, if any, to, but excluding, interest accrued after the date of
such repurchase notice. If certain fundamental changes referred to as make-whole fundamental changes occur, the conversion rate for the
Convertible Notes may be increased.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 4cm 0pt 1.25in; text-align: justify; text-indent: 0.25in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;Subject to the provisions
of the Indenture, the Subsidiary may redeem for cash all or a portion of the Convertible Notes for cash, at its option, at a redemption
price equal to 100% of the principal amount of the Convertible Notes to be redeemed, plus accrued and unpaid interest on the notes to
be redeemed, if the last reported closing price of the Company&#x2019;s ordinary shares has been at least 130% of the exchange price then
in effect for at least 20 trading days during any 30 consecutive trading day period, and in the event of certain tax law changes.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0cm"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;The Convertible
Notes are accounted for as a single liability measured at its amortized cost, as no other embedded features require bifurcation and recognition
as derivatives according to ASC 815-40.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2cm; text-align: justify; text-indent: 0cm"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Three months&lt;br/&gt;
 ended&lt;br/&gt;
    March 31,&lt;br/&gt;
 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Liability component:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left"&gt;Principal amount&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;75,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;Issuance costs&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(4,223&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Net&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;70,777&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Amortized issuance costs&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;830&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Net carrying amount&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;71,607&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2cm; text-align: justify; text-indent: -2cm"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The total issuance costs of the Convertible
Notes amounted to $4,223 and are amortized to interest expense at an annual effective interest rate of 7.37%, over the term of the Convertible
Notes.&lt;/p&gt;</gmda:DisclosureOfNotesAndOtherExplanatoryInformationsExplanatoryTextBlock>
    <gmda:PrincipalAmount contextRef="c28" decimals="-6" unitRef="usd">75000000</gmda:PrincipalAmount>
    <gmda:AnnualInterestPercentage contextRef="c29" decimals="5" unitRef="pure">0.05875</gmda:AnnualInterestPercentage>
    <us-gaap:DebtInstrumentConvertibleConversionDate contextRef="c2">2026-02-15</us-gaap:DebtInstrumentConvertibleConversionDate>
    <us-gaap:ConvertibleNotesPayable contextRef="c2" decimals="-3" unitRef="usd">1000000</us-gaap:ConvertibleNotesPayable>
    <us-gaap:TemporaryEquitySharesIssued contextRef="c2" decimals="4" unitRef="shares">56.3063</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:ConvertibleNotesPayableCurrent contextRef="c2" decimals="-3" unitRef="usd">1000000</us-gaap:ConvertibleNotesPayableCurrent>
    <us-gaap:SharePrice contextRef="c2" decimals="2" unitRef="usdPershares">17.76</us-gaap:SharePrice>
    <us-gaap:ConvertibleNotesPayableCurrent contextRef="c30" decimals="-3" unitRef="usd">1000000</us-gaap:ConvertibleNotesPayableCurrent>
    <us-gaap:DebtInstrumentRedemptionPricePercentage contextRef="c0" decimals="2" unitRef="pure">1</us-gaap:DebtInstrumentRedemptionPricePercentage>
    <us-gaap:DebtInstrumentRedemptionPricePercentage contextRef="c31" decimals="2" unitRef="pure">1</us-gaap:DebtInstrumentRedemptionPricePercentage>
    <gmda:ExchangePricePercentage contextRef="c0" decimals="2" unitRef="pure">1.30</gmda:ExchangePricePercentage>
    <gmda:ScheduleOfLiabilityAndEquityComponentConvertibleNotesTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Three months&lt;br/&gt;
 ended&lt;br/&gt;
    March 31,&lt;br/&gt;
 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Liability component:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left"&gt;Principal amount&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;75,000&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;Issuance costs&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(4,223&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Net&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;70,777&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Amortized issuance costs&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;830&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Net carrying amount&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;71,607&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2cm; text-align: justify; text-indent: -2cm"&gt;&#160;&lt;/p&gt;</gmda:ScheduleOfLiabilityAndEquityComponentConvertibleNotesTableTextBlock>
    <gmda:AmountOfPrincipal contextRef="c0" decimals="-3" unitRef="usd">75000000</gmda:AmountOfPrincipal>
    <gmda:UnamortizedIssuanceCosts contextRef="c0" decimals="-3" unitRef="usd">-4223000</gmda:UnamortizedIssuanceCosts>
    <gmda:NetIssuanceCosts contextRef="c0" decimals="-3" unitRef="usd">70777000</gmda:NetIssuanceCosts>
    <us-gaap:AmortizationOfFinancingCosts contextRef="c0" decimals="-3" unitRef="usd">830000</us-gaap:AmortizationOfFinancingCosts>
    <gmda:NetCarryingAmountincludingAccruedInterest contextRef="c0" decimals="-3" unitRef="usd">71607000</gmda:NetCarryingAmountincludingAccruedInterest>
    <us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock contextRef="c0" decimals="-3" unitRef="usd">4223000</us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock>
    <us-gaap:DebtInstrumentInterestRateBasisForEffectiveRate contextRef="c0">7.37%</us-gaap:DebtInstrumentInterestRateBasisForEffectiveRate>
    <us-gaap:FairValueDisclosuresTextBlock contextRef="c0">&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2cm; text-align: justify; text-indent: -2cm"&gt;NOTE 5:	FAIR
VALUE MEASUREMENTS&lt;/p&gt;&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2cm; text-align: justify; text-indent: -2cm"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;The following tables present the fair
value of money market funds and marketable securities as of March 31, 2022 and December 31, 2021:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-left: 0pt; text-indent: 0pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;March 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December 31, 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-left: 0pt; text-indent: 0pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Level 1&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Level 2&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Level 1&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Level 2&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; text-align: left; text-indent: 0pt; padding-left: 0pt"&gt;Cash equivalents:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 28%; text-align: left; text-indent: 0pt; padding-left: 0pt"&gt;Money market funds&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;36,581&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-15"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;36,581&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;51,021&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-16"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;51,021&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: 0pt; padding-left: 0pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left; text-indent: 0pt; padding-left: 0pt"&gt;Marketable securities:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt"&gt;Corporate debentures&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-17"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;13,389&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;13,389&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-18"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;19,605&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;19,605&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: 0pt; padding-left: 0pt"&gt;Government debentures&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-19"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;14,272&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;14,272&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-20"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;20,429&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;20,429&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: 0pt; padding-left: 0pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; text-indent: 0pt; padding-left: 0pt"&gt;Total assets measured at fair value&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;36,581&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;27,661&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;64,242&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;51,021&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;40,034&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;91,055&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <gmda:ScheduleOfFairValueOfMoneyMarketFundsAndMarketableSecuritiesTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-left: 0pt; text-indent: 0pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;March 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December 31, 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-left: 0pt; text-indent: 0pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Level 1&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Level 2&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Level 1&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Level 2&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="font-weight: bold; text-align: left; text-indent: 0pt; padding-left: 0pt"&gt;Cash equivalents:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 28%; text-align: left; text-indent: 0pt; padding-left: 0pt"&gt;Money market funds&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;36,581&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-15"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;36,581&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;51,021&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-16"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;51,021&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: 0pt; padding-left: 0pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left; text-indent: 0pt; padding-left: 0pt"&gt;Marketable securities:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt"&gt;Corporate debentures&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-17"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;13,389&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;13,389&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-18"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;19,605&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;19,605&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: 0pt; padding-left: 0pt"&gt;Government debentures&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-19"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;14,272&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;14,272&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-20"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;20,429&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;20,429&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: 0pt; padding-left: 0pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; text-indent: 0pt; padding-left: 0pt"&gt;Total assets measured at fair value&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;36,581&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;27,661&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;64,242&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;51,021&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;40,034&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;91,055&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</gmda:ScheduleOfFairValueOfMoneyMarketFundsAndMarketableSecuritiesTableTextBlock>
    <us-gaap:MoneyMarketFundsAtCarryingValue contextRef="c32" decimals="-3" unitRef="usd">36581000</us-gaap:MoneyMarketFundsAtCarryingValue>
    <us-gaap:MoneyMarketFundsAtCarryingValue contextRef="c2" decimals="-3" unitRef="usd">36581000</us-gaap:MoneyMarketFundsAtCarryingValue>
    <us-gaap:MoneyMarketFundsAtCarryingValue contextRef="c34" decimals="-3" unitRef="usd">51021000</us-gaap:MoneyMarketFundsAtCarryingValue>
    <us-gaap:MoneyMarketFundsAtCarryingValue contextRef="c3" decimals="-3" unitRef="usd">51021000</us-gaap:MoneyMarketFundsAtCarryingValue>
    <gmda:CorporateDebentures contextRef="c33" decimals="-3" unitRef="usd">13389000</gmda:CorporateDebentures>
    <gmda:CorporateDebentures contextRef="c2" decimals="-3" unitRef="usd">13389000</gmda:CorporateDebentures>
    <gmda:CorporateDebentures contextRef="c35" decimals="-3" unitRef="usd">19605000</gmda:CorporateDebentures>
    <gmda:CorporateDebentures contextRef="c3" decimals="-3" unitRef="usd">19605000</gmda:CorporateDebentures>
    <gmda:GovernmentDebentures contextRef="c33" decimals="-3" unitRef="usd">14272000</gmda:GovernmentDebentures>
    <gmda:GovernmentDebentures contextRef="c2" decimals="-3" unitRef="usd">14272000</gmda:GovernmentDebentures>
    <gmda:GovernmentDebentures contextRef="c35" decimals="-3" unitRef="usd">20429000</gmda:GovernmentDebentures>
    <gmda:GovernmentDebentures contextRef="c3" decimals="-3" unitRef="usd">20429000</gmda:GovernmentDebentures>
    <us-gaap:FairValueNetAssetLiability contextRef="c32" decimals="-3" unitRef="usd">36581000</us-gaap:FairValueNetAssetLiability>
    <us-gaap:FairValueNetAssetLiability contextRef="c33" decimals="-3" unitRef="usd">27661000</us-gaap:FairValueNetAssetLiability>
    <us-gaap:FairValueNetAssetLiability contextRef="c2" decimals="-3" unitRef="usd">64242000</us-gaap:FairValueNetAssetLiability>
    <us-gaap:FairValueNetAssetLiability contextRef="c34" decimals="-3" unitRef="usd">51021000</us-gaap:FairValueNetAssetLiability>
    <us-gaap:FairValueNetAssetLiability contextRef="c35" decimals="-3" unitRef="usd">40034000</us-gaap:FairValueNetAssetLiability>
    <us-gaap:FairValueNetAssetLiability contextRef="c3" decimals="-3" unitRef="usd">91055000</us-gaap:FairValueNetAssetLiability>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="c0">&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2cm; text-align: justify; text-indent: -2cm"&gt;NOTE 6:	CONTINGENT
LIABILITIES AND COMMITMENTS&lt;/p&gt;&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2cm; text-align: justify; text-indent: -2cm"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.75in"/&gt;&lt;td style="width: 0.5in"&gt;a.&lt;/td&gt;&lt;td style="text-align: justify"&gt;Legal proceedings:&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2cm; text-align: justify; text-indent: 0cm"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0cm"&gt;From time to time
the Company or its subsidiaries may be involved in legal proceedings and/or litigation arising in the ordinary course of business. While
the outcome of these matters cannot be predicted with certainty, the Company does not believe it will have a material effect on its consolidated
financial position, results of operations, or cash flows.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2cm; text-align: justify; text-indent: 0cm"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.75in"/&gt;&lt;td style="width: 0.5in"&gt;b.&lt;/td&gt;&lt;td style="text-align: justify"&gt;Bank guarantees:&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2cm; text-align: justify; text-indent: 0cm"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0cm"&gt;As of March 31,
2022, the Company obtained bank guarantees in the amount of $3,266, primarily in connection with an Investment Center grant of up to
$3,106 expected to be received in 2022 which requires a bank guarantee in order to ensure the fulfillment of the grant terms.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 74.7pt; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.75in"/&gt;&lt;td style="width: 0.5in"&gt;c.&lt;/td&gt;&lt;td&gt;Government grants:&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2cm; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0cm"&gt;The Company has received grants from the IIA to finance its research
and development programs in Israel, through which the Company received IIA participation payments in the aggregate amount of $37.3 million
through March 31, 2022, of which $34.7 million is royalty-bearing grants and $2.6 million is non-royalty-bearing grants. In return, the
Company is committed to pay IIA royalties at a rate of&#160;3-3.5%&#160;of future sales of the developed products, up to 100%of the amount
of grants received plus interest at LIBOR rate. Through March&#160;31, 2022, no royalties have been paid or accrued. The Company&#x2019;s
contingent royalty liability to the IIA at March&#160;31, 2022, including grants received by the Company and the associated LIBOR interest
on all such grants totaled to $44.9 million.&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:RoyaltyGuaranteesCommitmentsAmount contextRef="c2" decimals="-3" unitRef="usd">3266000</us-gaap:RoyaltyGuaranteesCommitmentsAmount>
    <us-gaap:BorrowingsUnderGuaranteedInvestmentAgreements contextRef="c2" decimals="-3" unitRef="usd">3106000</us-gaap:BorrowingsUnderGuaranteedInvestmentAgreements>
    <us-gaap:GrantsReceivableCurrent contextRef="c2" decimals="-5" unitRef="usd">37300000</us-gaap:GrantsReceivableCurrent>
    <us-gaap:RoyaltyExpense contextRef="c0" decimals="-5" unitRef="usd">34700000</us-gaap:RoyaltyExpense>
    <us-gaap:AmortizationOfAdvanceRoyalty contextRef="c0" decimals="-5" unitRef="usd">2600000</us-gaap:AmortizationOfAdvanceRoyalty>
    <us-gaap:DerivativeForwardInterestRate contextRef="c36" decimals="2" unitRef="pure">0.03</us-gaap:DerivativeForwardInterestRate>
    <us-gaap:DerivativeForwardInterestRate contextRef="c37" decimals="3" unitRef="pure">0.005</us-gaap:DerivativeForwardInterestRate>
    <us-gaap:SaleOfStockPercentageOfOwnershipAfterTransaction contextRef="c0" decimals="2" unitRef="pure">1</us-gaap:SaleOfStockPercentageOfOwnershipAfterTransaction>
    <us-gaap:GrantsReceivable contextRef="c2" decimals="-5" unitRef="usd">44900000</us-gaap:GrantsReceivable>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="c0">&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2cm; text-align: justify; text-indent: -2cm"&gt;NOTE 7:	SHAREHOLDERS'
EQUITY&lt;/p&gt;&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2cm; text-align: justify; text-indent: -2cm"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.75in"/&gt;&lt;td style="width: 0.5in"&gt;&lt;span style="font-weight: normal"&gt;a.&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-weight: normal"&gt;Ordinary
                                            shares:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2cm; text-align: justify; text-indent: -2cm"&gt;&lt;span style="font-weight: normal"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0cm"&gt;Subject to the Company&#x2019;s
amended and restated Articles of Association, the holders of the Company&#x2019;s ordinary shares have the right to receive notices to
attend and vote in general meetings of the Company&#x2019;s shareholders, and the right to share in dividends and other distributions
upon liquidation&lt;span style="font-family: Times New Roman, Times, Serif"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2cm; text-align: justify; text-indent: 0cm"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.75in"/&gt;&lt;td style="width: 0.5in"&gt;b.&lt;/td&gt;&lt;td style="text-align: justify"&gt;Warrants to investors:&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2cm; text-align: justify; text-indent: 0cm"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0cm"&gt;As part of its 2017
investment round, the Company granted certain investors 4,323,978 warrants that will expire in July 2022. As of March 31, 2022, 1,010,466
of such warrants have been exercised into the Company&#x2019;s ordinary shares.&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <gmda:UnderwritersDescription contextRef="c0">Subject to the Company&#x2019;s
amended and restated Articles of Association, the holders of the Company&#x2019;s ordinary shares have the right to receive notices to
attend and vote in general meetings of the Company&#x2019;s shareholders, and the right to share in dividends and other distributions
upon liquidation.&#160;</gmda:UnderwritersDescription>
    <gmda:ExpiryDate contextRef="c0">As part of its 2017
investment round, the Company granted certain investors 4,323,978 warrants that will expire in July 2022.</gmda:ExpiryDate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted contextRef="c38" decimals="0" unitRef="shares">4323978</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted contextRef="c39" decimals="0" unitRef="shares">1010466</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;NOTE 8:	SHARE-BASED COMPENSATION&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3cm; text-align: justify; text-indent: -1cm"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.75in"/&gt;&lt;td style="width: 0.5in"&gt;a.&lt;/td&gt;&lt;td style="text-align: justify"&gt;Option plans:&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 74.7pt; text-align: justify; text-indent: 0cm"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0cm"&gt;On November 23,
2014, the Company&#x2019;s Board of Directors approved, subject to the approval of the shareholders, creation of the Company&#x2019;s ordinary
C share class, with nominal value NIS 0.01 per share and classification of 1,500,000 ordinary shares for such class of shares, whereby
1,152,044 of such shares were allocated to the Company&#x2019;s employees under the amended 2014 Israel Share Option Plan (the &#x201c;2014
Plan&#x201d;). The exercise price of the options granted under the 2014 Plan may not be less than the nominal value of the shares into
which the options are exercised. The options vest primarily over three years. There are no cash settlement alternatives. On December
29, 2014, the Company&#x2019;s shareholders ratified and approved the aforesaid actions.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3cm; text-align: justify; text-indent: 0cm"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0cm"&gt;On January 23, 2017,
the Company&#x2019;s Board of Directors approved the Company&#x2019;s 2017 Share Incentive Plan (the &#x201c;2017 Plan&#x201d; and together
with the 2014 Plan, the &#x201c;Option Plans&#x201d;), and the subsequent grant of options to the Company&#x2019;s employees, officers and
directors. Pursuant to the 2017 Plan, the Company initially reserved for issuance 312,867 ordinary shares, nominal value NIS 0.01 each.
On February 28, 2017, the Company&#x2019;s shareholders approved the 2017 Plan.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0cm"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0cm"&gt;The 2017 Plan provides
for the grant of awards, including options, restricted shares and restricted share units to the Company&#x2019;s directors, employees,
officers, consultants and advisors.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0cm"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0cm"&gt;On June 26, 2017
and on December 28, 2017, the Company&#x2019;s Board of Directors approved the reservation of 463,384 and 559,764 additional ordinary
shares, respectively, for issuance under the 2017 Plan (totaling, including previous plans, an aggregate of 1,338,015 ordinary Shares).&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0cm"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify"&gt;On February 25, 2021 and November
17, 2021, the board of directors and shareholders, respectively, approved an amendment and restatement of the 2017 Plan. The 2017 Plan,
as amended, also contains an &#x201c;evergreen&#x201d; provision, which provides for an automatic allotment of ordinary shares to be added
every year to the pool of ordinary shares available for grant under the 2017 Plan. Under the evergreen provision, on January 1 of each
year (beginning January 1, 2022), the number of ordinary shares available under the 2017 Plan automatically increases by the lesser of
the following: (i) 4% of our outstanding ordinary shares on the last day of the immediately preceding year; and (ii) an amount determined
in advance of January 1 by the board of directors.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3cm; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0cm"&gt;The Company estimates
the fair value of stock options granted using the binominal option-pricing model. The option-pricing model requires a number of assumptions,
of which the most significant are the expected stock price volatility and the expected option term.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0cm"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0cm"&gt;Expected volatility
was calculated based upon the Company&#x2019;s historical share price and historical volatilities of similar entities in the related sector
index. The expected term of the options granted is derived from output of the option valuation model and represents the period of time
that options granted are expected to be outstanding. The risk-free interest rate is based on the yield from U.S. treasury bonds with
an equivalent term. The Company has historically not paid dividends and has no foreseeable plans to pay dividends.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0cm"&gt;The following table
lists the inputs to the binomial option-pricing model used for the fair value measurement of equity-settled share options for the above
Options Plans as of March 31, 2022:&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4cm; text-align: justify; text-indent: -1cm"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Three months&lt;br/&gt;

    ended &lt;br/&gt;
    March 31,&lt;br/&gt;
 2022&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left; text-indent: -11.35pt; padding-left: 14.15pt"&gt;Dividend yield&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;0&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -11.35pt; padding-left: 14.15pt"&gt;Expected volatility of the share prices&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;66&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -11.35pt; padding-left: 14.15pt"&gt;Risk-free interest rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1.8&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -11.35pt; padding-left: 14.15pt"&gt;Expected term (in years)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3cm"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0cm"&gt;Based on the above
inputs, the fair value of the options was determined to be $1.71 - $1.85 per option at the grant date.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 74.7pt; text-align: justify; text-indent: 0cm"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.75in"/&gt;&lt;td style="width: 0.5in"&gt;b.&lt;/td&gt;&lt;td style="text-align: justify"&gt;The following table summarizes the number
                                            of options granted to employees under the Option Plans as of March 31, 2022 and related information:&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3cm; text-align: justify; text-indent: -1cm"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-left: 0pt; text-indent: 0pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;Amount&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;of&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;options&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;average&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;exercise&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-left: 0pt; text-indent: 0pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-indent: 0pt; padding-left: 0pt"&gt;Balance as of December 31, 2021&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;4,411,424&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;6.01&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: 0pt; padding-left: 0pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: 0pt; padding-left: 0pt"&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,181,100&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2.93&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: 0pt; padding-left: 0pt"&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(47,426&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1.60&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: 0pt; padding-left: 0pt"&gt;Forfeited&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(301,215&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6.74&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt; text-indent: 0pt; padding-left: 0pt"&gt;Expired&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(18,349&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;6.70&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: 0pt; padding-left: 0pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt; text-indent: 0pt; padding-left: 0pt"&gt;Balance as of March 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;5,225,534&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;5.31&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: 0pt; padding-left: 0pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt; text-indent: 0pt; padding-left: 0pt"&gt;Exercisable as of March 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2,417,453&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;5.90&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3cm"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0cm"&gt;As of March 31,
2022, there are $11,848 of total unrecognized costs related to share-based compensation that are expected to be recognized over a period
of up to four years.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3cm; text-align: justify; text-indent: 0cm"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.75in"/&gt;&lt;td style="width: 0.5in"&gt;&lt;span style="font-family: Times New Roman, Times, Serif"&gt;c.&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;A summary of restricted shares and restricted share units activity
as of March&#160;31, 2022 is as follows:&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 74.7pt 0pt 0; text-align: justify; text-indent: 0cm"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-left: 0pt; text-indent: 0pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;Amount of&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;restricted
                                            shares and restricted shares units&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;average&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;grant
                                            date&lt;br/&gt;
 fair value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-left: 0pt; text-indent: 0pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-indent: 0pt; padding-left: 0pt"&gt;Unvested as of December 31, 2021&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;531,477&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;5.48&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: 0pt; padding-left: 0pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: 0pt; padding-left: 0pt"&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;937,300&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2.93&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: 0pt; padding-left: 0pt"&gt;Vested&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(42,911&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;9.46&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-indent: 0pt; padding-left: 0pt"&gt;Forfeited&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(75,117&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;6.26&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: 0pt; padding-left: 0pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt; text-indent: 0pt; padding-left: 0pt"&gt;Unvested as of March 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,350,749&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;3.54&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.75in"/&gt;&lt;td style="width: 0.5in"&gt;&lt;span style="font-size: 10pt"&gt;d.&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;The
                                            total share-based compensation expense related to all of the Company's equity-based awards,
                                            recognized for the three months ended March 31, 2022 and 2021 is comprised as follows:&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-left: 0pt; text-indent: 0pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Three months ended&lt;br/&gt;
    March 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-left: 0pt; text-indent: 0pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-left: 0pt; text-indent: 0pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; text-indent: 0pt; padding-left: 0pt"&gt;Research and development expenses, net&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;465&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;311&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt"&gt;Commercial expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;290&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;171&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: 0pt; padding-left: 0pt"&gt;General and administrative expenses&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;439&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;431&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; text-indent: 0pt; padding-left: 0pt"&gt;Total share-based compensation&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,194&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;913&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:SaleOfStockPricePerShare contextRef="c40" decimals="2" unitRef="ilsPershares">0.01</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:EmployeeStockOwnershipPlanESOPNumberOfAllocatedShares contextRef="c40" decimals="0" unitRef="shares">1500000</us-gaap:EmployeeStockOwnershipPlanESOPNumberOfAllocatedShares>
    <us-gaap:EmployeeStockOwnershipPlanESOPNumberOfSuspenseShares contextRef="c41" decimals="0" unitRef="shares">1152044</us-gaap:EmployeeStockOwnershipPlanESOPNumberOfSuspenseShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="c42">P3Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="c43" decimals="0" unitRef="shares">312867</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:SaleOfStockPricePerShare contextRef="c43" decimals="2" unitRef="ilsPershares">0.01</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="c44" decimals="0" unitRef="shares">463384</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="c45" decimals="0" unitRef="shares">559764</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="c46" decimals="0" unitRef="shares">1338015</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <gmda:OrdinarySharesOutstandingPercentage contextRef="c2" decimals="2" unitRef="pure">0.04</gmda:OrdinarySharesOutstandingPercentage>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Three months&lt;br/&gt;

    ended &lt;br/&gt;
    March 31,&lt;br/&gt;
 2022&lt;/td&gt;&lt;td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left; text-indent: -11.35pt; padding-left: 14.15pt"&gt;Dividend yield&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;0&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -11.35pt; padding-left: 14.15pt"&gt;Expected volatility of the share prices&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;66&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; text-indent: -11.35pt; padding-left: 14.15pt"&gt;Risk-free interest rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1.8&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: -11.35pt; padding-left: 14.15pt"&gt;Expected term (in years)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;8&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3cm"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="c0" decimals="2" unitRef="pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c0" decimals="2" unitRef="pure">0.66</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c0" decimals="3" unitRef="pure">0.018</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c0">P8Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue contextRef="c47" decimals="2" unitRef="usdPershares">1.71</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue contextRef="c48" decimals="2" unitRef="usdPershares">1.85</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-left: 0pt; text-indent: 0pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;Amount&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;of&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;options&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;average&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;exercise&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-left: 0pt; text-indent: 0pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-indent: 0pt; padding-left: 0pt"&gt;Balance as of December 31, 2021&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;4,411,424&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;6.01&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: 0pt; padding-left: 0pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: 0pt; padding-left: 0pt"&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,181,100&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2.93&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: 0pt; padding-left: 0pt"&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(47,426&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1.60&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: 0pt; padding-left: 0pt"&gt;Forfeited&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(301,215&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6.74&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt; text-indent: 0pt; padding-left: 0pt"&gt;Expired&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(18,349&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;6.70&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: 0pt; padding-left: 0pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt; text-indent: 0pt; padding-left: 0pt"&gt;Balance as of March 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;5,225,534&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;5.31&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: 0pt; padding-left: 0pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt; text-indent: 0pt; padding-left: 0pt"&gt;Exercisable as of March 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;2,417,453&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;5.90&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3cm"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="c3" decimals="INF" unitRef="shares">4411424</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="c3" decimals="2" unitRef="usdPershares">6.01</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <gmda:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrosses contextRef="c0" decimals="INF" unitRef="shares">1181100</gmda:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrosses>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="c0" decimals="2" unitRef="usdPershares">2.93</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <gmda:StockIssuedDuringPeriodSharesStockOptionesExercised contextRef="c0" decimals="INF" unitRef="shares">47426</gmda:StockIssuedDuringPeriodSharesStockOptionesExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="c0" decimals="2" unitRef="usdPershares">1.6</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <gmda:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriods contextRef="c0" decimals="INF" unitRef="shares">301215</gmda:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriods>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice contextRef="c0" decimals="2" unitRef="usdPershares">6.74</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod contextRef="c0" decimals="INF" unitRef="shares">18349</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice contextRef="c0" decimals="2" unitRef="usdPershares">6.7</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="c2" decimals="INF" unitRef="shares">5225534</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="c2" decimals="2" unitRef="usdPershares">5.31</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <gmda:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableInPeriod contextRef="c0" decimals="INF" unitRef="shares">2417453</gmda:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableInPeriod>
    <gmda:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisableInPeriodWeightedAverageExercisePrice contextRef="c2" decimals="2" unitRef="usdPershares">5.9</gmda:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisableInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue contextRef="c2" decimals="-3" unitRef="usd">11848000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="c0">P4Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-left: 0pt; text-indent: 0pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;Amount of&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;restricted
                                            shares and restricted shares units&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;average&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;grant
                                            date&lt;br/&gt;
 fair value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-left: 0pt; text-indent: 0pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-indent: 0pt; padding-left: 0pt"&gt;Unvested as of December 31, 2021&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;531,477&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;5.48&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: 0pt; padding-left: 0pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-indent: 0pt; padding-left: 0pt"&gt;Granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;937,300&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2.93&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: 0pt; padding-left: 0pt"&gt;Vested&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(42,911&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;9.46&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-indent: 0pt; padding-left: 0pt"&gt;Forfeited&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(75,117&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;6.26&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-indent: 0pt; padding-left: 0pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 4pt; text-indent: 0pt; padding-left: 0pt"&gt;Unvested as of March 31, 2022&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,350,749&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;3.54&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;</us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="c3" decimals="INF" unitRef="shares">531477</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue contextRef="c3" decimals="INF" unitRef="usdPershares">5.48</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="c0" decimals="INF" unitRef="shares">937300</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue contextRef="c0" decimals="INF" unitRef="usdPershares">2.93</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod contextRef="c0" decimals="INF" unitRef="shares">42911</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodIntrinsicValue contextRef="c0" decimals="INF" unitRef="usdPershares">9.46</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="c0" decimals="INF" unitRef="shares">75117</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue contextRef="c0" decimals="INF" unitRef="usdPershares">6.26</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber contextRef="c2" decimals="INF" unitRef="shares">1350749</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue contextRef="c2" decimals="INF" unitRef="usdPershares">3.54</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-left: 0pt; text-indent: 0pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Three months ended&lt;br/&gt;
    March 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-left: 0pt; text-indent: 0pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-left: 0pt; text-indent: 0pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; text-indent: 0pt; padding-left: 0pt"&gt;Research and development expenses, net&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;465&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;311&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt"&gt;Commercial expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;290&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;171&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: 0pt; padding-left: 0pt"&gt;General and administrative expenses&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;439&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;431&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; text-indent: 0pt; padding-left: 0pt"&gt;Total share-based compensation&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,194&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;913&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c0" decimals="-3" unitRef="usd">465000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c4" decimals="-3" unitRef="usd">311000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:CostsAndExpensesRelatedParty contextRef="c0" decimals="-3" unitRef="usd">290000</us-gaap:CostsAndExpensesRelatedParty>
    <us-gaap:CostsAndExpensesRelatedParty contextRef="c4" decimals="-3" unitRef="usd">171000</us-gaap:CostsAndExpensesRelatedParty>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c0" decimals="-3" unitRef="usd">439000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c4" decimals="-3" unitRef="usd">431000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c0" decimals="-3" unitRef="usd">1194000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c4" decimals="-3" unitRef="usd">913000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EarningsPerShareTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;NOTE 9:	BASIC AND DILUTED NET LOSS PER SHARE&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3cm; text-align: justify; text-indent: -1cm"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0cm"&gt;&lt;span style="font-weight: normal"&gt;Basic
net loss per ordinary share is computed by dividing net loss for each reporting period by the weighted-average number of ordinary shares
outstanding during each year. Diluted net loss per ordinary share is computed by dividing net loss for each reporting period by the weighted
average number of ordinary shares outstanding during the period, plus dilutive potential ordinary shares considered outstanding during
the period, in accordance with ASC No. 260-10 &#x201c;Earnings Per Share&#x201d;. The Company experienced a loss as of March 31, 2022;
hence all potentially dilutive ordinary shares were excluded due to their anti-dilutive effect.&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3cm; text-align: justify; text-indent: -1cm"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify; text-indent: 0in"&gt;Details of the number
of shares and loss used in the computation of loss per share:&lt;/p&gt;&lt;p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3cm; text-align: justify; text-indent: -2cm"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Three months ended March 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="text-align: center; font-weight: bold; border-bottom: Black 1.5pt solid"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Weighted number of shares&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;Net loss attributable to equity holders of
                                                                                 the Company&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Weighted number of shares&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;Net loss attributable to equity holders of
                                                                                 the Company&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="width: 52%; text-indent: -8.5pt; padding-left: 11.35pt"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; text-indent: -8.5pt; padding-left: 11.35pt"&gt;For the computation of basic and diluted
    loss&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;59,474,366&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;20,223&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;59,122,973&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;19,186&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Three months ended March 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="text-align: center; font-weight: bold; border-bottom: Black 1.5pt solid"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Weighted number of shares&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;Net loss attributable to equity holders of
                                                                                 the Company&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Weighted number of shares&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;Net loss attributable to equity holders of
                                                                                 the Company&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="width: 52%; text-indent: -8.5pt; padding-left: 11.35pt"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt; text-indent: -8.5pt; padding-left: 11.35pt"&gt;For the computation of basic and diluted
    loss&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;59,474,366&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;20,223&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;59,122,973&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;19,186&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <gmda:WeightedAverageNumberOfSharesOutstandingBasicAndDiluted contextRef="c49" decimals="INF" unitRef="shares">59474366</gmda:WeightedAverageNumberOfSharesOutstandingBasicAndDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted contextRef="c49" decimals="-3" unitRef="usd">20223000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <gmda:WeightedAverageNumberOfSharesOutstandingBasicAndDiluted contextRef="c50" decimals="INF" unitRef="shares">59122973</gmda:WeightedAverageNumberOfSharesOutstandingBasicAndDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted contextRef="c50" decimals="-3" unitRef="usd">19186000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <dei:EntityTaxIdentificationNumber contextRef="c0" id="hidden-fact-0">00-0000000</dei:EntityTaxIdentificationNumber>
    <us-gaap:CommitmentsAndContingencies
      contextRef="c2"
      id="hidden-fact-1"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="c3"
      id="hidden-fact-2"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:TreasuryStockValue
      contextRef="c2"
      id="hidden-fact-3"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:TreasuryStockValue
      contextRef="c3"
      id="hidden-fact-4"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures
      contextRef="c9"
      id="hidden-fact-5"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures
      contextRef="c4"
      id="hidden-fact-6"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures
      contextRef="c19"
      id="hidden-fact-7"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures
      contextRef="c20"
      id="hidden-fact-8"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures
      contextRef="c0"
      id="hidden-fact-9"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:TreasuryStockSharesRetired
      contextRef="c21"
      id="hidden-fact-10"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="c20"
      id="hidden-fact-11"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="c0"
      id="hidden-fact-12"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="c19"
      id="hidden-fact-13"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="c24"
      id="hidden-fact-14"
      unitRef="shares"
      xsi:nil="true"/>
    <us-gaap:MoneyMarketFundsAtCarryingValue
      contextRef="c33"
      id="hidden-fact-15"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:MoneyMarketFundsAtCarryingValue
      contextRef="c35"
      id="hidden-fact-16"
      unitRef="usd"
      xsi:nil="true"/>
    <gmda:CorporateDebentures
      contextRef="c32"
      id="hidden-fact-17"
      unitRef="usd"
      xsi:nil="true"/>
    <gmda:CorporateDebentures
      contextRef="c34"
      id="hidden-fact-18"
      unitRef="usd"
      xsi:nil="true"/>
    <gmda:GovernmentDebentures
      contextRef="c32"
      id="hidden-fact-19"
      unitRef="usd"
      xsi:nil="true"/>
    <gmda:GovernmentDebentures
      contextRef="c34"
      id="hidden-fact-20"
      unitRef="usd"
      xsi:nil="true"/>
    <dei:AmendmentFlag contextRef="c0">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate contextRef="c0">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalPeriodFocus contextRef="c0">Q1</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey contextRef="c0">0001600847</dei:EntityCentralIndexKey>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#hidden-fact-3"
          xlink:label="hidden-fact-3"
          xlink:type="locator"/>
        <link:footnote id="ix_0_footnote" xlink:label="ix_0_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">represents an amount lower than $1.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-3"
          xlink:to="ix_0_footnote"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#hidden-fact-14"
          xlink:label="hidden-fact-14"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#hidden-fact-8"
          xlink:label="hidden-fact-8"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#hidden-fact-12"
          xlink:label="hidden-fact-12"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#hidden-fact-5"
          xlink:label="hidden-fact-5"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#hidden-fact-11"
          xlink:label="hidden-fact-11"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#hidden-fact-7"
          xlink:label="hidden-fact-7"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#hidden-fact-6"
          xlink:label="hidden-fact-6"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#hidden-fact-10"
          xlink:label="hidden-fact-10"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#hidden-fact-9"
          xlink:label="hidden-fact-9"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#hidden-fact-13"
          xlink:label="hidden-fact-13"
          xlink:type="locator"/>
        <link:footnote id="ix_1_footnote" xlink:label="ix_1_footnote" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Represents an amount lower than $1.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-14"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-8"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-12"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-5"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-11"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-7"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-6"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-10"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-9"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="hidden-fact-13"
          xlink:to="ix_1_footnote"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>49
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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M<[^:*IRYC9>4Y2 TDX(H6(R<2_]B$EO[TN '@XW>&A.;R5S*!SNY34>.9X&
M0V*L!XH_:Y@ Y]818ORI?3I-2"O<'C][ORESQUSF5,-$\I\L-=G(B1V2PH(6
MW-S)S6>H\XFLOT1R77Z336WK.20IM)%Y+4:"G(GJES[6==@2^-TC@J 6!*\5
MA+4@+!.MR,JTKJFAXZ&2&Z*L-7JS@[(VI1JS8<(^Q9E1N,M09\83*5)\)I 2
M'&G)64H-3JXHIR(!,K..-3F[%[1(&>Z<D[,I52!,!H8EE.MS\I&\?Q>'O> 3
M<8G.<%,/78-H-H";U!A7%49P!.,+51T2^A](X 5!BWQR6GX-22/W=^4N%J2I
M2M!4)2C]A4?\S0Q6 7O5$+D@-TQ@+1CE9"HU*YOOU^5<&X4M^/M$L+ )%I;!
MND>"?5,I1E!/=?'(BBJRIKP <L8$^8IO CZ%!^"X ZHR.F^K<!6E7T:Q+^]Z
M['4\K,9ZNXXO&.TDT&T2Z+XI 5J83"KV%](VS,I7M$7@1U[UV6-]C>4.<-0
M1V\"OM6Z:(>-#A!Z'K98UX_V6 \-H\&@[X7QH!VUUZ#VWH2*![$V5.#BLHVW
MUX;1[06#>(^WU? $;[_A[9_D_8Y7B2Z05Q[KZC;LRF=\NG5?,-K!C1O<^+]P
MVR#C@Y+U(]_O[U$>6NTWJ[MU6MN;$L^^)1.:<%B@QNOT4:RJVZ>:&+DJ#_"Y
M-'@=E,,,+VQ0U@#W%U*:YXF]$YJ_ .-_4$L#!!0    ( $P]K%02AKS:D ,
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MNYF-MMS8-%W+=IO9: M:IF^Z'9[7LY3^\##%HX!-4]\U3,_O@%2/4_HSY^F
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M+J-]_2'4 &U9-D[B$U"4W+1U)I\V\DUI6#8R@B>N"G[:A)#FFL*C;!1F0W'
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M#I"G]-;(5 ./@US4%495F3@@>=(\2:59H,%'=*"'%P8H90Y,TO]<Q!)LSG[
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M0?S^B0A2_8$>5;)?T,=7E.NE1DWH 4/@S"]56S6;YS4(#V8Q6Z18X@Q*MN.
M&R3OI>=^BF*K3BEZ1GU(_YI.)>KO.%!'NUEGF$\T%Q!UD4N_3G .8PG[,C>.
MM7OM.BI75U_?)&MO]KO#_+1=DUZ@PAH &6?9NRZ"WCAY*MW>R' RBMI'GN*
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MC@ \&I1=L>J#,%'\'$2:P_5M)^:(08*+^94X&1_]<)@-D_NU(Q)EO&4G/_4
M<Y3,&B3A8_+E);\.Q.R(Y2JY\7R9RBF"1E<X3">3J?B0X*HO9EDZF\V2BSXP
M_7SQR32+ZW+<6[:Q2+WS<7J<S6*"@^7#_L+R-;V[Y)=MWA'B08.%LQ)KTL/
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MBM7"WJK=)VSK&3B^7 GCO[!K?-,L@+PV5E4MF#*HN&PD^]F>PP'@-'X#D+2
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MUR(CH<R3U4]4X$'H7^.RNB,X<V<M97<4G?+88G/.8!T,,1%$;EOGL2Y%UL*
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MT20<Q!?^<V]/HSW+AV$?P]1P$(MA=Q#54MGM!^G[4!_J# =0?]B]Z(G;7:J
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MYM5E"+H:B=7&JL*/H8VR--3\,J-_$:B= -UO%;VTX\89J/^7C'X 4$L#!!0
M   ( $P]K%2PO?3W&08  "00   9    >&PO=V]R:W-H965T<R]S:&5E=#$V
M+GAM;(U82V_C-A"^ZU<0+E"T0/R(\]@@FP1PLGT=%AMLFO90]$")8XM=BM22
M5+SNK^_,4))E;^SN)1:E>7PS\\V0S,W:^4^A!(CB2V5LN!V5,=;7TVDH2JAD
MF+@:+'Y9.E_)B$N_FH;:@U2L5)GI?#:[G%92V]'=#;][]'<WKHE&6WCT(C15
M)?WF'HQ;WXY.1]V+CWI51GHQO;NIY0J>(#[7CQY7T]Z*TA78H)T5'I:WH\7I
M]?TER;/ 'QK68? L*)+<N4^T^$W=CF8$" P4D2Q(_'F!!S"&#"&,SZW-4>^2
M%(?/G?6?.7:,)9<!'ISY4ZM8WHZN1D+!4C8F?G3K7Z&-YX+L%<X$_BO62?9\
M/A)%$Z*K6F5$4&F;?N67-@\#A:O9 85YJS!GW,D1HWPGH[R[\6XM/$FC-7K@
M4%D;P6E+17F*'K]JU(MWBZ)PC8W:KL2C,[K0$$Y$ODF+C?BA>_GCS32B.U*:
M%JWI^V1Z?L#TF7CO;"R#^,DJ4+OZ4X398YUW6._G1PV^EWXBSDY/Q'PVGQ^Q
M=];'?L;VSKX]=O'7(@_1(U?^/N+@O'=PS@[.#SAX#B#<4D"(&OD#X;4<'K5
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M%18!4J<MGA[$^9O9>#X31-[Y[.T[R&/ZEMSSMD<E^H#)]^)#8@D+G[[=8;\
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MQZ<[:5I$5_,],'<1;Y7\6.(U'CP)X/>EP[C:!3GH_S%P]Q]02P,$%     @
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M.2NA4DQ41,)JXMV$U[>A%=B(;PRV:F=,3"D+(5[-Y"&?>(%Q!!R6VJ2@>-O
M'7!N,J&/7UU2KV<:X>[X(_MG6SP6LZ *[@3_SG)=3+RA1W)8T8;K)['] EU!
MB<FW%%S9*]FVL1D&+QNE1=F)T4')JO9.W[H7L2.(P@."J!-$UG<+LB[OJ:;3
ML11;(DTT9C,#6ZI5HSE6F:\RUQ*?,M3IZ2-@28J<WX.FC*L+<DGF^.7SA@,1
M*R3I1C+-, 1GW 03SNB"\7;QC+"*/!>B4;3*U=C7:,DD]I<=_K;%1P?P7ZF\
M(G'XB41!%+W,[\GYV<7?67PLJ*\JZJN*;-KX0-K_*>''S4)IB7_'SR/@N ?'
M%CPX #9EN-Y"JTJMRFR4#48.,'+C8 UZUN 4*W:Q6E6RPPJS0ZRD9R6G6 ,7
M*W&QAFY6VK/24ZS$Q4KW67&8NEE9S\I.L5(7*]MC9:/ C1KVJ.%1U',!V#97
M&J0+.-P#IF'L!HYZX.@X4&C*25/E3"U%4VG(N[^_IN_85[5SNX[V? RC)'0;
M"8,_328X:N41E+HF#V7=&!<,O4A0VMDN@CT#E\FA-Q'N=+GPJ($9\K!DLJ&\
M 6<?<)H)][9MEL7__M[^3O<U)QGVM#6K%")6* NN,BQ&MH=#.]&BM@UY(32V
M=SLL\$ %:0+P^4H(_3$Q/;X_HJ>_ 5!+ P04    " !,/:Q4,IALF)D#  "9
M#   &0   'AL+W=O<FMS:&5E=',O<VAE970R-RYX;6R]5\%NVS@0/7>_@A!2
M( &RDBA%LE/8!A*G10MLVB#>; _%'FAI;!&52)6DXN3OEZ04R6AE)L$"O=BD
MQ/?FS9!\'L]V7'R7!8!"#U7)Y-PKE*K?!8',"JB(]'D-3+_9<%$1I:=B&\A:
M ,DMJ"J#* S3H"*4>8N9?78C%C/>J)(RN!%(-E5%Q.,EE'PW][#W]."6;@ME
M'@2+64VVL )U5]\(/0MZEIQ6P"3E# G8S+T+_&Z)IP9@5_Q#82?WQLBDLN;\
MNYE\RN=>:!1!"9DR%$1_W<,2RM(P:1T_.E*OCVF ^^,G]@\V>9W,FDA8\O(K
MS54Q]Z8>RF%#FE+=\MU'Z!)*#%_&2VD_T:Y;&WHH:Z3B50?6"BK*VF_RT!5B
M#Z!YQ@%1!XA^!J0' '$'B&VBK3*;UA519#$3?(>$6:W9S,#6QJ)U-I29;5PI
MH=]2C5.+)6?W(!1=EX!6P"@7Z#-7($_19WV&CJ] $5K*$_0GNEM=H>.C$W2$
M B0+(D BRM =HTHO/C+COPO>2,)R.0N4EF8"!%DGX[*5$1V0@=$U9ZJ0Z#W+
M(1_!+]WXV($/=$GZND1/=;F,G(0?8.TCG)ZB*(SPF!XW_)H('\78PB.'G+C?
MIMCRQ?]SF[[]I8'HDX)*_NL(>]:'/;-ASPZ$O6"L(:7>6P5ZOQ6J063 E+[?
M8UOLYDK\Z21YZQ"5]*(2)]$U48V@ZA'E1(WI6+KA[<XFIW^\>:,W)W4(2GM!
MJ9-Q?W.8V154DT>B9V/B6JK44AF/O5_@, QGP?V(@$DO8.(4\$7DE&D3?KJ7
MQ_HRKNSP9$Q"2X;#/0U)ZL=A&H_+F/8RIDX9-X*RC-;ZP)"*-TR-Q9Z^(OWS
M/NZY,^[[AZP@; NH%C0#F_T5+TLBI#FP;5%&"]'2GN^+F?B3=%P-#@=+#9UZ
M;J%NA)8D.T6C=N:FT$7QP]!U6_">P^/7E,=YAY?/<.'X65W1H"MZW;49U1/]
M<F#.HNC 0<6#G>+879/-!FP#,7B;.. FSS!-_'CBK,?@M=AMD/OUL.:.OEU#
MM0;A<G(\N"9.?N=/"![<$;OM\6*[%;#5U34'\#F#N,2_&N0D.6@1>+!([/;(
MEYA31_$R=\*#+6*W+[[(#]P4#C\(]IJ_"L36]L0292;)M@_LG_9]]X7M-H-A
M>=NTZZYE2YE$)6PT-/0G^D2)M@]N)XK7MI5<<Z4;4SLL]'\'$&:!?K_A^D1U
M$Q.@_S>R^ ]02P,$%     @ 3#VL5*^:LK^= @  M@8  !D   !X;"]W;W)K
M<VAE971S+W-H965T,C@N>&ULK55/3]LP%/\J5L0!)"!ITC852B.UL&D<ABHZ
MML.T@YN\-A:.'6RGA7WZ/3LA=*,-EUU:VWF_?[;SDNRD>M0%@"'/)1=ZZA7&
M5%>^K[,"2JHO904"GZRE*JG!J=KXNE) <P<JN1\&P=@O*1->FKBUA4H361O.
M!"P4T7594O4R!RYW4V_@O2[<LTUA[(*?)A7=P!+,0[50./,[EIR5(#23@BA8
M3[W9X&H^L?6NX#N#G=X;$YMD)>6CG=SF4R^PAH!#9BP#Q;\M7 /GE@AM/+6<
M7B=I@?OC5_;/+CMF65$-UY+_8+DIIM[$(SFL:<W-O=Q]@3;/R/)EDFOW2W9M
M;>"1K-9&EBT8'91,-/_TN=V'/4 X. ((6T#H?#="SN4--31-E-P19:N1S0Y<
M5(=&<TS80UD:A4\9XDQZ+<46E&$K#F0)@DE%[J0!?4[N\$:<WH"AC.LS<D&6
M>!_R&LODFG!&5XPS\T*HR D\U7:8R;*2 H31ML04@"MOY,*RDA/"!/E6R%HC
M4">^P0C6B)^U=N>-W?"(W8A\E<(4FGP2.>1_XWV,WN4/7_//PU["KU1=DFAP
M3L(@#!^6-^3TY*R'-NJV-7*TT1':_[)9/V<K;13>VU\]CH:=HZ%S-#SB:*&8
MR%A%.:&EK(4YM/<-P]@QV+=YF\:C( @2?WM >-0)CWJ%;[6NJ<AL0&T.'GF#
M'^W)7@S#,#HL.^YDQ[VR>'T/:8W?:<5!',>'M>).*^[5FI42#^XWY(1]&#9^
M9V 2'=GA22<_^2@JR:A2+TQL>DYW\OYT!^/@W^C^7B\I06U<Q]28!UF;MM*M
M=DUYUO2BM_*FH^.[M6%"$PYKA :7,:9639=L)D96KC.MI,$^YX8%?EA V0)\
MOI;X'K03*]!]JM(_4$L#!!0    ( $P]K%1<V7TZF@,  $@/   9    >&PO
M=V]R:W-H965T<R]S:&5E=#(Y+GAM;+5776_:,!3]*U:TATWJFMCY "I VJCV
M(:U2M;;;P[0'0R[%:A)GM@/;OY]MTB2%X#*5O4"<W'MRSHWOL3W></$@5P *
M_<ZS0DZ\E5+EA>_+Q0IR*L]Y"85^LN0BITH/Q;TO2P$TM4EYYI,@2/R<LL*;
MCNV]:S$=\TIEK(!K@625YU3\>0\9WTP\[#W>^,KN5\K<\*?CDM[##:B[\EKH
MD=^@I"R'0C)>( '+B?<.7\R(3; 1WQAL9.<:&2ESSA_,X',Z\0+#"#)8* -!
M]=\:9I!E!DGS^%6#>LT[36+W^A']@Q6OQ<RIA!G/OK-4K2;>T$,I+&F5J:]\
M\PEJ0;'!6_!,VE^TJ6,##RTJJ7A>)VL&.2NV__1W78A. HX.)) Z@1R;$-8)
MH16Z969E75)%IV/!-TB8:(UF+FQM;+96PPKS&6^4T$^9SE/3#Y0)](UF%: K
MH+(2H+^1DNCU)2C*,OD&O44W>NZD50:(+]'2Q*]MO![EO( _FHYXT!-N616I
M1+1(ZQMTKE,D+"K!% .I@>YN+M'K5V_0*\0*=+OBE=31<NPK+<30\1<UZ?=;
MTN0 Z2LJSE&(SQ )".E)G[G3+V'1I..GZ;XN7U-#TM206+SP -Z,RA6"7Q73
M=3'%NW!@A@UF:#&C0Q+W*MM7IBU&8C%,PZZG81(/M:9UMQK[43&VRM<]!*.&
M8.04?=7WC5W*XP8X=BJ?<5%R017H;ISK<NHIV:M]BQ)W5.$P'(YVM/=$C9(@
M[M>>-!03)\6/? VB,(WR#,=D_^T1&9 =COM1)(C(J)_CH.$X<'*\Y8IFB$H)
MNIOS;6NGB*I.!_<Q'NQQ22(2[3+>CQKA(#Y0U6'#>.ADW%K1&?I<E)629^@+
MK"%#&/VX@GP.XJ=C?HV:UXQ.UJTX:&TT.$&_UB#Q,PW;$^;H6-SQ>GS:GL6M
M!6)RDJYUPYA-RX4LZ0(FGMZ52!!K\*:HU^)?#O14:NO,V&W-1W>_&^=?M+X<
MZ*G6UN1Q]#]<I$9]=I[OA[GF>;N"8/<2<MA)R#%.@MMU ">G\Y+6N;';NH_T
M$B?(O\RNEP,]%=H:/AZ>V(]:D\>CT_C1Z*AM1%_8X7T$:9<-XEXVCO82LK\D
M]&TE>L(<>PG2KAP$_P\?J%&[6T\R2))='^@)BX(@C'98^YUCCCECZNESSPJ)
M,ECJO.!\H&6+[;%M.U"\M">?.5?Z'&4O5_JH"\($Z.=+SM7CP!RFFL/S]"]0
M2P,$%     @ 3#VL5"*!T>L2 P  80H  !D   !X;"]W;W)K<VAE971S+W-H
M965T,S N>&ULQ5;?;]HP$/Y7K*B36FDE<0*!5H!4Z*95*A/JC^UAVH,A1V(U
MMIEMH/WO9SL0F$K</DSJ2V([ON_[[LZ^7'\CY),J #1Z9B57@Z#0>GD9AFI>
M ".J)9; S9>%D(QH,Y5YJ)822.:,6!G&492&C% >#/MN;2J'?;'2)>4PE4BM
M&"/R902EV P"'.P6[FA>:+L0#OM+DL,]Z,?E5)I96*-DE %75' D83$(KO#E
M"*?6P.WX06&C#L;(NC(3XLE.;K)!$%E%4,)<6PAB7FL80UE:)*/CSQ8TJ#FM
MX>%XA_[5.6^<F1$%8U'^I)DN!D$O0!DLR*K4=V+S#;8.=2S>7)3*/=&FVINV
M S1?*2W8UM@H8)17;_*\#<2!08P;#.*M0>QT5T1.Y3719-B78H.DW6W0[,"Y
MZJR-.,IM5NZU-%^IL=/#L>":\ARX1K>4S&A)-06%",_06#!&M<F 5NCT&C2A
MI3I#)XAR]%"(E3)[5#_41H2%"N=;PE%%&#<0)FAB* N%OO ,LG_M0R.^]B#>
M>3"*O8 3(ELHP9]1',7QX_TU.CTY\\ F=6 2!YO\K\#\NC4(Z$8#4[\]_.V:
MO^WXVPW\(\*?4+XBDG -EIB)%=?'XEWAI ['7L+U,(G3M!^NC[!W:O:.E_V&
MKT$Y%]'</$"BW KQJ*CP.H<J<-2@(JU5I%X55WDN(2<:/+SI:]YN$D7'B;LU
M<==+?"=>2*E?SF= I#D$E?-'#WOW-7V[VT3?J^E[7OKO@I_+=TOHO<I_G#8I
MN*@57'@53$':O)NZC,3"W'AS LQY0-+DXI@$/QB.HE84??)<"ASMRU7DQ7H0
MFI2>8&S-#Z/1;E\TA0,?E$GLY9U03MF*H5\38#.0OAN.XSUH_"$U!N^+'$[>
M<= M:5-JWP!(WLKLOMYA?\&;D.=W1WA?QG#G8R*\+V'87\/>$6$_0-3J'(]P
M>/#79R!SU]LH-+>5LFH ZM6Z?[JJNH;]]JKY,O_0G'*%2E@8TZC5-5&553]3
M3;18NAYB)K3I2-RP,#T@2+O!?%\(H7<32U!WE<._4$L#!!0    ( $P]K%1\
MO@"7<P,  #\)   9    >&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;+U6WV_;
M-A!^SU]Q4(%N PSKAQW;26T#3IIM*18@:-#UH=@#+9TMKA2IDF<[^>][I!35
M'1QAV("^V")Y]WW?W?%TFA^,_>Q*1(+'2FFWB$JB^C*.75YB)=S0U*CY9&-L
M)8B7=AN[VJ(H@E.EXBQ))G$EI(Z6\[!W;Y=SLR,E-=Y;<+NJ$O;I"I4Y+*(T
M>MYX+[<E^8UX.:_%%A^0/M3WEE=QAU+("K631H/%S2):I9=7:7 (%G]*/+BC
M9_"AK(WY[!>WQ2)*O")4F).'$/RWQVM4RB.QCB\M:-1Q>L?CYV?T7T/P',Q:
M.+PVZJ,LJ%Q$LP@*W(B=HO?F\#NV 9U[O-PH%W[AT-B.QQ'D.T>F:IU9025U
M\R\>VT0<.<R2%QRRUB$+NANBH/*M(+&<6W, ZZT9S3^$4(,WBY/:5^6!+)]*
M]J/E0RDLED85:-U/</-E)^D)?GZ+)*1RO\QC8@YO&><MWE6#E[V -X([HZET
M<*,+++[WCUE;)S![%GB5]0+>"3N$43J +,DRY]6Z'M11%_8HH([^4]CPZ0^V
MAUO"ROW5PS;NV,:!;?P"VP?.A3U82<S&5\;E5M;^3IY*;R^2[]%+5XL<%Q$W
MH4.[QVCYL%O_S9<<R "5"->FJH5^>OUJEJ73-^Y,<!-Q+4#H@OO(D2!>K"S)
M7*$#LX&5<R:7PBL:!(0V,?[L!" 86TC-+0Q-.: 4>PR&UK> EV$Q1VXVT(99
MV(+,F2!B&4'$WA""U+!%C58HJ/CR2KU]D<\=%6L0$+XC"\<>KY![63")"S:&
MC2SO.;)RO?/!N;-=S2\");G<10AW^/I5.DG>])3XO"OQ>6^);QYKR2H8%D]5
MM=]YY: 6EGS\DAS?]'1Z)O6>:\6E([!FIXO!<6I@:X7V9<S1\I75T%@;KMEX
M,,I&@XOI# [">BO.?BF(7RM* 38JV>'=3CV%EAKV!#_I@I_TZO>"X;:5 )_N
ML%JC[6N<:0<\_0%M.NO89KUA_-8F]6.;N%.%;!#. X*?>/OEF//-Z9['^Q/4
M%QWU12]U2_EO<I<FWU[MR0_(7GHT2M+_G;\6XCB!:9(FX\GD'PF,CV9:A78;
M)K>#G'N!FO'6[79?!ZMF)GXS;SXM>(1LI7:@<,.NR7#*[+:9ULV"3!TFY-H0
MS]OP6/(7#EIOP.<;PV^L=N$)NF^FY5=02P,$%     @ 3#VL5/;I-&%:!
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M&(5DU;!7 RU*UR1OA#8MMWO<FY\<D':!>;\50I\&%J#Y;5K]"U!+ P04
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MSQ](8X#?UT+HP\0$:![4Z ]02P,$%     @ 3#VL5!3A(]ZX @  Y 8  !D
M  !X;"]W;W)K<VAE971S+W-H965T,S<N>&ULS55-;^(P$/TKHZB'5MIM2 +T
M0X!48%=;J:U0V6X/50^&#,2J8Z>V ^V_W[$3LI2E:(][(;8S[\U[,V;26RO]
M8C)$"V^YD*8?9-86EV%HYAGFS)RJ B6]62B=,TM;O0Q-H9&E'I2+,&ZUNF'.
MN P&/7\VT8.>*JW@$B<:3)GG3+\/4:AU/XB"S<$]7V;6'82#7L&6.$7[4$PT
M[<*&)>4Y2L.5!(V+?G 578XZ+MX'_.*X-EMK<$YF2KVXS77:#UI.$ J<6\?
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M?<(0LHIIPW8PCL0QAD MNFLTBI#5B>#CS@^V2\(PCMT(8&X%88@AL!MQ!%,
M&C D#,TYN'<>!?4Y%;2_@TU_ U!+ P04    " !,/:Q4EXJ[',     3 @
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M]99WZNW#HW1^['FN\?QW4AWZ;]UX_+!\;D[8&7"V< V]_P502P,$%     @
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M8U!R;W!S+V%P<"YX;6Q02P$"% ,4    " !,/:Q4"'AKKNT    K @  $0
M            @ &O    9&]C4')O<',O8V]R92YX;6Q02P$"% ,4    " !,
M/:Q4F5R<(Q &  "<)P  $P              @ '+ 0  >&PO=&AE;64O=&AE
M;64Q+GAM;%!+ 0(4 Q0    ( $P]K%20MP =5 4  !X6   8
M  " @0P(  !X;"]W;W)K<VAE971S+W-H965T,2YX;6Q02P$"% ,4    " !,
M/:Q4*7B_#=H&  #E&P  &               @(&6#0  >&PO=V]R:W-H965T
M<R]S:&5E=#(N>&UL4$L! A0#%     @ 3#VL5&Z&%^[* @  #@@  !@
M         ("!IA0  'AL+W=O<FMS:&5E=',O<VAE970S+GAM;%!+ 0(4 Q0
M   ( $P]K%02AKS:D ,  '8*   8              " @:87  !X;"]W;W)K
M<VAE971S+W-H965T-"YX;6Q02P$"% ,4    " !,/:Q4ZQ9CI[L%  "K&@
M&               @(%L&P  >&PO=V]R:W-H965T<R]S:&5E=#4N>&UL4$L!
M A0#%     @ 3#VL5-Q-'<%!!@  +A@  !@              ("!72$  'AL
M+W=O<FMS:&5E=',O<VAE970V+GAM;%!+ 0(4 Q0    ( $P]K%0!P[(=H0T
M  \A   8              " @=0G  !X;"]W;W)K<VAE971S+W-H965T-RYX
M;6Q02P$"% ,4    " !,/:Q4+?.Z' P&   "#P  &               @(&K
M-0  >&PO=V]R:W-H965T<R]S:&5E=#@N>&UL4$L! A0#%     @ 3#VL5 G?
MRF^T P  \0<  !@              ("![3L  'AL+W=O<FMS:&5E=',O<VAE
M970Y+GAM;%!+ 0(4 Q0    ( $P]K%3 *JP6M@8  ,0/   9
M  " @=<_  !X;"]W;W)K<VAE971S+W-H965T,3 N>&UL4$L! A0#%     @
M3#VL5%K,^(?] @  AP8  !D              ("!Q$8  'AL+W=O<FMS:&5E
M=',O<VAE970Q,2YX;6Q02P$"% ,4    " !,/:Q4 )H3<NP$  !W"@  &0
M            @('X20  >&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+ 0(4
M Q0    ( $P]K%0 P\9[*P,  ,$&   9              " @1M/  !X;"]W
M;W)K<VAE971S+W-H965T,3,N>&UL4$L! A0#%     @ 3#VL5-5Y61/B"0
MLQ@  !D              ("!?5(  'AL+W=O<FMS:&5E=',O<VAE970Q-"YX
M;6Q02P$"% ,4    " !,/:Q4[J=).*X#  "C"   &0              @(&6
M7   >&PO=V]R:W-H965T<R]S:&5E=#$U+GAM;%!+ 0(4 Q0    ( $P]K%2P
MO?3W&08  "00   9              " @7M@  !X;"]W;W)K<VAE971S+W-H
M965T,38N>&UL4$L! A0#%     @ 3#VL5&R? /KX @  60<  !D
M     ("!RV8  'AL+W=O<FMS:&5E=',O<VAE970Q-RYX;6Q02P$"% ,4
M" !,/:Q41W_Y@9D"  !F!0  &0              @('Z:0  >&PO=V]R:W-H
M965T<R]S:&5E=#$X+GAM;%!+ 0(4 Q0    ( $P]K%3OJ#KLR (  !<&   9
M              " @<IL  !X;"]W;W)K<VAE971S+W-H965T,3DN>&UL4$L!
M A0#%     @ 3#VL5!*>&A<A!   %0H  !D              ("!R6\  'AL
M+W=O<FMS:&5E=',O<VAE970R,"YX;6Q02P$"% ,4    " !,/:Q4FQ_SH9X"
M  #2!0  &0              @($A=   >&PO=V]R:W-H965T<R]S:&5E=#(Q
M+GAM;%!+ 0(4 Q0    ( $P]K%2.X@U;<0,  ($(   9              "
M@?9V  !X;"]W;W)K<VAE971S+W-H965T,C(N>&UL4$L! A0#%     @ 3#VL
M5(#A+>VT 0  IP,  !D              ("!GGH  'AL+W=O<FMS:&5E=',O
M<VAE970R,RYX;6Q02P$"% ,4    " !,/:Q4(FM$5VT"  !H!@  &0
M        @(&)?   >&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+ 0(4 Q0
M   ( $P]K%3\-FG8"0(  *H$   9              " @2U_  !X;"]W;W)K
M<VAE971S+W-H965T,C4N>&UL4$L! A0#%     @ 3#VL5"C!>;ZB @  K@<
M !D              ("!;8$  'AL+W=O<FMS:&5E=',O<VAE970R-BYX;6Q0
M2P$"% ,4    " !,/:Q4,IALF)D#  "9#   &0              @(%&A
M>&PO=V]R:W-H965T<R]S:&5E=#(W+GAM;%!+ 0(4 Q0    ( $P]K%2OFK*_
MG0(  +8&   9              " @1:(  !X;"]W;W)K<VAE971S+W-H965T
M,C@N>&UL4$L! A0#%     @ 3#VL5%S9?3J: P  2 \  !D
M ("!ZHH  'AL+W=O<FMS:&5E=',O<VAE970R.2YX;6Q02P$"% ,4    " !,
M/:Q4(H'1ZQ(#  !A"@  &0              @(&[C@  >&PO=V]R:W-H965T
M<R]S:&5E=#,P+GAM;%!+ 0(4 Q0    ( $P]K%1\O@"7<P,  #\)   9
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M970S-2YX;6Q02P$"% ,4    " !,/:Q4$J[R>K@"  !<!P  &0
M    @('SHP  >&PO=V]R:W-H965T<R]S:&5E=#,V+GAM;%!+ 0(4 Q0    (
M $P]K%04X2/>N (  .0&   9              " @>*F  !X;"]W;W)K<VAE
M971S+W-H965T,S<N>&UL4$L! A0#%     @ 3#VL5.[S"XH\ P  %!,   T
M             ( !T:D  'AL+W-T>6QE<RYX;6Q02P$"% ,4    " !,/:Q4
MEXJ[',     3 @  "P              @ $XK0  7W)E;',O+G)E;'-02P$"
M% ,4    " !,/:Q4,\=>#&T#   M&0  #P              @ $AK@  >&PO
M=V]R:V)O;VLN>&UL4$L! A0#%     @ 3#VL5)D^HH1\ 0  EA8  !H
M         ( !N[$  'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#
M%     @ 3#VL5*IG%&&8 0  "Q<  !,              ( !;[,  %M#;VYT
D96YT7U1Y<&5S72YX;6Q02P4&     "T +0 R#   .+4

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>51</ContextCount>
  <ElementCount>216</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>15</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>5</UnitCount>
  <MyReports>
    <Report instance="f10q0322_gamidacell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gamidacell.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="f10q0322_gamidacell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>001 - Statement - Condensed Consolidated Balance Sheets (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gamidacell.com/role/ConsolidatedBalanceSheet</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="f10q0322_gamidacell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>002 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gamidacell.com/role/ConsolidatedBalanceSheet_Parentheticals</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Unaudited) (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="f10q0322_gamidacell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>003 - Statement - Condensed Consolidated Statements of Operation (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gamidacell.com/role/ConsolidatedIncomeStatement</Role>
      <ShortName>Condensed Consolidated Statements of Operation (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="f10q0322_gamidacell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>004 - Statement - Condensed Consolidated Statements of Changes in Shareholders??? Equity (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gamidacell.com/role/ShareholdersEquityType2or3</Role>
      <ShortName>Condensed Consolidated Statements of Changes in Shareholders??? Equity (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="f10q0322_gamidacell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>005 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gamidacell.com/role/ConsolidatedCashFlow</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="f10q0322_gamidacell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>006 - Disclosure - General</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gamidacell.com/role/General</Role>
      <ShortName>General</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="f10q0322_gamidacell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>007 - Disclosure - Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gamidacell.com/role/SignificantAccountingPolicies</Role>
      <ShortName>Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="f10q0322_gamidacell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>008 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gamidacell.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="f10q0322_gamidacell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>009 - Disclosure - Convertible Senior Notes, Net</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.gamidacell.com/role/ConvertibleSeniorNotesNet</Role>
      <ShortName>Convertible Senior Notes, Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="f10q0322_gamidacell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>010 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gamidacell.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="f10q0322_gamidacell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>011 - Disclosure - Contingent Liabilities and Commitments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gamidacell.com/role/ContingentLiabilitiesandCommitments</Role>
      <ShortName>Contingent Liabilities and Commitments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="f10q0322_gamidacell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>012 - Disclosure - Shareholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gamidacell.com/role/ShareholdersEquity</Role>
      <ShortName>Shareholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="f10q0322_gamidacell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>013 - Disclosure - Share-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gamidacell.com/role/ShareBasedCompensation</Role>
      <ShortName>Share-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="f10q0322_gamidacell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>014 - Disclosure - Basic and Diluted Net Loss Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gamidacell.com/role/BasicandDilutedNetLossPerShare</Role>
      <ShortName>Basic and Diluted Net Loss Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="f10q0322_gamidacell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>015 - Disclosure - Accounting Policies, by Policy (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gamidacell.com/role/AccountingPoliciesByPolicy</Role>
      <ShortName>Accounting Policies, by Policy (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.gamidacell.com/role/SignificantAccountingPolicies</ParentRole>
      <Position>16</Position>
    </Report>
    <Report instance="f10q0322_gamidacell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>016 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gamidacell.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.gamidacell.com/role/Leases</ParentRole>
      <Position>17</Position>
    </Report>
    <Report instance="f10q0322_gamidacell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>017 - Disclosure - Convertible Senior Notes, Net (Tables)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.gamidacell.com/role/ConvertibleSeniorNotesNetTables</Role>
      <ShortName>Convertible Senior Notes, Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.gamidacell.com/role/ConvertibleSeniorNotesNet</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="f10q0322_gamidacell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>018 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gamidacell.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.gamidacell.com/role/FairValueMeasurements</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="f10q0322_gamidacell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>019 - Disclosure - Share-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gamidacell.com/role/ShareBasedCompensationTables</Role>
      <ShortName>Share-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.gamidacell.com/role/ShareBasedCompensation</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="f10q0322_gamidacell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>020 - Disclosure - Basic and Diluted Net Loss Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gamidacell.com/role/BasicandDilutedNetLossPerShareTables</Role>
      <ShortName>Basic and Diluted Net Loss Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.gamidacell.com/role/BasicandDilutedNetLossPerShare</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="f10q0322_gamidacell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>021 - Disclosure - General (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gamidacell.com/role/GeneralDetails</Role>
      <ShortName>General (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.gamidacell.com/role/General</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="f10q0322_gamidacell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>022 - Disclosure - Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gamidacell.com/role/LeasesDetails</Role>
      <ShortName>Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.gamidacell.com/role/LeasesTables</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="f10q0322_gamidacell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>023 - Disclosure - Leases (Details) - Schedule of operating lease costs</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gamidacell.com/role/ScheduleofoperatingleasecostsTable</Role>
      <ShortName>Leases (Details) - Schedule of operating lease costs</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.gamidacell.com/role/LeasesTables</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="f10q0322_gamidacell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>024 - Disclosure - Leases (Details) - Schedule of operating leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gamidacell.com/role/ScheduleofoperatingleasesTable</Role>
      <ShortName>Leases (Details) - Schedule of operating leases</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.gamidacell.com/role/LeasesTables</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="f10q0322_gamidacell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>025 - Disclosure - Leases (Details) - Schedule of maturities of lease liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gamidacell.com/role/ScheduleofmaturitiesofleaseliabilitiesTable</Role>
      <ShortName>Leases (Details) - Schedule of maturities of lease liabilities</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.gamidacell.com/role/LeasesTables</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="f10q0322_gamidacell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>026 - Disclosure - Convertible Senior Notes, Net (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.gamidacell.com/role/ConvertibleSeniorNotesNetDetails</Role>
      <ShortName>Convertible Senior Notes, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.gamidacell.com/role/ConvertibleSeniorNotesNetTables</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="f10q0322_gamidacell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>027 - Disclosure - Convertible Senior Notes, Net (Details) - Schedule of liability and equity components of the convertible notes</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.gamidacell.com/role/ScheduleofliabilityandequitycomponentsoftheconvertiblenotesTable</Role>
      <ShortName>Convertible Senior Notes, Net (Details) - Schedule of liability and equity components of the convertible notes</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.gamidacell.com/role/ConvertibleSeniorNotesNetTables</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="f10q0322_gamidacell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>028 - Disclosure - Fair Value Measurements (Details) - Schedule of fair value of money market funds and marketable securities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gamidacell.com/role/ScheduleoffairvalueofmoneymarketfundsandmarketablesecuritiesTable</Role>
      <ShortName>Fair Value Measurements (Details) - Schedule of fair value of money market funds and marketable securities</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.gamidacell.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="f10q0322_gamidacell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>029 - Disclosure - Contingent Liabilities and Commitments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gamidacell.com/role/ContingentLiabilitiesandCommitmentsDetails</Role>
      <ShortName>Contingent Liabilities and Commitments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.gamidacell.com/role/ContingentLiabilitiesandCommitments</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="f10q0322_gamidacell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>030 - Disclosure - Shareholders' Equity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gamidacell.com/role/ShareholdersEquityDetails</Role>
      <ShortName>Shareholders' Equity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.gamidacell.com/role/ShareholdersEquity</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="f10q0322_gamidacell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>031 - Disclosure - Share-Based Compensation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gamidacell.com/role/ShareBasedCompensationDetails</Role>
      <ShortName>Share-Based Compensation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.gamidacell.com/role/ShareBasedCompensationTables</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="f10q0322_gamidacell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>032 - Disclosure - Share-Based Compensation (Details) - Schedule of fair value measurement of equity-settled share options</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gamidacell.com/role/ScheduleoffairvaluemeasurementofequitysettledshareoptionsTable</Role>
      <ShortName>Share-Based Compensation (Details) - Schedule of fair value measurement of equity-settled share options</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.gamidacell.com/role/ShareBasedCompensationTables</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="f10q0322_gamidacell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>033 - Disclosure - Share-Based Compensation (Details) - Schedule of stock option plans</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gamidacell.com/role/ScheduleofstockoptionplansTable</Role>
      <ShortName>Share-Based Compensation (Details) - Schedule of stock option plans</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.gamidacell.com/role/ShareBasedCompensationTables</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="f10q0322_gamidacell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>034 - Disclosure - Share-Based Compensation (Details) - Schedule of restricted shares activity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gamidacell.com/role/ScheduleofrestrictedsharesactivityTable</Role>
      <ShortName>Share-Based Compensation (Details) - Schedule of restricted shares activity</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.gamidacell.com/role/ShareBasedCompensationTables</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="f10q0322_gamidacell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>035 - Disclosure - Share-Based Compensation (Details) - Schedule of share-based compensation expense</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gamidacell.com/role/ScheduleofsharebasedcompensationexpenseTable</Role>
      <ShortName>Share-Based Compensation (Details) - Schedule of share-based compensation expense</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.gamidacell.com/role/ShareBasedCompensationTables</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="f10q0322_gamidacell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>036 - Disclosure - Basic and Diluted Net Loss Per Share (Details) - Schedule of number of shares and loss used in the computation of net loss per share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gamidacell.com/role/ScheduleofnumberofsharesandlossusedinthecomputationofnetlosspershareTable</Role>
      <ShortName>Basic and Diluted Net Loss Per Share (Details) - Schedule of number of shares and loss used in the computation of net loss per share</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.gamidacell.com/role/BasicandDilutedNetLossPerShareTables</ParentRole>
      <Position>37</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="f10q0322_gamidacell.htm">f10q0322_gamidacell.htm</File>
    <File>f10q0322ex31-1_gamidacell.htm</File>
    <File>f10q0322ex31-2_gamidacell.htm</File>
    <File>f10q0322ex32-1_gamidacell.htm</File>
    <File>f10q0322ex32-2_gamidacell.htm</File>
    <File>gmda-20220331.xsd</File>
    <File>gmda-20220331_cal.xml</File>
    <File>gmda-20220331_def.xml</File>
    <File>gmda-20220331_lab.xml</File>
    <File>gmda-20220331_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="287">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="30">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>54
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "f10q0322_gamidacell.htm": {
   "axisCustom": 1,
   "axisStandard": 7,
   "contextCount": 51,
   "dts": {
    "calculationLink": {
     "local": [
      "gmda-20220331_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "gmda-20220331_def.xml"
     ]
    },
    "inline": {
     "local": [
      "f10q0322_gamidacell.htm"
     ]
    },
    "labelLink": {
     "local": [
      "gmda-20220331_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "gmda-20220331_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "gmda-20220331.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd",
      "https://xbrl.sec.gov/sic/2022/sic-2022.xsd"
     ]
    }
   },
   "elementCount": 300,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2022": 16,
    "http://www.gamidacell.com/20220331": 4,
    "http://xbrl.sec.gov/dei/2022": 5,
    "total": 25
   },
   "keyCustom": 30,
   "keyStandard": 186,
   "memberCustom": 3,
   "memberStandard": 12,
   "nsprefix": "gmda",
   "nsuri": "http://www.gamidacell.com/20220331",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0322_gamidacell.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:EntityRegistrantName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "000 - Document - Document And Entity Information",
     "role": "http://www.gamidacell.com/role/DocumentAndEntityInformation",
     "shortName": "Document And Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0322_gamidacell.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:EntityRegistrantName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0322_gamidacell.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "gmda:DisclosureOfNotesAndOtherExplanatoryInformationsExplanatoryTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "009 - Disclosure - Convertible Senior Notes, Net",
     "role": "http://www.gamidacell.com/role/ConvertibleSeniorNotesNet",
     "shortName": "Convertible Senior Notes, Net",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0322_gamidacell.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "gmda:DisclosureOfNotesAndOtherExplanatoryInformationsExplanatoryTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0322_gamidacell.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "010 - Disclosure - Fair Value Measurements",
     "role": "http://www.gamidacell.com/role/FairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0322_gamidacell.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0322_gamidacell.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "011 - Disclosure - Contingent Liabilities and Commitments",
     "role": "http://www.gamidacell.com/role/ContingentLiabilitiesandCommitments",
     "shortName": "Contingent Liabilities and Commitments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0322_gamidacell.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0322_gamidacell.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "012 - Disclosure - Shareholders' Equity",
     "role": "http://www.gamidacell.com/role/ShareholdersEquity",
     "shortName": "Shareholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0322_gamidacell.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0322_gamidacell.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "013 - Disclosure - Share-Based Compensation",
     "role": "http://www.gamidacell.com/role/ShareBasedCompensation",
     "shortName": "Share-Based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0322_gamidacell.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0322_gamidacell.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "014 - Disclosure - Basic and Diluted Net Loss Per Share",
     "role": "http://www.gamidacell.com/role/BasicandDilutedNetLossPerShare",
     "shortName": "Basic and Diluted Net Loss Per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0322_gamidacell.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0322_gamidacell.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:UseOfEstimates",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "015 - Disclosure - Accounting Policies, by Policy (Policies)",
     "role": "http://www.gamidacell.com/role/AccountingPoliciesByPolicy",
     "shortName": "Accounting Policies, by Policy (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0322_gamidacell.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:UseOfEstimates",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0322_gamidacell.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "016 - Disclosure - Leases (Tables)",
     "role": "http://www.gamidacell.com/role/LeasesTables",
     "shortName": "Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0322_gamidacell.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0322_gamidacell.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "gmda:ScheduleOfLiabilityAndEquityComponentConvertibleNotesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "017 - Disclosure - Convertible Senior Notes, Net (Tables)",
     "role": "http://www.gamidacell.com/role/ConvertibleSeniorNotesNetTables",
     "shortName": "Convertible Senior Notes, Net (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0322_gamidacell.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "gmda:ScheduleOfLiabilityAndEquityComponentConvertibleNotesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0322_gamidacell.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "gmda:ScheduleOfFairValueOfMoneyMarketFundsAndMarketableSecuritiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "018 - Disclosure - Fair Value Measurements (Tables)",
     "role": "http://www.gamidacell.com/role/FairValueMeasurementsTables",
     "shortName": "Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0322_gamidacell.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "gmda:ScheduleOfFairValueOfMoneyMarketFundsAndMarketableSecuritiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0322_gamidacell.htm",
      "contextRef": "c2",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "001 - Statement - Condensed Consolidated Balance Sheets (Unaudited)",
     "role": "http://www.gamidacell.com/role/ConsolidatedBalanceSheet",
     "shortName": "Condensed Consolidated Balance Sheets (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0322_gamidacell.htm",
      "contextRef": "c2",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0322_gamidacell.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "019 - Disclosure - Share-Based Compensation (Tables)",
     "role": "http://www.gamidacell.com/role/ShareBasedCompensationTables",
     "shortName": "Share-Based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0322_gamidacell.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0322_gamidacell.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "020 - Disclosure - Basic and Diluted Net Loss Per Share (Tables)",
     "role": "http://www.gamidacell.com/role/BasicandDilutedNetLossPerShareTables",
     "shortName": "Basic and Diluted Net Loss Per Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0322_gamidacell.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0322_gamidacell.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "gmda:ResponseRatePercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "021 - Disclosure - General (Details)",
     "role": "http://www.gamidacell.com/role/GeneralDetails",
     "shortName": "General (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0322_gamidacell.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "gmda:ResponseRatePercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0322_gamidacell.htm",
      "contextRef": "c2",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseRemainingLeaseTerm",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "022 - Disclosure - Leases (Details)",
     "role": "http://www.gamidacell.com/role/LeasesDetails",
     "shortName": "Leases (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0322_gamidacell.htm",
      "contextRef": "c2",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseRemainingLeaseTerm",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0322_gamidacell.htm",
      "contextRef": "c0",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "023 - Disclosure - Leases (Details) - Schedule of operating lease costs",
     "role": "http://www.gamidacell.com/role/ScheduleofoperatingleasecostsTable",
     "shortName": "Leases (Details) - Schedule of operating lease costs",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0322_gamidacell.htm",
      "contextRef": "c0",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:OperatingLeasesOfLesseeDisclosureTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0322_gamidacell.htm",
      "contextRef": "c2",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "024 - Disclosure - Leases (Details) - Schedule of operating leases",
     "role": "http://www.gamidacell.com/role/ScheduleofoperatingleasesTable",
     "shortName": "Leases (Details) - Schedule of operating leases",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:OperatingLeasesOfLesseeDisclosureTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0322_gamidacell.htm",
      "contextRef": "c2",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0322_gamidacell.htm",
      "contextRef": "c2",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "025 - Disclosure - Leases (Details) - Schedule of maturities of lease liabilities",
     "role": "http://www.gamidacell.com/role/ScheduleofmaturitiesofleaseliabilitiesTable",
     "shortName": "Leases (Details) - Schedule of maturities of lease liabilities",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0322_gamidacell.htm",
      "contextRef": "c2",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0322_gamidacell.htm",
      "contextRef": "c29",
      "decimals": "5",
      "first": true,
      "lang": null,
      "name": "gmda:AnnualInterestPercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "026 - Disclosure - Convertible Senior Notes, Net (Details)",
     "role": "http://www.gamidacell.com/role/ConvertibleSeniorNotesNetDetails",
     "shortName": "Convertible Senior Notes, Net (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0322_gamidacell.htm",
      "contextRef": "c29",
      "decimals": "5",
      "first": true,
      "lang": null,
      "name": "gmda:AnnualInterestPercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "pure",
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "gmda:ScheduleOfLiabilityAndEquityComponentConvertibleNotesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0322_gamidacell.htm",
      "contextRef": "c0",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "gmda:AmountOfPrincipal",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "027 - Disclosure - Convertible Senior Notes, Net (Details) - Schedule of liability and equity components of the convertible notes",
     "role": "http://www.gamidacell.com/role/ScheduleofliabilityandequitycomponentsoftheconvertiblenotesTable",
     "shortName": "Convertible Senior Notes, Net (Details) - Schedule of liability and equity components of the convertible notes",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "gmda:ScheduleOfLiabilityAndEquityComponentConvertibleNotesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0322_gamidacell.htm",
      "contextRef": "c0",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "gmda:AmountOfPrincipal",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "gmda:ScheduleOfFairValueOfMoneyMarketFundsAndMarketableSecuritiesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0322_gamidacell.htm",
      "contextRef": "c2",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:MoneyMarketFundsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "028 - Disclosure - Fair Value Measurements (Details) - Schedule of fair value of money market funds and marketable securities",
     "role": "http://www.gamidacell.com/role/ScheduleoffairvalueofmoneymarketfundsandmarketablesecuritiesTable",
     "shortName": "Fair Value Measurements (Details) - Schedule of fair value of money market funds and marketable securities",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "gmda:ScheduleOfFairValueOfMoneyMarketFundsAndMarketableSecuritiesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0322_gamidacell.htm",
      "contextRef": "c2",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:MoneyMarketFundsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0322_gamidacell.htm",
      "contextRef": "c2",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "ilsPershares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "002 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parentheticals)",
     "role": "http://www.gamidacell.com/role/ConsolidatedBalanceSheet_Parentheticals",
     "shortName": "Condensed Consolidated Balance Sheets (Unaudited) (Parentheticals)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0322_gamidacell.htm",
      "contextRef": "c2",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "ilsPershares",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0322_gamidacell.htm",
      "contextRef": "c2",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RoyaltyGuaranteesCommitmentsAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "029 - Disclosure - Contingent Liabilities and Commitments (Details)",
     "role": "http://www.gamidacell.com/role/ContingentLiabilitiesandCommitmentsDetails",
     "shortName": "Contingent Liabilities and Commitments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0322_gamidacell.htm",
      "contextRef": "c2",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RoyaltyGuaranteesCommitmentsAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0322_gamidacell.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "gmda:UnderwritersDescription",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "030 - Disclosure - Shareholders' Equity (Details)",
     "role": "http://www.gamidacell.com/role/ShareholdersEquityDetails",
     "shortName": "Shareholders' Equity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0322_gamidacell.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "gmda:UnderwritersDescription",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0322_gamidacell.htm",
      "contextRef": "c42",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "031 - Disclosure - Share-Based Compensation (Details)",
     "role": "http://www.gamidacell.com/role/ShareBasedCompensationDetails",
     "shortName": "Share-Based Compensation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0322_gamidacell.htm",
      "contextRef": "c42",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0322_gamidacell.htm",
      "contextRef": "c0",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "032 - Disclosure - Share-Based Compensation (Details) - Schedule of fair value measurement of equity-settled share options",
     "role": "http://www.gamidacell.com/role/ScheduleoffairvaluemeasurementofequitysettledshareoptionsTable",
     "shortName": "Share-Based Compensation (Details) - Schedule of fair value measurement of equity-settled share options",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0322_gamidacell.htm",
      "contextRef": "c0",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "pure",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0322_gamidacell.htm",
      "contextRef": "c3",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "033 - Disclosure - Share-Based Compensation (Details) - Schedule of stock option plans",
     "role": "http://www.gamidacell.com/role/ScheduleofstockoptionplansTable",
     "shortName": "Share-Based Compensation (Details) - Schedule of stock option plans",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0322_gamidacell.htm",
      "contextRef": "c3",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0322_gamidacell.htm",
      "contextRef": "c3",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "034 - Disclosure - Share-Based Compensation (Details) - Schedule of restricted shares activity",
     "role": "http://www.gamidacell.com/role/ScheduleofrestrictedsharesactivityTable",
     "shortName": "Share-Based Compensation (Details) - Schedule of restricted shares activity",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0322_gamidacell.htm",
      "contextRef": "c3",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0322_gamidacell.htm",
      "contextRef": "c0",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "035 - Disclosure - Share-Based Compensation (Details) - Schedule of share-based compensation expense",
     "role": "http://www.gamidacell.com/role/ScheduleofsharebasedcompensationexpenseTable",
     "shortName": "Share-Based Compensation (Details) - Schedule of share-based compensation expense",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0322_gamidacell.htm",
      "contextRef": "c0",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0322_gamidacell.htm",
      "contextRef": "c49",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "gmda:WeightedAverageNumberOfSharesOutstandingBasicAndDiluted",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "036 - Disclosure - Basic and Diluted Net Loss Per Share (Details) - Schedule of number of shares and loss used in the computation of net loss per share",
     "role": "http://www.gamidacell.com/role/ScheduleofnumberofsharesandlossusedinthecomputationofnetlosspershareTable",
     "shortName": "Basic and Diluted Net Loss Per Share (Details) - Schedule of number of shares and loss used in the computation of net loss per share",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0322_gamidacell.htm",
      "contextRef": "c49",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "gmda:WeightedAverageNumberOfSharesOutstandingBasicAndDiluted",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0322_gamidacell.htm",
      "contextRef": "c0",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "gmda:ResearchAndDevelopmentExpensesNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "003 - Statement - Condensed Consolidated Statements of Operation (Unaudited)",
     "role": "http://www.gamidacell.com/role/ConsolidatedIncomeStatement",
     "shortName": "Condensed Consolidated Statements of Operation (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0322_gamidacell.htm",
      "contextRef": "c0",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "gmda:ResearchAndDevelopmentExpensesNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0322_gamidacell.htm",
      "contextRef": "c5",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "004 - Statement - Condensed Consolidated Statements of Changes in Shareholders\u2019 Equity (Unaudited)",
     "role": "http://www.gamidacell.com/role/ShareholdersEquityType2or3",
     "shortName": "Condensed Consolidated Statements of Changes in Shareholders\u2019 Equity (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0322_gamidacell.htm",
      "contextRef": "c5",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0322_gamidacell.htm",
      "contextRef": "c0",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "005 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)",
     "role": "http://www.gamidacell.com/role/ConsolidatedCashFlow",
     "shortName": "Condensed Consolidated Statements of Cash Flows (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0322_gamidacell.htm",
      "contextRef": "c0",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0322_gamidacell.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "006 - Disclosure - General",
     "role": "http://www.gamidacell.com/role/General",
     "shortName": "General",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0322_gamidacell.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0322_gamidacell.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "007 - Disclosure - Significant Accounting Policies",
     "role": "http://www.gamidacell.com/role/SignificantAccountingPolicies",
     "shortName": "Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0322_gamidacell.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0322_gamidacell.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "008 - Disclosure - Leases",
     "role": "http://www.gamidacell.com/role/Leases",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f10q0322_gamidacell.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 15,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.gamidacell.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.gamidacell.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.gamidacell.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.gamidacell.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.gamidacell.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "localname": "DocumentInformationLineItems",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.gamidacell.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_DocumentInformationTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package."
       }
      }
     },
     "localname": "DocumentInformationTable",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.gamidacell.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.gamidacell.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r346"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.gamidacell.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r347"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.gamidacell.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.gamidacell.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.gamidacell.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.gamidacell.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.gamidacell.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.gamidacell.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r344"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.gamidacell.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.gamidacell.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.gamidacell.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r344"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.gamidacell.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r350"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Entity Ex Transition Period",
        "terseLabel": "Entity Ex Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.gamidacell.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.gamidacell.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r344"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.gamidacell.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.gamidacell.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r349"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.gamidacell.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r344"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.gamidacell.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r344"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.gamidacell.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r344"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.gamidacell.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r344"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.gamidacell.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.gamidacell.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r343"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.gamidacell.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r345"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.gamidacell.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.gamidacell.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "gmda_AccumulatedDeficit": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated deficit",
        "label": "AccumulatedDeficit",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "AccumulatedDeficit",
     "nsuri": "http://www.gamidacell.com/20220331",
     "presentation": [
      "http://www.gamidacell.com/role/GeneralDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gmda_AmountOfPrincipal": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Principal amount.",
        "label": "AmountOfPrincipal",
        "terseLabel": "Principal amount"
       }
      }
     },
     "localname": "AmountOfPrincipal",
     "nsuri": "http://www.gamidacell.com/20220331",
     "presentation": [
      "http://www.gamidacell.com/role/ScheduleofliabilityandequitycomponentsoftheconvertiblenotesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gmda_AnnualInterestPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Annual Interest Percentage.",
        "label": "AnnualInterestPercentage",
        "terseLabel": "Annual interest percentage"
       }
      }
     },
     "localname": "AnnualInterestPercentage",
     "nsuri": "http://www.gamidacell.com/20220331",
     "presentation": [
      "http://www.gamidacell.com/role/ConvertibleSeniorNotesNetDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "gmda_BasicandDilutedNetLossPerShareDetailsScheduleofnumberofsharesandlossusedinthecomputationofnetlosspershareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basic and Diluted Net Loss Per Share (Details) - Schedule of number of shares and loss used in the computation of net loss per share [Line Items]"
       }
      }
     },
     "localname": "BasicandDilutedNetLossPerShareDetailsScheduleofnumberofsharesandlossusedinthecomputationofnetlosspershareLineItems",
     "nsuri": "http://www.gamidacell.com/20220331",
     "presentation": [
      "http://www.gamidacell.com/role/ScheduleofnumberofsharesandlossusedinthecomputationofnetlosspershareTable"
     ],
     "xbrltype": "stringItemType"
    },
    "gmda_BasicandDilutedNetLossPerShareDetailsScheduleofnumberofsharesandlossusedinthecomputationofnetlosspershareTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basic and Diluted Net Loss Per Share (Details) - Schedule of number of shares and loss used in the computation of net loss per share [Table]"
       }
      }
     },
     "localname": "BasicandDilutedNetLossPerShareDetailsScheduleofnumberofsharesandlossusedinthecomputationofnetlosspershareTable",
     "nsuri": "http://www.gamidacell.com/20220331",
     "presentation": [
      "http://www.gamidacell.com/role/ScheduleofnumberofsharesandlossusedinthecomputationofnetlosspershareTable"
     ],
     "xbrltype": "stringItemType"
    },
    "gmda_CashEquivalentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CashEquivalentsAbstract",
        "terseLabel": "Cash equivalents:"
       }
      }
     },
     "localname": "CashEquivalentsAbstract",
     "nsuri": "http://www.gamidacell.com/20220331",
     "presentation": [
      "http://www.gamidacell.com/role/ScheduleoffairvalueofmoneymarketfundsandmarketablesecuritiesTable"
     ],
     "xbrltype": "stringItemType"
    },
    "gmda_ClinicalTrialOnOutcomes": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Clinical trial on outcomes.",
        "label": "ClinicalTrialOnOutcomes",
        "terseLabel": "Clinical trial on outcomes"
       }
      }
     },
     "localname": "ClinicalTrialOnOutcomes",
     "nsuri": "http://www.gamidacell.com/20220331",
     "presentation": [
      "http://www.gamidacell.com/role/GeneralDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "gmda_CommercialExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.gamidacell.com/role/ConsolidatedIncomeStatement": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of commercial expenses.",
        "label": "CommercialExpenses",
        "terseLabel": "Commercial expenses"
       }
      }
     },
     "localname": "CommercialExpenses",
     "nsuri": "http://www.gamidacell.com/20220331",
     "presentation": [
      "http://www.gamidacell.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gmda_ContingentLiabilitiesandCommitmentsDetailsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contingent Liabilities and Commitments (Details) [Line Items]"
       }
      }
     },
     "localname": "ContingentLiabilitiesandCommitmentsDetailsLineItems",
     "nsuri": "http://www.gamidacell.com/20220331",
     "presentation": [
      "http://www.gamidacell.com/role/ContingentLiabilitiesandCommitmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "gmda_ContingentLiabilitiesandCommitmentsDetailsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contingent Liabilities and Commitments (Details) [Table]"
       }
      }
     },
     "localname": "ContingentLiabilitiesandCommitmentsDetailsTable",
     "nsuri": "http://www.gamidacell.com/20220331",
     "presentation": [
      "http://www.gamidacell.com/role/ContingentLiabilitiesandCommitmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "gmda_ConvertibleSeniorNotesNetDetailsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Senior Notes, Net (Details) [Line Items]"
       }
      }
     },
     "localname": "ConvertibleSeniorNotesNetDetailsLineItems",
     "nsuri": "http://www.gamidacell.com/20220331",
     "presentation": [
      "http://www.gamidacell.com/role/ConvertibleSeniorNotesNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "gmda_ConvertibleSeniorNotesNetDetailsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Senior Notes, Net (Details) [Table]"
       }
      }
     },
     "localname": "ConvertibleSeniorNotesNetDetailsTable",
     "nsuri": "http://www.gamidacell.com/20220331",
     "presentation": [
      "http://www.gamidacell.com/role/ConvertibleSeniorNotesNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "gmda_ConvertibleSeniorNotesPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ConvertibleSeniorNotesPolicyTextBlock",
        "terseLabel": "Convertible senior notes"
       }
      }
     },
     "localname": "ConvertibleSeniorNotesPolicyTextBlock",
     "nsuri": "http://www.gamidacell.com/20220331",
     "presentation": [
      "http://www.gamidacell.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "gmda_CorporateDebentures": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of corporate debentures.",
        "label": "CorporateDebentures",
        "terseLabel": "Corporate debentures"
       }
      }
     },
     "localname": "CorporateDebentures",
     "nsuri": "http://www.gamidacell.com/20220331",
     "presentation": [
      "http://www.gamidacell.com/role/ScheduleoffairvalueofmoneymarketfundsandmarketablesecuritiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gmda_DisclosureOfNotesAndOtherExplanatoryInformationsExplanatoryAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure Of Notes And Other Explanatory Informations Explanatory [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfNotesAndOtherExplanatoryInformationsExplanatoryAbstract",
     "nsuri": "http://www.gamidacell.com/20220331",
     "xbrltype": "stringItemType"
    },
    "gmda_DisclosureOfNotesAndOtherExplanatoryInformationsExplanatoryTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The disclosure of notes and other explanatory information as part of a complete set of financial statements.",
        "label": "DisclosureOfNotesAndOtherExplanatoryInformationsExplanatoryTextBlock",
        "terseLabel": "CONVERTIBLE SENIOR NOTES, NET"
       }
      }
     },
     "localname": "DisclosureOfNotesAndOtherExplanatoryInformationsExplanatoryTextBlock",
     "nsuri": "http://www.gamidacell.com/20220331",
     "presentation": [
      "http://www.gamidacell.com/role/ConvertibleSeniorNotesNet"
     ],
     "xbrltype": "textBlockItemType"
    },
    "gmda_DocumentAndEntityInformationAbstract": {
     "auth_ref": [],
     "localname": "DocumentAndEntityInformationAbstract",
     "nsuri": "http://www.gamidacell.com/20220331",
     "xbrltype": "stringItemType"
    },
    "gmda_ExchangePricePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ExchangePricePercentage",
        "terseLabel": "Exchange price percentage"
       }
      }
     },
     "localname": "ExchangePricePercentage",
     "nsuri": "http://www.gamidacell.com/20220331",
     "presentation": [
      "http://www.gamidacell.com/role/ConvertibleSeniorNotesNetDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "gmda_ExpiryDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ExpiryDate",
        "terseLabel": "Expire date"
       }
      }
     },
     "localname": "ExpiryDate",
     "nsuri": "http://www.gamidacell.com/20220331",
     "presentation": [
      "http://www.gamidacell.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "gmda_FairValueMeasurementsDetailsScheduleoffairvalueofmoneymarketfundsandmarketablesecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurements (Details) - Schedule of fair value of money market funds and marketable securities [Line Items]"
       }
      }
     },
     "localname": "FairValueMeasurementsDetailsScheduleoffairvalueofmoneymarketfundsandmarketablesecuritiesLineItems",
     "nsuri": "http://www.gamidacell.com/20220331",
     "presentation": [
      "http://www.gamidacell.com/role/ScheduleoffairvalueofmoneymarketfundsandmarketablesecuritiesTable"
     ],
     "xbrltype": "stringItemType"
    },
    "gmda_FairValueMeasurementsDetailsScheduleoffairvalueofmoneymarketfundsandmarketablesecuritiesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurements (Details) - Schedule of fair value of money market funds and marketable securities [Table]"
       }
      }
     },
     "localname": "FairValueMeasurementsDetailsScheduleoffairvalueofmoneymarketfundsandmarketablesecuritiesTable",
     "nsuri": "http://www.gamidacell.com/20220331",
     "presentation": [
      "http://www.gamidacell.com/role/ScheduleoffairvalueofmoneymarketfundsandmarketablesecuritiesTable"
     ],
     "xbrltype": "stringItemType"
    },
    "gmda_ForTheComputationOfDilutedLossMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ForTheComputationOfDilutedLossMember",
        "terseLabel": "For the computation of diluted loss [Member]"
       }
      }
     },
     "localname": "ForTheComputationOfDilutedLossMember",
     "nsuri": "http://www.gamidacell.com/20220331",
     "presentation": [
      "http://www.gamidacell.com/role/ScheduleofnumberofsharesandlossusedinthecomputationofnetlosspershareTable"
     ],
     "xbrltype": "domainItemType"
    },
    "gmda_GeneralAndAdministrativeExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.gamidacell.com/role/ConsolidatedIncomeStatement": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "General and administrative expenses.",
        "label": "GeneralAndAdministrativeExpenses",
        "terseLabel": "General and administrative expenses"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenses",
     "nsuri": "http://www.gamidacell.com/20220331",
     "presentation": [
      "http://www.gamidacell.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gmda_GovernmentDebentures": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of government debentures.",
        "label": "GovernmentDebentures",
        "terseLabel": "Government debentures"
       }
      }
     },
     "localname": "GovernmentDebentures",
     "nsuri": "http://www.gamidacell.com/20220331",
     "presentation": [
      "http://www.gamidacell.com/role/ScheduleoffairvalueofmoneymarketfundsandmarketablesecuritiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gmda_IssuanceExpensesOnCredit": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance expenses on credit.",
        "label": "IssuanceExpensesOnCredit",
        "terseLabel": "Issuance expenses on credit"
       }
      }
     },
     "localname": "IssuanceExpensesOnCredit",
     "nsuri": "http://www.gamidacell.com/20220331",
     "presentation": [
      "http://www.gamidacell.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gmda_LesseeOperatingLeaseLiabilityPaymentsDueYearSix": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in Sixth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "LesseeOperatingLeaseLiabilityPaymentsDueYearSix",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearSix",
     "nsuri": "http://www.gamidacell.com/20220331",
     "presentation": [
      "http://www.gamidacell.com/role/ScheduleofmaturitiesofleaseliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gmda_LossPerShareAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "LossPerShareAxis",
        "terseLabel": "Loss Per Share [Axis]"
       }
      }
     },
     "localname": "LossPerShareAxis",
     "nsuri": "http://www.gamidacell.com/20220331",
     "presentation": [
      "http://www.gamidacell.com/role/ScheduleofnumberofsharesandlossusedinthecomputationofnetlosspershareTable"
     ],
     "xbrltype": "stringItemType"
    },
    "gmda_NetCarryingAmountincludingAccruedInterest": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "It represents of net carrying amount including accrued interest.",
        "label": "NetCarryingAmountincludingAccruedInterest",
        "terseLabel": "Net carrying amount"
       }
      }
     },
     "localname": "NetCarryingAmountincludingAccruedInterest",
     "nsuri": "http://www.gamidacell.com/20220331",
     "presentation": [
      "http://www.gamidacell.com/role/ScheduleofliabilityandequitycomponentsoftheconvertiblenotesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gmda_NetIssuanceCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net issuance costs.",
        "label": "NetIssuanceCosts",
        "terseLabel": "Net"
       }
      }
     },
     "localname": "NetIssuanceCosts",
     "nsuri": "http://www.gamidacell.com/20220331",
     "presentation": [
      "http://www.gamidacell.com/role/ScheduleofliabilityandequitycomponentsoftheconvertiblenotesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gmda_OrdinarySharesOutstandingPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "OrdinarySharesOutstandingPercentage",
        "terseLabel": "Ordinary shares outstanding percentage"
       }
      }
     },
     "localname": "OrdinarySharesOutstandingPercentage",
     "nsuri": "http://www.gamidacell.com/20220331",
     "presentation": [
      "http://www.gamidacell.com/role/ShareBasedCompensationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "gmda_PrincipalAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "It represents of principal amount.",
        "label": "PrincipalAmount",
        "terseLabel": "Aggregate principal amount"
       }
      }
     },
     "localname": "PrincipalAmount",
     "nsuri": "http://www.gamidacell.com/20220331",
     "presentation": [
      "http://www.gamidacell.com/role/ConvertibleSeniorNotesNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gmda_ResearchAndDevelopmentExpensesNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.gamidacell.com/role/ConsolidatedIncomeStatement": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research and development expenses, net.",
        "label": "ResearchAndDevelopmentExpensesNet",
        "terseLabel": "Research and development expenses, net"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensesNet",
     "nsuri": "http://www.gamidacell.com/20220331",
     "presentation": [
      "http://www.gamidacell.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gmda_ResponseRatePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Response rate percentage., description",
        "label": "ResponseRatePercentage",
        "terseLabel": "Response rate percentage, description"
       }
      }
     },
     "localname": "ResponseRatePercentage",
     "nsuri": "http://www.gamidacell.com/20220331",
     "presentation": [
      "http://www.gamidacell.com/role/GeneralDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "gmda_ScheduleOfFairValueMeasurementOfEquitySettledShareOptionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of fair value measurement of equity-settled share options [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfFairValueMeasurementOfEquitySettledShareOptionsAbstract",
     "nsuri": "http://www.gamidacell.com/20220331",
     "xbrltype": "stringItemType"
    },
    "gmda_ScheduleOfFairValueOfMoneyMarketFundsAndMarketableSecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of fair value of money market funds and marketable securities [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfFairValueOfMoneyMarketFundsAndMarketableSecuritiesAbstract",
     "nsuri": "http://www.gamidacell.com/20220331",
     "xbrltype": "stringItemType"
    },
    "gmda_ScheduleOfFairValueOfMoneyMarketFundsAndMarketableSecuritiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ScheduleOfFairValueOfMoneyMarketFundsAndMarketableSecuritiesTableTextBlock",
        "terseLabel": "Schedule of fair value of money market funds and marketable securities"
       }
      }
     },
     "localname": "ScheduleOfFairValueOfMoneyMarketFundsAndMarketableSecuritiesTableTextBlock",
     "nsuri": "http://www.gamidacell.com/20220331",
     "presentation": [
      "http://www.gamidacell.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "gmda_ScheduleOfLiabilityAndEquityComponentConvertibleNotesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule Of Liability And Equity Components Convertible Notes Table Text Block.",
        "label": "ScheduleOfLiabilityAndEquityComponentConvertibleNotesTableTextBlock",
        "terseLabel": "Schedule of liability and equity components of the convertible notes"
       }
      }
     },
     "localname": "ScheduleOfLiabilityAndEquityComponentConvertibleNotesTableTextBlock",
     "nsuri": "http://www.gamidacell.com/20220331",
     "presentation": [
      "http://www.gamidacell.com/role/ConvertibleSeniorNotesNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "gmda_ScheduleOfLiabilityAndEquityComponentsOfTheConvertibleNotesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of liability and equity components of the convertible notes [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfLiabilityAndEquityComponentsOfTheConvertibleNotesAbstract",
     "nsuri": "http://www.gamidacell.com/20220331",
     "xbrltype": "stringItemType"
    },
    "gmda_ScheduleOfMaturitiesOfLeaseLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of maturities of lease liabilities [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfMaturitiesOfLeaseLiabilitiesAbstract",
     "nsuri": "http://www.gamidacell.com/20220331",
     "xbrltype": "stringItemType"
    },
    "gmda_ScheduleOfNumberOfSharesAndLossUsedInTheComputationOfNetLossPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of number of shares and loss used in the computation of net loss per share [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfNumberOfSharesAndLossUsedInTheComputationOfNetLossPerShareAbstract",
     "nsuri": "http://www.gamidacell.com/20220331",
     "xbrltype": "stringItemType"
    },
    "gmda_ScheduleOfOperatingLeaseCostsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of operating lease costs [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfOperatingLeaseCostsAbstract",
     "nsuri": "http://www.gamidacell.com/20220331",
     "xbrltype": "stringItemType"
    },
    "gmda_ScheduleOfOperatingLeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of operating leases [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfOperatingLeasesAbstract",
     "nsuri": "http://www.gamidacell.com/20220331",
     "xbrltype": "stringItemType"
    },
    "gmda_ScheduleOfRestrictedSharesActivityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of restricted shares activity [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfRestrictedSharesActivityAbstract",
     "nsuri": "http://www.gamidacell.com/20220331",
     "xbrltype": "stringItemType"
    },
    "gmda_ScheduleOfShareBasedCompensationExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of share-based compensation expense [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationExpenseAbstract",
     "nsuri": "http://www.gamidacell.com/20220331",
     "xbrltype": "stringItemType"
    },
    "gmda_ScheduleOfStockOptionPlansAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of stock option plans [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfStockOptionPlansAbstract",
     "nsuri": "http://www.gamidacell.com/20220331",
     "xbrltype": "stringItemType"
    },
    "gmda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableInPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options or other stock instruments for which the right to exercisable has lapsed under the terms of the plan agreements.",
        "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableInPeriod",
        "terseLabel": "Amount of options and restricted share unites, Exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableInPeriod",
     "nsuri": "http://www.gamidacell.com/20220331",
     "presentation": [
      "http://www.gamidacell.com/role/ScheduleofstockoptionplansTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "gmda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriods": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of options, Forfeited.",
        "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriods",
        "negatedLabel": "Amount of options and restricted share unites, Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriods",
     "nsuri": "http://www.gamidacell.com/20220331",
     "presentation": [
      "http://www.gamidacell.com/role/ScheduleofstockoptionplansTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "gmda_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrosses": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of options, Granted.",
        "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrosses",
        "terseLabel": "Amount of options and restricted share unites, Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrosses",
     "nsuri": "http://www.gamidacell.com/20220331",
     "presentation": [
      "http://www.gamidacell.com/role/ScheduleofstockoptionplansTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "gmda_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisableInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that exercisable.",
        "label": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisableInPeriodWeightedAverageExercisePrice",
        "terseLabel": "Weighted average exercise price, Exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisableInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://www.gamidacell.com/20220331",
     "presentation": [
      "http://www.gamidacell.com/role/ScheduleofstockoptionplansTable"
     ],
     "xbrltype": "perShareItemType"
    },
    "gmda_ShareBasedCompensationDetailsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation (Details) [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationDetailsLineItems",
     "nsuri": "http://www.gamidacell.com/20220331",
     "presentation": [
      "http://www.gamidacell.com/role/ShareBasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "gmda_ShareBasedCompensationDetailsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation (Details) [Table]"
       }
      }
     },
     "localname": "ShareBasedCompensationDetailsTable",
     "nsuri": "http://www.gamidacell.com/20220331",
     "presentation": [
      "http://www.gamidacell.com/role/ShareBasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "gmda_ShareholdersEquityDetailsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shareholders' Equity (Details) [Line Items]"
       }
      }
     },
     "localname": "ShareholdersEquityDetailsLineItems",
     "nsuri": "http://www.gamidacell.com/20220331",
     "presentation": [
      "http://www.gamidacell.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "gmda_ShareholdersEquityDetailsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shareholders' Equity (Details) [Table]"
       }
      }
     },
     "localname": "ShareholdersEquityDetailsTable",
     "nsuri": "http://www.gamidacell.com/20220331",
     "presentation": [
      "http://www.gamidacell.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "gmda_StockIssuedDuringPeriodSharesStockOptionesExercised": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock issued during period shares stock options exercised.",
        "label": "StockIssuedDuringPeriodSharesStockOptionesExercised",
        "negatedLabel": "Amount of options and restricted share unites, Exercised"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionesExercised",
     "nsuri": "http://www.gamidacell.com/20220331",
     "presentation": [
      "http://www.gamidacell.com/role/ScheduleofstockoptionplansTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "gmda_TwoThousandSeventeenStockCompensationPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "TwoThousandSeventeenStockCompensationPlanMember",
        "terseLabel": "2017 Share Incentive Plan [Member]"
       }
      }
     },
     "localname": "TwoThousandSeventeenStockCompensationPlanMember",
     "nsuri": "http://www.gamidacell.com/20220331",
     "presentation": [
      "http://www.gamidacell.com/role/ShareBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gmda_TwoZeroOneFourIsraelShareOptionPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "TwoZeroOneFourIsraelShareOptionPlanMember",
        "terseLabel": "2014 Israel Share Option Plan [Member]"
       }
      }
     },
     "localname": "TwoZeroOneFourIsraelShareOptionPlanMember",
     "nsuri": "http://www.gamidacell.com/20220331",
     "presentation": [
      "http://www.gamidacell.com/role/ShareBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "gmda_UnamortizedIssuanceCosts": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "It represents of unamortized discount.",
        "label": "UnamortizedIssuanceCosts",
        "terseLabel": "Issuance costs"
       }
      }
     },
     "localname": "UnamortizedIssuanceCosts",
     "nsuri": "http://www.gamidacell.com/20220331",
     "presentation": [
      "http://www.gamidacell.com/role/ScheduleofliabilityandequitycomponentsoftheconvertiblenotesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "gmda_UnderwritersDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The description related to underwriters description.",
        "label": "UnderwritersDescription",
        "terseLabel": "Underwriters description"
       }
      }
     },
     "localname": "UnderwritersDescription",
     "nsuri": "http://www.gamidacell.com/20220331",
     "presentation": [
      "http://www.gamidacell.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "gmda_WeightedAverageNumberOfSharesOutstandingBasicAndDiluted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).",
        "label": "WeightedAverageNumberOfSharesOutstandingBasicAndDiluted",
        "terseLabel": "Weighted number of shares"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasicAndDiluted",
     "nsuri": "http://www.gamidacell.com/20220331",
     "presentation": [
      "http://www.gamidacell.com/role/ScheduleofnumberofsharesandlossusedinthecomputationofnetlosspershareTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r135",
      "r136",
      "r137",
      "r138",
      "r152",
      "r161",
      "r187",
      "r188",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r314",
      "r315",
      "r340",
      "r341"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum [Member]"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.gamidacell.com/role/ContingentLiabilitiesandCommitmentsDetails",
      "http://www.gamidacell.com/role/ShareBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r135",
      "r136",
      "r137",
      "r138",
      "r152",
      "r161",
      "r187",
      "r188",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r314",
      "r315",
      "r340",
      "r341"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum [Member]"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.gamidacell.com/role/ContingentLiabilitiesandCommitmentsDetails",
      "http://www.gamidacell.com/role/ShareBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r131",
      "r135",
      "r136",
      "r137",
      "r138",
      "r152",
      "r161",
      "r178",
      "r187",
      "r188",
      "r209",
      "r210",
      "r211",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r314",
      "r315",
      "r340",
      "r341"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.gamidacell.com/role/ContingentLiabilitiesandCommitmentsDetails",
      "http://www.gamidacell.com/role/ShareBasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r131",
      "r135",
      "r136",
      "r137",
      "r138",
      "r152",
      "r161",
      "r178",
      "r187",
      "r188",
      "r209",
      "r210",
      "r211",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r314",
      "r315",
      "r340",
      "r341"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.gamidacell.com/role/ContingentLiabilitiesandCommitmentsDetails",
      "http://www.gamidacell.com/role/ShareBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r26",
      "r278"
     ],
     "calculation": {
      "http://www.gamidacell.com/role/ConsolidatedBalanceSheet": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Trade payables"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gamidacell.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r21",
      "r38",
      "r39",
      "r40",
      "r305",
      "r319",
      "r320"
     ],
     "calculation": {
      "http://www.gamidacell.com/role/ConsolidatedBalanceSheet": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gamidacell.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r20"
     ],
     "calculation": {
      "http://www.gamidacell.com/role/ConsolidatedBalanceSheet": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional Paid in Capital, Common Stock",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gamidacell.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r73",
      "r74",
      "r75",
      "r218",
      "r219",
      "r220",
      "r239"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional paid-in capital",
        "verboseLabel": "Additional Paid-in Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gamidacell.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustment to reconcile loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gamidacell.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r213"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-Based Payment Arrangement, Expense",
        "terseLabel": "Total share-based compensation"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gamidacell.com/role/ScheduleofsharebasedcompensationexpenseTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfAdvanceRoyalty": {
     "auth_ref": [
      "r51",
      "r63"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The expense charged against earnings for the periodic recognition of the advance royalties. These royalties are paid in one accounting period, but are deducted from earnings over time through amortization. For example, royalties that are required to be paid in advance of production from a mineral, oil, or gas property and amortized over the period of right to produce these items.",
        "label": "Amortization of Advance Royalty",
        "terseLabel": "Non-royalty-bearing grants"
       }
      }
     },
     "localname": "AmortizationOfAdvanceRoyalty",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gamidacell.com/role/ContingentLiabilitiesandCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfFinancingCosts": {
     "auth_ref": [
      "r48",
      "r63",
      "r154",
      "r253"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to debt issuance costs.",
        "label": "Amortization of Debt Issuance Costs",
        "terseLabel": "Amortized issuance costs"
       }
      }
     },
     "localname": "AmortizationOfFinancingCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gamidacell.com/role/ScheduleofliabilityandequitycomponentsoftheconvertiblenotesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfFinancingCostsAndDiscounts": {
     "auth_ref": [
      "r63",
      "r154",
      "r157",
      "r158",
      "r253"
     ],
     "calculation": {
      "http://www.gamidacell.com/role/ConsolidatedCashFlow": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.",
        "label": "Amortization of Debt Issuance Costs and Discounts",
        "terseLabel": "Amortization of issuance costs"
       }
      }
     },
     "localname": "AmortizationOfFinancingCostsAndDiscounts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gamidacell.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r12",
      "r71",
      "r118",
      "r120",
      "r123",
      "r127",
      "r141",
      "r142",
      "r143",
      "r144",
      "r145",
      "r146",
      "r147",
      "r148",
      "r149",
      "r150",
      "r151",
      "r229",
      "r233",
      "r244",
      "r276",
      "r278",
      "r292",
      "r303"
     ],
     "calculation": {
      "http://www.gamidacell.com/role/ConsolidatedBalanceSheet": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gamidacell.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gamidacell.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r4",
      "r25",
      "r71",
      "r127",
      "r141",
      "r142",
      "r143",
      "r144",
      "r145",
      "r146",
      "r147",
      "r148",
      "r149",
      "r150",
      "r151",
      "r229",
      "r233",
      "r244",
      "r276",
      "r278"
     ],
     "calculation": {
      "http://www.gamidacell.com/role/ConsolidatedBalanceSheet": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gamidacell.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gamidacell.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsNoncurrent": {
     "auth_ref": [
      "r71",
      "r127",
      "r141",
      "r142",
      "r143",
      "r144",
      "r145",
      "r146",
      "r147",
      "r148",
      "r149",
      "r150",
      "r151",
      "r229",
      "r233",
      "r244",
      "r276"
     ],
     "calculation": {
      "http://www.gamidacell.com/role/ConsolidatedBalanceSheet": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.",
        "label": "Assets, Noncurrent",
        "totalLabel": "Total non-current assets"
       }
      }
     },
     "localname": "AssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gamidacell.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Noncurrent [Abstract]",
        "terseLabel": "Non-current assets:"
       }
      }
     },
     "localname": "AssetsNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gamidacell.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BorrowingsUnderGuaranteedInvestmentAgreements": {
     "auth_ref": [
      "r311"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of the sum of the obligations to contract holders to provide to them an agreed upon rate of return pursuant to the terms of the underlying contract. These contracts represent lending by the contract holders to the entity in return for a guaranteed (primarily fixed) interest rate until maturity, unless called earlier if the contracts provide that option to the contract holders (usually institutions). There is little or no insurance risk for the entity.",
        "label": "Borrowings under Guaranteed Investment Agreements",
        "terseLabel": "Investment center grant amount"
       }
      }
     },
     "localname": "BorrowingsUnderGuaranteedInvestmentAgreements",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gamidacell.com/role/ContingentLiabilitiesandCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r3",
      "r9",
      "r65"
     ],
     "calculation": {
      "http://www.gamidacell.com/role/ConsolidatedBalanceSheet": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gamidacell.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "auth_ref": [
      "r59",
      "r65",
      "r67"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations",
        "periodEndLabel": "Cash and cash equivalents at end of period",
        "periodStartLabel": "Cash and cash equivalents at beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gamidacell.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": {
     "auth_ref": [
      "r59",
      "r245"
     ],
     "calculation": {
      "http://www.gamidacell.com/role/ConsolidatedCashFlow": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect",
        "totalLabel": "Increase (decrease) in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gamidacell.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r16",
      "r17",
      "r18",
      "r69",
      "r71",
      "r88",
      "r89",
      "r94",
      "r97",
      "r99",
      "r107",
      "r108",
      "r109",
      "r127",
      "r141",
      "r145",
      "r146",
      "r147",
      "r150",
      "r151",
      "r159",
      "r160",
      "r163",
      "r167",
      "r173",
      "r244",
      "r348"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gamidacell.com/role/ShareBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r34",
      "r296",
      "r308"
     ],
     "calculation": {
      "http://www.gamidacell.com/role/ConsolidatedBalanceSheet": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Contingent liabilities and commitments"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gamidacell.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r132",
      "r133",
      "r134",
      "r139",
      "r339"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "CONTINGENT LIABILITIES AND COMMITMENTS"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gamidacell.com/role/ContingentLiabilitiesandCommitments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonClassCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Classification of common stock that has different rights than provided to Class A or B shares, representing ownership interest in a corporation.",
        "label": "Common Class C [Member]",
        "terseLabel": "Ordinary C Share [Member]"
       }
      }
     },
     "localname": "CommonClassCMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gamidacell.com/role/ShareBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r35"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Number of shares reserved for issuance"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gamidacell.com/role/ShareBasedCompensationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r73",
      "r74",
      "r239"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Ordinary shares"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gamidacell.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Ordinary shares par value (in New Shekels per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gamidacell.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Ordinary shares authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gamidacell.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Ordinary shares Issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gamidacell.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r18",
      "r173"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Ordinary shares outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gamidacell.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r18",
      "r278"
     ],
     "calculation": {
      "http://www.gamidacell.com/role/ConsolidatedBalanceSheet": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Ordinary shares NIS 0.01 par value; 150,000,000 shares authorized at March 31, 2022 (unaudited) and December 31, 2021; 60,021,415 and 59,970,389 shares issued at March 31, 2022 (unaudited) and December 31, 2021, respectively; 59,946,298 and 59,970,389 shares outstanding as of March 31, 2022 (unaudited) and December 31, 2021, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gamidacell.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertibleLongTermNotesPayable": {
     "auth_ref": [
      "r32"
     ],
     "calculation": {
      "http://www.gamidacell.com/role/ConsolidatedBalanceSheet": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of long-term debt (with maturities initially due after one year or beyond the operating cycle if longer) identified as Convertible Notes Payable, excluding current portion. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.",
        "label": "Convertible Notes Payable, Noncurrent",
        "terseLabel": "Convertible senior notes, net"
       }
      }
     },
     "localname": "ConvertibleLongTermNotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gamidacell.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertibleNotesPayable": {
     "auth_ref": [
      "r14",
      "r294",
      "r304",
      "r321"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Including the current and noncurrent portions, carrying value as of the balance sheet date of a written promise to pay a note, initially due after one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the issuer or the holder.",
        "label": "Convertible Notes Payable",
        "terseLabel": "Convertible notes payable"
       }
      }
     },
     "localname": "ConvertibleNotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gamidacell.com/role/ConvertibleSeniorNotesNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertibleNotesPayableCurrent": {
     "auth_ref": [
      "r29"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of the portion of long-term debt due within one year or the operating cycle if longer identified as Convertible Notes Payable. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.",
        "label": "Convertible Notes Payable, Current",
        "terseLabel": "Principal amount"
       }
      }
     },
     "localname": "ConvertibleNotesPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gamidacell.com/role/ConvertibleSeniorNotesNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertibleNotesPayableMember": {
     "auth_ref": [
      "r13",
      "r293",
      "r302",
      "r321"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Written promise to pay a note which can be exchanged for a specified quantity of securities (typically common stock), at the option of the issuer or the holder.",
        "label": "Convertible Notes Payable [Member]",
        "terseLabel": "Convertible Notes Payable [Member]",
        "verboseLabel": "Convertible Notes [Member]"
       }
      }
     },
     "localname": "ConvertibleNotesPayableMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gamidacell.com/role/ConvertibleSeniorNotesNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostsAndExpenses": {
     "auth_ref": [
      "r49"
     ],
     "calculation": {
      "http://www.gamidacell.com/role/ConsolidatedCashFlow": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total costs of sales and operating expenses for the period.",
        "label": "Costs and Expenses",
        "terseLabel": "Financing expense (income), net"
       }
      }
     },
     "localname": "CostsAndExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gamidacell.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpensesRelatedParty": {
     "auth_ref": [
      "r50"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Costs of sales and operating expenses for the period incurred from transactions with related parties.",
        "label": "Costs and Expenses, Related Party",
        "terseLabel": "Commercial expenses"
       }
      }
     },
     "localname": "CostsAndExpensesRelatedParty",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gamidacell.com/role/ScheduleofsharebasedcompensationexpenseTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentConvertibleConversionDate": {
     "auth_ref": [
      "r152"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date debt instrument can be converted into equity, in YYYY-MM-DD format.",
        "label": "Debt Instrument, Convertible, Conversion Date",
        "terseLabel": "Maturity date"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleConversionDate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gamidacell.com/role/ConvertibleSeniorNotesNetDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_DebtInstrumentInterestRateBasisForEffectiveRate": {
     "auth_ref": [
      "r31",
      "r252"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of any adjustments made to the stated rate to determine the effective rate.",
        "label": "Debt Instrument, Interest Rate, Basis for Effective Rate",
        "terseLabel": "Effective interest rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateBasisForEffectiveRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gamidacell.com/role/ConvertibleSeniorNotesNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPricePercentage": {
     "auth_ref": [
      "r301"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage price of original principal amount of debt at which debt can be redeemed by the issuer.",
        "label": "Debt Instrument, Redemption Price, Percentage",
        "terseLabel": "Repurchase price"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPricePercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gamidacell.com/role/ConvertibleSeniorNotesNetDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r63",
      "r129"
     ],
     "calculation": {
      "http://www.gamidacell.com/role/ConsolidatedCashFlow": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "terseLabel": "Depreciation of property, plant and equipment"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gamidacell.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeForwardInterestRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stated rate on an interest rate forward or futures contract.",
        "label": "Derivative, Forward Interest Rate",
        "terseLabel": "Royalties rate"
       }
      }
     },
     "localname": "DerivativeForwardInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gamidacell.com/role/ContingentLiabilitiesandCommitmentsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r189",
      "r190",
      "r214",
      "r215",
      "r216",
      "r224"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "terseLabel": "SHARE-BASED COMPENSATION"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gamidacell.com/role/ShareBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r47",
      "r78",
      "r79",
      "r80",
      "r81",
      "r82",
      "r86",
      "r88",
      "r97",
      "r98",
      "r99",
      "r103",
      "r104",
      "r240",
      "r241",
      "r298",
      "r313"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Net loss per share attributable to ordinary shareholders, basic and diluted (in Dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gamidacell.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r100",
      "r101"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Basic and diluted net loss per share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gamidacell.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r100",
      "r101",
      "r102",
      "r105"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "BASIC AND DILUTED NET LOSS PER SHARE"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gamidacell.com/role/BasicandDilutedNetLossPerShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EmployeeBenefitsAndShareBasedCompensation": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for employee benefit and equity-based compensation.",
        "label": "Employee Benefits and Share-Based Compensation",
        "terseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "EmployeeBenefitsAndShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gamidacell.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r29"
     ],
     "calculation": {
      "http://www.gamidacell.com/role/ConsolidatedBalanceSheet": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Employees and payroll accruals"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gamidacell.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis": {
     "auth_ref": [
      "r223"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of employee stock ownership plan.",
        "label": "Employee Stock Ownership Plan (ESOP) Name [Axis]"
       }
      }
     },
     "localname": "EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gamidacell.com/role/ShareBasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeStockOwnershipPlanESOPNumberOfAllocatedShares": {
     "auth_ref": [
      "r222"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The shares or units in an ESOP trust that have been assigned to individual participant accounts based on a known formula. IRS rules require allocations to be nondiscriminatory generally based on compensation, length of service, or a combination of both. For any particular participant such shares or units may be vested, unvested, or partially vested.",
        "label": "Employee Stock Ownership Plan (ESOP), Number of Allocated Shares",
        "terseLabel": "Ordinary shares"
       }
      }
     },
     "localname": "EmployeeStockOwnershipPlanESOPNumberOfAllocatedShares",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gamidacell.com/role/ShareBasedCompensationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_EmployeeStockOwnershipPlanESOPNumberOfSuspenseShares": {
     "auth_ref": [
      "r222"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares contributed to the ESOP that have not yet been released, committed to be released, or allocated to participant accounts. Suspense shares generally collateralize ESOP debt.",
        "label": "Employee Stock Ownership Plan (ESOP), Number of Suspense Shares",
        "terseLabel": "Ordinary shares issued"
       }
      }
     },
     "localname": "EmployeeStockOwnershipPlanESOPNumberOfSuspenseShares",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gamidacell.com/role/ShareBasedCompensationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain": {
     "auth_ref": [
      "r221"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Entities identify multiple employee stock ownership plans by unique name.",
        "label": "Employee Stock Ownership Plan (ESOP), Plan [Domain]"
       }
      }
     },
     "localname": "EmployeeStockOwnershipPlanESOPPlanDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gamidacell.com/role/ShareBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r0",
      "r43",
      "r44",
      "r45",
      "r73",
      "r74",
      "r75",
      "r77",
      "r83",
      "r85",
      "r106",
      "r128",
      "r173",
      "r174",
      "r218",
      "r219",
      "r220",
      "r226",
      "r227",
      "r239",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r273",
      "r316",
      "r317",
      "r318"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gamidacell.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r153",
      "r155",
      "r156",
      "r179",
      "r180",
      "r181",
      "r182",
      "r183",
      "r184",
      "r185",
      "r186",
      "r242",
      "r279",
      "r280",
      "r281"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gamidacell.com/role/ScheduleoffairvalueofmoneymarketfundsandmarketablesecuritiesTable"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r243"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "FAIR VALUE MEASUREMENTS"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gamidacell.com/role/FairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r153",
      "r179",
      "r180",
      "r185",
      "r186",
      "r242",
      "r279"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Fair Value, Inputs, Level 1 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gamidacell.com/role/ScheduleoffairvalueofmoneymarketfundsandmarketablesecuritiesTable"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r153",
      "r155",
      "r156",
      "r179",
      "r180",
      "r185",
      "r186",
      "r242",
      "r280"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Fair Value, Inputs, Level 2 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gamidacell.com/role/ScheduleoffairvalueofmoneymarketfundsandmarketablesecuritiesTable"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r153",
      "r155",
      "r156",
      "r179",
      "r180",
      "r181",
      "r182",
      "r183",
      "r184",
      "r185",
      "r186",
      "r279",
      "r280",
      "r281"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gamidacell.com/role/ScheduleoffairvalueofmoneymarketfundsandmarketablesecuritiesTable"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueNetAssetLiability": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of asset after deduction of liability.",
        "label": "Fair Value, Net Asset (Liability)",
        "terseLabel": "Total assets measured at fair value"
       }
      }
     },
     "localname": "FairValueNetAssetLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gamidacell.com/role/ScheduleoffairvalueofmoneymarketfundsandmarketablesecuritiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": {
     "auth_ref": [
      "r63"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.",
        "label": "Gain (Loss) on Disposition of Property Plant Equipment",
        "terseLabel": "Purchase of property, plant and equipment on credit"
       }
      }
     },
     "localname": "GainLossOnSaleOfPropertyPlantEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gamidacell.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r52"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative expenses"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gamidacell.com/role/ScheduleofsharebasedcompensationexpenseTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GrantsReceivable": {
     "auth_ref": [
      "r19"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of amounts due under the terms of governmental, corporate, or foundation grants.",
        "label": "Grants Receivable",
        "terseLabel": "Total grants"
       }
      }
     },
     "localname": "GrantsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gamidacell.com/role/ContingentLiabilitiesandCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GrantsReceivableCurrent": {
     "auth_ref": [
      "r19"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of amounts due under the terms of governmental, corporate, or foundation grants. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.",
        "label": "Grants Receivable, Current",
        "terseLabel": "Aggregate amount"
       }
      }
     },
     "localname": "GrantsReceivableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gamidacell.com/role/ContingentLiabilitiesandCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [
      "r62"
     ],
     "calculation": {
      "http://www.gamidacell.com/role/ConsolidatedCashFlow": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "terseLabel": "Decrease in accrued expenses and current liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gamidacell.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableTrade": {
     "auth_ref": [
      "r62"
     ],
     "calculation": {
      "http://www.gamidacell.com/role/ConsolidatedCashFlow": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Payable, Trade",
        "terseLabel": "Increase (decrease) in trade payables"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableTrade",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gamidacell.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "auth_ref": [
      "r62",
      "r265"
     ],
     "calculation": {
      "http://www.gamidacell.com/role/ConsolidatedCashFlow": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation for operating lease.",
        "label": "Increase (Decrease) in Operating Lease Liability",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gamidacell.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPostemploymentObligations": {
     "auth_ref": [
      "r62"
     ],
     "calculation": {
      "http://www.gamidacell.com/role/ConsolidatedCashFlow": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the current portion of the liability that represents various benefits due to former or inactive employees, their beneficiaries, and covered dependents after employment but before retirement.",
        "label": "Increase (Decrease) in Postemployment Obligations",
        "terseLabel": "Accrued severance pay, net"
       }
      }
     },
     "localname": "IncreaseDecreaseInPostemploymentObligations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gamidacell.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r62"
     ],
     "calculation": {
      "http://www.gamidacell.com/role/ConsolidatedCashFlow": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Increase in prepaid expenses and other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gamidacell.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r57",
      "r60",
      "r66"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Cash paid for interest"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gamidacell.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentTypeAxis": {
     "auth_ref": [
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of investments.",
        "label": "Investment Type [Axis]"
       }
      }
     },
     "localname": "InvestmentTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gamidacell.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentTypeCategorizationMember": {
     "auth_ref": [
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset obtained to generate income or appreciate in value.",
        "label": "Investments [Domain]"
       }
      }
     },
     "localname": "InvestmentTypeCategorizationMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gamidacell.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InvestmentsAndCash": {
     "auth_ref": [
      "r310"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of investments and unrestricted cash as of the balance sheet date.",
        "label": "Investments and Cash",
        "terseLabel": "Cash"
       }
      }
     },
     "localname": "InvestmentsAndCash",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gamidacell.com/role/GeneralDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestorMember": {
     "auth_ref": [
      "r274",
      "r275"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business entity or individual that puts money, by purchase or expenditure, in something offering potential profitable returns, such as interest income or appreciation in value.",
        "label": "Investor [Member]",
        "terseLabel": "2017 Investor [Member]"
       }
      }
     },
     "localname": "InvestorMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gamidacell.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeaseCost": {
     "auth_ref": [
      "r269",
      "r271"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease cost recognized by lessee for lease contract.",
        "label": "Lease, Cost",
        "terseLabel": "Total lease costs"
       }
      }
     },
     "localname": "LeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gamidacell.com/role/ScheduleofoperatingleasecostsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r269"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Schedule of operating lease costs"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gamidacell.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r270"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Schedule of maturities of lease liabilities"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gamidacell.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r270"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "terseLabel": "Total undiscounted lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gamidacell.com/role/ScheduleofmaturitiesofleaseliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "auth_ref": [
      "r270"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gamidacell.com/role/ScheduleofmaturitiesofleaseliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r270"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gamidacell.com/role/ScheduleofmaturitiesofleaseliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r270"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gamidacell.com/role/ScheduleofmaturitiesofleaseliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r270"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Less: Imputed interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gamidacell.com/role/ScheduleofmaturitiesofleaseliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseRemainingLeaseTerm": {
     "auth_ref": [
      "r262"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Remaining Lease Term",
        "terseLabel": "Lease term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRemainingLeaseTerm",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gamidacell.com/role/LeasesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r272"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "LEASES"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gamidacell.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r24",
      "r71",
      "r127",
      "r244",
      "r278",
      "r295",
      "r306"
     ],
     "calculation": {
      "http://www.gamidacell.com/role/ConsolidatedBalanceSheet": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total Liabilities and Shareholders\u2019 Equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gamidacell.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and Shareholders\u2019 Equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gamidacell.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r5",
      "r30",
      "r71",
      "r127",
      "r141",
      "r142",
      "r143",
      "r145",
      "r146",
      "r147",
      "r148",
      "r149",
      "r150",
      "r151",
      "r230",
      "r233",
      "r234",
      "r244",
      "r276",
      "r277",
      "r278"
     ],
     "calculation": {
      "http://www.gamidacell.com/role/ConsolidatedBalanceSheet": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gamidacell.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gamidacell.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesNoncurrent": {
     "auth_ref": [
      "r6",
      "r7",
      "r8",
      "r14",
      "r15",
      "r71",
      "r127",
      "r141",
      "r142",
      "r143",
      "r145",
      "r146",
      "r147",
      "r148",
      "r149",
      "r150",
      "r151",
      "r230",
      "r233",
      "r234",
      "r244",
      "r276",
      "r277"
     ],
     "calculation": {
      "http://www.gamidacell.com/role/ConsolidatedBalanceSheet": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer.",
        "label": "Liabilities, Noncurrent",
        "totalLabel": "Total non-current liabilities"
       }
      }
     },
     "localname": "LiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gamidacell.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Noncurrent [Abstract]",
        "terseLabel": "Non-current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gamidacell.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MarketableSecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Marketable Securities [Abstract]",
        "terseLabel": "Marketable securities:"
       }
      }
     },
     "localname": "MarketableSecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gamidacell.com/role/ScheduleoffairvalueofmoneymarketfundsandmarketablesecuritiesTable"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MarketableSecuritiesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.gamidacell.com/role/ConsolidatedBalanceSheet": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in marketable security, classified as current.",
        "label": "Marketable Securities, Current",
        "terseLabel": "Marketable securities"
       }
      }
     },
     "localname": "MarketableSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gamidacell.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MoneyMarketFundsAtCarryingValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investment in short-term money-market instruments (such as commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and so forth) which are highly liquid (that is, readily convertible to known amounts of cash) and so near their maturity that they present an insignificant risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify as cash equivalents by definition. Original maturity means an original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three-years ago does not become a cash equivalent when its remaining maturity is three months.",
        "label": "Money Market Funds, at Carrying Value",
        "terseLabel": "Money market funds"
       }
      }
     },
     "localname": "MoneyMarketFundsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gamidacell.com/role/ScheduleoffairvalueofmoneymarketfundsandmarketablesecuritiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r59"
     ],
     "calculation": {
      "http://www.gamidacell.com/role/ConsolidatedCashFlow": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gamidacell.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash Flows From Financing Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gamidacell.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r59"
     ],
     "calculation": {
      "http://www.gamidacell.com/role/ConsolidatedCashFlow": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash provided by (used in) investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gamidacell.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash Flows From Investing Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gamidacell.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r59",
      "r61",
      "r64"
     ],
     "calculation": {
      "http://www.gamidacell.com/role/ConsolidatedCashFlow": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gamidacell.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash Flows From Operating Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gamidacell.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r1",
      "r41",
      "r42",
      "r45",
      "r46",
      "r64",
      "r71",
      "r76",
      "r78",
      "r79",
      "r80",
      "r81",
      "r84",
      "r85",
      "r95",
      "r118",
      "r119",
      "r121",
      "r122",
      "r124",
      "r127",
      "r141",
      "r142",
      "r143",
      "r145",
      "r146",
      "r147",
      "r148",
      "r149",
      "r150",
      "r151",
      "r241",
      "r244",
      "r297",
      "r312"
     ],
     "calculation": {
      "http://www.gamidacell.com/role/ConsolidatedCashFlow": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gamidacell.com/role/ConsolidatedCashFlow",
      "http://www.gamidacell.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": {
     "auth_ref": [
      "r87",
      "r90",
      "r91",
      "r92",
      "r93",
      "r96",
      "r99"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.",
        "label": "Net Income (Loss) Available to Common Stockholders, Diluted",
        "terseLabel": "Net loss attributable to equity holders of the Company"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gamidacell.com/role/ScheduleofnumberofsharesandlossusedinthecomputationofnetlosspershareTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Noncash Investing and Financing Items [Abstract]",
        "terseLabel": "Significant non-cash transactions:"
       }
      }
     },
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gamidacell.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r53"
     ],
     "calculation": {
      "http://www.gamidacell.com/role/ConsolidatedIncomeStatement": {
       "order": 2.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "negatedLabel": "Financial expenses, net"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gamidacell.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NotesPayableCurrent": {
     "auth_ref": [
      "r28"
     ],
     "calculation": {
      "http://www.gamidacell.com/role/ConsolidatedBalanceSheet": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.",
        "label": "Notes Payable, Current",
        "terseLabel": "Accrued interest of convertible senior notes"
       }
      }
     },
     "localname": "NotesPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gamidacell.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r117"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Operating segment"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gamidacell.com/role/GeneralDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r118",
      "r119",
      "r121",
      "r122",
      "r124"
     ],
     "calculation": {
      "http://www.gamidacell.com/role/ConsolidatedIncomeStatement": {
       "order": 1.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "negatedTotalLabel": "Total operating loss"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gamidacell.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r263",
      "r271"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "terseLabel": "Operating lease costs"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gamidacell.com/role/ScheduleofoperatingleasecostsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r261"
     ],
     "calculation": {
      "http://www.gamidacell.com/role/ConsolidatedBalanceSheet": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gamidacell.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r261"
     ],
     "calculation": {
      "http://www.gamidacell.com/role/ConsolidatedBalanceSheet": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Long-term operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gamidacell.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r260"
     ],
     "calculation": {
      "http://www.gamidacell.com/role/ConsolidatedBalanceSheet": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gamidacell.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r268",
      "r271"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted average discount rate"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gamidacell.com/role/ScheduleofoperatingleasesTable"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r267",
      "r271"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted average remaining lease term (in years)"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gamidacell.com/role/ScheduleofoperatingleasesTable"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears": {
     "auth_ref": [
      "r255",
      "r257"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Operating Leases, Future Minimum Payments, Due in Five Years",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueInFiveYears",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gamidacell.com/role/ScheduleofmaturitiesofleaseliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears": {
     "auth_ref": [
      "r255",
      "r257"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Operating Leases, Future Minimum Payments, Due in Four Years",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueInFourYears",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gamidacell.com/role/ScheduleofmaturitiesofleaseliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock": {
     "auth_ref": [
      "r140",
      "r254",
      "r255",
      "r256",
      "r258"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for lessee's operating leases. Includes, but is not limited to, description of lessee's operating lease, existence and terms of renewal or purchase options and escalation clauses, restrictions imposed by lease, such as those concerning dividends, additional debt, and further leasing, rent holidays, rent concessions, or leasehold improvement incentives and unusual provisions or conditions.",
        "label": "Lessee, Operating Lease, Disclosure [Table Text Block]",
        "terseLabel": "Schedule of operating leases"
       }
      }
     },
     "localname": "OperatingLeasesOfLesseeDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gamidacell.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r2",
      "r237"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "terseLabel": "GENERAL"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gamidacell.com/role/General"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r29"
     ],
     "calculation": {
      "http://www.gamidacell.com/role/ConsolidatedBalanceSheet": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Accrued expenses and other current liabilities"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gamidacell.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesNoncurrent": {
     "auth_ref": [
      "r33"
     ],
     "calculation": {
      "http://www.gamidacell.com/role/ConsolidatedBalanceSheet": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Noncurrent",
        "terseLabel": "Accrued severance pay"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gamidacell.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r11"
     ],
     "calculation": {
      "http://www.gamidacell.com/role/ConsolidatedBalanceSheet": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other long-term assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gamidacell.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLongTermInvestments": {
     "auth_ref": [
      "r10",
      "r309"
     ],
     "calculation": {
      "http://www.gamidacell.com/role/ConsolidatedBalanceSheet": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term investments classified as other.",
        "label": "Other Long-Term Investments",
        "terseLabel": "Severance pay fund"
       }
      }
     },
     "localname": "OtherLongTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gamidacell.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": {
     "auth_ref": [
      "r54"
     ],
     "calculation": {
      "http://www.gamidacell.com/role/ConsolidatedCashFlow": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.",
        "label": "Payments to Acquire Businesses, Net of Cash Acquired",
        "negatedLabel": "Proceeds from restricted deposits"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gamidacell.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireMarketableSecurities": {
     "auth_ref": [
      "r126"
     ],
     "calculation": {
      "http://www.gamidacell.com/role/ConsolidatedCashFlow": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for purchase of marketable security.",
        "label": "Payments to Acquire Marketable Securities",
        "negatedLabel": "Purchase of marketable securities"
       }
      }
     },
     "localname": "PaymentsToAcquireMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gamidacell.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r55"
     ],
     "calculation": {
      "http://www.gamidacell.com/role/ConsolidatedCashFlow": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchase of property, plant and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gamidacell.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r25"
     ],
     "calculation": {
      "http://www.gamidacell.com/role/ConsolidatedBalanceSheet": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gamidacell.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PresentValueOfFutureMinimumLeasePaymentsSaleLeasebackTransactions": {
     "auth_ref": [
      "r259"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of minimum lease payments for sale-leaseback transactions accounted for using the deposit method or as a financing.",
        "label": "Present Value of Future Minimum Lease Payments, Sale Leaseback Transactions",
        "terseLabel": "Present value of lease liabilities"
       }
      }
     },
     "localname": "PresentValueOfFutureMinimumLeasePaymentsSaleLeasebackTransactions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gamidacell.com/role/ScheduleofmaturitiesofleaseliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r56"
     ],
     "calculation": {
      "http://www.gamidacell.com/role/ConsolidatedCashFlow": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds from issuance of convertible senior notes, net"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gamidacell.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock": {
     "auth_ref": [
      "r56"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from issuance of callable preferred stock which is identified as being convertible to another type of financial security at the option of the issuer or the holder.",
        "label": "Proceeds from Issuance of Redeemable Convertible Preferred Stock",
        "terseLabel": "Convertible notes"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gamidacell.com/role/ConvertibleSeniorNotesNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": {
     "auth_ref": [],
     "calculation": {
      "http://www.gamidacell.com/role/ConsolidatedCashFlow": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period.",
        "label": "Proceeds from Sale and Maturity of Marketable Securities",
        "terseLabel": "Proceeds from maturity of marketable securities"
       }
      }
     },
     "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gamidacell.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r56",
      "r217"
     ],
     "calculation": {
      "http://www.gamidacell.com/role/ConsolidatedCashFlow": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from exercise of options"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gamidacell.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r1",
      "r41",
      "r42",
      "r45",
      "r58",
      "r71",
      "r76",
      "r84",
      "r85",
      "r118",
      "r119",
      "r121",
      "r122",
      "r124",
      "r127",
      "r141",
      "r142",
      "r143",
      "r145",
      "r146",
      "r147",
      "r148",
      "r149",
      "r150",
      "r151",
      "r228",
      "r231",
      "r232",
      "r235",
      "r236",
      "r241",
      "r244",
      "r299"
     ],
     "calculation": {
      "http://www.gamidacell.com/role/ConsolidatedIncomeStatement": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "negatedTotalLabel": "Loss"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gamidacell.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r130",
      "r278",
      "r300",
      "r307"
     ],
     "calculation": {
      "http://www.gamidacell.com/role/ConsolidatedBalanceSheet": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property, plant and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gamidacell.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r225",
      "r289",
      "r342"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development expenses, net"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gamidacell.com/role/ScheduleofsharebasedcompensationexpenseTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedInvestmentsNoncurrent": {
     "auth_ref": [
      "r337",
      "r338"
     ],
     "calculation": {
      "http://www.gamidacell.com/role/ConsolidatedBalanceSheet": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents the noncurrent portion of investments which are not defined as or included in marketable (debt, equity, or other) securities that are pledged or subject to withdrawal restrictions.",
        "label": "Restricted Investments, Noncurrent",
        "terseLabel": "Restricted deposits"
       }
      }
     },
     "localname": "RestrictedInvestmentsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gamidacell.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r0",
      "r73",
      "r74",
      "r75",
      "r77",
      "r83",
      "r85",
      "r128",
      "r218",
      "r219",
      "r220",
      "r226",
      "r227",
      "r239",
      "r316",
      "r318"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gamidacell.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r266",
      "r271"
     ],
     "calculation": {
      "http://www.gamidacell.com/role/ConsolidatedCashFlow": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gamidacell.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RoyaltyExpense": {
     "auth_ref": [
      "r51"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.",
        "label": "Royalty Expense",
        "terseLabel": "Royalty-bearing grants"
       }
      }
     },
     "localname": "RoyaltyExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gamidacell.com/role/ContingentLiabilitiesandCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RoyaltyGuaranteesCommitmentsAmount": {
     "auth_ref": [
      "r291"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount the entity has committed to make for future royalty guarantees.",
        "label": "Royalty Guarantees, Commitments, Amount",
        "terseLabel": "Bank guarantees amount"
       }
      }
     },
     "localname": "RoyaltyGuaranteesCommitmentsAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gamidacell.com/role/ContingentLiabilitiesandCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of subsidiary's or equity investee's stock owned by parent company after stock transaction.",
        "label": "Sale of Stock, Percentage of Ownership after Transaction",
        "terseLabel": "Percentage of interest rate"
       }
      }
     },
     "localname": "SaleOfStockPercentageOfOwnershipAfterTransaction",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gamidacell.com/role/ContingentLiabilitiesandCommitmentsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.",
        "label": "Sale of Stock, Price Per Share",
        "terseLabel": "Nominal per share value (in New Shekels per share)"
       }
      }
     },
     "localname": "SaleOfStockPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gamidacell.com/role/ShareBasedCompensationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r99"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Schedule of number of shares and loss used in the computation of net loss per share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gamidacell.com/role/BasicandDilutedNetLossPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r212"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Schedule of share-based compensation expense"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gamidacell.com/role/ShareBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": {
     "auth_ref": [
      "r191"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.",
        "label": "Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]",
        "terseLabel": "Schedule of restricted shares activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gamidacell.com/role/ShareBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r191",
      "r204",
      "r205"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Schedule of stock option plans"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gamidacell.com/role/ShareBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r207"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of fair value measurement of equity-settled share options"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gamidacell.com/role/ShareBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r62"
     ],
     "calculation": {
      "http://www.gamidacell.com/role/ConsolidatedCashFlow": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "terseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gamidacell.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue": {
     "auth_ref": [
      "r203"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average intrinsic value of award forfeited under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Intrinsic Value, Amount Per Share",
        "terseLabel": "Weighted average grant date fair value, Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gamidacell.com/role/ScheduleofrestrictedsharesactivityTable"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue": {
     "auth_ref": [
      "r201"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average intrinsic value of award granted under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Intrinsic Value, Amount Per Share",
        "terseLabel": "Weighted average grant date fair value, Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gamidacell.com/role/ScheduleofrestrictedsharesactivityTable"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue": {
     "auth_ref": [
      "r199",
      "r200"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average intrinsic value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instrument Other than Option, Nonvested, Intrinsic Value",
        "periodEndLabel": "Weighted average grant date fair value, Unvested ending",
        "periodStartLabel": "Weighted average grant date fair value, Unvested beginning"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gamidacell.com/role/ScheduleofrestrictedsharesactivityTable"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r199",
      "r200"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Amount of restricted shares and restricted shares units, Unvested ending",
        "periodStartLabel": "Amount of restricted shares and restricted shares units, Unvested beginning"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gamidacell.com/role/ScheduleofrestrictedsharesactivityTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r202"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedLabel": "Amount of restricted shares and restricted shares units, Vested"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gamidacell.com/role/ScheduleofrestrictedsharesactivityTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodIntrinsicValue": {
     "auth_ref": [
      "r202"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average intrinsic value of award vested under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Intrinsic Value, Amount Per Share",
        "terseLabel": "Weighted average grant date fair value, Vested"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gamidacell.com/role/ScheduleofrestrictedsharesactivityTable"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r210"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gamidacell.com/role/ScheduleoffairvaluemeasurementofequitysettledshareoptionsTable"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r209"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected volatility of the share prices"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gamidacell.com/role/ScheduleoffairvaluemeasurementofequitysettledshareoptionsTable"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r211"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gamidacell.com/role/ScheduleoffairvaluemeasurementofequitysettledshareoptionsTable"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted": {
     "auth_ref": [
      "r198"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net number of non-option equity instruments granted to participants.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Granted",
        "terseLabel": "Granted Warrants"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gamidacell.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": {
     "auth_ref": [
      "r197"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period",
        "negatedLabel": "Amount of options and restricted share unites, Expired"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gamidacell.com/role/ScheduleofstockoptionplansTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r196"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Amount of restricted shares and restricted shares units, Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gamidacell.com/role/ScheduleofrestrictedsharesactivityTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [
      "r194"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Amount of restricted shares and restricted shares units, Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gamidacell.com/role/ScheduleofrestrictedsharesactivityTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r192",
      "r193"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Amount of options and restricted share unites, ending balance",
        "periodStartLabel": "Amount of options and restricted share unites, beginning balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gamidacell.com/role/ScheduleofstockoptionplansTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r192",
      "r193"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Weighted average exercise price, ending balance",
        "periodStartLabel": "Weighted average exercise price, beginning balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gamidacell.com/role/ScheduleofstockoptionplansTable"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "auth_ref": [
      "r206"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "terseLabel": "Share-based compensation non-vested (in Dollars)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gamidacell.com/role/ShareBasedCompensationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r195"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted average exercise price, Exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gamidacell.com/role/ScheduleofstockoptionplansTable"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r197"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted average exercise price, Expired"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gamidacell.com/role/ScheduleofstockoptionplansTable"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r196"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted average exercise price, Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gamidacell.com/role/ScheduleofstockoptionplansTable"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r194"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted average exercise price, Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gamidacell.com/role/ScheduleofstockoptionplansTable"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks of a company.",
        "label": "Share Price",
        "terseLabel": "Exchange price (in Dollars per share)"
       }
      }
     },
     "localname": "SharePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gamidacell.com/role/ConvertibleSeniorNotesNetDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r208"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gamidacell.com/role/ScheduleoffairvaluemeasurementofequitysettledshareoptionsTable"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r206"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Options vest period"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gamidacell.com/role/ShareBasedCompensationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average grant-date fair value of options vested.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value",
        "terseLabel": "Grant date fair value per share (in Dollars per share)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gamidacell.com/role/ShareBasedCompensationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Balance (in Shares)",
        "periodStartLabel": "Balance (in Shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gamidacell.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShortTermDebtTypeAxis": {
     "auth_ref": [
      "r27"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of short-term debt arrangement.",
        "label": "Short-Term Debt, Type [Axis]"
       }
      }
     },
     "localname": "ShortTermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gamidacell.com/role/ConvertibleSeniorNotesNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShortTermDebtTypeDomain": {
     "auth_ref": [
      "r26"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of short-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing.",
        "label": "Short-Term Debt, Type [Domain]"
       }
      }
     },
     "localname": "ShortTermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gamidacell.com/role/ConvertibleSeniorNotesNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShortTermLeaseCost": {
     "auth_ref": [
      "r264",
      "r271"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less.",
        "label": "Short-Term Lease, Cost",
        "terseLabel": "Short-term lease costs"
       }
      }
     },
     "localname": "ShortTermLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gamidacell.com/role/ScheduleofoperatingleasecostsTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r68",
      "r72"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "SIGNIFICANT ACCOUNTING POLICIES"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gamidacell.com/role/SignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r16",
      "r17",
      "r18",
      "r69",
      "r71",
      "r88",
      "r89",
      "r94",
      "r97",
      "r99",
      "r107",
      "r108",
      "r109",
      "r127",
      "r141",
      "r145",
      "r146",
      "r147",
      "r150",
      "r151",
      "r159",
      "r160",
      "r163",
      "r167",
      "r173",
      "r244",
      "r348"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gamidacell.com/role/ShareBasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r0",
      "r37",
      "r43",
      "r44",
      "r45",
      "r73",
      "r74",
      "r75",
      "r77",
      "r83",
      "r85",
      "r106",
      "r128",
      "r173",
      "r174",
      "r218",
      "r219",
      "r220",
      "r226",
      "r227",
      "r239",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r273",
      "r316",
      "r317",
      "r318"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gamidacell.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gamidacell.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r73",
      "r74",
      "r75",
      "r106",
      "r290"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gamidacell.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": {
     "auth_ref": [
      "r173",
      "r174"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Gross",
        "terseLabel": "Grant of restricted shares (in Shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gamidacell.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r17",
      "r18",
      "r173",
      "r174",
      "r195"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "terseLabel": "Exercise of options (in Shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gamidacell.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures": {
     "auth_ref": [
      "r17",
      "r18",
      "r173",
      "r174"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock related to Restricted Stock Awards forfeited during the period.",
        "label": "Stock Issued During Period, Value, Restricted Stock Award, Forfeitures",
        "terseLabel": "Grant of restricted shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gamidacell.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r37",
      "r173",
      "r174"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Exercise of options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gamidacell.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r18",
      "r22",
      "r23",
      "r71",
      "r125",
      "r127",
      "r244",
      "r278"
     ],
     "calculation": {
      "http://www.gamidacell.com/role/ConsolidatedBalanceSheet": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Balance",
        "periodStartLabel": "Balance",
        "totalLabel": "Total Shareholders\u2019 Equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gamidacell.com/role/ConsolidatedBalanceSheet",
      "http://www.gamidacell.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Shareholders\u2019 equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gamidacell.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Note [Abstract]"
       }
      }
     },
     "localname": "StockholdersEquityNoteAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r70",
      "r160",
      "r162",
      "r163",
      "r164",
      "r165",
      "r166",
      "r167",
      "r168",
      "r169",
      "r170",
      "r171",
      "r172",
      "r174",
      "r177",
      "r238"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "SHAREHOLDERS' EQUITY"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gamidacell.com/role/ShareholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental disclosures of cash flow information:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gamidacell.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TemporaryEquitySharesAuthorized": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Shares Authorized",
        "terseLabel": "Treasury ordinary shares par value"
       }
      }
     },
     "localname": "TemporaryEquitySharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gamidacell.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TemporaryEquitySharesIssued": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Shares Issued",
        "terseLabel": "Ordinary shares (in Shares)"
       }
      }
     },
     "localname": "TemporaryEquitySharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gamidacell.com/role/ConvertibleSeniorNotesNetDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TreasuryStockMember": {
     "auth_ref": [
      "r36",
      "r175"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares of an entity that have been repurchased by the entity. This stock has no voting rights and receives no dividends. Note that treasury stock may be recorded at its total cost or separately as par (or stated) value and additional paid in capital. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Treasury Stock [Member]",
        "terseLabel": "Treasury shares"
       }
      }
     },
     "localname": "TreasuryStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gamidacell.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockShares": {
     "auth_ref": [
      "r36",
      "r175"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.",
        "label": "Treasury Stock, Shares",
        "terseLabel": "Treasury ordinary shares"
       }
      }
     },
     "localname": "TreasuryStockShares",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gamidacell.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TreasuryStockSharesRetired": {
     "auth_ref": [
      "r18",
      "r173",
      "r174"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common and preferred stock retired from treasury during the period.",
        "label": "Treasury Stock, Shares, Retired",
        "terseLabel": "Treasury shares (in Shares)"
       }
      }
     },
     "localname": "TreasuryStockSharesRetired",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gamidacell.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TreasuryStockValue": {
     "auth_ref": [
      "r36",
      "r175",
      "r176"
     ],
     "calculation": {
      "http://www.gamidacell.com/role/ConsolidatedBalanceSheet": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.",
        "label": "Treasury Stock, Value",
        "terseLabel": "Treasury ordinary shares of NIS 0.01 par value; 75,117 and 0 shares at March 31, 2022 (unaudited) and December 31, 2021 respectively."
       }
      }
     },
     "localname": "TreasuryStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gamidacell.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TreasuryStockValueAcquiredCostMethod": {
     "auth_ref": [
      "r173",
      "r174",
      "r175"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.",
        "label": "Treasury Stock, Value, Acquired, Cost Method",
        "terseLabel": "Treasury shares"
       }
      }
     },
     "localname": "TreasuryStockValueAcquiredCostMethod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gamidacell.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r110",
      "r111",
      "r112",
      "r113",
      "r114",
      "r115",
      "r116"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gamidacell.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_WarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Warrant [Member]",
        "terseLabel": "Warrant [Member]"
       }
      }
     },
     "localname": "WarrantMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gamidacell.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r86",
      "r99"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted average number of shares used in computing net loss per share attributable to ordinary shareholders, basic and diluted (in Shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.gamidacell.com/role/ConsolidatedIncomeStatement"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 5
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(12))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "https://asc.fasb.org/topic&trid=2144383"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8672-108599"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org/topic&trid=2144648"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org/topic&trid=2127136"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12069-110248"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(23))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "https://asc.fasb.org/topic&trid=2208762"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "https://asc.fasb.org/topic&trid=2122149"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(l)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=SL79508275-113901"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=109244661&loc=d3e17540-113929"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=109244661&loc=d3e17540-113929"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=109244661&loc=d3e17540-113929"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org/topic&trid=2228938"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "https://asc.fasb.org/topic&trid=2197479"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "840",
   "URI": "https://asc.fasb.org/extlink&oid=123389372&loc=d3e36991-112694"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(Note 3)",
   "Topic": "840",
   "URI": "https://asc.fasb.org/extlink&oid=123403562&loc=d3e38371-112697"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "840",
   "URI": "https://asc.fasb.org/extlink&oid=123406913&loc=d3e41499-112717"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "840",
   "URI": "https://asc.fasb.org/extlink&oid=123406913&loc=d3e41502-112717"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "840",
   "URI": "https://asc.fasb.org/extlink&oid=123406913&loc=d3e41502-112717"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "840",
   "URI": "https://asc.fasb.org/extlink&oid=123386454&loc=d3e45280-112737"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/subtopic&trid=77888251"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Topic": "928",
   "URI": "https://asc.fasb.org/extlink&oid=6473578&loc=d3e63223-108013"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Subparagraph": "e",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16)(a))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.1(f))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.1,2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.14)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(13))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=120401414&loc=d3e603758-122996"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 6))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 6))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 6))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=120413173&loc=SL6242262-115580"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=127002003&loc=SL6242269-115581"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r343": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r344": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r345": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r346": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r347": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r348": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402"
  },
  "r349": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29,30)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(8))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.3)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3000-108585"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(24))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(25))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(26))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1278-109256"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2626-109256"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>55
<FILENAME>0001213900-22-025709-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001213900-22-025709-xbrl.zip
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M25ID@F/K(.%X*N5IK0)FL 4Z. )&7E&7?37<GB\Z8F!,M6-IYM@UB!HC>"+
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MT^_])&-CUCDJ=$(3WPQ^BK!'<NMDP8))*%K.RJ]MU"<X>QHXG+,?L.S 95=
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ME&W@F[O6O[Y\W,=*B&RMB,C"Q?/5;ZR:=CER%'LD>PH=(A^A+^_$"8-#+QY
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M,C3M8@OW]'/WXILVA(O&+D$BL.^>#C>K>['T=F%3@6)W=ADR@\L8,R@]ABP
M^<:EY@[8-?!;=[OL#L#XWK<T7S=@CY^ OP%'LWU7LW3W0RIXOM66:G-LB=P;
MI^76A^-IX'#.?L!R Y== 8GJHOM6Z$5+Z?\OND5'SI LH*-)&F_CX?1O2=-4
MN>C&74L.(Q3EB*6R:\<>LKL1=S0/5;@.V$(OAF<47F1R# "DZ872;KV;:>M=
M4='^2<[%V;4F 3L8J]WU[@![-U@B#4#S:'XOXUNU2CNA3^D.,8:=VLRFI^?-
MX54='=TOJ-(SSV8.!YKN&:#!FD")^(G%/=9#H>2C,0"JM1U*)"V42.<["-^=
MVLSQENT\X N]95_14=DS*%,9+>>1@]?(&RML9&(_!3!5&?88'.%%+!B,A:D%
M\4,NZJ*^[MS1[4!F'?F>#C(ITA6*XS*I2?E:^(.!__/?F'W/V7N#=)</"@J+
M@E%4G%)[:;M47G E3I5*#5/4%+-E%NBR^T;'BV TI?+7UNU^LB.<>TNE:L55
M(!Y2^5-Q<[;W:B1M>F5_:,.:_PK5$,-U?<I%[.'%WE>2CI_JKA_*IX!9?37<
M'@:&%W K]6R5D?;[2MSKPZN>PINS%]P]<J^:'&Z[ 'W9[I?!VF6:Z_+]O14/
MN/Y=_Z?+.WB.NZZG&1;7;ZRKW[V!9CWS:]L)C_\=3__=T+J&N3!!I]EZ>\I[
M,8!4=ZM\/^7],.7)BH]"%*?HWU@];'7%OW+QWQLK!?;F6 "ME>1^T?I_<8[J
M/&%W5EN>#YZ#V[I8[VFOY_C8 9/#ZTF3&FGC3=C!&[P=]Z 7<"K#1^?471?V
M0:K#(OU@7?6@,+AE;)BP$28;@!R]ZR.'XR2QP+?BDF?0]@;<V8PZLDFV>R_.
M^I7WN>/PP*D &N@=GI>$[0(:.TTQ).&P6>]Z\&NJRRL2=IW]AC?GO2ZA\H&R
MOQQ-)TZ,N5B'=&- W)!E=B^.]H3G3%/CH)S5=K$SYP;ORC+(3:DFU57 5;S@
MF$I5FAMLBN2))A64"7G2\X%?8*;\K#:_,#GJ;78F6$I,P'&E'O@] F@:!?AL
MN0UX["VQ"7:P*@;KBGJVW"%27 ^*=0K8C^D$&\[C6)>MWZ;)Q#EP+K!FUB)F
MU]X[]HNA<_W+^*>+7KS0@1$EV*9):6PJ[5KV]@)']KUUQ%65TT;V6NSM\.S=
M980[M9EUN/)*6?DWU@MWCUGY.Q#QV]WS[M1F-N+'O/>=WD 3C?^WF>!8G H!
MY@(5/S[9G1X<QN'W\ICW>$A,C J.N*!O]TJQ\_WU6^8!LYIR6ETE7KI;WLKX
M_1AJSB\N:D5=WO.=_0ZISN#X1WB\Q_!TB]!;35'-LOE+L8O!(K@]/<YUE_51
M$0$$(73'VR*IXBA*'A/5K4>-/#0_Y%GO^MFH2VTHZN[.7"F,QO)E9>E<%)/$
M&9L0J?.1[1K>_KLG-L="O_BN87'7Y2[8OW=]-$'D-WH*,[>98OKD6^LLG4]K
M[6,IU\[;,-M@?:%W=B3=5*P[9N^EJQ:CTH''8-N^VG3=XK;&!^<X^T*/2[*S
M;[K$3#E-,8IR+_A?/NC:N'-V";[F.6=3V7F;Z.F^NVQPIS93+$]>R3<;U2<>
M?;-%6JZ[>YJ=VLPF@_ES[#"^6P-9<W,+',K4R^)<KZM#JUE=M]!GFZD2D_0?
M5CD"_0-L:1O"2V89MB-ZHT[D[+]Q"W>/ ;"1JW0CZ>FN?VD/A[9%5VL!XZDJ
M[79!UL@Q56QG-[,3J6)Q9T0_5(RW[8+8!W_L'+LVM"[2^"%2J!Q'!EVL'R(;
MOE2EULX^I&:+G'IWV=].;29/7CRWZH@8+I57X%\PV>4%R,S:XY(]O%#X_ZOH
M+ ]A3(\"4I8^^4'L23'9?CKU_NIWS_3Q]@3%\P^:QZ_Z?=[S4O@'U;IR6E^C
M;&W_3+CMH6 2\HVVTDJ1[[P'$1SI,4RZJ$SS6)<_&Y:%6A)FL1$ #UOHKC/^
M;2WJ!+H4=/C5<$>VJYG? .&CH &-Y1F6SW69Y+VPVKS95$[S+,-Y"ZK6Z=YC
M7:VU%;5=4);#T2&^ [I8,4*@L50$<&RYD);YO[EY;KMQ^QLUI=K,[E0[R)&*
M"U&MKC/E<C=PK;8;2KN86;Y'/K^G?#Y5:L C_-WHPRLMCP'AE(G9>XYFN8*"
MCGWKCXD!>P#: O6@()05]0=!^>%PW5@:#-U5:;@T!OKV=(!5'%#/0UT[#\@C
MZ/=]9UT2;2PHY4GAGMN0G,YX%5)7+^[_%2G,8?Q-,RP<871G8<W.77^BU"]%
MG9^J *R.2GVA'N5U<51+T;FVT!M^C(_MA)J731/W1R.3!L=J)M/!_C-MUW<X
M39$EK;QOVJ_,L 0= TD=-?-]4!_)C4;]2@%Q-%<<:_X.DN6NUT%. .8>('7+
M%]:YUZK+NP.\"?F7AQH?W)&/5"N\L1'0FQQ]_33@V./1'HXT:XQ12\IF99K#
M2YI%-_+9 98[TAP/>:TWX"Y.^PB&>_=BP[V#!#%XW W'?%?RGYU-?[8KM7E'
MF@%K:79D_#U-J _FW)^S]B?V-\WTX6]J-$B>*'EFU'T<U&HM =8TZW[Y2.$(
M#K.'2(70DXD3!6?YQ)[&(SA'Q]&Z1N\3NP5.(LY[:^/1FO$??0Q^18=&B$4#
M[N<<O^MP[5>YRX%]P;HC@F-\LZV$S2*8X@>.H7,"7<DOC^\7SQ$AJ/BK2']H
MS-#_.-'^K%;;.+1%N]C.B/IOVA N&KODILF^>WHEU61Z5*B*W=DM,0S/1M[
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M%[S!' ]' Z!Y]O[V+]_!@OVJ>5K$&>O-4MP,QH^F7SPAV(G,@L.\ GP"S1,
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M %?9[M^34X2#D^@VQU;M^ O3X-A<RA,#;FE,IX;K D3#]E,XT %/C@,'4*/
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MQG7]-&YC5;-9U\@ZOV@NUW$3'(QH7+^#]/=,X8XOX^B1>^$+[*"'X=:V[D@
M"]1%(YC<;^(4H;%6C1EK0E[@'*EZK:Z<M4]GC;;7D/@'F@S><X0J,?C_YYMC
MLF\KTUR.=1(&O"A+ '>V=X!3E:I:51H) 3;T7)"%'@(P<CCPW]SI&2[%G))U
MA&F1?KB#KN(#YN*H>^ FZD4TZW(&<]E'8:WYFAPXW7PW!)G2I]*4+G_I/%Y1
M7N']U>UCY^GF[C9T4.2"X'I*<T,MR)K."^&!C9T? ;T%E2=EYJ%@B0QG.1:G
MZ2QPSVTLVR4OZJGG3(W;,EWO+'9KOXA13: 2E$!-:BB)$NJ+#=(39?Q74 9Z
MI!9IHY$#/P8URIVT@,478%E*@W+2@.PY7*!FB7E;NI2F9<_47/@=9:I8]A"^
M-$5Q+KN]>635A4I&8SKV,3^\ 6R.WW.'T)6H!1BF>X]1#Z$+5*JS-6!L!' 4
MFT83F#9N].$Z!^?-L-=L"M'5<&3:8\[I*&%TYAXN]-7CW3UP<<#P7;]C M4A
M83Z*0RS6=9K5JE)-B-G,."!@GT+YH0/C.<47@+,!=WAW7%I\;K7H<S_Z+@5^
M4QU;;=:4:F.VC(P%*IX\]2M'- <0G>/]85QNT(57Z7+(:> 1PMLF\P,8;8U)
M1HS[9^_Q45RG5OV$3Y;P4_JW^NF#B%H%FB5F=_6"!%YFTR)N:-!$+Z87TN*8
M8"QS>TWNDKHO,@PF+UC\ E,4SBY%^0O!>W#CH8XK-A9\A194+/6,QKPNTA<;
MD]%);-1SKOO.*U"<RZU$*Z"[W KH3EL! LSNWV!W(!@L_4KFB#W9^-&=[[D>
MW%]0 /Y.WE9X!C:N/?,'/@3+D&:R6Q[2A:^93]P9@C+A#1S.V9AKCCNM.Q%(
MD%8<!*_(67:YYYFT1R ACSL6Q8_="@..' S/*]7.%#:?(\>Y*H9#@=%(+V/
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M^'F,2'*!7F.-/-@=HU U[U38ZM(BBX75R[T!UWV*8"2FW(O4+)EQ$W#=3J3
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MG4@@IM^$]+98#3U5ZHW9<7^I4)0$Y0_K(S?UNS(X=W<K$7VYN)Y!XOI,8[G
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M.78-"@E=&Y9F42+PI0TRP9//L ?N^J9'C]R-N!P965E:P+H1$.?KX@A?]]G
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MR$_[!;_$ P3))89#3?HK>$^10X:2$,[P(@&$&]&-?A^8*I*2(Y*0^HX]G ,
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MI?XQ$PDX<OXD">B5/ ]2X&ARZFS ,FUV@ZD9S)/?0-8WG);M%?VMKO"B="E
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M2*9+P<PEUUIJ68D,S 'GMQRDXX$?<F0+'-)!C,$5> *:*A)^!3@9+B\ ;R2
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MS+<M<"ET1N8DBO4[4U.XT#3DI_CCK]G4ESDI3B "'8\UY9@&%91-[0X@]_1
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MQ@^6S,:]CMH7NT_A38,M!WJ'$TA))!6WK4+4=L#3< G%'PP.8@F?='(PK?D
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MJE4]Q-@6W%49@):IAMSF-VYK:O+?=))BN[/> 85SOPY>["/)G,[G]89>BE7
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M\8N=U/G#R:6]>'\IY]:)M#]SHN.F'M0?NZJ/#_N\V2Q0C(2R/72S;;^7X"C
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MH>N+Z%U6F)^*%5H+XOA\.5K6-TB;8U\?O:?#^&TN8;&=*&TO+T^O@Z*#;PC
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M9Y'+6ZA"L*^*TYY.Y1($Y$MFM&8GP.<8L$&MF2_+JJ@N^.N*)E#]PGI,"A_
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M,M,!+</D)Q695"3H@72".THTO9 G@/Z_!_F_L",6Z P"Q)^=U2$G5GA\1W:
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M)IM$>'QR9E<$%4Q+HL24 06C]9GF)ME7'TQ!'%3*!].1TX.# 4FV--*X:DD
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M<'JP*1?I955CA\>Y,S7/E(%;I05=-R=GB I<65!S+C &Y1 -NF[+E16LWJW
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M"JRZK$OQS4&7\)*2V[3;OBCI*%IUBU=^5_<1;_O6KZ.B76W)BWGYQ:NWJAQ
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M\>*/R!<[=OO:%8M/GO_ATXO%E]87[%NIK&A*,"W^9<S/,GBBA,_#_VZ;2\&
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MD-''L.W";,=(D. ?B5J__*&%)[GM73RJW72O8A#OOTM.)Z8I0LH +W7IO$<
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M8H+*BCW+:V*_$*^_/DUNX2_A#54^RA000Q5RPNH#4JK$U<KK>3H5LXMTY\]
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M35H^2Z*F[(8 +I#.3&8"O)][\@'G=TV/QEAJJ^OAO\&"F.Y&6K_%M65AB7D
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M^C.P3S3/-DG[$5V[O ,BWV0Z]<U9:4KU$XB5K5@1^""SAUNZ/&<XW9^#>T)
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M^8@[1%)>DF\(^ZKS@^FQHI;D>,5N@:$^VOX)BY#? I93=5=M1K2,W^]:SLK
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MET-P5/?5&E40C)IJ2^/ ]^K2M?3()_VB3M?_]>I5#0S [6XU3;(9X:+T!:1
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M2MEPWI;=#8B@KMZ\K_W1O6*>G)>???:2W=/ZJ#WB<C[(ON-$'Q&!]J2+ACG
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M6W"=EC]!M9^NO/-U@?\V/1=U!0<O/:$+B^>R%Y["7C"\(@_9#J(*J6UH0@/
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M/QVJOKK>O#NG[R[B9XW1^N#TVX9#[BL%JFD(X_^[$@MI;B0W0&R3-$'I4JL
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M0IE[R04W 4!PM-CY"2?^IH6CH+QD29*A8A?'P;NO*\W7&Z?F ]\EV0SY*AH
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M<S0B(%B@6M\GED:L!F.*XQ+FK&:89^X]('K9<D E>%OCQ4X9E7=LJ,R@:19
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M:,HGGM]E RP;X!$W !<Y'];G+QR\0_G.-UC=]HA",RK2)5,0.*W]W#6;HFD
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M&$U-"SX4]I" @0YL.);F::0#-^4)Q7':EZ=<I'PJBS ^AG/,$9*A.$5^7@]
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MX6A&CH? 6\P06$XB7R9&72BM:O_QI%4]7Z=5K0)S+-4#K)5^!ZD!4P48F5:
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M5BTA#D=OF2?3T4+KXW)M%L;M$),?AC(C ?1"FF@K$F4P/ U!V-.+MG@8PK&
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M3B&\_SW\-@H3;^9%JLJH*T)]-;1]MX:#R,G$E9CY9D*":+*44%/K(5)Y4Z?
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M+M99BP++$;I4 VVT3N)T&A*&:(2"<M.K>(P$X%^:_(BW'CG6.;ZZX=540V.
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M#-U]<A<N?8T0N&*M&&1$$AJ%ES=I&;TJ.A[5D[N<>WB78"MH;F=_CO"7+M&
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M> VS6G+&D()T<_JJ6:=KT#-LJG-CSFWKZWD+$2;I]X$HT-**R_D>!(13H+H
MNT>"R0< I#EG])R>B5<-]D67J?^X 7^%OVQ4CM"L1131(3;!SCR45Q:/-8#6
M%PE3,9UF9>E:M69AX[@B(74"7)!$V*PC,GJ=:9D=A+;Q7@\\*AE2+>OFTEC:
MHGS#?L3ZD=5OFK\8F8>"$B.H3RO*\S- SKX(HR$9+M07!(B:]58&[7)@8IEA
M//<*#&(8WS8R7C3@Y/Q:?Q-58$LP/:_>N#YJZDQ5F0&\46$_#)H^Q<"Z;-#+
MN)##;C2( @?0S6CEYKQE9\G<UX8+);KM;AN6 LCXF_YWF,#NB@+4WP#VA[G
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M\(/'[E?:73F_T@K>]?W!K0 6-5XT0[J[=SW&=/[P)2\*OR##R&=V8!AI9E1
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MP=R(NY/?O,1^H]GML%:GV[UNM-L7E^_?5FH5_WQSW6C-GW_0DSVGQ]Z;1<-
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MP@M^NE5PA (1?586OC.CS]'^ U!+ P04    " !,/:Q4HU7)=, #   &#@
M'0   &8Q,'$P,S(R97@S,BTQ7V=A;6ED86-E;&PN:'1M[5=M;]I($/Z.Q'\8
M6;HHD8RQ25.U@2(9VVFH*%#L2)>/B[V.]\Y>N^MU$^[7WZPQ+B5IE5;A^N5
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MLK#>GK\:JGRHH:E*%*P4-;5FXQ>0R/]J^)X:!L]7 ^-8\3)2+S&65TD8QS+
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M:2.&KLARPK<GLGP[ _1V)62&0#OO(1:R=)LC,!$!Y1&-X!V180+G?1-K.A@
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MZ(--\1 FA3E5A]*OP&K=!AK)S[ULA9YR4B:BAMM2*O'8HT'X(N"2<6*SG0]
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MHR/5[CK&IV&E>5HIJ57R^-S+/1]CECOJLR-\5#[JG+EWGUYOCXLY_?%H=#R
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M[-N';]^^W6?_FG[5MZN^2(8]W/]T=3DU']'2V+-=/S!<DQ+P[7<^^_#2,XV
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MX[&'?_$;<[_T9+*F"%C[*'KWB!;94/WE14-I3C$C2C<BA.GZ2@AQ85[QLW&
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MS)'@A;#UT:+T@T6P0IBZZXQWDD<6&I#BN?G-\ Y9*.K7Q6C6N7F*_8MZJB_
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M6)P:,+B:M4@COW6ISLDG:H(9Q3''8&EJ\>#HGM(-^TC<JM'/CCJ"H$ #)(D
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M -<EGKML"0@U?I')ZDOR7[807UCG(ZL2.5"051&]QI75+'30O*SR-IZ-K'*
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M1WQ <" H3%,)36-QDT\H]:U%D11TT$P$@L^)6JQ>&R>-QY"'K>?\"Q+$O7V
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M#]GJI3+T+(UB70D?Y>+1XN'83L9IE2 =%.6FM:Z<,CWI>5K9STY*7^M'L1B
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M'TI9C[*+(/J<H LB#Z@L15<N8?.\TY>'QG6J0R[M-D#>_^ZSTN:KZ!8#FGZ
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M".E65OIG2  2%2>.PN-8+C1VSA(5/M8:973AKGVJG.&8G%&@X!-E'\J>5(V
MT>U%V5X6G+ 2<*1'D$\T\(8%:,7^4V!=W=KK0GA(B2D'&A!0CT;ILENNBR2J
MQ9KLM2(?7^*X(,9C/P/UW=Y*$^F>0(H>&8NYD!\Z*Y^$KA34GIQTJ*3?"JVA
MJTVL?IMO=M8 0-I@JG4YSD#/5E&PAR1A4C/O<^P#)<_*1$2EYR'17.//0P)
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M5>P[P3)<[E,WVK+:A]S22MEPE,)X!#%-V8PO[3W*\U%H>X%EJ)H_6<#Y3 2
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M-Z/,:@#D-P)]TA &*N0% \AH1(<?(3K!RJ$I18''% FNAC^WN_UN%]#'7">
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MLBV$.2J$3K"ECIJ54,L:J&1!>&N#)6F\J-7*I_TI( V^Z$G'9_5$2XQ3GW4
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M9.-31FWR&_+#/;F^ :7_#U!+ P04    " !,/:Q4Q.?L( DI  !@?@( %0
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M),1?DFX4$V?-XIT)@< 2;$4U\CW9SD;@9T@*D6%"306+2Y[YA+60S<<NP>/
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MO"J\285FK&(B(>S&#T++_0.O@)R06K"C\ACK&9/*JW<L0[H2B9%$D-5;/@5
M8XCX%5>>"F#W-1$7/HO>W_L>Q&VJ FPD>Z/*A%0@O6,1LO*8(CLB5#=>'=[-
M<-BS1+X";"3RJ#(AE4?O@(.J/$X?[7OVG*5W-7<MP%%XT_6L2"4#4-^@>MKS
M28MLEMX:G5BAU3TN6#SH4 MX3"Y:$V]2L0'$&1K?3?UTP AB;QG9;_\/4$L!
M A0#%     @ 3#VL5$E,7H5Y#P( NED/ !<              ( !     &8Q
M,'$P,S(R7V=A;6ED86-E;&PN:'1M4$L! A0#%     @ 3#VL5*?*(9,W!P
MA28  !T              ( !K@\" &8Q,'$P,S(R97@S,2TQ7V=A;6ED86-E
M;&PN:'1M4$L! A0#%     @ 3#VL5)+"G!(N!P  E28  !T
M ( !(!<" &8Q,'$P,S(R97@S,2TR7V=A;6ED86-E;&PN:'1M4$L! A0#%
M  @ 3#VL5*-5R73  P  !@X  !T              ( !B1X" &8Q,'$P,S(R
M97@S,BTQ7V=A;6ED86-E;&PN:'1M4$L! A0#%     @ 3#VL5 [F]*BH P
MW0T  !T              ( !A"(" &8Q,'$P,S(R97@S,BTR7V=A;6ED86-E
M;&PN:'1M4$L! A0#%     @ 3#VL5%J1$_.X#@  YXD  !$
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L &=M9&$M,C R,C S,S%?<')E+GAM;%!+!08     "@ * +P"  "L\P(    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
